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Executive summary 
Glässer’s disease is a bacterial disease prevalent amongst weaning pigs responsible for 
causing large economic losses to the pig industry worldwide. The etiologic agent of Glässer’s 
disease is Haemophilus parasuis which is associated with lung infections and can also cause 
fibrinous polyserositis, arthritis, and septicaemia in the swine population. Stress factors, such 
as transport, unfavorable environment and swine management conditions can trigger the 
disease. Measures to control disease such as the use of antibiotics and autogenous vaccines 
lack the ability to adequately control this organism and, therefore, outbreaks of H. parasuis 
induced disease can result in severe mortalities and morbidity.  
There are reports of many non-typeable H. parasuis strains isolated from clinical samples and 
the extensive strain variation within serovar groups makes commercial vaccine development 
significantly challenging. Commercial vaccines are largely based on killed antigen and hence 
lack effectiveness due to their poor cross-reactivity with other H. parasuis serovars; mainly 
due to the high heterogeneity among H. parasuis strain. It is anticipated that live attenuated 
vaccines may evoke a stronger and more cross protective immune response compared to 
humoral immunity induced by killed vaccines, due to their ability to replicate within the host, 
at least to some level. Development of commercial medium for the live attenuated vaccine is 
challenging, as H. parasuis is a very difficult organism to grow in culture. The primary aim of 
the project was to develop and design a suitable liquid growth medium for cultivating an 
attenuated vaccine candidate for commercial manufacture. In order to produce this vaccine to 
large-scale, the media components must comply with international regulatory standards. The 
nutritional requirement of H. parasuis is complex. It requires culture media supplemented 
with specific pyridine nucleotides or precursors such as NADH. Moving towards the 
development of a regulatory compliant media formulation required an understanding of the 
specific needs for growth. Experiments were conducted by systematic addition and 
elimination of chemical components from the formulation. The development of the growth 
media also required the elimination of components that were of animal origin (e.g. Bovine 
Spongiform Encephalitis [BSE] free) and substitution of such components with plant-derived 
raw materials. 
Research activates also included the determination of endotoxin levels present in the vaccine 
as well as establishing a preservation technique based on freeze drying to allow storage for 
transport of the vaccine final product. Overall, a new regulatory compliant broth media has 
been successfully developed for the growth of the aroA gene mutated H. parasuis vaccine 
 xii 
 
candidate. High yields of viable cells have been cultured in stainless steel fermentors, glass 
fermentors and wave bags. While the vaccine dosage has not yet been established and 
assuming a vaccine dose of 108 cfu/pig and losses incurred on post freeze dry, the yield 
obtained from a small wave bag would give 500,000 - 1000, 000 doses. 
The diagnosis of H. parasuis depends upon the ability to isolate and differentiate this 
organism from other organisms that may be present in a clinical sample. The fragile nature of 
H. parasuis makes this bacterium difficult to isolate and diagnose. This project also addressed 
the development of molecular tools to differentiate and identify the vaccine candidate from 
its own parent strain as well as closely related species. Multilocus sequence typing based on 
housekeeping genes is a highly discriminative genotyping technique, and was also explored in 
this project to generate a specific profile for H. parasuis Australian isolates following the 
deposition of sequences in the H. parasuis database. This approach was subsequently used to 
understand the evolution of strains and pathogenesis of a set of Australian H. parasuis 
isolates including the vaccine candidate. Cluster analysis softwares such as eBURST was used 
to study the relatedness of each isolate with respect to countries, serotypes and disease. The 
results presented in the thesis report provide a detailed investigation into the genetic 
makeup of housekeeping genes of a group of twenty Australian H. parasuis isolates allowing 
us better to understand the relationship between Australian isolates and global isolates. 
 
  
 
 
 
 
 
CHAPTER 1: 
Literature review 
 
 2 
 
1.1 General Introduction 
Haemophilus parasuis: General Description 
Haemophilus parasuis is a small pleomorphic gram negative, non-motile bacillus of the family 
Pasteurellaceae (belonging to the γ subclass of Proteobacteria class) (Figure 1.1, Figure 1.2). 
Most of the bacteria included in the genus Haemophilus have been described as serious swine 
pathogens causing infectious diseases. H. parasuis is a facultative anaerobe [1]. That is, it can 
make ATP (Adenosine Triphosphate) by aerobic respiration if oxygen is present, but is also 
capable of switching to anaerobic respiration if oxygen is absent. Numerous studies have 
grown H. parasuis at microaerophilic conditions, where a small percentage of oxygen and an 
elevated percentage of CO2 [2, 3]. It can exist as a commensal inhabitant of the upper 
respiratory tract or as an opportunistic pathogen of swine causing fibrinous polyserositis, 
septicaemia and arthritis (Glässer’s disease). The majority of the swine population as early as 
one week of age caries this organism in their nose without any signs of disease [4]. Therefore, 
it is considered as early colonizer of upper respiratory tract of pigs. Early biochemical 
characterization suggested it to be very similar to H. suis which required both factor X 
(hemin, iron-containing porphyrin) and factor V (Nicotinamide adenine dinucleotide, 
coenzyme) for growth [5]. De novo synthesis or recycling of pyridine nucleotide or NAD via 
nicotinic acid or quinolinic acid is not possible for the members of the Pasteurellaceae family 
as they lack pyridine nucleotide salvage pathway. Hence an exogenous source of V-factor or 
pyridine nucleotide is necessary even when it  is grown on complex liquid medium [6]. H. 
parasuis strains traditionally isolated or cultured using a nurse streak of Staphylococus aureus 
on Horse Blood Agar (HBA) plate (Figure 1.2). Biberstein and White subsequently 
demonstrated that H. parasuis required only V factor for in vitro growth and thus added the 
prefix “para” to this organism as it lacks the requirement for X- factor supplementation [7]. 
The phylogeny of members of the family Pasteurellaceae (Figure 1.1) has been studied using 
DNA-DNA hybridization [8], rRNA-DNA hybridization and 16S rRNA sequencing [9]. These 
studies revealed cross-hybridization ability between most of the strains and similarity 
towards A. indolicus. Several typing methods were used to study Pasteurellaceae phylogeny 
which included serotyping, multilocus enzyme electrophoresis, PFGE, AFLP and ERIC-PCR.  
Recently multilocus sequence typing (MLST) based on housekeeping genes and multilocus 
variable number of tandem repeats (MLVA) of putative virulence genes also emerged as a 
means to analyse the phylogenetic relationship of Pasteurellaceae family. Development of a 
MLST database for H. parasuis based on the seven housekeeping genes (atpD, InfB, mdh, rpoB, 
g3pd, 6pgD and frdB) revealed genetic heterogeneity within the species [10].   
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Figure 1.1: Taxonomic position of H. parasuis, an updated neighbour-joining consensus tree 
using 16s rRNA gene sequences [11, 12]. 
 
Figure 1.2 A: Strain showing double morphology growing on chocolate agar, B: 
Staphylococcus nurse streak and H. parasuis satellite growth, C: Gram staining and resulting 
in pink rods (pleomorphic) [11]. 
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1.2 Serotypes of H. parasuis 
According to the proposal of Biberstein and White in 1969 there were nine strains of H. 
parasuis. Kielstein and Rapp-Gabrielson (1992) defined 15 serovars of H. parasuis based on 
heat-stable somatic antigens by immunodiffusion test (KRG scheme). Immune diffusion test 
used was developed using the original proposal of Nicolet and colleagues (1986). The authors 
also demonstrated differences in their virulence with strains ranging from highly virulent to 
non-virulent in pigs. Serovars 1, 5, 10, 12, 13 and 14 have been shown to be highly virulent as 
defined by their ability to cause death or morbidity within four days. Serovars 2, 4 and 15 
have been found to be moderately virulent and serovar 8 mildly virulent while serovar 3, 6, 7, 
9 and 11 have been shown to be avirulent [13]. Protection of pigs from heterologous strains 
of the same serovars were reported when pig was vaccinated with serovar 4 and 5 [14]. 
There were reports from Australia, China, Japan, Germany and Spain about outbreaks from 
serovar 2, 4, 5, 12, 14 and non-typeable H. parasuis disease isolates [15]. Although the 
prevalence of different serovars of H. parasuis can differ depending on the country, the most 
frequently identified serovars are serovar 4, 5 and 13 [16]. As the non-typeable strains 
produce only small amounts of specific antigens, they are unable to detect by the gel diffusion 
test. It is possible that the isolation of non-typeable strains from different farms could 
represent different serovars or groups of serovars. Even though the KRG scheme of 
serotyping was modified using indirect haemagglutination, 15% of strains are still non-
typeable [9, 17, 18]. Non-typeable strains are un-encapsulated strains (NTHi) because they 
lack capsular antigens and different from the encapsulated strains (serotypes). Non-typeable 
strains are now classified generally based on Multi Locus Sequence Typing (MLST) for most 
of the pathogens.  The occurrence of more than one serovars along with non-typeable strains 
was also identified among herds, and this has been confirmed using DNA restriction 
endonuclease analysis (REA) [19]. In contrast to genotyping, serological assays for serotyping 
uses antisera, which has been, raised against antigens from H. parasuis isolates. For the study 
they have used antigens like LPS, outer membrane proteins Omp’s (PalA, Omp2 and D15) 
were used to generate antisera from small animals like rabbits. Serotyping methodology is 
performed with gel diffusion assays (based on raised antigens that are autoclaved) and 
indirect haemagglutination (based antigens kept at room temperature) [20]. Therefore, the 
antigens raises immune response in vitro and correlates with vaccine strategy although actual 
pathogenicity of H. parasuis organism could change in vivo especially when the animal 
exposed to stress factors such as transport, unfavorable environment, herd management or 
practices such as early weaning. Overall, serotyping is now regarded as an expensive 
methodology for differentiation and characterisation of H. parasuis strain as it is not widely 
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available as the reagents are costly to produce [21]. Due to extensive antigenic and genetic 
diversity amongst H. parasuis strains has made the quest for a suitable vaccine has been 
difficult.  
Association of phenotypic characteristics such as encapsulation, whole cell protein profile 
and outer membrane protein profile with virulence among the strains of H. parasuis strains 
were indicated by Kielstein and Rapp-Gaberielson [13]. Differences in phenotypic traits in 
addition to serovar differences in the species allows some strains to become more pathogenic 
or to colonize more effectively during inoculation into Specific Pathogen Free (SPF) pigs. 
Growth can result in the development of a biofilm that allows the bacteria to evade physical 
and chemical assaults. A biofilm is composed of extracellular polysaccharides that adhere to 
either biotic or abiotic surfaces. The study revealed that most serovars of H. parasuis could 
form biofilms in vitro. The phenotype responsible for the biofilm formation is coupled with 
the recovery sites of the strains. It is mentioned that even the non-virulent serovars could 
produce biofilm much higher than the virulent strains [22]. The serovars, except for the 
reference strains 3 and 8 of H. parasuis were shown to form a biofilm at different levels in a 
polystyrene microtitre assay. In a study conducted by Vorachit it was observed that virulent 
isolates have the capability to switch their outer protein profile from biofilm formation to 
another profile needed for the invasion and this competence helps them to enter into the 
lung, brain and other internal organs causing systemic infections [23]. The persistent 
infection might be due to the upper respiratory tract providing a suitable biotic surface for 
biofilm formation. The capsule formation phenomenon in H. parasuis strains is clearly 
illustrated by previous papers though different strains have different chemical composition 
(repeating units of a-galactosyl-aN-acetylglucosamine) [24]. The studies carried out by 
numerous researchers are consistent in that there is an extreme heterogeneity among H. 
parasuis strains and hence difficulty in truly understanding the mechanism behind 
pathogenicity. Therfore, further studies are required to reach a satisfactory conclusion [25].  
 
 
 
 
 
 6 
 
1.3 Glässer’s Disease: Infection of H. parasuis serotypes 
Glässer’s disease is a common bacterial disease among weaning pigs that cause large 
economic lose to the pig industries worldwide. In 1910, Karl Glässer idetifined in young pigs, 
a small gram negative rod as the causative agent for fibrinous serositis and polyarthritis. The 
organism was first isolated in 1943 by Hjarre and Wranmby. The etiologic agent of Glässer’s 
disease is Haemophilus parasuis and was named by Biberstein and White as they found it 
does not require ‘X’ factor for in vitro growth. 
 H. parasuis is commonly isolated from the nasal cavities of apparently healthy pigs and 
sometimes as an etiological agent of Glässer's syndrome (fibrinous polyserositis, arthritis, 
septicaemia), or associated with lung infections. The importance of Glässer’s disease is 
elevated as the swine industry started expanding globally.  Initially, this disease was 
considered as a sporadic occurrence in 1-4 month old pigs when placed under stress [26]. 
However, in 1990 there occurred an increase and the dominance in the severity of this 
disease causing respiratory and systemic syndromes in pigs. A possible reason for the 
outbreaks was considered to be new trends in pig farming that includes medicated early 
weaning (MEW) of piglets and the management of high health status pigs [27]. There are two 
major pig production systems, all in/all out (AIAO) and continuous flow strategy. AIAO 
system allows pigs of same age or size to be housed together in a room. The animals stay 
together until they are moved to the next stage of production. Most growing/finishing swine 
facilities operate a continuous flow barn in which different stages of pigs are housed in 
proximity to one another and the facilities are never empty. Occurrence of Glässer’s is 
globally spreading because of the unusual stresses which comprise sudden changes in the 
environment, prolonged transport introduction to new herds, early weaning or co-infection 
with other bacteria or virus. Since there are a number of diseases that also show similar 
clinical signs and lesions to H. parasuis infection, the diagnosis and pathogenicity studies can 
be difficult. Nevertheless, Glässer’s disease remains a significant disease in modern age-
segregated production systems. Neonatal pigs are often exposed to and colonized by the 
organism early in life. Colostral antibodies usually protect pigs from disease until they 
eventually develop active immunity at 7-8 weeks old. This active immunity protects pigs from 
further exposure. However, young pigs without either passive or active immunity can be 
affected severely when exposed to the organism.  
Vaccines that have mostly been based on inactivated (killed) or autogenous bacterins have 
not curbed the disease to any significant degree [28]. Antimicrobial treatments have been 
utilized as a major weapon for combating this pathogen. However, the significant use of 
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antibiotics has likely contributed to the establishment of antibiotic resistant strains of H. 
parasuis [28]. Compared to few years ago, the percentage of resistance has been increasing 
globally. High frequencies of resistance were been observed in Spain (Table 1.1) [29]. 
Table 1.1: Percentage of antibiotic resistant isolates of H. parasuis from different countries in 
swine population [29]. 
Country 
Percentage of isolates that were resistant 
USA Denmark Spain UK 
Number of isolates 124 52 30 30 
Year 
Antimicrobial 
agent 
1996 
 
2004 2002 - 2004 1995 - 2005 
Amikacin 6 - - - 
Ampicillin 0 0 57 7 
Ceftiofur 2 0 7 0 
Cephalothin 0 - - - 
Erythromycin - 0 40 0 
Fluoroquinolones 0 0 20 0 
Gentamicin 4 - 27 10 
Florfenicol - 0 0 0 
Neomycin - - 33 20 
Penicillin 2 - 60 0 
Spectinomycin - - 23 10 
Tetracycline 15 0 40 7 
Tiamulin - 0 40 3 
Tilmicosin - 0 - - 
Trimethoprim/ 
sulphonamide 
6 4 53 10 
Tylosin - - 40 0 
-, Not tested                   
 1.4 Clinical Signs of Glässer’s Disease 
H. parasuis strains can cause primary as well as secondary infections. Glässer's disease is 
commonly characterized by polyserositis, pericarditis, arthritis and meningitis. H. parasuis is 
frequently isolated from lung tissue, but since the bacterium can also be isolated from the 
upper respiratory tracts of healthy pigs the meninges, pericardium, pleura, peritoneum, and 
joints are better samples for diagnosis of clinical disease [30, 31].  
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Figure 1.3 A: Swelling of tarsal joints in a pig with Glässer’s disease- Chronic lesions causes 
reduction in growth yield and the disease will reveal only at the finishing stage of animals. B: 
Arthritis caused by H. parasuis; on opening the affected joint fibrinous arthritis is usually 
observed [32].  
The manifestation of acute Glässer’s disease in pigs is mostly by rapid depression along with 
an elevated temperature. The pig will lose appetite and it will exhibit reluctance to rise on its 
feet. H. parasuis attacks the smooth surface of the joints, lining of the intestines of intestine, 
lungs, heart and brain. In young growing pigs, meningitis (inflammation of  membranes that 
surround the brain and spinal cord) and middle ear infections are common together with 
pneumonia (severe lung infection), heart sac infection, peritonitis (inflammation of 
membranes that covers abdominal wall and organs) and pleurisy (inflammation of the linings 
of chest and lung walls). H. parasuis also causes individual cases of arthritis and lameness 
with acute pain. However, piglets can be protected through colostral antibodies up to 5 or 6 
week's age.  Sudden death could happen in healthy suckling piglets and its common as a 
result of this disease. Some piglets often develop their own immunity during the suckling 
stage but become subclinical carriers. Post weaning stress can increase the frequency of 
shedding of pathogenic organism subsequently affecting animals that haven not yet 
developed their own active immunity [33]. In chronic cases weaned piglets suffering from 
Glässer’s are often pale and poor growing. H. parasuis is carried in the tonsils and 
nasopharynx of most healthy adult pigs, and piglets are usually infected from their mother 
within a few days of birth. If these piglets also consume protective colostral antibodies, then 
many piglets may develop subclinical infections and acquire protective immunity. However, 
in situations where piglets consume insufficient colostral antibody or where piglets are 
mixed post weaning with piglets derived from other farm sources that have a different strain 
of H. parasuis, then those piglets will lack protective maternal antibody and may develop 
clinical signs of Glässer’s disease. In endemic herds, clinical signs will, therefore, usually 
include septicaemia and respiratory signs approximately 2 weeks after weaning [34, 35]. 
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Figure 1.4 A: Petechie in the kidney (purple or red spots caused by broken capillary blood 
vessels leading to kidney failure) caused by H. parasuis in a case of sudden death. B: Pig with 
Glässer’s disease. Obvious presence of fibrin in the peritoneal cavity (fibrinous peritonitis) 
and pericardiac cavity (fibrinous pericarditis) [32]. 
H. parasuis can be a primary pathogen or it can be associated with other diseases such as 
porcine reproductive and respiratory syndrome virus (PRRSV) or swine influenza virus (SIV), 
Pseudorabies virus and Porcine circovirus PCV-2 [34, 36]. The clinical signs of H. parasuis are 
often similar to clinical signs as a secondary pathogen or opportunistic to other bacterial 
infections such as Streptococcus suis, Escherichia coli and Mycoplasma hyorhinis. Most 
frequently, H. parasuis in combination with Streptococus suis infection causes 
septicaemia. Diagnostic confirmation of disease is essential in order to implement correct 
therapeutic action. Maternal and natural immunity is important in the prevention of H. 
parasuis infection. It is useful to identify the most prevalent serovars in a given area in order 
to effectively control Glässer's disease [37].  
 
Figure 1.5:  Yellowish fluid in case of fibrinous exudation; abdominal cavity of a pig with 
Glässer’s disease [32]. 
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1.5 Pathogenesis of H. parasuis 
Infectivity of an organism depends upon how fast the organism can colonize inside pigs [38], 
Colonisation can happen in weaning pigs by different microorganisms. Early studies 
charactrised H. parasuis, Streptococcus suis and A. suis as early colonizing agents in the pig 
industry [39]. The diagnosis of this disease became a challenge because of early colonization 
of H. parasuis in the nasal cavity and tonsils of piglets [13]. Immunoglobulin (IgA) protease 
activity is essential for the defense mechanism of mucosal immunity in the host. H. parasuis 
strains have the ability to cleave swine IgA and thus it explains how it can evade mucosal host 
defense mechanisms and spread systemically [40]. Ability of this organism to colonize in the 
upper respiratory tract of porcine without causing disease often masks the actual diagnosis of 
H. parasuis disease [41]. Often morethan one serotypes of H. parasuis can be isolated from a 
single pig. The isolation of heterogeneous strains along with non-typeable strains limits the 
usefulness of serotyping [42]. Isolation of H. parasuis strain swabs from nasal, tonsillar area 
and other respiratory sites such as the trachea has been used for isolation and identification 
[35, 43, 44]. As previously discussed in Section 1.1, there have been a number of studies 
carried out to find out the mystery behind pathogenesis or virulence of H. parasuis of diferent 
strains.  
However, there are still no conclusions regarding the virulence of specific serotypes. As 
previously mentioned, the 15 serotypes are assigned to highly virulent, moderately virulent, 
mildly virulent and avirulent based on the severity in causing clinical disease or death in pigs. 
Disagreement in the classification still exists as virulence or pattern of disease changes 
according to environmental conditions, heterogeneity of serovar and strains; difference in 
host mechanism including genetics, presence of another organism or even route of infection. 
All of these factors contribute to the discrepancy observed in the pathogenicity of H. parasuis 
strains [39]. There are cases where intraperitoneal inoculation of serovar 4 in SPF pigs 
caused mild virulence causing systemic infection but when inoculated intranasally it did not 
cause disease but rather offered protection through the respiratory defence mechanism when 
tested in SPF pigs of 13 weeks of age. In the same study, the Nagasaki strain developed 
systemic infections (pyrexia and nervous disorders) when inoculated intranasally. The 
inoculation of higher dose (1010 cfu of serovar 4) when administered intranasally caused 
sudden death in SPF pigs. Hence it  was not clear whether or not the strain could offer 
protection [44, 45]. More than likely, the previously used lower dose of the strain offered a 
controlled exposure whereas the higher dose just leaded to disease. 
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Major research has focused on the association of fimbriae, lipopolysaccharide (LPS), capsule 
expression, transferrin-binding proteins [46], neuraminidase (sialidase) activity [47], TolC, 
disulfide interchange protein precursor DsbA and DsbC and auto transporter adhesins, 
trimeric auto transporters [48], whole cell protein profiles and outer membrane proteins 
(OMP) [49] with the colonization of the upper respiratory tract. OMP family of proteins can 
function as a virulence factor causing adhesion, invasion, or assist in evasion of host defence’s 
subsequently causing clinical disease or death [50]. Similarity between OMP and DNA profiles 
has been observed in systemic H. parasuis strains established the importance of building up 
an OMP profile of strains isolated from different organs [25]. The pre-condition of infections 
is often described as the attachment of fimbriae by the help of adhesions to the surface of 
epithelial cells [51]. During the genome characterization of serotype 5 it has been identified 
that four pilABCD genes (mediating bacterial adherence) are responsible for the coding of 
type IV fimbriae in H. parasuis strain and the protein expressed showed identity (CDSs share 
68%, 68%, 50% and 44%) with the ApfABCD proteins of A. pleuropneumoniae [52, 53]. It has 
been studied that both avirulent and virulent strain expresses capsular material, and the 
expression acts as a phagocytosis resistance mechanism of virulence. Bacterial enzyme 
neuraminidase, whose substrate is sialic acid, was also studied in the past for virulence [54]. 
A recent study on hhdBA gene (putative haemolysin gene operon) indicated that the presence 
of hhdA gene from field isolate can be a potential virulence factor [4]. Although there have 
been an enormous number of studies, no research study has been turned out with a 
convincing conclusion. Possibly, it may be that virulence factors responsible for causing the 
disease might be expressed during the natural course of infection and cannot be suitably 
replicated in vitro conditions. 
1.6 Treatments for H. parasuis- Glässer’s disease 
1.6.1 Antibiotics as lifesavers for swine population during Glässer’s 
outbreak 
Antibiotics have been used as a lifesaving invention for both human and animal diseases. 
However, the unforeseen capabilities of microorganisms to mutate or to interchange genes 
have led to the increase of multi-drug resistant bacteria. It has been a worldwide concern for 
the treatment failures against many animals and human pathogens [55]. In animal 
husbandry, antibiotics are used either for direct treatment of an existing infection or as 
prophylactic use for the prevention of disease. Low levels of antibiotics such as Avoparcin, 
Virginamycin, Tylosin, and Bacitracin are registered in Australia as a growth promoting 
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antimicrobial agents for pigs, chicken and cattle. Figure 1.6 signifies the danger of extensive 
use of antimicrobials. Different bacterial species or genera developed a wide variety of 
antibiotic resistance in a short time of period from the period of discovery to occurrence of 
resistant bacteria. The extensive use led the bacteria to rapidly alter environmental 
conditions or adapt a variety of escape mechanism from the inhibitory action of 
antimicrobials that include transfer of horizontal mobile genetic elements carrying one or 
more resistance genes [56]. The subsequent transfer of selected resistant bacteria from 
animals to humans through the food chain by a simple process called horizontal transfer has 
been well understood thorough decades especially pertaining to zoonotic pathogens such as 
Salmonella [57]. Likewise, the transfer can also occur from human to animals by either skin 
contact or consumption (meat and egg products). The significant additional cost is required 
to manage the resistant bacteria in humans and animals, and this increase in cost is now 
directly proportional to rates of resistance [57].  
H. parasuis antimicrobial susceptibility test has been performed using disk diffusion 
technique on a range of drugs as shown in Table 1.2 & Figure 1.7. The study has shown 
resistance genes to antibiotics that have been commonly used in swine herds in China [58]. 
The study suggested genotypic methods provide more information on antibiotic resistance. 
Tet B and Beta-lactam resistance gene has been seen in H. parasuis outbreak [59, 60]. 
However, the isolates from Czech Republic and Switzerland showed a low percentage of 
resistance towards tetracycline, but very high percentage of resistance towards erythromycin 
(84%) [33]. Most of the drugs showed susceptibility towards Danish H. parasuis isolates in 
2004, even though they showed decreased susceptibility towards fluoroquinolone and 
ciprofloxacin. Several multi resistances in bacteria were found in Spanish isolates following a 
study where Spanish and thirty isolates of H. parasuis (British) were tested against 19 
different antibiotics compared for antimicrobial susceptibility. It was found that most of the 
antimicrobials were Spanish isolates were susceptible [61]. As seen from Table 1.2 and 
Figure 1.7, the occurrence of antimicrobial resistance contrasts significantly between 
countries and even regions and individual herds. A continuous surveillance of antimicrobial 
resistance of clinical isolates is mandatory to guide veterinarians to prescribe antibiotics for a 
particular outbreak in the swine population. A conservative and specific approach should be 
implemented to minimize the escalating use of antibiotics for prevention or control of disease 
and growth. There is no alternative to escape or avoid resistance development in pathogens 
but it is possible to greatly reduce the development and spread of resistance properties by 
choosing more effective preventive measures such as proper animal handling practices and 
importantly an intelligent vaccination program. 
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Figure 1.6: Flowchart depicting the transfer of antibiotic resistant gene from food/pet 
animals to humans [57]. 
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Table 1.2: Distribution of serovars and antimicrobial resistance of Chinese H. parasuis 
isolates; Antimicrobial test was performed by agar dilution, Antimicrobial resistance was 
detected in each serovar included in this study [62]. 
Antimicrobial Serovar Total 
 
1 2 3 4 5 7 8 9 10 12 13 14 15 NTa  
4b 2b 1b 16b 29b 1b 1b 1b 2b 10b 12b 2b 1b 28b 110b 
Ampicillin    2 3     1 1   3 10 
Cefaclor    1 4      1   3 9 
Ciprofloxacin    3 8     2 1   5 19 
Enrofloxacin 2 1  11 24 1   1 8 8 2  20 78 
Erythromycin         1   1   2 
Gentamicin    4 1   1      1 7 
Levofloxacin     5     1    1 7 
Penicillin    2 1      1   3 7 
Spectinomycin     6     1  1  3 11 
Tetracycline    2          2 4 
Trimethoprim/s
ulphamethoxazol
e 
2 1 1 8 12  1  1 3 6 2 1 11 49 
Tiamulin     1          1 
Total 4 2 1 33 65 1 1 1 3 16 18 6 1 52 204 
a NT, non-typeable. 
b Number of isolates. 
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Figure 1.7: Antimicrobial susceptibility and resistance study done with H. parasuis isolates at 
the University of Minnesota Veterinary diagnostic laboratory.  
1.6.2 Technological breakthrough in Vaccines  
The development of vaccines is considered to be one of the major medical achievements to 
mankind. Small pox vaccine was firstly implemented more than 200 years ago and today the 
technologies responsible for many success stories in saving both human and animal lives. The 
tactics of attenuation or inactivation of an infectious microorganism was first developed in 
Louis Pasteur’s laboratory and continue to be used even today in vaccine development 
(Figure 1.8). 
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Figure 1.8: Representation of vaccine development stages from Pasteur’s principle [63]. 
“Vaccines licensed so far have all been developed by following Pasteur’s principles: “isolate, 
inactivate and inject” the causative microorganism. This led to the development of killed, live 
attenuated and subunit vaccines. Recent technological breakthroughs have amplified the 
potential of the vaccines developed by Pasteur’s principles by making it easier to 
manufacture structures mimicking killed viral vaccines (virus-like particles or VLPs) by 
engineering replicating and non-replicating recombinant vectors that mimic live vaccines and 
by providing new forms of subunit vaccine such as conjugate and recombinant vaccines." 
Vaccine technology has been advanced with approaches comprising mostly of killed or live 
attenuated microorganisms, partially purified components of an organism, detoxified toxins 
or polysaccharides. Many modern technologies have emerged from genetic engineering such 
as recombinant DNA technology, synthetic peptides, structural vaccinology, reverse 
vaccinology and glycoconjugation [64]. To supplement the effectiveness of vaccines there 
have also been significant efforts made towards the development novel adjuvants with 
immunostimulatory properties that stimulate B and/or T-cell responses for developing on 
adaptive immune response (Figure 1.9). Cytokines such as granulocyte/macrophage colony-
stimulatory factor, interleukin IL-2 are also used as effective adjuvants to enhance the 
immune response. 
 17 
 
 
Figure 1.9: Diagrammatic representation of developing adaptive immune response in pig 
after vaccination; it is specific for each pathogen. Vaccines enhanced by adjuvants help 
antigen presenting cells (APC) to ingest and to produce more cytokines and will be 
“remembered” (memory), so the animal’s resistance to disease will be increased [65]. 
1.6.3 Veterinary vaccines 
Since vaccination aims to mimic the development of naturally acquired immunity, the 
technology in development of a vaccine against infectious disease is essentially the same for 
human and animal vaccines. The studies on cowpox virus and human small pox virus 
illustrated that there is a close relationship between human and animal infection [65]. 
Vaccines, however, can be designed to fulfill different criteria. For example, companion 
animals and human vaccines are concerned for better health and welfare whereas vaccines 
for livestock may be to not only improve health and welfare but to increase yield and hence 
add cost benefit for the industry. Continuous emergence of drug resistant bacteria (Section 
1.6.1) and the rise of new disease have expanded the global market for vaccines within 
animal health to approximately 23%.  
Vaccination platforms require the successful release of antigenic proteins from pathogens to 
the specific compartments of the host immune system to allow the presentation of antigens in 
an optimal form [66]. Following vaccination, the innate and adaptive immune systems are 
activated within the host by the help of APC’s such as phagocytic cells [macrophages, 
monocytes/dendritic cells]. The mucosal immune system offers the major immune defense 
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barrier for more than 90% of potential pathogens. The mature T-cells and B-cells in the 
mucosal lymphoid tissues have been stimulated by antigen and then B cells divides into 
plasma cells and releases IgA molecules which can be found in most of the mucosal surfaces 
throughout the body (common immunity). Macrophages derived from monocytes are 
stationed throughout the tissues and organs of the body and many of them are a part of 
mononuclear phagocytic system. Important tasks of macrophage include (1) killing of foreign 
matters such as microbes, infected cells, tumor cells (innate immune response), (2) 
Processing of antigens from pathogens via T–lymphocytes (adaptive immune response Figure 
1.9), (3) nonspecific body defenses by secreting inflammatory responses as cytokines. 
Systemic infection can be caused by pathogens as Salmonella species, when it can survive and 
replicate within the host macrophage [67, 68]. During an infection, macrophages reacts by 
secreting cytokines such as tumour necrosis factor (TNF) a, interleukin (IL)-1, IL-6, IL-10, IL-
12 and chemokines such as macrophage inflammatory protein (MIP)-1 and MIP-2. 
The prevention of disease needs both innate and acquired immunity in flocks or herds. Innate 
immune responses include phagocytic cells, cells that release inflammatory mediators, 
natural killer cells, cytokines and some molecules as complement proteins. Dendritic cells 
(DC) are the most essential cells responsible for the initiation of primary T-cell responses and 
activation of naive T-cells [69, 70]. Macrophages are efficient in engulfing, and killing of 
bacteria whereas DC’s specialize in antigen presentation [71]. APC’s processes and presents 
part of foreign antigens on the surface uses MHC or CD1 molecules. Disease resistance 
mechanism of an individual utilizes antigen presenting structures called the major 
histocompatibility complex (MHC) molecules, MHC class I for direct presentation and class II 
mostly for indirect presentation [72]. Killed antigens mostly activate B cells using Th1 and 
Th2 cells, Th1 cells releases IFNγ which induces B cells to produce opsonizing antibodies 
(cellular response) and Th 2 cells releases interleukins (IL4, 5, 13) and it induces B cells to 
produce neutralizing antibodies against that particular antigen (humoral response) (Figure 
1.10 and Figure 1.11). 
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Figure 1.10: Representation of the immune mechanism triggered by vaccination that 
protects animals from pathogens [73]. 
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Figure 1.11: Schematic representation of success of vaccines [74]. 
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The significant components of potent vaccines will generate (1) adaptive immune responses 
against antigens, (2) effective signals from the immune system or from adjuvant to signal the 
innate immune system to produce specific antigen response, (3) delivery system that ensures 
the antigen and adjuvant are transported together and to the correct location to raise 
sufficient immune response [75]. Natural invasiveness can be the best delivery method to 
mimic the natural immunity response from a pathogen. Therefore, live attenuated vaccines 
may offer the best approach as it contains all the above components. Advantage of live 
attenuated vaccine includes the ability to produce limited infection in their host adequate to 
induce an immune response but not to cause disease. Live vaccines also stimulates better cell 
mediated immunity. It is also important that the vaccination be administrated at the correct 
time to ensure that the host is protected from disease prior to natural exposure. Furthermore, 
timing may need to be considered to avoid possible interference of maternal antibody. 
1.7 Previous studies on H. parasuis vaccine development 
Numerous studies have been conducted to identify the protective immunogens for the 
development of a successful vaccine. Traditionally outbreaks of Glässer’s disease in farms 
have been managed by treatments based on killed bacteria. Killed or inactivated vaccines are 
developed by inactivating the pathogen by heat or chemical treatment and hence eliminating 
the organism’s ability to replicate inside the host. This type of vaccine keeps the pathogen 
intact and it often consists on whole cell or pathogen components or by-products so that the 
immune system can recognize it. Killed vaccines of H. parasuis are often safe and but they 
offer only homologous protection (same strain, isolate or serovars). Subunit and toxoid 
vaccines also developed for Glässer’s disease offering homologous protection. For example, 
vaccine comprising outer membrane proteins (OMP’s) of H. parasuis (produced under iron 
restricted condition) and other native proteins have been reported as effective subunit 
vaccine to control Glässer’s caused by serovars 5 (Nagasaki strain) [76]. It is important to 
note that the treatments used to inactivate an organism can also affect the native stage of the 
antigen making it less immunogenic. There were a number of vaccine candidates with outer 
membrane proteins such as Wza, Omp2, Omp5, D15 and PalA, whole cell-HPS 06257, genes-
OmpA, virulence-associated trimeric autotransporters (VtaA) and tbp which also claim 
protection and immune responses against only homologous strains or serotypes of H. 
parasuis or the bacteria present in the respective vaccines [77]. VtaA genes were identified as 
good candidates to improve vaccine efficiency as they are late antigens when related to initial 
(Omp P5 and Omp P6) antigens [78]. 
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Autogenous vaccines (live/killed) are comprised of disease producing bacteria or virus 
isolated from the affected farm for farm specific strain protection.  Selection of H. parasuis 
strain for autogenous vaccine is challenging as the animal may have more than one strain, 
and it is suggested that an isolate obtained from brain (CNS) of the affected animal be a better 
selection for the preparation of autogenous vaccine compared to other isolates from joints, 
lungs [79]. Autogenous vaccines usually fail when a new animals are introduced carrying a 
different or new strain of H. parauis. However, when a new killed vaccine is prepared using 
the new dominant strain of H parasuis from the field, there is a possibility for the efficacy of 
vaccination to return.  
Phenotypic markers such as OMP, LPS, and capsular polysaccharides have been analysed by 
immunoblot assay, and it was found that the presence of antibodies against OMP was 
associated with protection against challenge but not LPS and capsular polysaccharide [37]. 
Cross protective immunity of serovar 2 and 5 has been studied in field trials in Japan with 
monovalent and bivalent bacterin vaccine (inactivated). Monovalent vaccine (serotype 2 or 
serotype 5) showed homologous protection and a bivalent vaccine (serotype 2 and serotype 
5) showed protection against both serotype 2 & 5. However, when the vaccinated pigs were 
mixed with a herd infected with a serotype 1 and 2 non-typeable, 9% of the pigs developed 
infection resulting in death. Serovars 1 (highly virulent) and 2 were isolated from the infected 
pigs but not serotype 4.  Since the study was not offering protection against heterologous 
strain (serovars 1 and non-typeable strain), researchers speculated the nasal infection of a 
live H. parasuis strain would be more likely to induce antibodies for common antigens of H. 
parasuis strains resulting in a better cross protection than bacterin vaccine administered via 
intramuscular or intratracheal injection [80].  
In 1997, Pijoan described the use of low dose live virulent three different strains of H. 
parasuis as an alternative method to control nursery mortality in farms [38]. Although there 
was a good percentage of protection, there were still concerns regarding the safety of using 
low dose live non-attenuated vaccines. In an evaluation study Oliveira stated that the lack of 
cross protection might be due to timing of vaccination or due to interference of maternally 
derived immunity [25]. She also demonstrated that the nursery mortality can be reduced by 
the implementation of low dose live virulent H. parasuis rather than autogenous or 
commercial vaccines. Choice of strains and serovars used in a controlled exposure 
vaccination regime is of significance importance, as a choice of highly virulent serovars may 
cause disease even at low doses. 
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Table 1.3: List of vaccines against Glässer’s disease available on Global market. 
1.7.1 Live attenuated vaccines for Glässer’s disease 
Researchers have developed a number of inactivated vaccine candidates, which offer partial 
protection that results in a reduction in mortality but not morbidity. It might be due to the 
incomplete expression of potential virulence factors as the vaccine strain is grown in the 
laboratory (in vitro) conditions. Growth in natural environments (in vivo) may trigger a 
different array of or levels of immunogenic antigens evoking a stronger cell-mediated and 
Product name Manufacturer Type of vaccine 
Glassinord® 
Intervet, Netherlands, 
1987 
Autogenous bacterin of whole cell - formalin killed 
H. parasuis 
Parapac® 
Schering-plough, 
Intervet/Merck 
Animal Health 
Chemically - inactivated cultures of H. parasuis. 
AR-Parapac+ER 
Intervet/Schering-
Plough Animal Health 
Chemically-inactivated cultures of H. parasuis, 
B.bronchiseptica, P. multocida Types A and D 
and E.rhusiopathiae, and chemically-inactivated 
toxin common to P.multocida Types A and D. 
Suvaxyn® HPS 
 
Fort Dodge Australia 
Pty 
H. parasuis serovars 4 and 5. 
Suvaxyn® MH/HPS 
 
Fort Dodge Australia 
Pty 
Bacterin, Combination vaccine for H. parasuis sv-
4&5, Mycoplasma Hyopneumoniae 
Hiprasuis® Glässer 
Laboratorios Hipra 
s.a., Spania 
Inactivated H. parasuis serotype 1 & 6 
Toxivac® Plus 
Parasuis 
BoehringerIngelheim 
A bacterin toxoid containing cell free and non-
toxic antigens of Pasteurella multocida as well as 
inactivated cultures 
of Bordetellabronchiseptica, Erysipelothrix 
rhusiopathiae and H.  parasuis 
Ingelvac-HP1,HPE1 
BoehringerIngelheim 
US 
H. parasuis Bacterin 
ParapleuroShield®P 
Grand laboratories, 
inc. USA 
Bacterin contains inactivated cultures of A. 
pleuropneumoniae serotypes 1, 5, and 7, H. 
parasuis and Pasteurella multocida Type A 
adjuvanted with Aluminum hydroxide 
Myco Silencer® 
MEH 
Intervet, US 2001 
Inactivated cultures of Erysipelothrix 
rhusiopathiae, 2 strains of H. parasuis and 
Mycoplasma hyopneumoniae in the patented 
Diluvac® Forte Adjuvant 
PorcilisGlasser-
suspended in Diluvac 
Forte® 
Intervet, fully 
registered vaccine 
from UK 
Inactivated whole bacterial cells of H. 
parasuis serotype 5 
ParaSail® Newport Laboratories 
Live attenuated strain of serotype 5 for serotype 4, 
5 & 13 of H. parasuis 
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antibody-mediated response and possibly offering a life-long immunity after one or two 
doses. Live attenuated strains will have the ability to take the natural route of infection 
(invasion and adhesion), without causing disease due to being debilitated. Modern molecular 
techniques allow one to knockout or partially delete a gene thereby creating an attenuated 
version of virulent parent strain. Reversion to virulence or the reacquisition of functional 
virulence genes from the wild strain or other bacteria in their microenvironment is still a 
possibility, although a remote one depending on the type of attenuation selected. Attenuation 
should ensure safety in terms of reverting to the disease state. By the same token, efficacy 
must not be compromised by over attenuating the organism. Hence, a balance between safety 
and efficacy must be achieved. 
A live attenuated commercial vaccine - “Parasail” was registered in 2010. The vaccine 
comprises attenuated serotype 5 (chemical mutagenesis) and has been shown to provide 
cross protection to serotype 4 and 13 (Table 1.4). It is administered intraperitoneally and the 
vaccine is only registered in US and not  Australia. Therefore, a live attenuated strain of H. 
parasuis has the potential to offer cross protection by careful design of vaccine and delivery 
method [81]. 
An attenuated vaccine strains should preferably maintain the ability to replicate, at least to 
some extent, within the host cells to allow for processing and presentation of pathogenic 
antigens thereby stimulating the production of cytokines to evoke an immune response. If the 
antigens are expressed or available exogenously, they are likely to follow a class II pathway, 
whereas if they are expressed endogenously the antigens may be directed to the class I 
pathway [82]. There are a number of live attenuated bacterial strains constructed 
successfully by disrupting genes responsible for biochemical pathways or specific virulent 
genes that has been studied. The genes commonly used to attenuate strains in the previous 
studies are tabulated below (Table 1.4). 
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Table 1.4: Proof of successful attenuation with different genes from the literature. 
Genes 
targeted for 
attenuation 
Species Responsible 
function of 
gene 
Attenuating
? 
Protecting
? 
Reference 
aroA 
 
Salmonella Typhimurium, 
Salmonella typhi, 
Shigella flexneri, 
Bordetella pertussis 
 
Aromatic 
amino acid 
biosynthetic 
enzymes 
y y [83-87]  
icsA Shigella flexneri Intracellular 
spreading 
factors 
y y [88] 
iuc Shigella flexneri Siderophores y y [88] 
guaB-A-virG Salmonella typhi Guanine 
nucleotide 
biosynthetic 
enzymes 
y y [89] 
Cya-crp Salmonella choleraesuis Adenylate 
cyclase and 
cAMP 
y y [90] 
thy Shigella flexneri Thymine 
biosynthetic 
enzymes 
y y [91] 
Oma 87 Pasteurella multocida Outer 
membrane 
antigen 
Y Y [92] 
ribGHAB A. pleuropneumoniae Riboflavin 
biosynthetic 
operon 
Y Y [93] 
Since the virulence-associated genes are not well identified for H. parasuis, it would be 
reasonable to consider an approach that has been effective for other species. The aroA 
deletion approach has been successfully used for Salmonella Typhimurium and (more 
recently) with Pasteurella multocida (PM). The aroA versions of these organisms are both 
available as registered vaccines as Vaxsafe® ST and Vaxsafe® PM, respectively. 
The aroA gene codes for the enzyme 5-enolpyruvyl-shikimate-3-phosphate (EPSP) synthase, 
which is purely responsible for aromatic biosynthetic pathway (Section 3.2 & Figure 1.12). 
Deletion in the aroA region of bacteria enables only limited replication of bacteria inside a 
host as it fails to synthesis the metabolites (aromatic amino acids) necessary for growth. 
Auxotrophic aroA mutants require a supply of aromatic amino acids from the host to 
replicate in vivo, but the supply inside the host is limited [92]. As the supply of limited 
metabolites (aroA mutant’s dependence on aromatic compounds, including aromatic amino 
acids, p-amino benzoic acid, and 2, 4-dihydroxybenzoate, for growth) ceases in the particular 
vertebrate tissue, the vaccine strains will be unable to multiply to any significant degree, but 
enough to evoke lasting immune responses for immunity against particular pathogens. 
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Figure 1.12: Shikimate Pathway representing the role aroA gene [92, 94].  
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1.8 Fermentation technology: Small-scale fermentation for 
optimization study 
Fermentation technology has been in use for centuries mainly for the production of alcohol in 
the olden days. More recently during the Second World War (1940), fermentation has been 
used for the production of antibiotics (by submerged culture of selected strains of 
filamentous bacteria and fungi). Development of new products instigated changes to 
fermentation technology and thus bioprocesses operations leading to the invention of 
different types of fermenters are now being used in the biotechnology world. For initial 
research studies, small-scale equipment is preferred over production size equipment.. Initial 
studies are generally conducted in closed systems such as falcon tubes or Schott bottles, 
bioreactors used for small-scale studies (scaling up from Schott bottles) should have 
minimum capabilities for, monitoring and controlling various parameters including pH, DO2, 
CO2 and temperature control [95]. Agitation is also another important feature to maintain the 
oxygen level inside the fermentor. 
Fermentation can be influenced by several factors that include physical parameters (pH, DO2, 
CO2, Temp., agitation speed (rpm), inoculum size) chemical parameters (medium 
composition), mode of operation (batch, fed-batch. continuous). Hence it is essential to 
optimize the parameters at a small-scale prior to scaling up to commercial or industrial scale 
[95]. 
Bacterial fermentation process operates mainly in three different modes: batch process, fed-
batch and continuous process, of which batch process is mostly commonly used. In order to 
develop or optimize a fermentation process, it is essential to decide which mode of operation 
is most suitable for the product. In batch process, a closed sterile system (shake flask, 
bioreactor, and disposable bags) containing sterile medium with all the nutrients required for 
the organism is added prior to the inoculation of the desired organism (starter culture). The 
process is terminated when the desired level of microbial growth has been achieved after a 
fixed period or the concentration of desired metabolite has been achieved [96]. Optical 
density values or plate counts could be used as an indicator for the growth. Counts at each 
time interval can be used to plot the live bacterial growth curve (Figure 1.13). Different 
phases obtained from the growth curve are a good indicator for when to terminate the 
fermentation process. It is also used to study and optimize the process further. 
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Figure 1.13: Growth curve of microorganism in batch culture [96]. 
1) Lag phase (phase which organism tries to adapt to the new environment) 
2) Transient acceleration phase (starts cell division and multiply) 
3) Exponential phase (log phase) (organism multiplies rapidly) 
4) Deceleration (organism slowly stops multiplication due to nutrient depletion) 
5) Stationary phase (cell division stops and no growth) 
6) Death Phase (organism starts to die; reduction cell numbers) 
Fed batch system is like a batch system in that it starts as batch process but at particular time 
points certain nutrients/substrates or inducers are added to the system to enhance the 
microbial mass or production of a particular product in the medium. The feeding strategy can 
be short or long period according to the nature of desired production. Different feeding 
strategies are used in fed batch system, which includes the addition of fresh nutrients, 
removal of culture at a fixed point of time, and or the addition of nutrients at a fixed point and 
it continues till it reaches a final volume. Continuous cultivation is not commonly used in 
early stage research but more likely used in industrial manufacturing. In this mode, a fresh 
supply of medium is added at the same rate that spent medium and cells are removed. This 
kind of cultivation prolongs the exponential phase of an organism in batch culture 
maintaining the culture volume, cell number, product and substrate concentrations, as well as 
the physical parameters [96]. Batch operation is safer compared to other operations in terms 
of risks from contamination. 
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Figure 1.14: Upstream operation in fermentation [97]; Success of fermentation relies on 
several factors that involved in upstream operation; careful designing and optimisation of 
parameters involved in fermentation leads to much easier and economical pathway for large-
scale production. 
Pilot scale study of optimization includes shake flask, Schott bottles, glass fermenters, 
stainless steel fermenters, bioreactor bags. The growth curve for H. parasuis was first 
demonstrated using Tryptone Yeast Extract (TYE) in a small volume (10 mL broth) [98]. It 
was shown that the wild strain could undergo twelve doublings before reaching stationary 
phase. Using TYE medium, an increase in endotoxin level was observed during stationary 
phase. Because of the lack of published material or available information regarding H. 
parasuis mass production using fermenters, it is critical to examine the requirements of H. 
parasuis for obtaining high titre using regulatory compliant and relatively inexpensive raw 
materials in liquid broth. 
1.9 Diagnostics specific to H. parasuis 
Correct diagnosis of the causative agent is crucial for developing control measures against H. 
parasuis infections as the clinical signs are very much similar to other infections caused by S. 
suis and A. pleuropneumoniae. Development in diagnosis of H. parasuis entirely depends upon 
the ability to isolate and differentiate this organism from the clinical samples. The fragile 
nature of H. parasuis makes diagnosis difficult in the field. When infected pigs are pre-
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medicated with antibiotics, it becomes even more difficult to isolate and in such cases 
immunohistochemistry of tissues can allow detection of H. parasuis antigens in tissues [43]. 
 For the diagnosis of field samples of H. parasuis there are five commonly techniques that 
include bacterial isolation, antimicrobial susceptibility testing, serotyping, detection by PCR 
and genotyping [58]. In which diagnostics are combined with above techniques that include 
immunohistochemistry (IHC) of tissues from clinical samples [43], oligonucleotide specific 
capture plate hybridization (OSCPH) assay [99], in situ hybridization [100]. In addition, 
several molecular methods restriction endonuclease fingerprinting [19]; multilocus enzyme 
electrophoresis [42], ERIC-enterobacterial repetitive intergenic consensus-PCR [101], and 
outer-membrane protein profiling [102] have also been developed for typing H. parasuis. 
1.9.1 Laboratory Diagnosis 
The diagnosis of H. parasuis infection often begins on the farm with close observation and or 
identification of clinical symptoms (Section 1.4). Laboratory diagnosis is always done after 
clinical diagnosis and it is based on herd history, clinical symptoms and necropsy along with 
bacterial isolation and identification. The selection of the sampling site is also important for 
an accurate diagnosis and characterization of this organism. For example, body ﬂuids from 
cases of a fibrinous polyserositis, including cerebrospinal ﬂuid are commonly used as 
samples for isolation [38, 103] (Figure 1.4 and Figure 1.5). As H. parasuis is regarded as a 
commensal organism and early colonizer of upper respiratory organs, sampling from lung 
isolates often misinterprets the actual diagnostics as this organism can invade the lung post-
mortem [30, 31]. As this organism can be easily overgrown by other bacteria, it can quickly 
become non-viable in clinical samples [104]. Amies media has been preferred over Stuart 
medium for transportation of samples (swabs) from the field to the laboratory contained at 4 
°C [17]. H. parasuis is very sensitive to temperature and physiological saline and Phosphate 
Buffered Saline (PBS). Detection level of H. parasuis was better at 5 °C compared to that the 
organism was undetectable at 42 °C (within one hour), at 37 °C (within 2 hours), and at 25 °C 
(within 8 hours) [105]. 
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Figure 1.15: Body fluids from H. parasuis infected sites (fibrinous exudate) of pig for 
diagnosis in the field; A: Sampling fibrinous exudate on the peritoneum using a sterile swab 
(ﬁeld case); B: Collecting peritoneal ﬂuid using a sterile syringe (ﬁeld case) [15]. 
From the first isolation of H. parasuis  till today S. aureus has been used as the nursing colony 
(Figure 1.2 B) to support the isolation of H. parasuis from the lesions of infected pigs [10]. In 
the laboratory H. parasuis is cultured on to enriched chocolate agar plates with a 
Staphylococcus aureus feeder streak as a source of V factor. H. parasuis takes 1 to 3 days to 
produce small brown to grey colonies on chocolate agar plates. Biochemical tests were 
performed normally with liquid culture PPLO both supplemented with NAD [10]. Since A. 
pleuropneumoniae can colonize in the same tissues of the swine as H. parasuis, it is important 
to differentiate between the two species. This can be done by conducting indole, catalase and 
urease biochemical tests as described in Table 1.5. 
For effective diagnosis, it is important to isolate H. parasuis from the site of infection such as a 
respiratory tract, pneumonic lungs or systemic lesions. Identification must include the 
differentiation of this organism from the related group of bacteria such as A. minor, A. 
indolicus and A. porcinus. The differentiation can be achieved by biochemical tests indole 
production, urease activity and catalase activity (Table 1.5). 
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Table 1.5: Shows differential characteristics of H. parasuis under biochemical tests [10]. 
 
1.9.2 Conventional PCR 
Limitation of bacteriological diagnosis such as prolonged incubation time, misclassifications 
of H. parasuis from biochemical studies [106, 107], difficulty due to its fastidious growth and 
uncharacteristic appearance led to the development of genetically based methodology.  Rapid 
confirmation of H. parasuis species is possible by direct analysis of fresh clinical material for 
viable or non-viable H. parasuis cells by PCR. Before the introduction of PCR, oligonucleotide 
specific capture plate hybridization (OSCPH) assay was extensively used, and the detection 
level was <102 cfu/mL (in pure culture). However, it showed cross-reaction with A. 
indolicus isolates. Since this methodology can be used only with pure culture, it was not 
always possible for pure isolation of H. parasuis from field, hence PCR diagnosis assays were 
developed. PCR methodology targeted 16s RNA following taxonomic and phylogenic analysis 
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[108]. When compared to traditional microbiological isolation the PCR was successful, and it 
allowed fast and sensitive identification of H. parasuis from pure cultures [108]. The first PCR 
test for H. parasuis targeted 16s RNA and primers were designed to produce an amplicon of 
821 base pair size. Oliveira’s group found this set of primer was sensitive (detects 102 
bacteria and 0.69 pg of DNA) for H. parasuis, but it also showed a weak positive band towards 
strains belonging to A. indolicus, A. porcinus, and A. minor [108].  Meanwhile, a nested PCR 
targeting 313 bp of 16s rRNA was developed [109] and proposed an increase in sensitivity to 
3 cfu/mL . However, the region targeted had the exact match with A. indolicus region [110]. 
Later PCR test [108] was improved for its specificity by designing a new set of primers that 
produced an amplicon of approximately 1090 base pairs specific only for H. parasuis. The 
improved PCR test was found to be highly species specific and hence regarded as more 
reliable for field diagnosis regardless of whether samples had contaminating flora from other 
closely related organisms [104]. The PCR method was found helpful to detect H. parasuis 
from clinical samples especially to detect the role of pathogen in mortality even in the 
absence of bacterial isolation. It is suggested that PCR targeting 821 bp be used for studies 
with pure culture or samples collected from systemic sites and the PCR targeting 1090 bp 
could be utilized for field studies as it is H. parasuis specific [104].  
1.9.3 Genotyping 
Differentiation of H. parasuis strains by genotyping methods such as REA (Restriction 
endonuclease Assay), ERIC-PCR (Enterobacterial repetitive intergenic consensus PCR), REP 
(Restriction endonuclease pattern), RFLP (Rapid Fragment Length polymorphism), SLST 
(Single locus sequence typing), MLST (Multi locus sequence typing) are the most recent 
typing methods employed for epidemiological studies or strain characterization. The ERIC-
PCR developed in 2000 has been used successfully for the epidemiological typing of H. 
parasuis [25, 111]. If the data from the isolation site, serotyping, genotyping (ERIC-PCR) and 
antimicrobial susceptibility are analysed in combination, epidemiological studies can be very 
useful [58]. This PCR technique allows random amplification of the H. parasuis genome. It is 
used widely when there is an outbreak and it detects genetic differences (mainly by deletion 
and insertion of mobile elements) among the isolates of the same serovar of the source of 
infection [15]. H parasuis reference strains (all 15) were analysed by ERIC-PCR and found 
reproducible and acceptable unique ERIC-PCR fingerprints. Hence, this can be used for the 
differentiation of field strains. Even though, REA and ERIC-PCR give acceptable differentiation 
of H. parasuis isolates, a comparative study performed illustrated that ERIC-PCR provies 
results within a shorter period than REA which requires pure DNA preparations. REA uses 
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restriction enzymes that digest whole DNA into fragments to enable a profile of isolates to be 
prepared [101]. However, it has fallen short as it analyses only pure bacterial cultures or high 
quality DNA. As mentioned, the isolation of pure culture from a clinical sample is not always 
possible. 
PCR-RFLP methods target a particular gene or specific DNA sequence present in the target 
isolate.  It can be applied to identify the desired organism within a mixed bacterial culture or 
samples. tbpA gene (1.9 Kb) encodes for transferring binding protein. The study was carried 
out based on the amplification of tbpA gene using RFLP-PCR [112]. This study showed that 
RFLP-PCR based on tbpA gene can be applied directly to biological samples or to mixed 
cultures without the need of isolation and purification. Especially for non-typeable isolates 
this technique is useful. De La Puente Redondo described the high sensitivity and a high 
degree of differentiation by RFLP-PCR targeting the tbpA gene for typing H. parasuis [112]. In 
China, a study was carried out recently where they analysed 50 clinical strains of H. parasuis 
to characterize 15 reference strains. Differentiation from PRRSV and PCV2 was accomplished 
by using RFLP-PCR targeting the tbpA gene [113]. The diversity in H. parasuis and 
Actinobacillus species has been studied using RFLP-PCR analysing the aroA gene, and it 
illustrates a significant aroA genetic diversity between these two species [114]. 
A single locus sequence typing (SLST) technique has been developed by Olvera and others to 
improve typing. It allowed for the study of heterogeneity of H. parasuis isolates by sequencing 
hsp60 gene [115]. Although the study provided information about a virulent cluster, it was 
not satisfactory because of its limited resolution. In order to maintain a good resolution, 
Olvera and group developed a Multilocus typing (MLST) of H. parasuis based on the 
sequencing of 450 - 600 bp fragments of core genes [115]. MLST helps to discriminate the 
strains from site of isolation and based on alignments of genome sequences from seven target 
housekeeping genes, atpD, infB, mdh, rpoB, 6pgd, g3pd and frdB with set of proposed primer 
sets [115]. Primer design and optimization study of the MLST scheme has been improved by 
standardizing. Standardizing the primers and the annealing temperature for all housekeeping 
gene is useful for highly heterogeneous sequences of H. parasuis to produce reproducible and 
robust results for the differentiation of H. parasuis strains [21]. This internet manageable 
epidemiological tool facilitates constant build-up of data from different origin of isolation and 
comparison of data from different parts of the world.  This method is highly discriminative 
based on 131 field isolates and 11 reference strains. This typing method could serve as fast 
and efficient tool for epidemiological surveillance and it provides effective information for the 
development of control measures such as vaccines. 
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 Changes in gene sequence are much more rapid in outer membrane proteins of this organism 
than housekeeping genes as the host interaction happens mostly with outer membrane 
antigens to adapt and to survive inside the host to colonize. Recently studied putative 
virulence genes were used in MLVA study [116] to perform cluster analysis for better 
understanding of H. parasuis epidemiology and its virulence, but the study could not establish 
a correlation with neither disease nor virulence. Due to these rapid changes in gene its har to 
tract epidemiology and hence housekeeping gene is better choice over other genes. Even 
though, the sequencing can be very expensive for routine applications, sequence based typing 
or MLST is a capable typing method for future global epidemiological studies and discovering 
a correlation between virulence, cross-immunity and genotype. 
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Table 1.6: Comparison of common bacterial typing method [117]. 
Typing technique 
Relative 
discriminatory power 
Relative 
repeatability 
Relative 
reproducibility 
Dispersed or 
focal parts of 
the genome 
Days 
required post 
culture 
Relative cost** Notes 
Sequencing of the 
entire genome. 
High High High Entire genome 
Months to 
years 
Very high  
Comparative 
hybridization against 
array containing 
entire gene sequence 
High Medium to high Medium to high Dispersed 
Weeks to 
months 
High 
Microarrays are 
increasingly available 
for human pathogens- 
not all genes will be 
present in the 
sequenced strain. 
 
Direct sequencing of 
one or more genetic 
regions 
Moderate to high 
(depends on gene 
choice) 
High High 
Focal if only one 
region 
2-3 
Equipment: 
Medium to High 
Labor & Supplies: 
Medium to High 
Initial selection of 
target genes might be 
time consuming. 
Multilocus sequence 
typing (MLST) 
Moderate to high 
(depends on gene 
choice) 
High High Dispersed 3+ 
Equipment: 
Medium to High 
Labor & Supplies: 
High 
Initial selection of 
target genes might be 
time consuming. 
Species specific 
Binary typing 
(presence/absence 
of selected genes or 
alleles across the 
genome) 
Moderate to high 
(depends on gene 
choice) 
High Potentially High 
Dispersed (if 
chose different 
genes across the 
genome) 
2-3 
Equipment: 
Medium 
Labor and 
supplies: Medium 
Reliability depend on 
DNA yield and purity 
Pulsed-field gel 
electrophoresis 
(PFGE) 
Moderate to High 
(depends on number of 
bands observed) 
Medium to High 
(depending on 
species) 
Medium to High Dispersed 3 
Equipment: 
High 
Labor and 
supplies: High 
Discrimination 
depends on type and 
number of enzymes 
selected. 
Restriction fragment 
length  
polymorphism 
(RFLP) 
Moderate to High 
(depends on number of 
bands 
observed) 
Medium to High Medium Dispersed 1-3 Medium  
Amplification of a Moderate to High High Medium to High Focal <1 Equipment: Low  
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single target gene 
specific to a 
pathogen 
(depends on gene 
choice) 
to Medium 
Labor and 
supplies: Low 
Amplified fragment 
length  
polymorphism 
(AFLP) 
Moderate to High High Medium to High Dispersed 2 
Equipment: Low 
to Medium 
Labor and 
supplies: Low 
 
 
Automated 
ribotyping 
Moderate High High Focal 1 
Equipment: High 
Labor and 
supplies: High 
Works for most 
bacterial species 
Ribosomal RNA gel 
electrophoresis 
Moderate High High Focal 1 
Equipment: Low 
Labor and 
supplies: Medium 
 
 
ERIC,REP, DRE, BOX, 
IS),(PGRS) 
Low to Moderate Medium Low 
Generally 
dispersed 
1 
Equipment: Low 
to Medium 
Labor and 
supplies: Low 
Patterns vary with 
equipment used 
RAPD, AP-PCR) Low to moderate Low Low Dispersed 1 
Equipment: Low 
to Medium 
Labor and 
supplies: Low 
Patterns vary with 
equipment used 
Restriction 
endonuclease on a 
single amplified 
product 
Low to moderate 
(depends on ampicon) 
High High Focal 1-2 
Equipment: Low 
to Medium 
Labor and 
supplies: Low 
 
Plasmid profiles Low High Medium Focal 1 
Equipment: Low 
Labor and 
supplies: Low 
 
*Focal corresponds to interrogating a single loci. Dispersed means multiple loci are interrogated. 
** Per isolate costs in US dollars in 2005, assuming all equipment are available, and the investigator has access to automatic sequencing, for PCR reactions are ~$5, PFGE~ $20, MLST ~ 
$140, comparative hybridization~ $1000 to $2000 and total genomic sequencing (assuming a strain has already been sequenced)~ $100,000 to $500,000. 
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1.9.4 Validation of a real time PCR for H. parasuis 
Hedegard described infB as an alternative to 16s RNA that can be useful as a genetic marker 
for the phylogenetic studies [118]. This paper studied infB gene to validate an RT-PCR. The 
study of RT-PCR indicated that it could perform better than culture methods, and it 
performed well for pure cultures, swabs from tissue or fluid, regardless of contamination by 
other bacterial species [119]. Comparison of conventional PCR with a real time PCR 
discovered that real time PCR has the potential to be highly sensitive and specific [120-122]. 
Using a short sequence of 16s rRNA in real time PCR, Blackall demonstrated a redundant 
amplification of Pasteurella mairii and it created problems in discriminating H. parasuis from 
this organism. Thus concluded 16s rRNA gene (short sequence) is not suitable to be used as a 
target for RT-PCR, as it failed in specificity and not as sensitive as RT-PCR (infB as target 
gene). Blackall and group subsequently showed the specificity of infB gene from other closely 
related H. parasuis organisms [113]. It was shown that conventional PCR and culture method 
was not sensitive as real time PCR to detect the low levels of H. parasuis from tonsil samples. 
Out of seven samples (tonsil tissue) seven of them showed positively when RT-PCR (infB as 
target gene) was used, and 3 of them indicated positive for conventional PCR [119]. RT-PCR 
using a unique set of primers (for a highly conserved region) offered high sensitivity and 
specificity towards the organism can be used as a time saving technique compared to H. 
parasuis culturing. Because of the potential of real time-PCR for quantification, it can also be 
used to monitor growth during fermentation in real time. 
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1.10 Global Impact 
The major areas where the distribution of Glässer’s disease has been studied are America, Europe, China and Australia [123].  
Table 1.7: H. parasuis serotype prevalence (%) in different countries [10]. 
Year Country (N) 
Serovar  Method Reference 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 NT IHA+IMD  
2004-
2002 
China (281) <0.1 2.5  24.2 19.2 <0.1 2.1  <0.1 <0.1 1.8 6.8 12.5 7.1 2.5 12.1 
IHA+IMD [124] 
2005 Australia (72), China (9) 1.2 1.2 1.2 25.9 17.3       2.5 3.7 1.2  25.9 IMD [20] 
2000 Australia (46)  4.3  2.2 39.1       4.3 8.7    41.3 IMD [111] 
1992-
1999 
Australia (31) 3.2 3.2  12.9 22.6    6.5   3.2 19.3   29.0 
IMD [14] 
1991-
2002 
Canada (250), USA (50) 3.0 8.0 1.0 27.0 15.0  11.0  1.0   8.0 13.0 3.0  10.0 
IMD [18] 
1999-
2001 
USA (98) 7.1 4.1 8.2 38.8 2.0  2.0     7.1 1.0 3.1  26.5 
IMD [15] 
1982-
1990 
Canada (108), USA (120), 
Australia (10), Brazil (5) 
2.1 8.3 1.2 16.1 24.3 0.4 3.7  1.2  0.8 6.6 11.1 8.6 0.4 15.2 
IMD [125] 
1998-
2002 
Denmark (103) 1.0 2.0  14.0 36.0 2.0 3.0  2.0   3.0 22.0 1.0 2.0 15.0 
IHA+IMD [126] 
2003 
Hungary, Romania, Servia 
(total = 903) 
<0.1 11.5  8.2 30.5      <0.1 <0.1  <0.1 14.3 30.1 
IMD [127] 
1998-
2002 
Spain (67) 6.0 4.0 2.0 13.0 15.0 1.0 7.0  2.0   6.0 2.0 1.0 2.0 9.0 
IHA [114] 
1993-
1997 
Spain (174) 2.8 9.2  16.0 18.4 2.3 4.0 0.6 1.7 0.6 1.2 2.9 8.0 2.9  29.3 
IHA [128] 
1987-
1991 
Germany (290) 4.1 5.5 1.4 17.2 23.8 1.7 2.1  4.1 2.4 2.4 2.8 4.5 1.7 0.7 26.2 
IHA [13] 
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1.10.1 Prevalence in Americas 
US and Canada 
In United States, approximately $145 million annual economic loss (U.S. Department of 
Agriculture [USDA], National Animal Health Monitoring System [NAHMS], 2007) was 
reported due to H. parasuis infections. A total of 300 isolates of H. parasuis were isolated from 
animals in North America and Canada. Samples of the organism, Canada (n = 250) and US (n = 
50) from 1991 to 2002 were evaluated. The serotyping of these isolates was performed by 
indirect haemagglutionation test. More than 90% of the samples could be serotyped, but 
some samples were found non-typeable even by immunodiffusion [18]. Analysis of the 250 
samples from Canada indicated a high prevalence of serovar 4 (27% of the samples), followed 
by serotypes 5 (15% of the samples), 13 (14% of the samples), 7 (12% of the samples), 2 (8% 
of the samples), and 12 (5% of the samples). Analysis of the 50 samples from the United 
States indicated that serotype 4 was the most prevalent (25% of the samples), followed by 
serotypes 12 (23% of the samples) and 5 (15% of the samples) [18]. The latest report from 
the USDA, NAHMS detailed that the occurrence of H. parasuis is on the upsurge with a 230% 
rise in nursery pig rate and a 340% rise in grower/finisher pig rate from 2000 to 2006. It was 
estimated by USDA and NAHMS in 2007 that the morbidity and mortality have been 
increased to 17.4% and 18.4% for nursery-age and grower finisher pigs. 
Brazil 
ERIC-PCR was used to study the prevalence of H. parasuis in 17 Brazilian pig herds, and 33 
genotypes were identified with a diversity index is of 0.96. Among 63 isolates comprising 
eight serovars (1, 2, 4, 5, 6, 9, 12 14 and non-typeable) serovar 4 was the most frequent 
(10/63, 15.9%), whereas 38/63 (60.3%) were non-typeable (NT) [129]. In another study H. 
parasuis, strains were obtained from the various states in Brazil and were serotyped using 
AFLP with a single enzyme and PFGE. The serotyping revealed that serovar 4 was the most 
prevalent (26.1%), followed by serovars 5 (17.4%), 14 (8.7%), 13 (4.4%) and 2 (4.4%), 
whereas 39% of the strains were considered as untypeable [130]. 
1.10.2 Occurrence in Europe 
Hungary, Romania and Serbia 
Post-mortem examination and serotyping of H. parasuis were performed in 401 weaned pigs 
with the clinical symptoms of Glässer’s disease in the country triangle of Hungary, Romania 
and Serbia. The piglets were farm bred in indoor and outdoor units. About 204 piglets were 
from indoors units, and 197 were from outdoor units. The common isolates in indoor units 
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were included H. parasuis serotypes 2, 5 and non typeable, while, in outdoor units, a high 
diversity (serotypes 1, 2, 4, 5, 11, 12, 14, 15, and non typeable) of H. parasuis serotypes was 
found (Table 1.7) [131]. 
Spain 
Among 327 strains of H. parasuis isolated, 174 strains (53.2%) were serotyped (1993 to 
1997). It was found that serovar 5 (18.4%), serovar 4 (16%), serovar 2 (9.2%) and serovar 
13 (18%) have been most frequently isolated in Spain. The rest of the strain (29.3%) was 
classified as non-typeable strains (Table 1.7) [128]. 
Denmark 
In a study performed at Denmark, 103 H. parasuis field isolates were isolated from diseased 
pigs (polyserositis, arthritis or meningitis) and were serotyped by indirect haemagglutination 
and 57 of the isolates were serotyped by immunodiffusion. The result indicated that serovar 
5 was the most prevalent (36%) followed by serovar 4 (13%) and serovar 13 (22%). Among 
them, 15% of the strains were non-typeable by IHA and most of the strains are found to be 
virulent [126]. 
1.10.3 Prevalence in China 
A total of 281 strains of H. parasuis were isolated from 17 provinces of China (September 
2002 to December 2004) and 112 H. parasuis strains were isolated from 536 pigs with 
clinical signs of Glässer’s disease in South China, for a frequency of 21% (September 2008 to 
December 2010). All these isolates were serotyped by both the gel diffusion (GD) and the 
indirect haemagglutination (IHA) tests. In 2002 to 2004, GD and IHA results specified serovar 
4 (24.2%) and serovar 5 (19.2%) were the most widespread serovar, followed by serovars 13 
(12.5%), 14 (7.1%) and 12 (6.8%), while 12.1% of the isolates could not be assigned to a 
serovar (non-typeable) [124]. During the year 2008 to 2010, the GD and IHA results 
displayed serovars 5 and 4 were found to be the most prevalent, at 23% and 17%, 
respectively, followed by serovars 2 (8%), 15 (7%), 13 (6%), and 12 (5%); 20% of the strains 
were non-typeable and it has been increased 8% [132]. 
1.10.4 Prevalence in Australia 
In a study with 31 isolates of H. parasuis obtained from Australian pigs, isolates were found to 
be serovars 1, 2, 4, 5, 9, 10, 12 and 13. Among 31 isolates five of them were non-typeable [14]. 
Serovar profiling of H. parasuis on Australian farms by sampling live pigs was performed, and 
a total of 556 H. parasuis isolates was genotyped, and 150 isolates were serotyped [133].  
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1.11 Research Aims 
The specific aims of this project were: 
1) To determine the nutritional requirements for the wild strain and attenuated 
candidate and to develop a liquid medium suitable for commercial large-scale 
production. 
2) To study and optimize different fermentation platforms and its possibility for 
achieving high titer. 
3) To identify the best procedure for freeze drying in terms of maintaining long term 
stability of strain. 
4) To design a molecular method to differentiate the vaccine candidate from other field 
strains of H. parasuis. 
5) To sequence and analyse twenty different H. parasuis Australian isolates to build up 
MLST database for Australian strains. 
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Summary and Hypothesis 
Pig meat production around the world has doubled since the last twenty years. Globally 83 
million tons of pig meats are produced every year with China being the world’s greatest 
producer of pork and Australia ranking at number 25 (Australian pork industry, 2013). 
Glässer’s disease has a major global impact to swine population and it is increasing at an 
alarming rate across the world. The pig production industries are therefore demanding 
serious need of effective control measures. The rapid transmission of this infection causes 
acute (such as meningitis, pneumonia, pericarditis, peritonitis, pleurisy) to chronic 
(polyarthritis with polyserositis, lameness, chronic erysipelas) diseases leading to unthrifty 
and runt pigs. Although there have been a number of control measures (phenoxymethyl 
penicillin, autogenous/multivalent vaccines) for Glässer’s disease, outbreaks still occur and, 
unfortunately; there has been no successful prevention measures. Available treatments are 
inadequate and the use of antibiotics will soon be significantly curbed. In an effort to work 
toward development of a live vaccine, the investigation into the growth characteristics of H. 
parasuis in a liquid medium was crucial. The complex liquid media was modified by 
eliminating animal products complying with the regulatory requirements for vaccine 
manufacturing. One of the primary aims of this research was to determine the nutritional 
requirements for the attenuated vaccine candidate of H. parasuis and thereafter to develop a 
regulatory compliant medium suitable for commercial large-scale production. Variations to 
the growth (broth) media were tested to determine the media formulation that consistently 
produced the highest number of live organisms per mL in a period acceptable for its 
commercial manufacturing. That is, the organism must grow to the highest possible titre in a 
reasonable amount of time. These criteria are important in the determination of whether a 
vaccine candidate can be feasibly produced. If the attenuation debilitates the growth of the 
organism such that it cannot be produced to commercially required volumes, or if the growth 
media does not support the growth of the organism well enough, then the vaccine candidate 
may not be a suitable commercial product.  
In addition to optimizing growth titre and times, individual components that are or animal 
origins were targeted, for the replacement to non-animal (e.g. plant derived) options. For 
example, soy protein sources were tested as alternative protein sources to animal derived 
proteins. The final growth medium for the large-scale production of H. parasuis vaccine must 
compliant to regulatory requirements. Physical parameters were found to be as essential as 
chemical parameters in terms of growing this organism in small-scale to large-scale vessels. 
Long-term preservation of manufactured product is an important aspect of vaccine 
development, as long-term stability is a critical aspect of registration. Also it is important to 
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define the method of preservation. Therefore, this project also investigated freeze drying 
program and preservatives.  
As the vaccine candidate is aroA-attenuated strain of H. parasuis, it is necessary to have a 
differentiating method to identity the vaccine strain. A molecular method to identify and 
differentiate the vaccine strain from other field strains of H. parasuis is an important assay for 
use in both quality control testing of the final product as well as diagnostics in the field. It is 
very useful to identify the use of the vaccine from field infections. Along with that the genetic 
characteristics of the vaccine strain, the identity assay can also be used to confirm genetic 
stability of the aroA deletion. It is important that the attenuation be found to be stably 
maintained during the manufacturing process that will entail a defined number of in vitro 
passages.  The mutational change to the aroA deletion site must remain intact and unaltered 
during the manufacturing process. 
The development of PCR assay involved the aroA deletion site which is unique to the vaccine 
strain and not to wild type strains. Vaccine strain contains 101 base pair deletion, allowing 
for the identification and differentiation of the vaccine strain. This was an important assay 
that was developed in this project useful for both QC testing of the final product as well as 
diagnostics in the field. It is very useful to identify the use of the vaccine from field infections. 
Epidemiological studies and comparison with closely related isolates of H. parasuis was 
conducted by MLST. Generated data of twenty Australian isolates were deposited in MLST H. 
parasuis database. This study identified the relationship between serotypes and genotyping 
(MLST generated data) between Australian isolates and between Australian isolates and 
global isolates.  
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CHAPTER 2:  
Determination of physical parameters for 
the growth of Haemophilus parasuis in 
complex liquid media 
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2.0 Introduction 
This chapter describes the importance of optimizing the physical parameters critical to 
bacterial growth. The physical parameters relevant for the optimal growth of H. parasuis 
were studied to ultimately allow for high yield of viable cells during the industrial 
manufacturing of this candidate vaccine. The responses to the various incubation conditions 
were determined by enumeration of total viable counts of H. parasuis. The growth curve was 
established using complex liquid medium for both parent and vaccine strain. 
2.1 Biochemical and biophysical requirement for bacterial 
growth 
There are varieties of culture media available in the market for the growth of bacteria. 
Different media can be used for different purposes such as isolation, maintenance of pure 
culture, identification, diagnosis and for storage. Some media has been developed to promote 
large-scale production of cell mass or by-products such as protein, enzymes. The nutritional 
requirement of bacteria are deeply interconnected to cellular responses. Mainly gene 
expression profiles and physiological responses and hence it is crucial to optimize physical 
and chemical requirements specific to each species, if not to each strain of bacteria. Medium 
composition or process-specific knowledge might not be published for most of the industrial 
fermentation process as new strains or mutants mostly requires major modification to 
common media available in the market. Such media is generally maintained as “trade secrets” 
if they are not other ways patented. For industrial application, the composition of media must 
be optimized to allow maximum yield in a cost effective manner. Furthermore, regulations for 
commercial use stipulate that the raw materials should preferably avoid the use of animal 
products that may contribute to bovine spongiform encephalopathy (BSE). BSE is also known 
as “mad cow disease” and the causative agent is responsible for fatal neurodegenerative 
disease. For safety reasons, it is necessary to avoid bovine based protein products in culture 
or fermentation media [134].  
Microbial growth is influenced by the composition of the growth medium or the site in which 
it is budding. The atomic composition of all living organisms includes carbon, hydrogen, 
nitrogen, oxygen, phosphorous and sulfur. Water acts as the predominant constituents for all 
living matter on earth. Bacterial growth purely depends on the source of energy from carbon 
and material for the biosynthesis of cellular materials as DNA, RNA, mitochondria, proteins, 
lipids and carbohydrates. Bacteria are chemoheterotrophic in that they derive their energy by 
ingesting building blocks (organic or inorganic sources) that they are themselves incapable of 
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creating. Oxidative phosphorylation is one of the major metabolic pathways which use the 
energy released by the oxidation of nutrients to produce molecules. ATP molecules produced 
in cells supply energy for metabolism and NAD in biochemical dehydrogenation [134]. 
There are different types of media used for different purposes. A selective media is the one in 
which the media raw materials are designed to prevent certain types or species of bacteria or 
to stimulate growth of desired species. A differential media is used to differentiate bacterial 
species based on some observable pattern of growth on a particular medium. An enrichment 
media contains certain raw materials that enhance only the growth of specific types or 
species of bacteria, for example, 25% NaCl is used to select Halococcus from other 
procaryotes. However, in this project, the media will be developed for the purpose of 
fermentation of a pure clone to high yields [134]. 
Culture for use in fermentation of bacteria can be categorized into different types depending 
on its composition. Complex liquid media or natural media are composed of undefined media 
components as blood, milk, yeast extract, malt extract, casein hydrolysate, beef or meat 
extract. Complex liquid media are commonly used to cultivate unknown bacteria or for 
fermentation of known bacteria. Such media also have the addition of inorganic salts and 
compounds to support growth [134,135]. 
Defined or minimal media is composed of know raw materials with precisely defined 
proportions such as a carbon source, amino acids, minerals and salts. Such media is 
developed to the exact requirements for growth or product formation by systematically 
adding or eliminating chemical species from the formulation. Defined media can be easily 
reproduced, have low foaming tendency, show translucency and allow easy product recovery 
and purification. 
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Table 2.1: Principal elements and its function as raw material in culture media [134]. 
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2.2 Chemical requirement for bacterial growth 
Nutrients of the media can be subdivided into energy sources (organic sources such as-
carbohydrate, protein, fat, sugars and inorganic sources such as NH4, nitrite, iron, H2S), 
elementary requirements (C, H, O, P, K, I, N, S, Ca, Fe, Mg), growth factors (including vitamins  
B1, biotin, pyroxidine, NAD, heme, amino acids). Table 2.1 outlines the various elements that 
are used in media and their physiological function. The components in a media are designed 
to mimic the natural habitat or similar nutritional conditions to allow growth of bacteria. 
Therefore, an artificial media must include source of energy (carbon), source of nitrogen, 
trace elements, growth factors and water [134].  
2.3 Physical conditions for bacterial growth 
The environmental condition in which the microorganism is cultured is of high importance as 
it could affect gene expression and other physiological responses of the bacteria [135]. In a 
fermentation system, it is important to optimize the environmental variables of pH, 
temperature, media composition and dissolved oxygen to encourage high yield of viable 
organisms.  
Bacteria can be classified into three categories based on their growth temperature (Figure 
2.1) psychrophiles or psychrophilic (0-20 °C), mesophiles or mesophilic (25-45 °C) and 
thermophiles or thermophilic (50-70 °C).  Some organism lives at temperatures above 70 °C 
and they are called thermoduric organisms. Thermusaquaticus grows best between 70 -75 °C 
and it has been used to produce heat stable enzyme (Taq polymerase). Each microorganism 
has its own temperature range (which growth occurs), and minimum and maximum 
temperature (outside of which growth is restricted). The optimum temperature for growth is 
between minimum and maximum temperature at which microorganisms grow faster.  
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Figure 2.1: Different groups of prokaryotes characterised based on suitable temperature. 
Most bacteria exhibit relatively narrow range of pH or hydrogen ion concentration during 
growth. Depending upon the optimum pH, they are grouped into categories as depicted in 
Figure 2.2. There are three fundamental points to be considered in which a bacteria grows; 
the minimum pH- in which the bacteria cannot propagate; the maximum pH- beyond which 
the organism cannot grow; and finally the optimum pH, at which the organism grows the 
best. Within these points, most bacteria adjust to a range close to the optimum pH during 
propagation. The pH may either drop or rise depending on the number of H+ ions generated, 
as a result, of metabolic activity. Most of the bacteria have a common range of pH which is 
near to neutrality, between 6.7 and 7.5.  To control the pH glass electrodes are used, and the 
values are adjusted by adding acids (HCl, KCl) or bases (NH3, NaOH) in diluted proportions as 
required [136]. 
 
Figure 2.2: Three environmental classes of prokaryote's growth vs. pH [136]. 
 51 
 
Each microorganism has its own oxygen respiratory requirement (as outlined in Table 2.2). 
Oxygen is always available from water. Some microorganism utilizes oxygen for their energy 
metabolism, and they are classified as aerobes, using oxygen for oxidation reactions in 
metabolism as part of aerobic respiration [137]. 
Table 2.2: Bacterial responses towards oxygen requirements and it characterisation [138]. 
 
2.4 H. parasuis - nutritional requirements 
H. parasuis demands special requirements. It requires the V-factor, a co-dehydrogenase 
diphosphopyridine adenine dinucleotide (NAD), for in vitro growth. It requires a nutritionally 
dense growth media, hence it is considered to be a fastidious organism [139]. The V-factor is 
strongly responsible in oxidation-reduction processes of the growing cell and is one of the 
two co-dehydrogenases (NAD or NADP). Other than NAD different precursors including NMN 
(nicotinamide mononucleotide), nicotinamide riboside except nicotinamide or nicotinic acid 
[140] can be used as a supplement for H. parasuis.  
The bacterial phenotype can be easily altered in an environment when the bacteria is 
deprived of essential nutrients. For example, phenotypic alteration of H. parasuis can happen 
during a natural course of infection significantly throughout the expression of virulence 
factors (variation in antigen levels) or in the production of lipopolysaccharides [141]. This 
paper also commented on the possibility of alteration in H. parasuis phenotype in the case 
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when the organism spreads from the respiratory mucosa (likely not NAD-limiting) to the 
deeper tissues (NAD limiting sites). When initial NAD concentration was reduced from about 
450 µM to about 15 µM, an increased adhesiveness and production of fimbriae along with 
altered capsule structure and outer membrane protein profiles were observed with A. 
pleuropneumoniae [142]. 
2.4.1 Medium requirements of H. parasuis 
V-factor is required by all members of Pasteurellaceae family and the satellite phenomenon 
first described as Haemophilus by Grassberger in 1897 [143]. The prerequisite for V-factor is 
a vital taxonomic standard for identification of members of the Pasteurellaceae. Figure 2.3 
shows the biosynthesis of NAD inside the organism, organism that are able to utilize NAM 
(nicotinamide) are V-factor independent and organism lacks the ability to convert NAM 
(nicotinamide) to NMN (nicotinamide mononucleotide) are V-factor dependant. Nicotinamide 
adenine dinucleotide (NAD+) and its phosphorylated and reduced forms, NADP+, NADH and 
NADPH play a key role in cellular metabolism and energy production as hydride-accepting 
and hydride donating coenzymes [145].  
Staphylococcus aureus and Pseudomonad can be used as a “good feeder” organism on test 
media. Pseudomonad secretes growth factors essential for Haemophilus when grown in a 
defined media [140, 144]. The paper also indicated the presence of V-factor in the liquid 
culture medium of Staphylococcus aureus. Nicotinic acid mononucleotide adenyltransferase is 
encoded by nadD gene in S. aureus. However, purified form of NADH can be used instead of S. 
aureus as a nursing strain. Contradictory  to the statement that H. parasuis requires only V 
factor for its growth, for the growth of H. parasuis (29755) in the whole genome sequencing 
project used 10 μg/mL hemin along with 10 μg/mL NAD in Brain Heart Infusion (BHI) 
medium, supplemented [146]. 
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Figure 2.3: Biochemical pathways for the biosynthesis of NAD [6].  
2.4.2 Different media and culture conditions for H. parasuis growth 
In the laboratory H. parasuis is cultured onto chocolate agar enriched with NAD. Chocolate 
agar is regarded as enriched media for H. parasuis as it contains lysed red blood cells along 
with KoEnzymes such as vitamins, amino acids and sugars including dextrose, L-Cysteine, L-
Glutamine, L-Cystine, Vitamin B12 and Thiamine. H. parasuis require one to three days to 
produce small brown to grey colonies in chocolate agar plates or translucent non- haemolytic 
colonies on blood agar at 37˚C. The size of the colonies differes between strains and the 
phenomenon behind this observation is not yet known [147]. Certain studies demonstrated 
that Muller-Hinton-NAD media appeared to be an excellent medium for heavy growth and 
susceptibility testing of Haemophilus species when compared to BHI, TSB (Tryptic Soy Broth) 
or Tryptose [148].  
Growth of H. parasuis was demonstrated only in a limited number of publications. Tryptic Soy 
Agar (TSA)/Broth supplemented with 10 mg/mL NAD and 5% bovine serum has been used 
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for culturing H. parasuis in liquid media. Lyophilized strains of H. parasuis were able to grow 
on TSA in air at 37˚C for 24 - 48 hours (circular agitation) [22]. Bacteria were cultured on a 
heated blood agar plate with S. aureus as nursing or helper strain when incubated for 24 
hours for the isolation of H. parasuis strain. Re-isolation of H. parasuis strains was made 
possible by incubating chocolate agar for 18 hours at 5% CO2 and 37 ˚C. 
Niven and O’Reilly proposed a culture media for H. parasuis consisting of 2% (w/v) tryptone, 
0.5% (w/v) yeast extract, 100 mM NaCl, 10 mM glucose and KOH to pH 7.4. NAD (5 µM) was 
filter sterilized and added to media prior to inoculation [98]. Niven reported that purified 
NADP supplementation instead of NAD yielded a good growth of H. parasuis. Incubation 
temperature was optimized as 37 ˚C in an environment not enriched with CO2 and agitation in 
a rotary shaker. For the transportation of clinical samples from animals, Amies system 
proved effective to assist the survival of H. parasuis from the sampling site [112]. The author 
also recommended using horse serum to prolong H. parasuis survivability in vitro.  
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2.5 Objectives  
The main objectives of this chapter include: 
1) To evaluate storage medium for the preparation of pre-master and secondary seeds. 
2) Conduct trials to investigate the best diluent for enumeration of colonies by serial 
dilution.  
3) To optimize physical parameters required for vaccine strain growth in liquid media. 
4) To establish a growth curve for vaccine strain in small-scale culture using complex 
liquid medium. 
5) To study the relation between pH and cell growth-using the vaccine strain cultured in 
complex liquid medium. 
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2.6 Materials, Methods and Results 
2.6.1 General procedures 
Laminar (HWS series) was used to perform all the experiments under aseptic conditions. 
Sterilization of glassware, media, solutions, eppendorf tubes, and pipette tips was performed 
by autoclaving at 121 °C for 20 min (Atherton). All solutions were dispensed using 
Finnpipette or Scorex for all volumes ranging from 0.1 μl to 1000 μl, and these were regularly 
calibrated as per manufactures recommendation. Filter sterilization was performed for 
solutions that are heat sensitive by using 0.2 µm cellulose acetate membranes (Minisart, 
Sartorious stedim). Weights were measured on top loading (ISSCO) or analytical balance. 
Centrifugation was performed using a HERAEUS multifuge 1S-R or Beckman Allegra 21R. 
Ultracentrifugation was performed by using Eppendorf centrifuge. BD Falcon tubes (50, mL 
10 mL) are used for a sample centrifugation at sterile conditions. Schott Duran measuring 
cylinders, bottles, and beakers were used to measure, to sterilize media, culture stocking and 
during the preparation of media (Schott Duran 3.3 low expansion Borosilicate glass). Milli-Q 
water (Liquipure, Melbourne, Australia) was used in the preparation of media, reagents. 
Microscopic analysis was performed using an Olympus CH light microscope at 1000X 
magnification under oil. The pH measurements were performed using Metrohm ion analysis 
and a portable pH checker by Hanna. Sodium hydroxide (5 M) and hydrochloric acid (5 M) 
(Merck) was used to adjust to desired pH for media preparation. Shaking cultures were 
incubated in Ratek incubators, and magnetic stirs (U-lab) were used for stirring experiments. 
Hot air oven was used in the preparation of chocolate agar plates. 
 Complex liquid media can be used as a platform to optimize environmental conditions for the 
bacteria and later it can be modified to a regulatory compliant medium that is relatively 
inexpensive and assures an economically success process. The optimization of bacterial 
growth was established following laborious and repeated experiments screening performed 
in small-scale including falcon tubes and Schott bottles. Testing of each new parameter was 
conducted in a sequential manner based on the previously tested and best performing 
parameter.  
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2.6.2 Preparation of complex liquid media 
Nutrient material whose exact chemical composition is not known is defined as complex 
liquid media. The composition of complex liquid media is shown in Table 2.3 A. Uniform 
mixing was obtained by preparing the media in a glass beaker with magnetic stirrer and slow 
addition of raw materials into milli-Q or distilled water. The final pH of prepared media was 
measured using a pH meter and adjusted with HCl (5 M) or NaOH (5 M) using Pasteur pipette. 
Sterilization of media was performed by autoclaving at 121 °C for 20 min. Autoclaved media 
was kept overnight at room temperature and a small aliquot removed to incubate in a warm 
room (37 °C)  to confirm media sterility prior to proceeding with each experiment. 
Table 2.3 A: List of media raw materials for complex liquid media preparation [59, 149]. 
 
2.6.3 Preparation of supplements 
Table 2.3 B: Supplement preparation for complex liquid media [59, 149]. 
 Note: O-A complex is a combination of bovine albumin faction V in normal saline and oleic 
acid in 0.05 NaOH (Appendix I) 
As the supplements are heat sensitive, the prepared supplement solutions were filter 
sterilized using 0.2 µm cellulose filters to a sterile bottle. The supplements were combined 
aseptically for the required volume of broth by firstly preparing the raw materials outlined in 
Table 2.3 B into a sterile container. The supplements were then filter sterilized before adding 
to the sterile broth. Small aliquots of 5 mL (falcon tube) supplemented and un-supplemented 
Media raw materials Manufacturer Total volume -100 mL 
Biostate peptone BBL 1 g 
NaCl Univar AR 1 g 
Starch BDH GPR 0.1 g 
Glucose Univar AR 0.05 g 
Yeast Extract Gibco BRL 0.05 g 
Distilled Water/Milli-Q Liquipure, 90.5 mL 
Supplements Manufacturer Total volume -100 mL 
0.1% NADH Sigma 2.5 mL 
0.05% Thiamine HCl Sigma 1 mL 
Heat inactivated Pig serum Gamma irradiated 1 mL 
O-A complex Sigma 5 mL 
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media were incubated at 37 °C for 48 hours as a sterility check prior to use of the remaining 
media in growth studies. 
2.6.3.1 Filtration of gamma irradiated pig serum 
Serum (i.e., blood plasma) is comprised of a rich source of nutrients both defined and 
undefined. Serum for commercial use was first gamma irradiated (25−40 kGy) to ensure the 
inactivation of viruses and other adventitious contaminants that may be present. Once 
irradiated, the serum was stored at -20 °C for long-term storage. Before its use, the serum 
was inactivated at 56 °C for 30 min. After heat inactivation, pig serum was filter sterilized 
under aseptic conditions into a sterile Schott bottle using a peristaltic pump and sterile 
column filter (PALL-SUPORAcropak 200, 0.2 µ). The sterile pig serum was then prepared into 
aliquots in sterile 50 mL falcon tubes and stored at -20 °C. To confirm the filter sterilization, a 
small aliquot of the pig serum was kept at 37 °C for sterility and checked after 48 hours 
incubation. It was then plated onto Horse blood Agar (HBA), Luria Broth Agar (LB), and 
Chocolate Agar (CA) plates as a further check on its sterility. 
2.6.4 Preparation of chocolate agar plates 
Horse blood agar (HBA-Thermo-Fischer) was used for the preparation of chocolate agar 
plates. Refrigerated HBA plates were thawed for 20 min. at room temperature and kept in a 
pre-heated oven with a temperature of 75 °C. After 20 min the plates were observed for the 
desired chocolate colour. The plates transferred to a cleaned (disinfected and UV irradiated) 
LAF and the plate covers left open for 30 min to cool agar and to dry. This assisted in avoiding 
condensation during incubation. Prior to their use, plates were kept at room temperature. 
As H. parasuis is a microaerophilic organism, it requires reduced levels of oxygen (~10%) and 
low levels of carbon dioxide (~5%) for growth atmosphere. Some microaerophilic organisms 
prefer different level of oxygen (0 to 10%). The different platforms available for culturing 
plates included a candle jar (3-5% CO2 and 8-10% O2), atmospheric oxygen (22%), GasPak jar 
(no oxygen at all, for anaerobes) and a Gaspak jar with sachets (small percentage of O2 and 
CO2). In laboratory scale experiments, it was possible to use readily available sachets that 
promised microaerophilic conditions (BD-GasPak jar) as shown in Figure 2.4 A.  For H. 
parasuis plate incubation GasPak EZ gas generating container sachets (Figure 2.4 A) and 
candle jars (Figure 2.4 B) were used to study the growth and time for incubation. The GasPak 
EZ Gas Generating Container Sachets produced anaerobic, microaerophilic (reduced oxygen) 
or CO2 enriched environments. The plates were incubated with a candle flame “On”. The flame 
becomes extinguished after the consumption of most of the O2 inside the jar and thus the 
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higher percentage of oxygen reduces and a minimum percentage of CO2 is maintained. The 
candle jar lowers O2 levels below 10% and raises CO2 levels from 0.03% to about 10%, 
favorable for H. parasuis to grow under microaerophilic condition [136].  It was found in this 
project that the growth was observed within 24 hours of incubation in candle jars, but it took 
48 hours to show the similar results in GasPak container system. As the candle jar offers a 
greater percentage of oxygen compared to the GasPak system, it might provide an 
explanation for the shorter growth period inside a candle jar. 
 
 
Figure 2.4 A: BD-GasPak platform for the growth microaerophilic or anaerobic organisms; B: 
Closed candle jar with chocolate agar plate cultures for incubation of H. parasuis. The jar on 
the left shows the start of incubation with the candle flame still alight due to a higher 
percentage of oxygen. The jar on the right shows plates with the candle flame extinguished 
due to the lower percentage of oxygen within the sealed jar. 
2.7 Bacterial strains 
All bacterial strains used in this study were obtained from Department of Primary Industries 
and Fisheries (DPI&F) Queensland in collaboration with Griffith University. H. parasuis 
strains Hps29 (serotype 2), Hps2001 (serotype 7), Hps1958 (serotype 7) isolated from 
Australian farms and used in the construction of aroA-ve vaccine strain. These were 
successfully transformed (TetR gene mutants of aroA gene), but only Hps29 was capable of 
being converted to aroA-ve. The TetR marker was removed from the site creating a 101 base 
pair deletion in aroA gene of the vaccine strain [59]. The Hps29 aroA-ve strain was sub-cloned 
and tested to growth. Subclone B4C6 was selected as the vaccine strain candidate, as it was 
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growing better than other clones at in vitro conditions (unpublished). Hps29 parent strain 
and Hps29 aroA-ve vaccine strain (B4C6) are used in this project. 
2.7.1 DNA extraction of parent strain and vaccine strain 
Genomic DNA extraction for parent strain and vaccine strain as briefly described was 
performed using the CTAB (Cetyltrimethyl Ammonium Bromide) extraction method [150]. 
Lawn culture of both strains was grown under microaerophilic conditions for 24 hours at 37 
°C. Bacterial cells were scraped using a sterile loop and harvested in 9.4 mL TE buffer and 0.1 
mL 0.5 M EDTA. After uniform mixing 0.5 mL 10%, (w/v) SDS and 50µl of proteinase K was 
added to the mixture and incubated at 37 °C water bath for 2 hours. Five M NaCl (1.8 mL) and 
1.5 mL of 10 % (w/v) CTAB in 0.7 M NaCl were added, and the mixture was incubated for 30 
min at 65 °C water bath. Five mL of chloroform/isoamyl alcohol was added to the mixture 
and centrifuged at 4700 g for 15 min at 4 °C. The top aqueous layer was transferred into a 
new falcon tube and 5 mL of 25:24:1 phenol/chloroform/isoamyl alcohol was added. This 
step was repeated twice to obtain pure DNA and precipitated by adding 0.6 volumes of 100% 
isopropanol. DNA strand was scooped out using sterile Pasteur pipette to an Eppendorf tube 
with 1mL 70% ethanol and centrifuged for one minute and allowed the Eppendorf tube to 
keep open to evaporate the ethanol completely. At the end of this procedure, the extracted 
DNA was dissolved in 50 μl of molecular grade water in a 1.5 mL Eppendorf tube and stored 
at -20 °C. Details of all reagents are included in Appendix V. 
2.7.2 Genetic characterization of aroA gene 
Primer design for aroA region of H. parasuis was done by using Prime 3 software  accessing 
the database of H. parasuis (serotype 5) genome sequence (Accession no: version: 
CP001321.1  GI:219690483). The primers designed are shown below. 
Forward primer:  5’ TCAAATCGTGCGTTGTTGTTGGC 3’  
Reverse primer:  3’ GCCCCTAATTTGTTACCCTTA 5’  
 The PCR Pre-master kit (PROMEGA), Table 2.4 B was used to amplify both parent and 
vaccine strain aroA region using above designed primers.  
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Table 2.4 A: PCR program for amplifying aroA gene. 
 
 
 
 
 
 
Table 2.4 B: PCR reagents for the amplification of gene using PCR Pre-master kit 
(PROMEGA). 
  1 X reaction  (ul) 
Mol.grade water 31.5 
 25mm Mg Cl2 5 
5X buffer 10 
dNTP’s 1 
Taqpolymerase 0.5 
Primers  
1.Primer 1 1 
2. Primer 2 1 
Template Broth 1 
After the PCR reaction, products were loaded onto a 1% agarose gel, and electrophoresed for 
80 min at 100 V to separate the DNA into fragments of decreasing molecular size. The gel was 
stained in ethidium bromide (0.5 μg/mL) bath for 10 min and de-stained in a running water 
bath for 20 min. The DNA bands were visualized using gel doc (BioRad) and the size of the 
gene fragment was compared with the molecular ladder (lane 1 - range 75 bp to 20000 bp) as 
shown in Figure 2.5. Band was then purified using PROMEGA kit and sequenced at Australian 
Genome Research Facility (AGRF) Brisbane. The sequence obtained from AGRF was subjected 
to analysis and the final sequence is shown below. Results of the sequence confirmed a 101 
base pair deletion in vaccine strain (B4C6) compared to the parent strain and there is no 
sequence added to the parent strain and hence there is no foreign DNA present in the 
attenuated strain. 
Step Temperature Time Stage Cycle 
Denaturing 94 °C 5.0 min Stage 1 1 
Annealing 94 °C 30 s       Stage 2:Step1 35 
 53 °C     40 s      Stage 2:Step2  
 72 °C 2.0 min     Stage 2:Step3  
Extension 72 °C 10.0 min     Stage3 1 
Store 4 °C       Infinite Holding  
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Figure 2.5: Agarose gel picture demonstrating the presence of amplified product from PCR; 
lane 1: DNA ladder (75 base pair to 20,000 base pair), lane 3: parent strain aroA gene 
amplified product size of ~1300 and lane 4 to 9: vaccine strain aroA gene amplified product 
size of ~1200. 
Sequence of aroA gene parent strain (Hps29)  
5’CATGCTGGCACGCAGTACGAATTTATTGGATAGCGATGATATTCGCCATATGCTCAATGCCTTGAAAGCTT
TGGGGGTGAATTATCAGCTTTCTGATAATAAAACCGTTTGTACCGTTGAGGGCGTGGGCGGTGCGTTTCAGTG
GCAAAATGGTTTGTCGCTGTTTTTAGGTAATGCCGGCACCGCAATGCGTCCTTTAACAGCGGCACTTTGTTTG
AAAGGTGAGCAAGAGGCTGAGGTGATTTTAACGGGCGAGCCGCGTATGAAAGAGCGTCCGATTAAACATTTGG
TTGATGCGTTATTGCAAGCGGGGGCTTCCGTGCAATATCTTGAAAATGAAGGCTATCCGCCGATTGCTATTCG
TAATTTGGGTATTCAAGGCGGCAAAATTCAGATTGATGGTTCGATTTCTTCGCAATTTTTGACCGCACTTTTG
ATGTCCGCACCCCTTGCCTCTGGCGATATGGAAATTGAGATTGTCGGTGAGTTGGTCTCCAAGCCTTATATTG
ATATTACCCTTGCGATGATGAAGGATTTTAGCGTGACAGTGTCGCATAATAATTATCAAACTTTCTTTGTTAA
AGGTAATCAGCATTATGTTTCTCCGCAAAAATATTTGGTTGAGGGCGATGCGTCCTCTGCCTCTTATTTCTTA
GCCGCAGGGGCAATTAAGGGGAAAGTGAAAGTGACGGGGATTGGTAAAAATTCCATTCAAGGCGACCGCTTGT
TTGCGGATGTGCTTGAGAAAATGGGCGCGAAAATCACTTGGGGGCGAAGATTTTATCCAAGCAGAGCAGGGGG
AGCTTAAAGGCATTGATATGGATATGAACCATATTCCTGATGCGGCAATGACGATTGCAACTACCGCTCTTTT
TGCTGAGGGTGAAACCGTTATTCGTAATATTTATAACTGGCGTGTGAAGGAAACAGATCGCTTGACAGCAATG
GCAACAGAGTTGCGTAAAGTTGGGGCGGAAGTGGAAGAAGGGGAAGATTTTATTCGTATTCAACCGCTTGCGT
TAGATAAGTTCCAACACGCTGAGATCGAAACCTATAACGATCACCGTATGGCGATGTGTTTCTCTTTGGTGGC
ATTGTCAAATACGCCACTGACGATTTTAGATCCGAAATGTACCGCAAAAACTTTCCCGACGTATTTTGATGAA
TTTGGGAAGATGTCTTGTAATTTTAGTAGGGAAGAAAAATAATCTTATTGGGATTGAGGCTAT 3’ 
Note: Highlighted sequence were targeted for deletion 
Sequence of aroA gene vaccine strain (B4C6) 
5’AAGTAACGAATTTATTGGATAGCGATGATATTCGCCATATGCTCAATGCCTTGAAAGCTTTGGGGGTGAAT
TATCAGCTTTCTGATAATAAAACCGTTTGTACCGTTGAGGGCGTGGGCGGTGCGTTTCAGTGGCAAAATGGTT
TGTCGCTGTTTTTAGGTAATGCCGGCACCGCAATGCGTCCTTTAACAGCGGCACTTTGTTTGAAAGGTGAGCA
AGAGGCTGAGGTGATTTTAACGGGCGAGCCGCGTATGAAAGAGCGTCCGATTAAACATTTGGTTGATGCGTTA
TTGCAAGCGGGGGCTTCCGTGCAATATCTTGAAAATGAAGGCTATCCGCCGATTGCTATTCGTAATTTGGGTA
TTCAAGGCGGCAAAATTCAGATTGATGGTTCGATTTCTTCGCAATTTTTGACCGCACTTTTGATGTCCGCAC^
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GTGTCGCATAATAATTATCAAACTTTCTTTGTTAAAGGTAATCAGCATTATGTTTCTCCGCAAAAATATTTGG
TTGAGGGCGATGCGTCCTCTGCCTCTTATTTCTTAGCCGCAGGGGCAATTAAGGGGAAAGTGAAAGTGACGGG
GATTGGTAAAAATTCCATTCAAGGCGACCGCTTGTTTGCGGATGTGCTTGAGAAAATGGGCGCGAAAATCACT
TGGGGCGAAGATTTTATCCAAGCAGAGCAGGGGGAGCTTAAAGGCATTGATATGGATATGAACCATATTCCTG
ATGCGGCAATGACGATTGCAACTACCGCTCTTTTTGCTGAGGGTGAAACCGTTATTCGTAATATTTATAACTG
GCGTGTGAAGGAAACAGATCGCTTGACAGCAATGGCAACAGAGTTGCGTAAAGTTGGGGCGGAAGTGGAAGAA
GGGGAAGATTTTATTCGTATTCAACCGCTTGCGTTAGATAAGTTCCAACACGCTGAGATCGAAACCTATAACG
ATCACCGTATGGCGATGTGTTTCTCTTTGGTGCATTGTCAAATACGCCCACTGACGATTTTAGATCCGAATGT
ACCGCAAAACTTTCCCGACGTATTTTGATGATTTTGGAAGATGTCTTGTACTTTAGTAGGAGATATATCTTAT
GGGATGAGCTATTTTAACAGCATAGAGAATCAAAGACGGGTACTGTCTACTGTAGGGTTACTACATTTCTGAT
CATAGCAAAGTCTTAATTAGGTAGAACACACTATACG 3’ 
2.7.3 Culture conditions 
No publications detailing optimal conditions for the growth of H. parasuis in liquid media 
were found at the time of commencement of this project. H. parasuis species is considered a 
mesophile. Therefore, the incubation temperature of 37 °C was used for its growth. In most of 
the studies, this organism has been grown under stationary and microaerophilic conditions. 
In limited studies, it has been grown under circular shaking and stirring at 185 rpm. In the 
project vaccine strain was found to require a longer period of incubation time (36 hours) 
compared to the parent strain (24 hours) on chocolate agar plates, whereas in liquid broth 
both strains were grown at same rate. 
Overnight culture preparation  
Overnight night broth cultures were used for both B4C6 and Hps29 for all experiments in this 
chapter. From -20 °C freezer secondary seed (Section 2.7.4) B4C6 and Hps29 Eppendorf 
tubes stored were thawed for 5 min at room temperature. Chocolate agar plates were spread 
with 50 µl of 0.1% NADH using a sterile L–spreader. Inside the laminar, a loop full of culture 
was spread onto pre-labeled chocolate agar plate using a sterile loop. Plates were kept inside 
a candle jar at 37 °C. Plates with Hps29 were incubated for 24 hours, and B4C6 was incubated 
for 36 hours. After the incubation period, plates were harvested for inoculation into sterile 
broth. For 200 mL of media, lawn culture from one plate is used to prepare overnight culture. 
Under aseptic conditions, lawn culture from each plate was scooped out with sterile L- 
spreader using sterile media and sterile pipette tips for resuspending. Hps29 and B4C6 lawn 
culture were inoculated into pre-warmed 200 mL of sterile media and grown overnight (24 
hours, stationary at 37 °C) in a sealed Schott bottle (1 L). After 24 hours the culture was 
harvested (overnight culture) and used for test experiments in this chapter. 
2.7.4 Preservation by pre-master seed and secondary seed 
Sterile McCartney bottles and falcon tubes containing 5 mL or 10 mL of the complex liquid 
medium were inoculated with a loop full of frozen culture and incubated at microaerophilic 
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conditions. Culture was then spread onto chocolate agar plates (supplemented with 50 µl of 
0.1% NAD) and incubated inside candle jar for 24 hours at 37 °C. For the preparation of pre-
master cell bank (pMCB), lawn culture from one chocolate plate was scraped out by sterile 
loop and inoculated into CryoBeads™ tube. After uniform distribution of cells the beads were 
kept for long time preservation. Each plate was used to make a single cryobead for 
preservation at -80°C for pre-master cell bank. Cells were recovered by taking a single bead 
(taken out from cryobead tube -80 °C) using sterile pipette tip and inoculating into 100 µl of 
sterile complex liquid medium. Then the resuspended pre-master seed was spread onto 
chocolate agar plate supplemented with NAD. The plates were then incubated at 37 °C inside 
a candle jar for 24 hours. pMCB (beads from cryobead tube) or the above plates were used for 
the preparation of secondary seed. 
For secondary seed, a storage medium was used. Modification was made to the original 
protocol of Saab [151] for the storage of Haemophilus influenza. The modification was made 
according to the growth requirement of H. parasuis parent and vaccine strains. Media 
components were optimized as it could not offer the same efficacy offered for H.  influenza. 
The viability of strains decreased after three months of storage in this study. Therefore, there 
was a need to study and modify the storage media. By enriching the media by the addition of 
10% pig serum to the original protocol, the media was modified and hence improved the 
efficacy of the storage medium for H. parasuis parent and the vaccine strain. 
The dry raw materials were accurately weighed and dissolved in 80 mL of milli-Q water. 10 
mL of 10% glycerol was added and mixed before autoclaving the medium for 15 min at 120 
°C. Once the media was cooled to room temperature, the filter sterilized pig serum was added. 
A small aliquot (1 mL) volume was removed from the final media preparation and kept at 37 
°C for the sterility check.  
Sterile McCartney bottles and falcon tubes containing 5 mL or 10 mL of the complex liquid 
medium were inoculated with five cryobeads from -80 °C (pre-master seed) and incubated at 
37 °C for 24 hours. Culture (10 mL) was pelleted down at 10,000 rpm for 15 min , and it was 
resuspended in 1 mL of storage media (Table 2.5) was made aliquots into sterile Eppendorf 
tubes or screw tubes. Pellet was resuspended and uniformly mixed; secondary seed culture 
was stored at -20 °C for immediate studies. Viability rate of secondary seed was analysed 
throughout the study. It is observed that there was no significant loss of cells during a six-
month period with the modified stock media. 
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Table 2.5: Media raw materials for the stock media (modified from [151]). 
2.8 Sample Analysis 
2.8.1 Viable Cell Counts 
Samples from each experiment were analysed for viable cell count by plating onto CA plates. 
CA plates were spread with 50 µl of 0.1% NADH using a sterile L–spreader (Techno-Plas 
Spreader bars). The plates were then left to dry under a laminar flow prior to being used for 
plating the sample dilution. After plating, the plates were labeled accordingly and kept inside 
a candle jar at 37 °C. Colonies were enumerated manually and recorded for data analysis. 
Figure 2.6: Serial dilution technique for viable cell count; first developed by Robert Koch; 
who established this method for enumeration of microorganisms by standard plate count 
method. It has been universally accepted as a reliable technique for the determination of 
viable bacterial cell counts. This method is based on the principle that when a liquid culture 
spreads on the agar plate each single microorganism forms a visible colony on the plate after 
required incubation and thus enumeration of appeared colonies represents the actual count 
of viable organism in the liquid culture [139]. 
Media Raw materials Manufacturer  100 mL 
10% Skim Milk Powder Bonlac Foods Ltd., Australia 10.0 g 
1% Glucose Merck,Germany 1.0 g 
0.5% Yeast Extract Oxoid Ltd, England 0.5 g 
10% Glycerol Science Supply, Australia 10 mL 
10% Pig Serum sterile Gamma irradiated 10 mL 
Milli-Q water Liquipure 80 mL 
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A set of serial dilutions were made aseptically using non-supplemented media for the initial 
studies. Being very sensitive to the external environment, choice of diluents required 
assessment. Each dilution was plated onto pre-labeled CA plates in triplicates and kept inside 
candle jar at 37 °C for 24 hours (parent strain) and 36 hours (vaccine strain). For accuracy of 
counting, only plates that contained between 20 and 200 colonies were included in the 
calculations of Total Viable Counts (TVC). To calculate the cfu/mL, the number of colonies 
was recorded. The average number of colonies (triplicate) was then multiplied by the 
appropriate dilution factor for the plates counted. 
Colony count x dilution factor (the inverse of the dilutions) = cfu/mL of original culture 
Statistics 
Statistical analysis of experiments performed by transforming the exponential data’s into 
logarithms to the base 10. Appropriate tests were used to ensure normality, equal variance in 
the transformed data before analysis of variance (ANOVA), and residuals were tested for 
normality. Error bars were included in the graphs, which were based on the standard 
deviation (plate triplicate count results). Enumeration of colonies was done in triplicate for 
all the experiments as well as independent biological repeats. Statistical analysis were 
performed for samples havested at 24 hours using one way ANOVA and the probability of 
distribution was tested using  Kolmogorov–Smirnov test (KS test). Statistical analyses 
performed using minitab 16 (Software) on experiments were described under Appendix X (A-
E). 
2.8.2 Optical Density value measurements 
Eppendorf Biophotometer was used to measure optical density value at 600nm with a light 
path of 1 cm using sterile growth medium as a blank in a sterile cuvette (Uvette Eppendorf, 
Germany). Samples were diluted in complex growth media (1:2) for OD600 measurements and 
culture was diluted if the reading was greater than one unit read. A nano drop (Thermo 
Fischer) spectrophotometer was also used for OD600 for measurement validation. Amount of 
sample required for a Nano drop measurement was one µl volume. 
2.8.3 Gram staining 
Culture was analysed by gram staining, using a single drop of the fresh culture onto a clean 
glass slide. The culture droplet was then heat fixed using a Bunsen burner by allowing the 
flame to heat the bottle of slide. After drying of the droplet of culture, couple of drops of 
crystal violet stain was dropped onto the dried smear. After one minute exposure to the stain, 
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the slide was gently washed in a slow flow of water, rinsing off the stain. Gram iodine 
(mordant) was dropped onto the violet stained smear for one minute for the formation of 
dye-iodine complex in the cytoplasm of the bacteria. The slide was gently washed with water. 
The bacteria cells were then decolorized using absolute ethyl alcohol or acetone (not 
exceeding 30 s for thin smears). After rinsing off the ethanol, safranin stain was added on to 
the slide and exposed for one minute before washing off the stain. Saffarin stains cell nuclei 
red colour. Excess water was removed using blotting paper and allowing to air dry before 
observing under microscope. Bacteria that hold on to primary dye iodine complex and remain 
violet in colour are referred to as being “Gram positive” and those which get decolorized and 
subsequently take up counterstain (pink/red) are referred to as being “Gram negative” [152]. 
An Olympus light microscope was used to view the stained cell differentiation at 1000 X using 
a coverslip for oil immersion technique. 
2.9 Effect of different diluents on serial dilution 
Study on various diluents was required to find out there is any influence of diluents with 
reproducibility of plate count. Various diluents were examined for their effect on total viable 
counts and reproducibility. The following diluents were tested: 0.1% peptone, saline 
( 0.1% w/v NaCl), 1 X PBS (per litre, 8.5 g NaCl, 6.8 g KH2PO4 and 11.4 g K2HPO4 Astral 
Scientific), Milli-Q sterile water, Merial commercial “Mareks” diluent, Supplemented complex 
liquid media and un-supplemented complex liquid media. 
Lawn culture of H. parasuis (B4C6) grown on CA plate were freshly inoculated into 200 mL of 
complex liquid media (pre-warmed) and grown overnight (24 hours, stationary at 37 °C) in a 
sealed Schott bottle (1 L). Fresh samples were used in serial dilutions using the various 
diluents shown above. Serial dilutions were done at three different time intervals which 
include at 0 hour (freshly after serial dilution), at 2 hours (after 2 hours from time of serial 
dilution; kept refrigerated at 4 °C) and after 4 hours (after 4 hours from time of serial 
dilution; kept refrigerated at 4 °C). The results of total viable counts were recorded for each 
diluent and shown in Figure 2.7.  
2.9.1 Result and observation of diluent effect on viability 
Figure 2.7 clearly shows that the choice of diluent can have an effect on the viability and 
hence on total viable count. In particular 0.1% peptone, saline, 1X PBS all gave lower counts 
by as much as 2 logs when compared with the counts obtained when using either Mareks 
diluent or complex liquid media (whether it was prepared with or without supplements). 
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Dilution of the culture in milli-Q also showed reduced counts of around one log. Mareks 
diluent is used for the vaccine dilution of Mareks viral vaccine in poultry. It is a commonly 
used diluent for live vaccines and hence was used in this set of studies. Since Mareks diluent 
is a standardized commercial diluent, it would be an appropriate diluent to use for final 
vaccine preparation prior to deliver. Complex liquid media would not be a suitable diluent for 
a registered vaccine. The treatements except Marek’s diluent, supplemented and un-
supplemented media were significantly different  (Appendix X, A). 
 
Figure 2.7: Effect on total viable count of H. parasuis using different diluents (Appendix X, A). 
*Different superscript letters are significantly different using an ANOVA where p<0.05. 
2.10 Effect of initial media pH on cell growth  
One of the most important physical parameters that could affect the fermentation process is 
the initial or starting pH of the media. Hence, it is critical to ascertain the optimal starting pH 
for the prepared media. Complex liquid media (pre-warmed) was prepared at pH of 6, 6.5, 
7.0, 7.5, 8.0, and 8.5 as stated in Section 2.6.2 and dispensed in 250 mL Schott bottle. The 
initial media pH was adjusted to desired pH using either HCl (5 M) or NaCl (5 M) as 
appropriate prior to autoclaving. After autoclaving, a small aliquot of each media was 
measured for any change in pH, and it was confirmed that there was no change in pH after 
autoclaving. In the same manner after the addition of supplements (Section 2.6.3), a small 
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aliquot was analysed for any pH variation to the originally adjusted pH. It was found that 
there was only negligible (0.01) variation from the original pH range mentioned above. The 
slight variation only occurred after the addition of supplements as the preparation includes 
NaOH and oleic acid (Section 2.6.3). Each labeled bottle was then inoculated with an 
overnight culture (B4C6) and kept for 24 hours incubation at 37 °C.  
 
Figure 2.8: Effect of initial medium pH on growth of H. parasuis B4C6 in complex liquid 
media. *Different superscript letters are significantly different using an ANOVA where 
p<0.05. (Appendix X, B). 
2.10.1 Results on initial medium pH vs. cell growth 
When a set of pH ranging from 6 to 8.5 was used as initial pH of the liquid media for in vitro 
growth of H. parasuis, significant effect on the viability of cells were observed (Figure 2.8). 
From the figure, it was clear that only a narrow range (7.5 to 8.0) was suitable for H. parasuis 
fermentation. Graph demonstrated that the organism was best grown at pH range 7.5 and 8.0, 
therefore for the rest of the studies it was decided to maintain the initial pH of the media at 
7.5 (promoted highest growth titer). Except pH 7.5 and 8.0, the statistical analysis showed 
that the means for the treatments were significantly different (ANOVA test, F= 4408.93, 
P<0.001). The greatest cell distributions were for pH 7.5 and 8.0, which were not significantly 
different from one another. 
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2.11 Effect of different agitation on growth  
Oxygen is a critical parameter for consideration when optimizing growth conditions in order 
to increase the fermentation yield. Transfer of oxygen is depended on numerous parameters 
such as foam, shape of the vessel, stirring or agitation speed, volume of fluid and density of 
the medium. As discussed, different groups of aerobes have different oxygen demands to 
support their metabolic reactions within the cell. H. parasuis is a facultative anaerobic 
organism. It requires a lower percentage of oxygen to promote growth or cell mass. The 
percentage of oxygen required for the optimal production of biomass raised the question as 
to whether it required being stationary, shaking or stirring. If agitation was required, at what 
level of speed was optimum. The increase in need of transfer of oxygen can be very much 
dependent on the density of culture media. Oxygen transfer rate (OTR) during fermentation 
could be increased by increasing the percentage of agitation or decreasing the viscosity of the 
media [153].  
Since H. parasuis requires only low levels of oxygen and H. parasuis does not grow to high 
density, experiments were conducted at the lowest shaking speed (50 rpm) and stirring using 
a magnetic stirring bead (50 rpm). Aliquots of sterile complex liquid media (50 mL - pre-
warmed) in 250 mL Schott bottle in triplicate were prepared and each bottle was inoculated 
with 1 mL of stock from -20 °C (H. parasuis vaccine strain - B4C6) and incubated under 
stationary, inside candle jar, shaking (50 rpm) and stirring (50 rpm) conditions. For the 
stirring experiment, the media was autoclaved with a medium sized stir bar in order to use a 
magnetic stirrer for stirring requirement. All aliquots were incubated at 37 °C for 12, 24 and 
48 hours and taken each tube for sample analysis. 
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2.11.1 Result on effect of agitation on H. parasuis growth 
 
Figure 2.9: Effect of agitation of H. parasuis (B4C6) growth in complex liquid media at 
different time intervals. *Different superscript letters are significantly different using an 
ANOVA where p<0.05. (Appendix X, C). 
Figure 2.9 shows that the growth of H. parasuis was similar when the growth media was 
either left stationary or was actively stirred during incubation. Similar maximum levels were 
reached after 24 hours of incubation. Both showed a similar decline in viable counts when 
incubation was continued to 48 hours. During stationary growth, a thin layer of biofilm 
formation was observed. This was not observed in the stirred culture broth. Upon shaking of 
the stationary culture, the biofilm that was settled on the bottom of the bottle dissolved back 
into solution. Hence, no discrepancy in the TVC plate counts was observed between the two 
groups. As clearly shown in the graph, shaking of the fermentation media resulted in the loss 
of viable cells. This may indicate that the mechanism of shaking either damages the cells or 
that the level of oxygen is different to stirred cultures. Lower levels of growth were observed 
when the culture was kept inside the candle jar; and this might be due to the lower 
percentage of oxygen available for H. parasuis growth in broth. The statistical analysis 
showed no significant difference between stationary and stirring conditions on growth, but 
growth inside candle jar and shaking was significantly different. According to Kolmogorov-
Smirnov (KS) test, the population distribution for the ANOVA was normal, there is no 
significant difference between the sample replicates (P>0.150) (Appendix X, C). 
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2.12 Effect of free air space during small-scale culture 
This study is designed to test the effect of working volume or free air space on towards the 
growth of H. parasuis B4C6. One litre Schott bottle containing varying volumes of media was 
used for this study. The complex liquid medium (2 L -pre-warmed) was inoculated with 200 
mL of overnight culture of H. parasuis B4C6. The medium was then aliquoted into different 
Schott bottles in duplicates for two set of study at different period (12 hours and 24 hours 
incubation). The free air space percentage ranged from 90% free air space (total volume of 
100 mL in 1 L bottle), 80% free air space (total volume of 200 mL in 1 L bottle), 75% free air 
space (total volume of 350 mL in 1 L bottle), and 50% free air space (total volume of 500 mL 
in 1 L bottle). Each bottle was inoculated aseptically with an overnight culture. The culture 
was then incubated using stationary conditions in a tightly sealed Schott bottle for 24 hours 
at 37°C in an incubator. The fresh sample was taken from one set of bottles at 12 hours and 
the second set at 24 hour incubation for sample analysis. 
2.12.1Result on effect of maintaining airspace during culture 
 
Figure 2.10: Effect of free air space on H. parasuis (B4C6) cell growth. * Different superscript 
letters are significantly different using an ANOVA where p<0.05. (Appendix X, D). 
Since the Schott bottle was a closed system, there was a significant effect of free air space on 
growth especially between 80% and 50% after 24 hours of incubation (Figure 2.10). Growth 
was best observed when 80% free air space was used and it had a close match to 90% free air 
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space to maintain growth.  At 12 hours of incubation, growth was at the same rate for all 
ratios. It appears likely that at the 12 hours’ time point, the bacterial cells had not reached a 
point where the effect of oxygen was a limiting factor. By 24 hour, the cells have likely 
reached their highest level of growth (as also seen in Figure 2.9) and hence the effect of 
available oxygen (or lack of) has a more significant impact on the viability. Statistical analysis 
showed that each treatment used were significantly different from each other (ANOVA test, 
F= 431.20, P<0.001) (Appendix X, D). 
2.13 Effect of inoculum percentage on cell growth 
There is no published data available regarding the optimum inoculum percentage or the 
effect of inoculum percentage on H. parasuis growth. Hence was necessary to test this 
parameter, as it does become an important factor when considering large-scale fermentation. 
Inoculum was prepared using H. parasuis B4C6 strain (2.13.1 and 2.13.2), and the secondary 
inoculum was used as inoculum for this study to reduce the load of dead cells that can 
accumulate from the plate. Different percentages of inoculum (1%, 5% 10% and 20% of the 
final volume) were examined for their impact on growth at 12, 24, 28 36 and 48 hours of 
incubation. A total volume of 200 mL of complex liquid media (pre-warmed) was used in a 1 
L Schott bottle with different percentage of inoculum.  
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2.13.1 Result on effect of growth on inoculum size 
Figure 2.11: Effect of H. parasuis B4C6 growth on different inoculum percentage using 
complex liquid media. *Different superscript letters are significantly different using an 
ANOVA where p<0.05 (Appendix X, E). 
In this study, it is demonstrated there was a notable effect on growth at different inoculum 
sizes. The lowest inoculum percentages used (1% and 5%) did not show an appreciable 
increase in growth over 24 hours. However, 10% inoculum volume did show a significant 
increase in growth. Increasing to 20% inoculum size has a negative effect on growth. In fact, 
there was no evidence of growth at all at this percentage. It appears quite clear that the 
percentage of inoculum used in the fermentation culture does have a significant impact on 
growth and final yield. According to the observed results, 10% inoculum size was chosen as 
the optimized inoculum size for fermentation in Schott bottles. 
2.14 Determination of growth curve using complex liquid 
media 
Growth dynamics was studied using closed culture vessel containing a single batch of 
medium (batch culture). Both H. parasuis vaccine strain and parent strains were used in these 
comparison studies to determine the growth curve. The growth of H. parasuis reproduction 
by binary fission can be plotted as the logarithm of a number of viable cells versus the 
incubation time. The resulting curve can be regarded as the growth curve of H. parasuis in 
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complex liquid medium. The study was designed incorporating the optimal parameters 
discovered from the previous experiments as detailed in this chapter. Complex liquid media 
was prepared for the preparation of primary, secondary and test culture, and the sterility was 
confirmed prior to all experiments. Secondary inoculum (Section 2.14.2) was used as 
inoculum (10%) for this experiment to use potent cells (harvested early stationary phase) to 
shorten the lag phase of the actual experiment.  
2.14.1 Preparation of primary inoculum 
Plates were prepared as previously described in Section 2.6.4 and spread with 100 µl of 
secondary seed stock culture (Hps29 and B4C6) that were stored at -20 °C. Plates were 
incubated as recommended inside a candle jar. Lawn culture was observed in all of the plates 
after 24 hours incubation for parent strain and 36 hours of incubation for parent strain. For 
200 mL of complex liquid media a whole lawn culture (one plate) was washed with 2 mL of 
sterile media and pipetted back to the Schott bottle aseptically. Schott bottle (2 L) was sealed 
properly and incubated stationary for 24 hours at 37 °C (80% free air space). Primary culture 
was analysed for total viable count using prepared plates and plating appropriate dilutions. 
2.14.2 Preparation of secondary inoculum 
For the preparation of secondary inoculum, 20 mL of primary culture was inoculated onto 
fresh supplemented media (180 mL – pre-warmed) in a 1 L Schott bottle maintaining 80% 
free air space. The bottle was sealed and incubated for 18 hours at 37 °C (early harvest at 
stationary phase). Sample weremplated to determine the initial cell count of the experiment.  
2.14.3 Final growth culture 
For the experimental preparation, 30 mL of secondary inoculum was inoculated into fresh 
supplemented 270 mL of media (pre-warmed) and then aliquoted into 50 mL falcon tubes 
containing 10 mL culture. As this study required analysis of plate count, pH and OD600 
measurements at different time intervals, aliquots of inoculated culture (10 mL) were made 
as aliquots into a number of  50 mL falcon tubes to avoid the introduction of oxygen by 
opening the lid at every time interval. That is, each tube was used only once for sampling. 
Tubes were labeled for each time interval and aliquots were arranged in tube rack 
(stationary) and kept incubating at 37 °C for  designed time intervals (0, 2, 4, 6, 8, 10, 12, 14, 
16, 18, 20, 22, 24, 36, 48 hours) for both parent and vaccine strain. The population of growth 
was monitored over a period, each time interval sample was serially diluted (in Mareks 
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diluent) and different dilutions were plated onto CA plates (triplicates). After incubation, 
plates were manually counted and recorded for plotting growth curve. The same samples 
were also used to measure pH, and OD600 and reading were recorded for sample analysis and 
interpretation. 
2.14.4 Result on determination of growth curve 
 
Figure 2.12: Determination of H. parasuis (B4C6 vaccine strain) using complex liquid media. 
Valid data was obtained after repeating the experiment three times (Figure 2.12). Using the 
average from the experimental data the growth curve was plotted. From the data, it was clear 
that initially the cells took a few hours to adapt or adjust to the new medium (lag phase) and 
after four hours growth of the cells resumed through division by the process of binary fission. 
The cells then entered into exponential phase (log phase). From the growth curve, a sudden 
drop after 24 hours was observed and thereafter without a significant stationary phase being 
reached. The cells rapidly entered into death phase resulting in the observed gradual 
decrease in cell count. Growth is expressed as change in a number of cells (of colony forming 
units) with respect to time. The results obtained were similar for H. parasuis parent strain 
and vaccine strain. Since it is grown in a very rich medium, there are sufficient aromatic 
amino acids to replace limiting factors required by the vaccine strain (aroA gene mutation). 
The attenuated organism has an absolute requirement for aromatic amino acids and aromatic 
vitamins. It can utilize the nutrients available from the complex liquid media, which is rich in 
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these aromatic compounds. The parent type has no such need for these aromatic compounds 
as it is able to synthesis them internally. As the organism reached post peak phase (in this 
experiment after 24 hours incubation) H. parasuis, which normally appears as small rods, 
became much longer in size as observed following gram staining. 
2.15 Correlation of pH with growth in complex liquid media 
 H. parasuis vaccine strain (B4C6) growth analysis was conducted using similar experiment 
set up mentioned in Section 2.13. The samples were analysed at different time intervals 
(0,8,12,14,16,18,20,22,24,28) and pH, OD600 measurements along with viable cell counts by 
plating were done. The result observed at different time points were recorded in Table 2.6.  
2.15.1 Results and observation on pH, OD vs growth 
It was found that the optical density values taken during sample analysis did not correlate 
with actual plate count results. This was observed in all of the experiments when complex 
liquid media was used as a diluent. When the cell density increased, there was a drop in OD600 
measurements specifically at 22 hours of incubation. Measurements were inconsistent; 
hence, the OD values were un-reliable. 
pH measurements were recorded at room temperature for each time interval and the values 
were plotted against the plate count reading. From the plot shown in Figure 2.13, a significant 
drop in pH was observed starting from 7.41 to 6.16 with the growth rate increasing, it is clear 
from the graph that pH drop can be used as a good indicator of H. parasuis growth in complex 
liquid medium. There was a little colour change in the media when the growth reached 18 
hours of incubation where the pH dropped to 6.4. The appearance of turbidity remained the 
same until 24 hours of incubation. 
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Table 2.6: pH and OD values measured along with plate count. 
 
 
 
 
 
 
 
 
 
Figure 2.13: Correlation between pH measurements and viable cell density of B4C6 (cfu/mL) 
in complex liquid medium.  
Time (hours) pH OD600 TVC (cfu/mL) 
0 7.46 0.079 5.00E+06 
12 6.87 0.216 1.00E+06 
14 6.67 0.272 1.00E+06 
16 6.53 0.285 2.00E+07 
18 6.4 0.301 1.00E+08 
20 6.31 0.297 6.00E+08 
22 6.26 0.029 4.00E+09 
24 6.18 0.024 8.00E+09 
28 6.11 0.027 6.70E+07 
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2.16 Discussion 
Little attention has been given to the culture conditions of H. parasuis, required to obtain 
maximum high titre log-phased cells to use in vaccine manufacturing. This chapter aimed to 
optimize the necessary physical parameters, which eventually assist with maximum growth 
(high titre of viable cells) during fermentation. A complex liquid media was used to study the 
physical parameters of H. parasuis in broth culture as it is a fastidious organism with specific 
nutritional requirements [154]. Both parent strain and vaccine strain were in all experiments 
and were found to show similar results. 
The registration of a product relies mainly on the production of MASTER seed of the vaccine 
strain. All registration work will be based on materials derived off the Master seed. In this 
project, all work was based on a pre-master and secondary seed. A storage medium was 
modified for secondary seed (Table 2.5) prior to conducting experiments. Number of 
passages for the preparation of pMCB (CryoBeads™ tubes) and secondary seeds were 
minimized (not more than five passages) to reduce the possibility of phenotypic variation, 
genetic drift and contamination. Efficacy in storage and recovery of cells from pMCB 
(CryoBeads™ tubes) were analysed using plates and broth and it proved to be efficient and 
reproducible for H. parasuis parent and vaccine strain. The rate of viability and growth 
performance for secondary seed was studied at the time of storage and during experiments. 
The viability in the modified medium was good enough to keep the cells stable without many 
losses in counts and hence the secondary seed was used for all the experiments performed in 
this chapter. 
Sample analysis was performed by plate count methods as the OD measurements were not 
correlating with plate counts. These can be because of the media raw materials; for example, 
bovine serum albumin precipitates out during incubation. 0.1% NADH prepared in milli-Q 
water gives a 0.8 reading at 600 nm which might be also be interfering with the OD values 
[155] in H. parasuis culture. Plate count method was used for the accumulation of data from 
all the experiments and hence it is crucial to identify the right diluent for serial dilution. As 
this organism is very sensitive to an external environment, it is good to choose a diluent 
which does not kill or which won’t allow the organism to grow during the serial dilution 
preparation. In this study (Section 2.9.1), it was observed that “Mareks” diluent was the best 
option as diluent. Even though the complex liquid medium showed similar results, it was 
more convenient to use the Mareks diluent. Furthermore, Mareks diluent can also be used to 
resuspend the lyophilized vaccine product prior to delivery. Similar results were also 
observed when Morozumi and Hiramune did their experiment on diluents [105], and they 
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have concluded H. parasuis as very sensitive to saline and PBS at different temperatures 
compared to H. pleuropneumoniae or P. multocida. 
Influence of initial pH on media was studied to evaluate the sensitivity of H. parasuis towards 
the hydrogen ion concentration in the media. Fermentation media was adjusted to different 
pH levels as an initiative to find out the best suitable starting pH for H. parasuis in small-scale 
fermentation study. The growth was severely affected as the acidity of media was increased. 
Growth improved as the pH increased. Initial media pH was found to be optimal at 7.5. The 
growth studies (Figure 2.13) showed that the pH values were dropped with time but not 
dramatically. This is desirable for batch fermentation as there may be no need to control pH 
during fermentation. The pH decreased gradually until it reached 6.1 after 24 hour 
fermentation. In a large-scale fermenter with a short fermentation time, there may be no 
need to adjust pH.  
H. parasuis is regarded as microaerophilic, the organism uses oxygen for energy yielding 
respiration (O2-dependent growth), and they are poisoned by oxygen when it is above the 
limit (21 volume %). There is not one clarification on the specific oxygen requirement of 
microaerophiles that  apply  to  all  organisms and hence the  factors  involved  seem  to vary  
considerably,  even  within  a single genus [156]. The optimum O2 level of microaerophiles 
depends on the species and strain. The experiments were conducted to study the aeration 
requirement of H. parasuis using stationary, shaking, stirring conditions. It was observed in 
this study (Figure 2.9) that shaking may have introduced or incorporated a higher percentage 
of oxygen than that required such that it negatively affected the growth of this organism. 
Growth inside candle jar might offer a lower percentage of oxygen (anaerobic condition) 
hence, the growth was also negatively affected. Stationary and stirring conditions on H. 
parasuis resulted in similar growth outcome as introduction of the lower percentage of 
oxygen helped the binary fission and metabolism of this particular organism. For practical 
reasons during small-scale culture, the culture was incubated under stationary conditions for 
all the experiments. A noticeable biofilm that formed on the bottom of the bottle under 
stationary condition was found to go back into solution followed a simple shaking of the 
bottle. There was also no effect on plate count. Since stirring at low speed also has same 
growth rate it can be used in large fermenter since it is not practicable to uniformly mix the 
settling products into solution. 
 During cell metabolism, the cell undergoes different biochemical reactions and so the cell 
both intakes and eliminates different types of gases such as nitrogen, oxygen carbon dioxide, 
sulphur. Therefore, a major gas transfer occurs during cell growth and hence the working 
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volume is critical to identify for each bacteria during fermentation in a closed system. It is 
identified in this chapter that there was significant growth reduction when the percentage of 
free air space was reduced from 90% to 50% (Figure 2.10). Reduction of working volume 
helped to improve the growth rate by three log increase and this indicates growth appears 
good at low working volumes. As the system used was closed Schott bottle there was only 
very less probability of gas exhaustion through the lid. Hence, this organism grown at lower 
working volumes and it is evident that there was a significant effect of free air space on H. 
parasuis culturing.  
Inoculum reliability in terms of size and quality is very much crucial for every fermentation 
process for effective reproducibility of culture. In this study, secondary inoculum was used as 
inoculum for the final experiment to reduce variability that could happen by inoculating 
colonies from plates or using primary inoculum (Section 2.14.1 and 2.14.2 for preparation). 
Secondary inoculum would contain a mixture of the higher percentage of living cells and the 
lower percentage of dead cells as it is harvested early log phase. Here in this study it is 
demonstrated there is an effect on growth with different inoculum percentage. Higher 
percentage (20%) of inoculum did not translate to higher growth. Similarly, a lower 
percentage (1%) of inoculum did not stimulate high growth. It was observed (Figure 2.11) 
that inoculum of 10% was optimum and produced the highest yield of live cells.  For 
industrial scale production, inoculum volume becomes an important factor. 
Complex liquid medium was inoculated with a given number of cells and the growth was 
monitored over a period. The data was plotted to yield a typical bacterial growth curve 
(Figure 2.12). The lag phase for H. parasuis seen in this study was around 4 hours 
representing adaptation of inoculated cells to a new environmental conditions [157]. After 
four hours of incubation, cells entered into their growth phase as they began multiplication, 
reaching a high titre of log 9 cfu/mL. The growth then entered into decline phase by 36 hours 
of incubation. The stationary phase was very short. Growth curves obtained in complex liquid 
medium for parent strain and vaccine strain demonstrated a similar pattern. The result from 
this chapter demonstrated the optimal parameters for the growth of H. parasuis in complex 
liquid media. 
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CHAPTER 3: 
Development of regulatory compliant 
growth media for small to medium scale 
production of H. parasuis vaccine strain 
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3.0 Introduction 
Chapter 2 explored the physical parameters required for the in vitro propagation of the 
parent and vaccine strains of H. parasuis at a small-scale (10 mL to 200 mL). It is necessary to 
confirm that the growth parameters and media components are scalable to ensure 
commercial feasibility. This chapter focuses on defining the liquid growth media for the 
growth of H. parasuis vaccine strain by comparing growth profiles of H. parasuis in complex 
media with growth in a series of modified media. Through a series of elimination and 
replacing studies, components essential to growth were identified. Specific media 
components were substituted with chemically similar components to allow for the 
development of a more registration compliant media composition (e.g. substituting animal-
based proteins with plant based protein sources). Ultimately, the finalized ‘regulatory 
compliant’ media required testing at large volume scale to ensure that growth is sustained at 
higher volumes. Fermentation platforms including solid fermentors as well as disposable 
bioreactor bags were tested. Endotoxin quantification of samples from different experiments 
was performed in this study. 
3.1 Regulatory compliant medium development 
A complex liquid medium is formulated by including raw materials of undetermined 
compositions while a defined medium is made of pure chemicals in specifically known 
proportions [158]. Most of the studies with H. parasuis used colonies grown on solid agar 
plates. Little information exists regarding the growth characteristics of H. parasuis in liquid 
media. Nevertheless, a complex formulation does exist for H. parasuis [59, 149] which has 
been used for solid media. However, it is not known whether all the components or the 
quantities present in the complex liquid media formulation are necessarily optimized. This is 
particularly important for commercial production to ensure that the correct levels of each 
component are supplied to ensure optimum and consistent growth. It is likely that the media 
contains excessive as well as unnecessary raw materials for growth. Some raw materials can 
have a positive or negative effect on bacterial cell metabolism or cell growth. For example, 
some functions of H. influenza are significantly affected by the omission of an essential 
component in the media while other functions remained unchanged [159].  An important 
function of a defined or regulatory compliant media is to ensure that all the necessary 
components are present and in their correct quantities to ensure maximum bacterial cell 
yield and in a predictable incubation time. Unlike wild type H. parasuis strains, the vaccine 
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strain has a deficiency in aromatic amino acid de novo synthesis and hence the composition of 
the media must ensure that these aromatic amino acids are present and accessible to the 
organism for in vitro growth. 
3.2 Role of key raw materials in growth medium 
Microbial growth medium is a nutritional environment in which bacteria can grow and 
multiply. Nutrient requirements for bacterial fermentation are classified as sources of carbon, 
nitrogen and sulfur, minerals, vitamins and other growth factors.  
Carbon: 
On a dry weight analysis biomass consists of 40 to 50% of carbon and hence the carbon 
source is an essential microbial growth raw material [160]. Organic materials such as 
proteins, lipids, carbohydrates (such as glucose, sucrose, starch) undergo oxidoreduction to 
release carbon for cell metabolism and functioning in microorganisms and eventually it is 
secreted from the cell as CO2.  Some organisms use single carbon source and other organisms 
use more than one carbon source for energy yielding mechanisms. H. parasuis is 
microaerophilic, and so CO2 from the air can also serve as a source of carbon [134]. Most 
bacterial media formulations have carbon as energy source, and it is usually present at higher 
percentage (0.2 to 25%) compared to other sources in the media. 
Carbohydrates are excellent energy sources composed of carbon, hydrogen, and oxygen. They 
can be divided into three broad classes: monosaccharides, disaccharides and polysaccharides. 
The concentration at which they are added to media requires control, as high amounts of 
glucose can lead to the accumulation of acetate and a reduction in pH that  can reduce 
biomass yield and expression levels of recombinant proteins in  E. coli and some other 
microorganisms by reducing pH [161]. Carbohydrates can be utilized via three major 
pathways or cycles, the Embden-Meyerhof pathway (EMP) in which the oxidation of glucose 
to pyruvate with the generation of ATP and NADH take place, the pentose-phosphate 
pathway (PPP) in which NADPH is regenerated from NADP+ through an oxidation/ reduction 
reaction, the Krebs or tricarboxylic acid cycle (TCA) which plays a key role in aerobic 
respiration of cells [162]. 
Nitrogen: 
Microorganisms need micro and macro elements to synthesis cellular material beside water 
and carbon sources. Some organisms use nitrogen as sole energy source rather than carbon. 
Other organisms utilize both as energy sources. Nitrogen has an essential role in anabolic 
synthesis of nitrogen containing cellular substances, such as amino acids, purines, DNA, and 
 85 
 
RNA. Different organisms use different forms of nitrogen, for example, Cyanobacteria utilizes 
gaseous nitrogen- (N2), other organisms use nitrogen from ammonium ions (- NH4+) and /or 
nitrogen from nitrates (-NO3-). The synthesis of ATP molecules requires nitrogen and 
phosphorous (PO43-) which helps to store and transfer of chemical energy within the cell. 
Inorganic forms like urea, NH4Cl and (NH4)2SO4 can be used as nitrogen sources in defined 
medium [163]. In synthetic medium urea raises the pH of the medium depending upon the 
buffer capacity of the system. In contrast, when using ammonium sulphate, the ammonium 
levels rise rapidly resulting in the release of free acid (H2NCOOP) which can reduce the pH 
dramatically as seen on the below reaction [134, 160]. 
    NH3+ATP + C02+H2NCOOP + ADP  
Trace elements: 
Phosphorous are used as the building blocks of phospholipids of the cell membrane. Sulfur 
(SO4, H2S) is used to synthesis amino acids bonds and sulfur containing vitamins such as 
thiamine and biotin [164]. Organic nutrients such as amino acids, peptones (in native forms 
or reduced forms) serve as sources of nitrogen, phosphorous and sulfur. Elements such as 
magnesium, potassium, calcium are also involved in cell metabolism and often act as 
cofactors for enzymes. Magnesium has an important role in growth and cell division by 
assisting in the synthesis of DNA and protein. The role of growth elements are tabulated in 
Table 2.1 of Chapter 2 [134]. Other trace elements such as iron, copper, molybdenum and zinc 
can often found in distilled water that is used for the preparation of media. However, defined 
amounts can be added according to the requirement  of a specific bacteria [164].  
3.3 Consequence of aroA gene deletion  
Inactivation of a key precursor for aromatic amino acid biosynthesis is a potential strategy for 
the construction of attenuated vaccine strains (e.g., attenuated aroA derivative of Pasteurella 
multocida B:2 [165], L. monocytogenes [166], Salmonella typhimurium) [167]. The shikimate 
pathway is critical for the biosynthesis of chorismate, the precursor for aromatic amino acids 
(phenylalanine, tyrosine, and tryptophan) and aromatic secondary metabolites, Figure 3.1 
[94]. 
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Figure 3.1: Synthesis of chorismate through shikimate pathway [94, 168]. 
Several other bacterial vaccines have been constructed by introduction of mutations or 
deletions within the aroA gene thereby rendering them auxotrophic and, therefore, 
dependent on an external source of aromatic amino acids for their survival. Various authors 
described and demonstrated the applicability of this strategy towards the development of 
attenuated vaccines [94, 169-173]. The deletion or the elimination of the function of the aroA 
gene renders the strain dependent on aromatic amino acids. However, the limitation can be 
overcome by supplying aroA mix or other sources like serum when culturing of the 
attenuated organism in vitro [174]. 
3.4 Need for scale up studies  
The process of vaccine development proceeds through various stages from concept to the 
final licensed product. The registered product must meet market volume while strictly 
adhering to a strict standard of manufacture that is governed by domestic and global 
regulatory agencies. The flowchart below represents the steps from concept of the products 
to licensed commercial product (Figure 3.2). 
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Figure 3.2: Role of scale-up strategy during commercial product development [175]. 
The experiments described in this chapter were mostly carried out on a small-scale, in Schott 
bottles for anaerobic fermentation or shake flasks for aerobic fermentation, to demonstrate 
proof of concept through trial and error based experiments. 
3.5 Regulatory requirements for manufacturing vaccine 
Regulations within the vaccine industry aim towards the production of vaccine that is well 
defined and safe. Agencies such as FDA (Food and Drug Administration), TGA (Therapeutic 
Goods Administration), APVMA (Australian Pesticides and Veterinary Medicines Authority) 
are committed to fostering the efficient, rapid development of vaccines needed for the public 
health. Vaccine manufacturing and process development approaches may vary from country 
to country according to the local needs, but mainly it intends to provide pure, potent, safe and 
effective vaccines for animal health maintenance (USDA, 2011). Licensing of veterinary 
vaccines requires manufacturing of both active raw material and finished product under 
Good manufacturing practices (GMP). Transmissible Spongiform Encephalopathies (TSE) are 
charactrised by altered prion proteins. TSE causes a slow degeneration of central nervous 
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system resulting in fatal brain disease. The disease is transmissible in both animals and 
humans. These prions are very hard to deactivate by heat or chemical. Bovine derived 
products are prohibited in the US and many other countries as it can have traces of Bovine 
spongiform encephalopathy (BSE). BSE has the potential for intercontinental spread of 
infections in animals and as well as in humans. Therefore, it is critical that the risk be 
sufficiently managed as many complex liquid media protein based components are bovine 
derived. Specific sources where TSE disease may be present are listed below: 
TSE (Transmissible Spongiform Encephalopathies) diseases in animals include: 
 Bovine spongiform encephalopathy (BSE) in cattle, BSE was first diagnosed in the 
United Kingdom in 1986) 
 Scrapie in sheep and goats 
 Chronic wasting disease (CWD) in cervids (deer and elk) 
 Transmissible mink encephalopathy (TME) in farmed mink 
 Feline spongiform encephalopathy (FSE) in fields (specifically domestic cats and 
captive large cats), and 
 Spongiform encephalopathy of exotic ungulates in zoos. 
Production containing this product should also take account of following factors: 
 Route of administration (pig and bird species are not naturally susceptible to 
infection via the oral route) 
 Quantity of animal material used in the medicinal product 
 Maximum therapeutic dosage (daily dose and duration of treatment), 
 Intended use of the medicinal product and its clinical benefit 
 Presence of a species barrier (European Commission, 2011/C 73/01).   
There are a number of regulatory requirements to assess if any animal products are included 
in the manufacturing process or the finished product. Animal's products commonly used for 
bacterial fermentation include beef extract, lanolin (wool derivative), lactose, gelatin, and 
collagen. A cautious approach is implemented to license the use of biological material as 
media components from species naturally affected by TSE diseases, particularly bovine 
species when used for the manufacture of medicinal products. These materials can be 
approved by obtaining TSE Certificate of Suitability issued by European Directorate for the 
Quality of Medicines & HealthCare (EDQM) (European Commission, 2011/C 73/01). 
However, it is far better to exclude the use of ANY bovine or animal-based components in 
 89 
 
media. This will allow for easier progression through commercial registration both in 
Australia and globally. 
3.6 Cost effective management in fermentation 
The success of any fermentation relies upon the ability to produce a successful fermented 
product and to sell the product to recover all the cost along with the desired profit. These 
include upstream and downstream processing specifically cost-effective management in 
choosing inexpensive and potent media components by the careful design of media raw 
materials. Cost effective management could apply not only on raw materials, but also on 
equipment; by using single use systems (disposable - filters, bioreactors, mixers, containers, 
tubing’s bags, membranes, sampling devices, probes, sensors and chromatography columns) 
over traditional hard body re-usable equipment. Another important factor is the labor and 
cost involved in sterilization of reusable equipment. The development, validation and 
verifications of sterilization procedures is labor intensive and a firm requirement for GMP. By 
using disposable fermentation bioreactor systems, this requirement is largely eliminated, 
hence ultimately reducing overall cost of manufacture [176]. 
Bioreactors or fermentors are the prominent technologies for the production of a high yield 
of microorganisms, primary or secondary metabolites or the production of mammalian cell 
lines. Fermentors are typically manufactured as static systems that can be used repeatedly. 
Equipment capacity ranges from small-scale (bench top) to large-scale (20,000 L or greater). 
Bench top or miniature bioreactors (stainless steel or glass) are more frequently utilized for 
scale up and scale down studies prior to an industrial application in which different mode of 
operations are also possible (batch/continuous fermentation, solid/liquid state 
fermentation). Over the past few decades, the designs and control of each vessel have been 
improved with automated processing and real-time control systems. Advantages of single use 
systems (SUS) over traditional equipment are listed in Figure 3.3.  
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Figure 3.3: List of reasons why single use systems could save money over traditional 
equipment’s [176]. 
3.6.1 Single use-bioreactor as a cost efficient technology 
Single-use bioreactors invented by Dr Vijay Singh, the first “wave” bioreactor was available to 
the market in 1996 and since then the wave-based design was adopted both for clinical 
research studies and large-scale production. The reduction in the cost of implementation and 
the decrease in the risk associated with cross-contamination in manufacturing facilities have 
significantly increased the use of these [177]. Biopharmaceutical benchmarks (2010) pointed 
out several advantages of single use bioreactors which include reduced capital equipment 
requirements, faster set-up times, minimal validation, the elimination of cleaning-in-place 
requirements and associated short production turnaround times [177]. This system also 
facilitates an easier pathway to meet the increased review criteria set by FDA that has been a 
major block for many drug approvals.  
Even though the emergence of the disposable wave bag was a success, there were a few 
barriers (Figure 3.4), including the existing investment made on stainless steel fermentors, 
shortage of expertise to handle the operations with bag, extractable or leachable compounds 
that could come in contact with the product of interest and the disposal of these plastic wares 
into the environment. These limitations have now been largely resolved through 
collaborative researcher with engineering firms. The advantages of modern single use system 
are listed in Figure 3.4, and their various markets are listed in Table 3.1. 
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Figure 3.4: List of barriers in single use system emergence cited in 2009 Bio process 
International end-user survey.  
Single use systems were most commonly used for cell culture (mammalian cell culture). They 
have recently proven to be flexibile and productive for microbial fermentations [178]. A 
number of cell lines (HEK, NS0, CHO, S2 and SF9) demonstrated successful propagation of 
inoculum in perfusion culture using WAVE bag bioreactor and shown it could achieve 5 to 10 
fold higher split ratio compared to traditional batch culture. Figure 3.5 shows a schematic 
drawing of perfusion cell line culture set up controlled by the processing unit [179]. Its 
potential in the manufacturing of H. parasuis culture remains to be demonstrated.  
 
Figure 3.5: Propagation of cells inside a WAVE Bioreactor equipped with automated control 
unit in a perfusion set-up [179]. 
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Table 3.1: List of market estimates on expenditures around the world for biopharmaceutical 
equipments [180].
 
3.7 Bacterial endotoxin and determination 
Endotoxin (lipopolysaccharide, LPS) is the major component of the outer membrane of Gram-
negative bacteria. Vaccine derived from these bacteria hence retains a considerable amount 
of endotoxin that should receive proper consideration. The receptors of the innate immune 
system are involved in the recognition of LPS and the initial signal transduction pathway 
[181]. LPS can have a profound immunostimulatory and inflammatory capacity and can result 
in tissue injury and septic shock that can result in sudden death [182]. This is due to the 
presence of endotoxin causing the release of several mediators (TNF, several interleukins, 
prostaglandins, CSF, platelet activating factor and free radicals) from the immune cells which 
can result in serious side effects on cells or organs [183].   
LPS is an important structural component of outer cell membrane of gram negative bacteria 
which is also responsible for the organization and stability of cell as depicted in Figure 3.6. 
Lipopolysaccharides characteristically are made of a hydrophobic domain known as lipid A 
(or endotoxin), a non-repeating “core” oligosaccharide, and a distal polysaccharide or O-
antigen [182]. LPS is linked to the cell membrane, but it is released continuously into the 
environment during cell life cycle (growth, division and death), and the amount of secretion is 
specific to the bacteria and its environmental conditions. Small amount of endotoxin in the 
final product, accumulated during the production process is often present in drugs, injectable 
and other biological and pharmaceutical products [183]. 
While the active LPS can cause serious side effects, a recent study showed that modified 
forms of endotoxin molecules (i.e., toxoid form) could be used as adjuvants in vaccine 
production. The toxoid can trigger the immune system allowing more immune cells 
(monocytes and macrophages) into the blood stream thus creating a general alarm that 
assists in recognition of  the key antigen [184] resulting in a cascade effect ultimately 
enhancing the immune response without causing a toxic effect. 
 93 
 
 
Figure 3.6: Electron micrograph of Escherichia coli (a), together with a schematic 
representation of the location of lipopolysaccharide (LPS; endotoxin) in the bacterial cell wall 
(b) and the architecture of LPS (c). Also shown is the primary structure of the toxic center of 
LPS, the lipid component (d) [182]. 
Due to the serious risk issues accompanied with endotoxin, the FDA has set guidelines for 
parenteral drugs and medical devices [185]. According to the United States Pharmacopeia 
(USP) the endotoxin limits were calculated by animal weight and its limit was set to no more 
than 5 EU/kg for most of the drugs (USP sets endotoxin limits by EU/kg), but not for other 
commercial vaccines. For commercial vaccines, the appropriate endotoxin levels are 
tabulated in Table 3.2. The allowable limit is dependent on the type of vaccine. For example, 
vaccines which are comprised of toxoids (Cholera vaccine) or whole cell vaccine will contain 
a much higher percentage of endotoxin compared with than purified forms of vaccines. 
Endotoxin levels are specific to each licensed vaccine. For gram negative bacterial vaccines 
such as an H. parasuis vaccine, the final product must contain a safe level of endotoxin. This 
limit must be consistently maintained through every production run to ensure safety of the 
final product.  
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Table 3.2: Recommended limits of endotoxin for different types of vaccines [186]. 
Quantification of endotoxins was not possible when rabbit pyrogen tests were used. In this 
test, the sample was injected into the animal, and the rise in temperature is assessed as an 
indicator for endotoxin estimation (rise of 0.5 °C indicated the presence of pyrogencity) 
[185]. The limulus amebocyte Lysate (LAL assay) is an acceptable standard assay for 
endotoxin estimation and quantification as an alternative for the detection of endotoxins by 
rabbit pyrogen tests. LAL assay is based on an enzyme Limulus Polyphemus extracted from 
cell lysates (blood cells from pericardium) of horseshoe crab. This enzyme forms clots in the 
presences of endotoxin. Various tests such as the gel clot assay method, kinetic chromogenic 
method and kinetic turbidimetric method also use this enzyme as their basis. It is claimed 
that chromogenic substrate assay (0.005 EU/mL) is more sensitive than gel clot assay (0.03 
EU/mL) [185, 186]. According to European pharmacopoeia (LAL assay by gel clot method), 
endotoxin concentration that is less than 1 x 106 IU/dose is acceptable unless a higher 
amount is shown to be safe by clinical trials. 
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3.8 Objective  
The main objectives of this chapter include: 
1) To examine the effect of different sources of nitrogen source for inclusion into the 
growth media. 
2) To examine the effect of replacing bovine serum with additional percentage of pig 
serum in the growth media. 
3) To investigate the effect of carbon sources and amounts on yield of the vaccine strain. 
4) To determine the growth in a regulatory compliant media for both parent strain and 
vaccine strain. 
5) To demonstrate the effect of growth media optimization in scale up at 3 litres, 15 litre 
fermentor and a disposable bag. 
6) To quantify endotoxin levels in different fermentation samples using endotoxin assay. 
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3.9 Material and Methods 
H. parasuis strains, vaccine strain (B4C6) and parent strain (Hps29) were used in this 
chapter. B4C6 is an abbreviated form and it stands for the aroA attenuated vaccine candidate 
of the parent strain Hps29 (serotype 2). General procedures for the preparation of media and 
supplements, B4C6 and Hps29 strain details are stated in Section 2.6 and 2.7 of Chapter 2. 
3.9.1 Preparation of overnight culture 
Overnight night broth cultures were used for both B4C6 and Hps29 in small-scale test 
experiments. From -20 °C freezer secondary seed (Section 2.7.4, Chapter 2), B4C6 and Hps29 
Eppendorf tubes were thawed for 5 min at room temperature. Chocolate Agar plates were 
spreaded with 50 µl of 0.1% NADH using a sterile L–spreader. Inside the laminar, a loop full 
of culture was spread onto pre-labeled chocolate agar plate using a sterile loop. Plates were 
kept inside a candle jar at 37 °C. Plates with Hps29 were incubated for 24 hours, and B4C6 
was incubated for 36 hours as optimized in Chapter 2. 
After incubation period, plates were harvested for inoculation into sterile broth. For 200 mL 
of media, lawn culture from one plate was used to prepare overnight culture. Under aseptic 
conditions, lawn culture from each plate was scooped out with sterile L- spreader using 
sterile media and sterile pipette tips for resuspending. Hps29 and B4C6 lawn culture were 
inoculated into pre-warmed 200 mL of sterile media and grown overnight (24 hours, 
stationary at 37 °C) in a sealed Schott bottle (1 L). After 24 hours the culture was harvested 
(overnight culture) and used for test experiments. 
3.9.1.1 Statistical Analysis 
Statistical analyses of experiments were completed by transforming the exponential data’s 
into logarithms to the base 10. Appropriate tests were used to ensure normality, equal 
variance in the transformed data before analysis of variance (ANOVA), and residuals were 
tested for normality (Section 3.9.3.1 and Section 3.9.4.1). Error bars were included in the 
graphs, which were based on the standard deviation (from plate triplicate count results). 
Enumeration of colonies was done in triplicate for all the experiments. Statistical analysis 
were performed for samples havested at 24 hours using one way ANOVA and the probability 
of distribution was tested using  Kolmogorov–Smirnov test (KS test). Statistical analyses 
using minitab 16 (Software) were performed on experiments as described under Appendix X 
(F,G). 
 97 
 
3.9.2 Comparative growth analysis of parent strain and vaccine 
strain in complex liquid media in Schott bottles 
A series of experiments were designed to evaluate significant differences in growth when 
Hps29 and B4C6 were grown in complex liquid media (Table 3.3). In Chapter 2, this 
experiment was performed using falcon tubes.  This experiment was designed to study the 
nature of growth by both strains in complex liquid media in Schott bottles. In order to 
perform the experiment, aliquots of complex liquid media in duplicates (180 mL in 1 L Schott 
bottle) were prepared and sterilized. The sterile media was then inoculated with overnight 
culture (10%) and 200 mL of total media was then incubated at 37 °C. Samples were analysed 
by plate count at different time intervals (0, 4, 8, 12, 16, 20, 24, 28, 34, 48 hours) to establish 
a growth curve  and to determine whether there is any significant growth difference because 
of the aroA attenuation in vaccine strain (B4C6).  
Note - In Chapter 2 (Section 2.14), this experiment was done using falcon tubes (10 mL in 50 
mL tube capacity)  
Table 3.3: List of raw materials in complex liquid media used in this study; media raw 
materials have been used for solid media culturing especially for Pasteurella family species 
organisms (Appendix I).  
 
  
Media raw materials 100 mL 
Biostate peptone 1 g 
NaCl 1 g 
Starch 0.1 g 
Glucose 0.05 g 
Yeast Extract 0.05 g 
Distilled Water 91 mL 
0.1% NADH 2.5 mL 
0.1% Thiamine HCl 0.5 mL 
Heat inactivated Pig serum 1 mL 
O-A complex 5 mL 
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3.9.2.1 Growth pattern analysis of Hps29 and B4C6 cultured in complex liquid 
media 
Parent type strains (Hps29) and vaccine strain (B4C6) were grown in complex liquid media 
for growth analysis under optimized parameters (stationary, pH 7.5, 10% inoculum, 80% free 
air space). Samples were collected at different time point over 48 hours incubation period at 
which time the samples were serially diluted for plating. Samples were plated immediately 
after each time points and were incubated for 24 hours and counted manually for 
enumeration. A growth curve was established with recorded total cell viable counts versus 
time interval to study the pattern of growth. 
 
Figure 3.7: Growth curves of parent strain and vaccine strain grown in complex liquid media. 
Figure 3.7 shows the growth curve of parent type and vaccine strains grown in complex 
liquid medium for 48 hours (similar pattern was observed in Figure 2.9). Peak titre (Log 10 
cfu/per mL) was reached after 24 hour's incubation that then declined drastically after 24 
hours for both strains. There was no significant difference in growth between parent strain 
and vaccine in complex liquid medium, even though the vaccine strain is aroA mutated. This 
could be because of the rich source of complex liquid media that delivers all aromatic amino 
acids, which was essential for its cell growth. 
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3.9.3 Preparation of nitrogen source to study the effect on cell 
density 
For the development of regulatory compliant media (RCM) based on the complex liquid 
media (Table 3.3, Appendix I) formulation it was essential to study the effect of different 
nitrogen source or combination of nitrogen source with other nutrients on vaccine strain 
(B4C6) growth. Complex liquid media (Appendix I) contains Biostate peptone (BP) as 
nitrogen and carbon source, and it is a mixed hydrolysate comprised of casein and yeast 
extract at a ratio of 65:35 (BBl, MSDS). Since the BP is comprised of complex protein sources 
of animal original, a series of experiments were designed to replace BP with a suitable 
alternative. Different sources of nitrogen were used in the study which included Tryptone 
(Oxoid - LP0042 pancreatic digest of casein), soy peptone (vegetable peptone, Oxoid - 
LP0044), Nzcase (casein digest), Biostate peptone (BBL), yeast extract (Oxoid), NH4Cl 
(MERCK) and (NH4)2SO4 (Merck). Each nitrogen source (Table 3.4) was used replacing 
biostate peptone from the original complex liquid medium raw material list (Table 3.3). 
Aliquots of medium were prepared in duplicates and sterilized as described in Chapter 2. 
Sterile media (190 mL) in a 1 L Schott bottle was incubated with 20 mL of overnight culture 
(B4C6) at 37 °C. Inoculated media was then incubated under optimized conditions 
(stationary, pH 7.5, 10% inoculum, 80% free air space) for 12 and 24 hours. Samples were 
analysed following serial dilution and plating techniques (Section 2.6). 
3.9.3.1 Result on effect of nitrogen source on B4C6 cell density 
Samples were analysed in triplicate on chocolate agar plates incubated inside a candle jar for 
36 hours at 37 °C. Plates were counted manually and recorded. The experiments were 
repeated three times and the results are plotted graphically (Figure 3.8). The sources of each 
nitrogen component are detailed in Table 3.4 and Control is highlighted in yellow. 
Table 3.4: Different nitrogen source used to study the effect on cell density. 
Label no: Nitrogen source 
N1 1% Tryptone 
N2 1% Soypeptone 
N3 1% Nzcase 
N4 1% Yeast extract 
N5 10% Ammonium chloride 
N6 10% Ammonium sulfate 
N7 1% Soypeptone + 0.5% yeast extract 
N8 1% Soypeptone+0.5% tryptone 
N9  1% Biostate peptone -control 
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Figure 3.8: Graphical representation of nitrogen source effect on B4C6 growth. *Different 
superscript letters are significantly different using an ANOVA where p<0.05 (Appendix X, F). 
Figure 3.8 clearly shows that there was a significant difference in growth rate between 
inorganic and complex nitrogen sources when compared against Biostate peptone (N9). 
Among the complex nitrogen sources N2 (1% soypeptone), N7 (1% soypeptone + 0.5% yeast 
extract) and N8 (1% soypeptone + 0.5% tryptone) all demonstrated growth that was 
comparable if not slightly better than 1% biostate peptone.  Statistical analysis showed the 
control (N9) was not significantly different from N8 and N9, but significantly different to N7. 
N7 resulted in high yield out of all combinations tested. The plant based soy peptone is 
clearly a suitable alternative complex protein source to the animal-based biostate peptone. 
Hence, the media raw material list was modified and tabulated as Table 3.5 (Appendix II, A).  
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Table 3.5: Version 1.1 of modified media; from the complex liquid media (version 1 - Table 
3.3) biostate peptone is replaced with neutralised soy peptone and the amount of yeast 
extract in original media is increased from 0.1 g to 0.5 g. 
 
 
 
 
 
 
3.9.4 Effect of replacing bovine serum albumin by increasing pig 
serum percentage 
Another animal-based component that was targeted in the complex liquid media was bovine 
serum albumin (BSA). Complex liquid media consists of 5% oleic acid-BSA complex consisting 
of 4.75% BSA (fraction V) in normal saline. To support the requirement for BSA, pig serum 
percentage present in the original formulation (1%) was increased, and the effect has been 
examined on B4C6 growth. Aliquots of modified complex liquid media (Appendix II, B, 
Version 1.2- Table 3.6) with different percentage (1%, 5%, 15% 10%, and 20% of total 
medium) of total pig serum were studied as a replacement to BSA in the raw material list. 
Each test group was compared to the control group, which contained 4.75% BSA in modified 
media (Table 3.5). Aliquots were prepared and sterilized in a 250 mL Schott bottle, and 
different percentage of filter sterilized pig serum was added.  
In order to inoculate the test and control groups or aliquots of media overnight culture were 
prepared (Section 3.9.1). Modified media (Table 3.6) without BSA was used in the 
preparation of overnight culture. Overnight culture (10%) was inoculated to the test and 
control groups and then incubated at optimized conditions (stationary, pH 7.5, 10% 
inoculum, 80% free air space). Samples were harvested after 12 hours and 24 hours and then 
analysed by plate counts. 
 
Media raw materials 100 mL 
Neutralised Soy peptone 1 g 
NaCl 1 g 
Starch 0.1 g 
Glucose 0.05 g 
Yeast Extract 0.5 g 
Distilled Water 91 mL 
0.1% NADH 2.5 mL 
0.1% Thiamine HCl 0.5 mL 
 Pig serum 1 mL 
O-A complex 5 mL 
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3.9.4.1 Result on replacing BSA with different percentage of pig serum 
Samples from the incubated culture were analysed by serial dilution and thereafter each 
dilution were plated onto CA plates. Plates (triplicate) were incubated for 36 hours and 
counted manually for enumeration. The studies were repeated three times and the results 
were used to plot a graph (Figure 3.9). 
 
Figure 3.9: Effect of replacement of BSA with different percentage of pig serum. *Different 
superscript letters are significantly different using an ANOVA where p<0.05 (Appendix X, G). 
Figure 3.9 illustrates clearly the effect of increasing pig serum as a replacement for BSA. 
Similar levels of growth were reached when the BSA was replaced with 10%, 15 % or 20% 
pig serum. 1% and 5% pig serum were not sufficient to reach growth levels comparable to 
the control group. It was clear that there was no need of increasing pig serum beyond 10% as 
there was no significant growth benefit gained by increasing beyond 10%. Serum is very rich 
in amino acid although the actual quantification of each component is unknown. 4.75% of 
BSA and 1% of pig serum was used in the original medium. When 4.75% of BSA was replaced 
with 10% of pig serum, the results obtained was similar to that obtained from the complex 
liquid medium. Statistically, the control and 10%, 15%, 20% did not show any significant 
difference, but in contrast, control was significantly different from 1% and 5% of additional 
pig serum (Appendix X, G).  
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Table 3.6: Version 1.2 of modified media; from the complex liquid media in which O-A 
complex was replaced with an additional percentage of pig serum (increased from 1 mL to 10 
mL). 
 
 
 
 
 
 
 
3.9.5 Effect of removing Thiamine.HCl from the medium on growth 
yield of vaccine strain 
Complex liquid media is comprised of Thiamine.HCl (0.5 mg for 100 mL of media). Pig serum 
consists of moderate levels of thiamine and hence the increase in serum percentage might be 
enough to replace the need for supplementation with Thiamine. In order to examine this, 
experiments of modified complex liquid media (Table 3.7, Appendix II, C, Version 3) of 50 mL 
was prepared in duplicates, in 250 mL Schott bottles with and without Thiamine.HCl. In order 
to inoculate the test groups or aliquots of media overnight culture was prepared (Section 
3.9.1). Modified media (Table 3.7) was used in the preparation of overnight culture. 
Overnight culture (10%) was inoculated to the test groups and then incubated at optimized 
conditions (stationary, pH 7.5, 10% inoculum, 80% free air space). Samples were harvested 
after 6 hours, 12 hours and 24 hours and then analysed by plate counts. 
Table 3.7: Version 1.3 of modified media; from the complex liquid media (version 1- Table 
3.3) in which 0.1 % Thiamine.HCl is excluded from the raw material list (Appendix II, C). 
  
 
 
 
 
  
Media raw materials 100 mL 
Neutralised Soy peptone 1 g 
NaCl 1 g 
Starch 0.1 g 
Glucose 0.05 g 
Yeast Extract 0.5 g 
Distilled Water 87 mL 
0.1% NADH 2.5 mL 
0.1% Thiamine HCl 0.5 mL 
 Pig serum 10 mL 
Media raw materials 100 mL 
Neutralised Soy peptone 1 g 
NaCl 1 g 
Starch 0.1 g 
Glucose 0.05 g 
Yeast Extract 0.5 g 
Distilled Water 87 mL 
0.1% NADH 2.5 mL 
 Pig serum 10 mL 
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3.9.5.1 Result on removing Thiamine.HCl from the medium 
Samples from the incubated culture were analysed by serially dilution, and different dilutions 
were plated onto CA plates for enumeration of colonies. Plates were incubated and counted 
manually for enumeration. The experiments were repeated three times and the results 
plotted graphically (Figure 3.10). 
 
Figure 3.10: Effect of different concentration of Thiamine.HCl on growth of vaccine strain 
over a 24 hour period of incubation. 
Figure 3.10 clearly demonstrates there was no benefit to the addition of Thiamine into the 
medium for growth yield when the medium holds 10% of pig serum. This might be because of 
the rich source of serum (which is rich in amino acids) used in the medium that must be 
delivering thiamine sufficient for the cell metabolism to happen. The result confirms that 
there was no requirement for supplementation with thiamine.HCl when 10% of pig serum 
was included in the growth medium (Table 3.6). 
3.9.6 Investigating the effect of increasing percentage of glucose 
Starch has oxygen-reducing properties and hence increasing starch will affect the total 
oxygen concentration available to the medium. Turning to another source of carbon, the 
effect of glucose concentration was observed with respect to the pH change and growth. 
Aliquots (90 mL in 1 L Schott bottle) of control group (0.05% glucose) and test group with 
different glucose percentage (0.1%, 0.5%, 1%, 2% and 3%) were prepared with modified 
media formulation (Appendix II, C, Version 1.3, Table 3.7) and sterilized. The tubes were 
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labeled for each time intervals and the media was inoculated with 10% overnight culture 
(B4C6) and incubated at 37 °C under optimized conditions (stationary, initial pH 7.5, 10% 
inoculum, 80% free air space). Samples were analysed by plate count at different time 
intervals (0, 4, 8, 12, 16, 20, and 24 hours) to investigate the association between pH, growth 
rate and glucose concentration. 
3.9.6.1 Result on the effect of glucose of concentration on growth 
Aliquots of the control group and test groups were incubated at optimized conditions for 
different time intervals at 37 °C. At each time point, the sample was processed for 
enumeration and the pH was measured and recorded. The serially diluted samples were then 
plated onto labeled CA plates and incubated for enumeration. Colonies were counted 
manually and the results plotted graphically (Figure 3.11). 
 
 
Figure 3.11: Effect of various glucose concentrations on B4C6 growth.  
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Figure 3.11 demonstrates the effect of the addition of glucose on yield of the vaccine strain 
over 24 hours. When assessed after 12 hours of incubation, the 3% glucose-containing 
medium showed the highest growth levels reaching Log10 8.8 cfu/ml followed by 1% and 2% 
glucose which both reached identical titres of Log10 8.3 at this stage. The lowest glucose 
containing media (0.5%, 0.1% and 0.05%) were all similarly lower with titres around Log10 
7.7 cfu/mL. 
However, despite the rapid growth rate for 3% glucose containing medium, the titre dropped 
dramatically after 12 hours of incubation reaching a titre of only Log10 5.1 cfu/mL at the 24 
hours’ time points. The 1% and 2% glucose containing medium also declined in titre after 12 
hours incubation but still fared better with titres Log10 7.6 cfu/ml and Log10 6.4 cfu/mL 
respectively reached at the 24 hours’ time point. The 0.5% glucose-containing medium 
reached growth titres similar to 1% glucose (Log10 7.6 cfu/mL). Interestingly, the highest 
overall titres were reached in the lowest glucose containing media (0.05% and 0.1%) with 
titres of Log10 9.8 cfu/mL reached in each case. 
The high rate of growth observed with a higher glucose containing media would have been a 
positive attribute had the titre reached the same level as that of the lower glucose containing 
media at 24 hours of incubation. That is, to reach a high titre in a shorter time would be 
highly valuable for production. However, there was still a whole Log10 difference in yield 
between the 12 hours mark for the 3% glucose containing media compared with the 24 hours 
mark for the 0.05% glucose containing media. Another important consideration is the rapid 
loss of viable cells soon after the 12 hours incubation when higher concentrations of glucose 
are used in the media. This makes it difficult to manage under commercial productions as it 
makes harvest times critical. 
The control of pH is extremely important in bacterial fermentation. Hence, it must be 
monitored during the growth period and adjusted as required. As cells grow, they can utilize 
nutrients within the media and produce acid by-products that can drastically lower pH. The 
drop in pH can then affect the viability of the cells. Table 3.8 shows the pH readings at each 
time point for each test media. Figure 3.11 shows the data graphically against the titres 
reached each time point. As the glucose concentration in the media increases, the pH drop at 
24 hours of incubation was also elevated and hence a more acidic environment is created. 
Except for 0.05 % and 0.1% the pH drop is below 6.1 at 24 hours of incubation. Even though 
0.05% and 0.1% gave same results, Figure 3.11 demonstrated 0.1% growth rate is more 
linear against time of incubation. The media was subsequently modified with 0.1% glucose 
replacing 0.05% (Table 3.9). 
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Table 3.8: pH variations during B4C6 growth on increasing glucose concentration in media; 
maximum titre obtained and corresponding pH obtained is highlighted with grey.  
 
Table 3.9: Version 1.4 of modified media (RCM); from the complex liquid media in which 
percentage of glucose presented in the original media is increased from 0.01 g to 0.1 g 
(Appendix II, D). 
  
 
Glucose concentration (%) 
 
0.05 0.1 0.5 1 2 3 
Time cfu/mL pH cfu/mL pH cfu/mL pH cfu/mL pH cfu/mL pH cfu/mL pH 
0 7.60E+06 7.56 7.37E+06 7.54 8.27E+06 7.56 8.10E+06 7.56 7.00E+06 7.54 5.50E+06 7.56 
4 6.00E+05 7.34 7.80E+05 7.31 5.63E+05 7.38 1.18E+06 7.31 8.80E+05 7.22 1.19E+06 7.26 
8 8.60E+06 7.16 8.67E+06 7.18 2.40E+07 7.08 1.53E+07 7.01 9.30E+06 7.03 8.33E+07 7.07 
12 6.50E+07 7.08 6.87E+07 7.01 6.87E+07 6.71 2.80E+08 6.61 2.90E+08 6.58 7.87E+08 6.59 
16 1.20E+08 6.84 5.07E+08 6.75 5.07E+08 6.41 6.80E+08 6.21 6.63E+08 6.14 5.20E+06 6.08 
20 5.60E+09 6.41 2.63E+09 6.38 1.40E+08 6.11 2.90E+07 6.02 2.80E+06 5.91 2.22E+06 5.89 
24 7.60E+09 6.22 8.13E+09 6.24 2.67E+07 6.01 6.40E+07 5.97 3.90E+06 5.88 1.42E+05 5.86 
Media raw materials 100 mL 
Neutralised Soy peptone 1 g 
NaCl 1 g 
Starch 0.1 g 
Glucose 0.1 g 
Yeast Extract 0.05 g 
Distilled Water 87 mL 
0.1% NADH 2.5 mL 
 Pig serum 10 mL 
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3.9.7 Comparative analysis of parent strain and vaccine strain 
grown regulatory compliant media (RCM) 
This experiment was similar to the study performed in Section 3.9.2 which evaluated growth 
differences between H. parasuis vaccine strain and parent strain grown in complex liquid 
media. This study however, evaluated the growth difference of the vaccine strain (B4C6) and 
parent strain (Hps29) when RCM (Table 3.9) was used. Aliquots (180 mL in 1 L Schott bottle) 
of RCM (in duplicates) were prepared and sterilized. Overnight culture (Section 3.9.1) was 
prepared using RCM, and 10% was used for inoculation after 24 hours and incubated at 37 °C. 
Samples were analysed by plate count at different time intervals (0, 4, 8, 12, 16, 20, 24, 28, 34, 
48 hours) to establish a growth curve and to determine whether there is any significant 
growth difference because of a change in media raw materials and concentration between 
parent and vaccine strain of H. parasuis. 
3.9.7.1 Result on growth pattern analysis of Hps29 and B4C6 with regulatory 
compliant media 
Parent type parental strain (Hps29) and the vaccine strain (B4C6) were grown in regulatory 
compliant media for growth analysis under optimized parameters as detailed in chapter 2. 
Different time intervals were taken for sample analysis and the samples were serially diluted 
for plating. Plates were incubated in triplicate for 36 hours and counted manually for 
enumeration. A growth curve was established which recorded total cell viable counts vs. time 
interval (Figure 3.12). 
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Figure 3.12: Growth curves of parent strain and vaccine strain grown in regulatory 
compliant media. 
The growth profile of the parent type parental strain (Hsp29) and the vaccine strain (B4C6) 
were originally compared in complex liquid media and shown to have almost identical 
growth patterns over 48 hours incubation (Figure 3.7). A similar study was conducted, this 
time examining the growth profile of the parent type parental strain (Hsp29) and the vaccine 
strain (B4C6) in the final Regulatory Compliant Media (RCM). Growth characteristics were 
compared between the vaccine strain and parent strain in RCM (Figure 3.12). Growth 
characteristics of the parent strain were similar to the growth obtained using complex liquid 
medium; there was a notable difference between the two strains in RCM. When compared 
between the growth of the two strains in RCM, the vaccine strain had a longer lag phase than 
the parent strain as the starting number of cells of the vaccine strain was Log10 6.9 cfu/mL 
and parent strain was Log10 7.5 cfu/mL. However, growth rate was similar when both strains 
reached exponential phase and hence similar yield (Log10 9.7 cfu/mL) could be observed at 
24 hours of incubation. A sudden decline was observed in complex liquid medium (Figure 
3.7) for both parent and vaccine strain after 24 hours incubation, but it was not observed 
when RCM was used. Fermentation was at the same rate even after 28 hours of incubation 
and hence a stationary phase was maintained. Fermentation of raw materials in the complex 
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liquid medium are most likely producing by-products at a more rapid rate and that are toxic 
to H. parasuis cells might be causing sudden decline in growth or nutrient deprivation.   
When comparing between the complex liquid media and RCM, the growth pattern of both 
vaccine strain and parent strain was identical until 24 hours of incubation. In complex liquid 
media, growth of vaccine strain started with concentration Log10 6.6 cfu/mL and reached 
highest peak at 24 hours of incubation Log10 9.8 cfu/mL, where in RCM growth started with 
Log10 6.9 cfu/mL and reached highest peak at 24 hours of incubation Log10 9.7 cfu/mL. In 
complex liquid media, growth of parent strain started with Log10 7.1 and reached highest 
peak at 24 hours of incubation Log10 9.8 cfu/mL; In RCM, growth (B4C6) started with Log10 
7.5 cfu/mL and reached highest peak at 24 hours of incubation Log10 9.9 cfu/mL. After 24 
hours there was drastic drop in number of cells was observed when complex liquid media 
was used, but in contrast a slow decline was observed when RCM was used. 
3.9.8 Growth of vaccine strain using RCM in 5 L pilot scale glass 
fermentor 
As part of the scale up study, the optimized incubation parameters (stationary, initial pH 7.5, 
10% inoculum, 80% free air space) were tested using the modified RCM (Table 3.9). All the 
cultures previously described were performed using closed Schott bottles of size ranging 
from 250 mL to 5 L. In this study, a 5 L bench-top fermentor was used, which was connected 
to a Biostat B to monitor various parameters such as temperature, pH, dissolved oxygen and 
stirring speed. Trial experiments (24 hours incubation period) were performed to analyse the 
effectiveness of optimized parameters and it was found that  growth pattern was entirely 
different from Schott bottles as it reached peak growth in a short period of incubation (6 - 10 
hours of incubation). A variation in optimized parameters had no significant effect observed 
as demonstrated in Schott bottle culture (Chapter 2) except for initial pH. 
 For industrial manufacture, it is not practical to maintain 80% free air space in large-scale 
fermentors. Hence, the percentage of free air space inside the 5 L glass fermentor, the free air 
space was decreased (from 80% to 40%) by increasing total volume of media to 3000 mL in 5 
L capacity fermentor. To compensate the increase in air space, a low speed (60 rpm) stirring 
was used to introduce a lower percentage of oxygen to the system. It was already found that 
stationary and stirring at low speed parameter had no significant effect on growth difference 
in Schott bottles. During the optimization of inoculum percentage (Chapter 2, Section 2.13) it 
was found that using 20% inoculum would be ideal for a short time period (<12 hours) 
incubation in Schott bottles rather using 10% inoculum. An adjusted set of parameters were 
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subsequently included low speed stirring (60 rpm), initial pH 7.5, 20% inoculum and 
minimum of 40% free air space. 
Primary inoculum and secondary inoculum was prepared using RCM as described in Section 
2.14.1 and 2.14.2 using Schott bottles. A primary inoculum of 100 mL and secondary 
inoculum of 400 mL was prepared for this experiment. Prior to inoculation, the inoculums 
were analysed by gram staining and plated onto solid media (Chocolate Agar, Horse Blood 
Agar, Malt Extract Agar, and Trypticase Soy Agar) for enumeration and sterility. Time interval 
for monitoring parameters includes 0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, 24 and 36 
hours. Each sample was taken out aseptically using a syringe from the sample port at the 
designated time intervals. The values from the plate count and pH were recorded and used 
for plotting growth analysis curve for B4C6 using 5 L bench top glass fermentor. 
Experimental set up of pilot scale fermentor 
A bench top glass fermentor connected to Biostat B was used for this study. The glass 
fermentor along with its attachments including as valves, seals, ports, tubing, and piping was 
sterilized by autoclaving with 2 L of milli Q water inside the body of the fermentor. Autoclave 
parameters were set at 121 °C for 40 min. Inoculum port, sampling port, exhaust ports were 
attached with piping, vial, filters and bottles along with probes (DO2, pH, temperature).  
Valves were loosened enough for the steam to circulate inside the fermentor for sterilization 
and to avoid pressure build up inside the equipment. Fittings were arranged and tied up to 
the fermentor; covered with an autoclavable bag prior to autoclaving. After autoclaving, the 
set up (Figure 3.13) was allowed to cool to room temperature at which point the sterile water 
was drained out using a peristaltic pump and sterile tubing through inoculum port. The same 
inoculum port was used aseptically inside a laminar to pump in the sterile medium. The 
autoclaved medium (2100 mL) and the sterile and inactivated pig serum (300 mL) were 
pumped into the fermentor the day before the experiment was to begin in order to check the 
sterility of the apparatus and to adjust the temperature prior to inoculation. Shafts were 
attached to the fermentor so that a minimum stirring speed of 60 rpm was used for the 
medium. On the day of the experiment, the secondary inoculum along with a filter sterilized 
1% NAD (5 mL) was pumped into the fermentor. Time at which the inoculum was fully 
drained into the fermentor was recorded as time zero and the sample was removed at “0” 
hour for enumeration and also samples were kept at room temperature for checking 
contamination.  
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Figure 3.13: Glass fermentor of 5 L capacity for batch fermentation. 
3.9.8.1 Result on growth pattern analysis using 5 L glass fermentor 
As part of the scale up study, a 5 L glass fermentor has been employed for the fermentation of 
vaccine strain (B4C6) in RCM using the optimized incubation parameters. Regular monitoring 
of dissolved oxygen and pH values were carried out. Different time intervals were taken for 
sample analysis and the samples were serially diluted for plating. Plates were incubated in 
triplicate for 36 hours and counted manually for enumeration. A growth curve in correlation 
with pH values was plotted for the growth at 3 L volume.  
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Figure 3.14: The effect of scale up on vaccine strain growth using glass fermentor (3 L 
growth media in 5 L fermentor). 
Figure 3.14 represents the growth pattern of the vaccine strain in RCM using a 5 L glass 
fermentor which contained a total volume of 3 L of growth media. Growth was monitored 
between 0 hour and 48 hours of incubation. The growth reached its highest titre at 6 hours of 
incubation when normally a highest titre is obtained at 24 hours of incubation inside a Schott 
bottle under optimized conditions. There was no lag phase observed, but the growth pattern 
looks more like an extension of the exponential phase. Exponential phase was observed till 6 
hours and a long stationary phase until 16 hours and thereafter decline phase was reached. 
The pH dropped gradually from 7.48 to 6.22 (at 16 hours) at which point the pH remained 
stable despite the cell viability drastically decreasing. The growth profile in the glass 
fermentor was clearly different to that observed in the Schott bottles. 
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3.9.9 Growth of H. parasuis vaccine strain using optimized 
regulatory compliant growth media in 15 L pilot scale stainless steel 
fermentor 
For scaling up study, the vaccine strain was grown in 15 L total volume of RCM (Table 3.9) 
using a 30 L fermentor. A primary inoculum of 600 mL volume (3.9.9.1) was initially 
prepared (600 mL), incubated for 24 hours in a 2 L Schott bottle. A secondary inoculum of 3 L 
volume (3.9.9.2) was prepared in a 5 L glass fermentor, which was incubated for 6 hours. 
RCM for the test experiment was sterilized outside using Schott bottles at 121 °C for 40 min. 
The fermentor was sterilized by in-situ steam sterilization for 1 hour and allowed to cool to 
30 °C prior to media inoculation. The medium was carefully pumped inside the fermentor 
through a sterile port using a peristaltic pump inside laminar flow cabinet to maintain aseptic 
conditions and the medium was adjusted to 37 °C. After reaching the desired temperature, 
the 3 L volume of inoculum was then pumped from a 5 L glass fermentor using sterile tubing 
and peristaltic pump into sterile 30 L stainless steel fermentor. Parameters were controlled 
using Biostat C connected to the fermentor. Time interval for monitoring parameters includes 
0, 2, 4, 5, 6, 7 and 8 hours. Samples were aseptically removed from the fermentor using a 
syringe from the sample port at designed time intervals. The values from the plate count and 
pH were recorded. 
3.9.9.1 Preparation of primary inoculum 
Plates were prepared as mentioned in Chapter 2 and the plates were spread with 100 µl of 
skim milk stock culture (vaccine strain) from -20 °C was used. Plates were incubated as 
recommended inside a candle jar. Lawn culture was observed in all of the plates after the 
period of incubation. 600 mL of primary inoculum using RCM was required and hence eight 
plates were used by each washing with 2 mL of sterile RCM and pipetted back to the Schott 
bottle aseptically. Schott bottle (2 L) was sealed properly and incubated for 24 hours at 37 °C. 
After the incubation, primary culture was analysed for total viable count using the prepared 
plates and by plating appropriate dilutions. Growth of B4C6 was enumerated and recorded as 
Log10 8.7 cfu/ml of 600 mL of secondary inoculum harvested from 2 L Schott bottle after 24 
hours of incubation. 
3.9.9.2 Preparation of secondary inoculum 
For the preparation of secondary inoculum, 600 mL of primary culture (20% inoculum, Log10 
11.4) was inoculated onto fresh supplemented media (2400 mL) in a 5 L glass fermentor and 
hence total volume of 3 L inoculated RCM was incubated as described in Section 3.8.8. 
Fermentation run using glass fermentor was performed so that the cell can be harvested by 
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the middle of the exponential phase (at 6 hours) and used as a fresh inoculum for the test run. 
10 mL of sample (secondary inoculum) was drawn out aseptically after 6 hours of incubation 
for sample analysis and to determine the initial cell count of the actual test run. For the test 
run using 30L stainless steel fermentor, inoculum (3 L) was transferred aseptically using 
sterile tubing and a peristaltic pump to the fermentor using one of the inoculum ports. 
Growth of B4C6 was enumerated and recorded as Log10 10.3 cfu per mL of 3 L secondary 
inoculum harvested from 5 L glass fermentor (Figure 3.15). 
3.9.9.3 Result on 30 litre stainless steel fermentation 
For this study, the growth parameters at a higher scale, 30 L capacity fermentor and 15 L 
working volume was used. The primary inoculum of 600 mL was prepared using RCM in a 
Schott bottle (2 L), and the sample was serially diluted and plated for enumeration. 
Secondary inoculum (3 L) was prepared using RCM inside a 5 L glass fermentor. At four 
different time intervals (0, 2, 4 and 6 hours) samples were withdrawn for growth analysis. 
After 6 hours of fermentation, the fermentation run was stopped for harvest as per previous 
study (Section 3.9.8). All samples were serially diluted and plated onto CA plates in triplicate 
and kept for 36 hours incubation. Plates were manually enumerated and a growth curve was 
plotted for secondary inoculum. 
 
Figure 3.15: Growth curve obtained during secondary inoculum culture in 5 L glass 
fermentor using RCM. 
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1.00E+11
1.00E+12
0 1 2 3 4 5 6 7
T
o
a
l 
v
ia
b
le
 c
el
ls
 c
fu
/m
L
Incubation Time (hours)
Secondary inoculum
Secondary inoculum
 116 
 
 
Figure 3.16: Growth curve seen in 30 L stainless steel fermentor using vaccine strain in RCM. 
The secondary inoculum was prepared in 5 L fermentor as observed previously (3.9.8) that it 
was possible to generate two-log higher growth when cultivated in fermentor. For the test 
run (15 L in 30 L fermentor), a 3 L inoculum was required. Secondary inoculum was 
harvested at early exponential phase and enumerated to determine the inoculum size for the 
test run. Early exponential phase harvest was designed so that all the potent cells (ready to 
divide) could be used in the test run as inoculum to develop a highly viable and highest titre 
culture possible within a short period. A 3 L of harvest (Log10 13.9 cells of total yield or Log10 
9.4 cells/mL) was used as initial inoculum for test run. 
Highest growth titre was observed at 4 hours of fermentation (Log10 11.4 cfu/mL) and a drop 
in tire was observed after 6 hours of incubation (Log10 10.27 cfu/mL). Initial concentration of 
cells (at time “0”) present in the test run was higher compared to all other experiments 
performed in this study. As percentage of inoculum used was higher than expected a high 
titre was found in a short period of incubation followed by a Log10 1 loss after 2 hours of 
incubation. For future experiments in 30 L capacities, (15 L working volume) percentage of 
inoculum will need to be maintained to approximately between Log10 7.5 and Log10 8.5 cfu per 
mL for high titre harvest around 6 hours of incubation. Scaling up in volume had a significant 
effect on growth titre by shortening the time requirement to achieve highest titre in the 
designed RCM. The parameters optimized from these experiments were transferable for the 
large-scale production of the vaccine strain in RCM. 
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3.9.10 Study of growth pattern in a disposable bioreactor bag using 
RCM 
The disposable bioreactor bag was pre-sterilized by gamma radiation and was ready for 
immediate use. The volume sized bag used in this study was a 10 L bag which has a working 
volume between 500 mL to 5 L. The cell-bag was inflated using a sterile air supply using an 
inlet 0.22 µm air filters. It was sealed by making sure it was visibly inflated. The bag was then 
partially filled with pre-warmed 2.4 L of supplemented RCM media (Table 3.9) and 600 mL of 
secondary inoculum (Section 3.8.9.1 and 3.8.9.2) was inoculated using sterile tubing and a 
peristaltic pump. The 10 L bag contained a final working volume of 3 L. The bag was then 
placed on to a rocking unit and clamped as shown in Figure 3.17. Whole apparatus was 
placed inside an incubator that was set at 37 °C and incubated for 24 hours. The rocking 
motion was adjusted to 20 rpm to provide uniform mixing and to maintain minimum oxygen 
transfer. Ports used in this experiment are shown in Figure 3.19. The inlet air filter was not 
used during fermentation, as there was no need for supply of oxygen or any other gas for this 
organism. The outlet filter was left attached to a sterile filter and it left open to exhaust the 
excess air inside the bag but still, keeping the bag inflated. 
Figure 3.17: Bioreactor bag set up with inoculum port (adapted from GE wave bioreactor 
2/10 Operator Manual 87-4500-23 AH). 
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Figure 3.18: Illustrative image of ports used in this experiment (adapted from GE wave 
bioreactor 2/10 Operator Manual 87-4500-23 AH). 
Sampling was performed every 2 hours until 24 hours to determine the growth pattern in cell 
bag. Samples were carefully taken (Figure 3.19) and pH was measured once the sample was 
removed from the bag. Samples were also analysed for any gram-positive contaminants by 
gram staining and then the sample was processed by serial dilution and different dilutions 
were plated onto CA plates for total viable cell count. Sterility of the culture was tested by 
HBA, CA, MEA and TSA plates. 
 
Figure 3.19: Aseptic sampling operation from wave bioreactor (adapted from GE wave 
bioreactor 2/10 Operator Manual 87-4500-23 AH). 
3.9.10.1 Result for growth curve observed using bioreactor bag 
Samplings were performed every two hours until 12 hours and then 24 hours; sample was 
serially diluted and plated on to CA plates. Plates were incubated for 36 hours for 
enumeration and to plot the growth curve. The study was designed to test yet another 
platform for the vaccine strain growth. The cell or wave bag has the benefit of saving on costs 
and labor. 
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Figure 3.20: Growth pattern analysis using bioreactor bag. 
Parameters used for the disposable bag supported high yield of live cells. As illustrated in the 
graph (Figure 3.20) the highest titre was observed at 8 hours of incubation with a peak titre 
of Log10 11.4 cfu/mL being reached. The peak titre for the 5 L glass fermentation (3 L working 
volume) was reached after 6 hours of incubation. The peak titre for the 30 L stainless steel 
fermentor (15 L working volume) was reached at 4 hours of incubation. Similar to the glass 
and the stainless steel fermentor there was no lag phase observed following inoculation in 
the cell bag. Hence, it was more like an extension of exponential phase. While the cell bag took 
4 hours longer to reach peak titre compared to the stainless steel fermentor and 2 hours 
longer than the glass fermentor, a higher titre was reached in the cell bag. 
In terms of efficiency, one can calculate the total yield obtained from each of these platforms. 
Table 3.10 outlines the total yield from each of the studies that had different working volume 
been harvested at their peak periods (Table 3.10). Even though the cell bag had only 1/5 of 
the working volume of the stainless steel fermentor, its yield was quite high making it more 
efficient to use a cell bag regardless of the fact that the incubation period was an extra 4 
hours. 
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Table 3.10: Total yield harvested at peak period from different working volumes and 
platforms. 
 
  
Fermentor Working 
volume 
(mL) 
Peak 
harvest 
time 
(hours) 
Initial  
cell count    
(cfu/mL) 
Peak titre 
(cfu/mL) 
Total yield 
(viable cells) 
5L glass 3,000 6 3.9 x 107 1.02 x 1011 3.06 x 1014 
30L stainless steel 15,000 4 3.3 x 109 1.09 x 1011 1.635 x 1015 
10L cell bag 3,000 8 5.87 x 108 4.1 x 1011 1.23 x 1015 
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3.9.11 Determination of endotoxin levels in the final product using 
LAL assay  
For the determination of endotoxin, an assay was performed using a fresh sample from the 
experiments (Table 3.11) to quantify the endotoxin concentration present in the culture. 
Pierce LAL chromogenic endotoxin quantification kit (Thermo scientific 88282) was used for 
microplate assays. Lyophilized E.coli endotoxin (over the range 15 - 40 EU/mL) was used as 
lysate standard. Endotoxin free water and pipette tips were used to perform this assay. 
Table 3.11: List of samples used to determine endotoxin concentration using Pierce LAL 
assay. 
 Sample processing 
Sample obtained from the experiments were measured for pH and ensured the pH was 
between 6 and 8 as per the requirement of the kit. It was stored in an Eppendorf at -20 °C for 
48 hours to stop the multiplication of bacteria in the culture. Before performing the 
experiment, the sample was completely thawed using a heating block set at 37 °C. The 
samples were vortexed to ensure uniformity of endotoxin in the sample as it can adhere to 
glass or plastic surfaces. Samples were serially diluted in endotoxin free water. Dilutions of 
10-4 and 10-5 were tested for endotoxin quantification in the assay to keep within the limits of 
standards used. 
Experimental set up for endotoxin assay 
Different concentrations (1.0, 0.5, 0.25, 0.1 EU/mL) of standard endotoxin was prepared for 
the standard curve. Before its use, the microplate was equilibrated in a heating block at 37 °C 
for 10 min. To the designed microplate wells 50 µl of prepared standard stock solution with 
known concentration and the unknown diluted samples were dispensed in duplicates. 
Endotoxin free water (50 µl) was used as a blank for this assay, and it was dispensed in 
duplicate carefully into the appropriate microplate wells. The plate was then covered with a 
lid and incubated for 5 min at 37 °C. After incubation, LAL reagent (50 µl) was added to each 
Samples Experiment Total volume Inoculum Harvested 
hour 
S1 Sample from bioreactor bag 
6 hours (3.9.10) 
3,000 mL 20% (2°) 6 
S2 Sample from 5 litre fermentor run 
6 hours (3.9.8) 
3,000 mL 20% (2°) 6 
S3 Sample from 30 litre fermentor 6 
hours  (3.9.9) 
15,000 mL 20% (2°) 6 
S4 
Sample from Schott bottle (3.9.9.1) 
600 mL Lawn culture 
from plate 
24 
 122 
 
well using a sterile pipette and the plate was covered with a lid and carefully mixed by gently 
shaking on a microplate shaker for 10 s. The plate was then incubated for 10 min at 37 °C. 
After 10 min 100 µl of substrate solution was added to each well maintaining consistent 
pipetting speed and accuracy. The plate was then covered and gently shaken for 10 s 
thenincubated for 6 min at 37 °C. The reaction was then stopped following the addition of 
25% acetic acid, then gently shaken on a plate shaker for 10 s. The plate was then read for 
absorbance measurement at 405 - 410 nm in a plate reader. The average absorbance of the 
blank was subtracted from all the individual standard and unknown sample replicates. The 
standard curve was plotted by using the blankly corrected data to determine the unknown 
endotoxin quantification from the graph.  
3.9.11.1 Results on endotoxin determination from vaccine strain culture 
The endotoxin concentration of the vaccine culture samples was calculated considering the 
dilution factor was taken for sample processing. A standard curve from the positive control 
was plotted using the E. coli endotoxin standard provided in the kit. The unknown values 
calculated from the spectrophotometer reading were measured against the standard curve to 
obtain the unknown concentration presented in each sample of interest (Figure 3.21). 
Table: 3.12: Results obtained from the standard curve for the quantification of endotoxin 
(EU/mL) in unknown samples. 
Samples Unknown 
concentration 
absorbance (X2) 
Concentration 
calculated from 
graph (EU/mL) 
Actual 
concentration in 
the sample 
EU/mL 
Endotoxin 
concentration 
EU/dose 
S1 0.2235 0.27487 2748.7 2.7x103 
S2 0.205 0.261464 2614.6 2.6x103 
S3 0.2085 0.264 2640.0 2.6x103 
S4 0.349 0.36582 3658.2 3.6x103 
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Figure 3.21: Standard curve for the quantitation of endotoxin in a chromogenic assay. 
From the standard curve, the unknown concentration of endotoxin was determined for four 
different samples (Table 3.12). One USP-EU is equal to one international unit of endotoxin; 
one EU equals approximately 0.1 to 0.2 ng endotoxin/mL of solution. Sample from the 
bioreactor (S1) was 2 hours prior to peak titre, sample (S2) was taken when peak titre has 
been obtained, sample (S3) was analysed 2 hours after the peak titre. Although S1, S2, S3 
were taken at different period, yet close to exponential phase, the endotoxin concentration 
found to be very close. Moreover, all of these experiments could be considered as a second 
passage as the test experiment was prepared from secondary inoculum hence the endotoxin 
concentration must be diluted over the passage. Sample (S4) from Schott bottle showed the 
highest concentration among other samples. This might be because of first passage directly 
from plate lawn culture. This sample was different from other samples as it was incubated in 
a closed system much longer (24 hours) than other samples (Table 3.11).  
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3.10 Discussion 
The ultimate aim of industrial fermentation was to harvest the highest yield of the final 
product (in this case as a live bacterial organism) in the most economical way while retaining 
quality. Live vaccine manufacture has the added complexity in that it was not only about 
highest cell mass but rather highest yield of viable organisms. Even though the vaccine 
candidate is aroA mutated the parent and vaccine strain propagated in a similar pattern and 
growth rate in complex liquid media. Hence, it suggests there is a rich source of aromatic 
amino acid present in the complex liquid medium. In this chapter, chemical requirements of 
the vaccine strain were studied to modify the complex liquid media into a regulatory 
compliant media that would be suitable for various regulatory agencies domestically and 
around the world. This was accomplished by replacing the complex animal products (BSA, 
biostate peptone) with non-animal-based protein sources such as soy peptone. 
Biostate peptone is a mixed hydrolysate comprised of casein (pancreatic digest) and yeast 
extract at a ratio of 65:35 (BBL. MSDS). Soy meal is whole soy extract. The composition of soy 
peptone content is similar to biostate peptone except soy peptone is more enriched with 
minerals, vitamins and fatty acid according to USDA National Nutrient Database for Standard 
Reference, Release 23 (2010) (Appendix III for soy peptone and biostate peptone 
composition chart). High yield in cells was observed when soy peptone and yeast extract was 
used in combination when compared with other combinations used. Yeast extract is rich in 
nitrogen source and it is safe to use as a media raw materials for the vaccine development in 
terms of regulatory requirements. Since the yield in number of viable cells was almost similar 
with the original complex liquid medium, the combination mentioned above is a suitable 
replacement for biostate peptone. 
 Different nitrogen sources were examined with respect to their effect on yield of the 
attenuated vaccine strain. The studies demonstrated a clear differentiation in growth when 
inorganic (Ammonium chloride, Ammonium sulphate) and organic sources (Soypeptone, 
Tryptone, Yeast extract, Biostate peptone) were used in the medium. Little is known about 
the physiochemical characteristics of inorganic salts on H. parasuis growth. The experiment 
conducted in this project showed that the organic source rather than inorganic nitrogen 
sources were better for the growth of H. parasuis. 
 Currently, serum is quiet commonly used as an active raw material (media raw material or as 
a stabilizing agent) during vaccine manufacturing as it is rich in several amino acids and 
immunoglobulin’s. Serums from pig, duck and calf are the commonly available and are 
sterilized by gamma irradiation followed by heat inactivation and filter sterilization. As 
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discussed previously, the potential presence of extraneous infectious agents especially from 
bovine serum represents a risk to the safety of the biological medicinal product. As this 
project includes a vaccine candidate targeted for swine population, pig serum has been 
selected as it also reduces the risk of transmission of adventitious agents from other animals. 
Complex liquid media including 4.75% of BSA was targeted to replace with an additional 
percentage of pig serum as the content of both serums remains rich and unknown. The 
experiment using different percentage of pig serum demonstrated that BSA could easily be 
replaced by increasing the percentage of pig serum from 1 to 10% of the total medium. 4.75% 
of BSA used in a complex liquid medium resulted in same yield as of 10%, 15%, and 20% of 
pig serum and hence it was decided to use 10% pig serum for further experiments instead of 
4.75% BSA. Eliminating or increasing the percentage of thiamine.HCl showed no significant 
effect on growth of vaccine candidate. The additional of extra yeast extract and pig serum 
eliminated the requirement of t hiamine.HCl as media. 
Glucose and starch are the main source of carbon in the designed medium, a good percentage 
of carbon sources are available from the neutralized soy peptone rather than it is just a 
nitrogen source. Carbon is used as a key energy source for the metabolism of microorganism 
[134]. This experiment designed under the hypothesis that the growth might get better with 
the addition of an extra percentage of glucose (carbon source) in the media and 0.2 to 25% 
was used. With the addition of glucose, fermentation happens fast or therefore, pH of the 
media drops very quickly creating a more acidic environment in broth. From the small-scale 
studies with the original medium (Chapter 2) pH drop was not dramatic. The increase in the 
percentage of glucose was adjusted to reduce the hours of incubation and to attain good 
growth when scaling up. Starch (large polysaccharide) consists of long chains of monomeric 
glucose linked by glycosidic bonds. Combination of glucose and starch is often used during 
fermentation. Bacteria that utilizes starch and produces an exo-enzyme called alpha-amylase 
that breaks the bonds between the glucose monomers in the starch such that the glucose 
monomers can be taken up into the cell and catabolized (a slow release of glucose). To keep a 
balance between glucose and starch it is essential to optimize the maximum concentration of 
glucose that can be used in the media without altering the pH. 
An early drop in pH was observed (Table 3.8) when glucose percentage was increased from 
0.1 to 0.5% and the same with 1%, 2% and 3% of glucose. This result explains the 
requirement for optimization of glucose. The drop in pH was more drastic with the higher 
percentage of glucose test groups compared to the 0.05 and 0.1% of glucose concentration.  
From the result it can be concluded that it is not ideal to increase the concentration of glucose 
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above 0.1% as the fermentation inside the cells happens more rapidly, causing the media to 
become more acidic more rapidly hence distressing the organism. 
Growth curve of both vaccine strain and parent strain was demonstrated using complex 
liquid media and regulatory compliant medium. Growth characteristics (Figure 3.7) of both 
strains were similar when it was grown in complex liquid medium, as the medium was rich 
enough to supply a good source of amino acids that the vaccine strains are unable to 
synthesise on its own. A high yield of ~Log10 10 colonies were observed per mL of culture 
when grown in complex liquid medium and RCM for 24 hours under optimized conditions 
(stationary, pH 7.5, 10% inoculum, 80% free air space). Modification of complex liquid media, 
RCM (Table 3.9) was used to study the growth characteristics of parent and vaccine strain. 
Most significant difference between the two growth curves obtained in Figure 3.7 and Figure 
3.12 was the introduction of stationary phase when RCM was used. There was no stationary 
phase observed as demonstrated with complex liquid medium was used (Figure 3.7). The 
presence of stationary phase prevents the sudden loss of cells when grown in Schott bottles 
especially during the preparation of primary or secondary inoculum. It also demonstrated a 
maximum yield close to Log10 10 for both parent and vaccine strain, establishing the 
modification was not affecting the yield of the vaccine strain. Both strains grew to Log10 10 in 
RCM. Different volumes of medium ranging from 100 mL to 3 L inside a Schott bottle was 
studied for vaccine strain growth and the maximum growth observed was Log10 10 cfu per 
mL at 24 hours incubation at 37 °C at stationary conditions. As the modification had a 
positive effect on growth of the vaccine strain, it was decided to confirm the optimized 
parameters with different platforms or by scaling up by volume. Apart from that, all those 
scaling up studies inside Schott bottles gave similar results for vaccine strain and parent 
strain. 
When H. parasuis was grown inside Schott bottles, the medium colour of both complex and 
RCM culture had resulted in only a little change in colour even after 24 hours of incubation. It 
was noticed that further incubation to 48 hours made the media  little cloudier. H. parasuis is 
a microaerophile, and it requires a certain percentage of oxygen to multiply. Similar to the 
technique in continuous culture devices, growth-limiting factor plays an important role in an 
increase of population density and growth rate. Here the addition of secondary inoculum to 
the test media extends the exponential phase of the growth by increasing population density 
and growth rate.  
It was required to confirm that the parameters optimized previously inside Schott bottle are 
also scalable inside a bench top bioreactor, stainless steel fermentor and disposable 
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bioreactor bag.  It was possible to perform scale up studies ranging from 100 mL to 3 L total 
volume in Schott bottles (1 L to 5 L capacity). In regards to medium scale fermentors (such as 
5 L, 30 L) it includes more labor and expense, especially to sterilize and prepare the large 
volumes of media. To perform growth studies of H. parasuis using fermentors, the optimized 
parameters (stationary, initial pH 7.5, 10% inoculum, 80% free air space) were initially tested 
in a few trial runs in a 5 L glass fermentor. Trial experiments (24 hours incubation period) 
were performed to analyse the effectiveness of optimized parameters. It was found that the 
growth pattern inside the glass fermentor was entirely different from Schott bottles. 
Compared to Schott bottle fermentation, the culture reached a higher peak growth in a short 
period of incubation (6 to 10 hours of incubation).  
As optimized in chapter 2, percentage of free air space (80%) was easy to maintain in Schott 
bottles. However, it is not suitable in a commercial setting as it ends up in loss of energy and 
labor to operate large vessels containing a reduced volume. Hence it was highly essential to 
study whether any other inclusion or change in parameter would assist in increasing working 
volume in fermentors. Percentage of air space was reduced from 80% to 40% and  low speed 
(60 rpm) stirring, which also increases the accessibility of oxygen to all, cells rather keeping 
the culture stationary. Increasing the initial load of cells from 10% to 20% also helped to 
reduce the period of incubation. With the help of a number of experiments, it was found that 
by maintaining an initial load of Log10 7.5 to Log10 8.5 cells per mL it is possible to attain a 
high titre using RCM under optimized parameters (low speed stirring (60 rpm), initial pH 7.5, 
20% inoculum, minimum of 40% free air space) in large-scale vessels (>= 5 L capacity 
fermentors). When glass fermentor (5 L) was used to cultivate vaccine strain using RCM, a 
high titre of log10 11 was observed in a short period in contrast to the titre obtained with 
Schott bottles. 
In chapter 2 incubation of culture at stationary and stirring conditions were studied in Schott 
bottles and both demonstrated similar growth results. When a similar study performed using 
5 L Schott bottles with 3 L working volume the result observed was similar to most of the 
results obtained from Schott bottles. The dynamics of glass fermentor seems to be supporting 
the culture much better, unlike the growth observed inside with Schott bottles even with the 
same volume. There was no lag phase observed in the growth pattern (Figure 3.14) of the 
vaccine strain when grown inside the glass fermentor. It could be explained as an extension 
of the exponential phase; as the secondary inoculum was harvested at the exponential phase. 
The percentage of oxygen inside a closed system would be decreasing by the late exponential 
phase and the oxygen acts as a limiting factor for the organisms. When the inoculum was 
introduced into fresh medium the organism multiplied by up taking the fresh oxygen 
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available in the medium. Hence, it reached a high titre of Log10 11 cfu per mL at 6 hours of 
incubation. After that, a long stationary phase was observed till 16 hours and thereafter a 
gradual decline phase. 
Increase in inoculum size from 10 to 20% in Schott bottles (Section 2.13) demonstrated a 
decrease in cell growth at the higher percentage used. The growth with 20% inoculum was 
successfully resulted in high titre of H. parasuis culture inside fermentors within a short 
period of fermentation. Incubation time to reach the highest titre was around six hours when 
20% inoculum used. A similar result was seen with 10% inoculum. With the peak titre was 
obtained at 10 hours (result not included). The dynamics of a fermentor and the increase in 
inoculum percentage from 10 to 20 % facilitated the organism to grow much faster reaching a 
live cell titre of Log10 11 cfu/mL was obtained at 6 hours of fermentation. Such a high titre 
was not observed in Schott bottles by either stirring or stationary culture. The pH dropped 
from 0 hours to 24 hours was not entirely related to the growth but possibly to the 
consumption of nutrients in the medium. Even in the rapid decline phase, there was only a 
slight drop in pH from 6.22 to 6.14. The pH drop was observed as 0.2 every 2 hours until 12 
hours of incubation inside glass fermentor. 
For the 30 L stainless steel fermentor, the secondary inoculum (Figure 3.15) was prepared 
inside a glass fermentor. A high titre (Log10 10.3 cfu per mL of 3 L) was reached. The initial 
load of cells was higher compared to other experiments. Hence, the peak titre was observed 
at 4 hours of incubation not at 6 hours of incubation. For future experiments, it is 
recommended to maintain a lower percentage of initial inoculum to slow growth down and to 
obtain a high tire in an acceptable fermentation time.   
The larger surface area available in a cell bag positively influenced cell growth and hence it 
had potential to obtain a high titre at 8 hours of incubation using RCM with a starter 
inoculum size of Log10 8 (secondary inoculum cultivated in Schott bottle). A drop in titre was 
observed just after the peak titre and thereafter a gradual decrease in number of viable cells. 
During the growth, pH values were dropped gradually with growth until 12 hours and after 
that it stabilized until 24 hours of incubation. As tabulated in Table 3.10, the efficiency of 
disposable bag was higher when compared with other platforms (5 L and 30 L fermentor); it 
offered a total yield of Log10 15 cells in 3 L of culture. The study performed using disposable 
bioreactor was a first time demonstration of H. parasuis fermentation and the efficiency could 
be increased by more optimization. Therefore, the disposable bag fermentation results 
showed here has the potential to be a suitable platform for the commercial production of 
vaccine candidate as it reduces labor and expense and produces high tires. 
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As high titre has been obtained by optimizing and attempting different strategies, accessing 
the quality of titre is also important. As reviewed previously, endotoxin levels are critical 
prior to vaccine registration and the main evaluation studies would be performed using 
animal models during clinical trials. Preliminary studies can be performed using kits within 
laboratories, and that was done in this study using samples stored from previous 
experiments. H. parasuis strain used in this study produce capsules and hence it is highly 
necessary to have an estimate of endotoxin concentration during in the culture, especially 
when it passes stationary phase of its growth. LAL assay is the most commonly used for in 
vitro quantification analysis for the endotoxin determination in vaccines. Since it is a 
colorimetric assay the interference of certain raw materials, which produce colour, causes 
failure of the assay. Endotoxin is measured in Endotoxin Units per millilitre (EU/mL). One 
USP-EU is equal to one international unit of endotoxin; one EU equals approximately 0.1 to 
0.2 ng endotoxin/mL of solution. The endotoxin concentration for the sample from Schott 
bottle is 3658.2 EU/mL, and it is comparatively higher than other samples (Table 3.12). This 
higher quantification could be because it was the first passage from the plates, and it was 
incubated longer (24 hours) than other samples. Dilution of samples (10-4 and 10-5) in 
endotoxin free water reduces the colour interference to the extent that could alter the result. 
Four different samples were used for this experiment; the first three samples (Table 3.11) 
harvested at 6 hours of incubation and fourth sample was incubated inside Schott bottle for 
24 hours. The first three samples had shown similar endotoxin quantities even though 
different platforms were used. Since the endotoxin limits in animals entirely depends on the 
tissue in which it directly contacted or the size and immune status of the animals more 
studies with animal models are required to comment on the concentration and its possible 
effects on vaccine efficacy. 
Animal proteins that added complexity in terms of regulations applied on vaccine 
manufacturing industry have been replaced by plant proteins. Complex liquid media was 
successfully turned into a regulatory compliant media (Table 3.9) for the manufacturing of 
vaccine candidate without losing viability. Experiments performed in this chapter 
successfully showed that the regulatory compliant media could support the growth of H. 
parasuis vaccine strain in both solid fermentors as well as the wave bag bioreactors.  
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CHAPTER 4:  
Investigation of freeze drying procedures 
for the long-term preservation of vaccine 
candidate strain 
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4.1 Introduction 
This chapter explains the principle and importance of freeze drying techniques for long-term 
preservation. The chapter reports how the harvested samples could be stored prior to freeze 
drying procedure. This study reports the effectiveness of different cryoprotectants and 
storage temperatures in preserving H. parasuis culture. The results include data acquired 
from the optimization of freeze drying program as well as the viability rate and explanations 
for the appearance of the final product. The results were tabulated, and the structure of the 
final freeze dried product was also included in this part of the chapter. Analysis for this study 
was performed using Christ Epsilon 2-10 D pilot-scale shelf freeze drier.  
4.2 Principle of freeze drying and its application 
Freeze drying is a process for long-term maintenance of product that degrade in the presence 
of water or solvents. It is an excellent invention crucial for preserving a wide variety of heat-
sensitive materials such as enzymes, proteins, microbes, pharmaceuticals, tissues and plasma. 
Although freeze drying is a complex and time consuming process it has been mainly utilized 
for commercial manufacturing of live vaccine products which require genetic stability and 
long-time preservation, promising not much loss in viability during transportation or over 
long time storage [187]. 
Freeze drying is a multistep process which comprises the following steps:- 
1) Culturing highly viable cells and harvesting 
2) Suspending them in a lyophilisation medium/buffer or cryoprotectant  
3) Subjecting them to the freezing and primary , secondary drying process 
4) Storing 
Bacterial freeze drying is a process that comprises culturing microbes into healthy phase and 
suspending in a lyophilisation medium [187]. Freeze drying is a process in which first the 
solvent is frozen and then removed by sublimation in a vacuum atmosphere. In this process, 
lyoprotectants plays a crucial role as it can make the cells stable, or it could ruin the whole 
process. Defining lyoprotectants for a specific product makes the freeze drying process more 
valuable. Lyoprotection was defined as the stabilization and prevention of the degradation of 
a macromolecule both during freeze drying and afterwards, during storage. Effective storage 
of bacterial culture often necessitates successful removal of cellular water content from the 
 132 
 
microorganisms and making them in an inactive state prior to their use to confirm long-term 
stability [188]. Good media have two main components: the lyoprotectant that stabilizes the 
cells when water is removed, and matrix agent that allows the entire sample to retain its 
shape during and after processing.  Disaccharides such as sucrose and trehalose are excellent 
lyoprotectants.  Matrix forming additives, often referred to as excipients, include mannitol, 
BSA, serum, and skim milk.  
4.2.1 Freeze drying principle 
 At atmospheric pressure (~1000 mbar) water has three physical states: - Solid, Liquid, Gas. 
Below the triple-point (6.1 m bar at 0 °C for pure water), only the solid and the gaseous states 
exist. The principle of freeze is drying / sublimation –drying based on this physical fact. The 
sample/material is first frozen to below its solidification temperature and the ice in the 
product is directly converted into water vapour without passing through the fluid state at 
very low temperature. The procedure consists of three critical steps, freezing, primary drying 
(sublimation) and secondary drying (desorption) [189]. 
Freezing is a critical step as it determines the quality of the final product. For an efficient 
freezing, slow cooling is required until the material is completely frozen. The ice nucleation 
temperature determines the size and morphology of the ice crystals. Cellular metabolism 
stops when all the water converts to ice crystals, at first the extracellular water becomes ice 
crystals before intracellular crystallizing and thus a change osmotic pressure occurs, the 
solvents tend to move from the extracellular environment to intracellular condition 
depending upon the permeability of cells [189]. Slow cooling rate (1 °C/min) and defined 
cryoprotective agent (specific for cells) is always preferred to minimize the osmotic 
imbalance (Figure 4.1) and ice crystal formation.  Permeability of cells, where solvent can 
move cross the cell membrane in turn depends on how the culture is produced whether it 
was cultured at aerated or anaerobic conditions. Aerated cultures have cells with permeable 
cell membrane where solvents can easily move and create osmotic balance to preserve, but 
anaerobic culture normally has thick cell membrane with permeable pores and, therefore, 
osmotic pressure builds up and thus it causes an imbalance [189]. 
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Figure 4.1: Cooling rate has a phenomenal effect on freeze drying; change in osmotic 
pressure damages the cells resulting futile freeze dried product. 
 Primary drying is sublimation of ice crystals from the product reducing pressure in the 
chamber (below the vapour pressure of ice ~50 - 200 nM) and providing heat to the product 
leaving behind a porous cake. Throughout primary drying, heat is transferred from the shelf 
to the product and from the frozen solution; ice sublimes and allows the water to leave a 
concentrated solute. The key to primary drying is to raise the temperature of the 
sample/product, so it is higher than the temperature of the cold trap and below the maximum 
allowable product temperature (eutectic temperature for a crystalline solute) [189]. This is 
the longest in three steps of freeze drying process, and it is mostly focused in industrial 
production for optimization of process curves. Secondary drying includes desorption of 
residual moisture from the product [190]. During secondary drying, the vacuum pressure 
forces out residual water trapped inside by increasing the temperature of the sample. 
Following secondary drying, both vials and ampoules must be sealed and refrigerated at -4 
°C.  
The stability of microorganism in terms of viability during freeze drying as well as and shelf 
period after freeze drying depends on number of factors: (1) media ingredients used to 
develop the product, (2) the diluent used to rehydrate the product, (3) type of cryoprotectant 
used, (4) rate of cooling and thawing, (5) growth stage of the culture at harvest, (6) cell 
size(%), (7) type, lipid content, water content and (8) initial density of cells [191]. It is 
essential to test the product before and after freeze drying and stability by monitoring the 
viability of the freeze dried cultures by testing at 30, 90, 180 and 365 days.  If the viability 
starts to decline rapidly, modification of the protocol is probably necessary. The cycle 
(program) used to freeze dry the vaccine strain culture in this study  is based on a program 
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developed for live vaccines by Bioproperties Pty. Ltd., mentioned in Table 4.3 and the stages 
are explained. 
A prolonged experimentation on freeze drying is needed to establish a freeze drying recipe 
and process control parameters, and it is carried out in lab scales to identify below listed 
values [192]. 
1) Product (composition/formulation/concentration, solid content, fill volume) 
2) Container (type, ampoule, geometry, stoppers) 
3) Equipment (freeze drier model, loading shelf trays, probes-number, position, type) 
4) Process (shelf temperature, chamber pressure, time (cooling, annealing, 
primary/secondary drying cycles)) 
Table 4.1: Cryoprotective Additives (CPA) used in freeze drying procedure [193]. 
Cryoprotectants 
Sulphoxides 
Dimethylsulfoxide 
Monohydric alcohols and derivatives 
Methanol 
Ethanol 
Polyvinyl alcohol 
Diols and derivatives 
Ethylene glycol 
Propylene glycol 
Trimethylene glycol 
Diethylene glycol 
Polyethylene glycol 
Polypropylene glycol 
Polyethylene oxide 
Triols 
Glycerol 
Polyalcohols 
Mannitol, sorbitol, dulcitol 
Monosaccharides 
Glucose 
Xylose 
Disaccharides 
Sucrose 
Lactose, maltose 
Trehalose 
Trisaccharides 
Raffinose 
Polysaccharides 
Dextran, mannan 
Dextrin 
Hydroxyethyl starch 
Ficoll 
 
Amides, N-alkylamides, imides 
Acetamide 
Methylacetamide 
Dimethylformamide 
Dimethylacetamide 
Succinimide 
Heterocyclic compounds 
Methylpyrrolidone 
Polyvinylpyrrolidone 
Amino acids and carbonic acids 
Proline 
Glycine 
Glutamic acid 
Amino butyric acid 
Glutaric acid 
Ammonium acetate 
EDTA 
Proteins, peptides, polypeptides and glycoproteins 
Blood serum, albumins 
Gelatin, peptones 
Shell extract 
Glycoproteins, mucin 
Valinomycin 
Gramicidin 
Complex substrates 
Yeast extract 
Malt extract 
Skimmed milk 
Honey 
Non-ionic surfactants 
Tween 80 
Triton, macrocyclon 
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Choice of excipient (s) relies on compatibility of bioactive material or product to be dried and 
the phase separation or vitrification of the excipients. As the product is live attenuated 
commercial vaccine of a fastidious organism (H. parasuis) serious attention should be given 
to the toxicity and safety of animals during vaccination as well as the cost of the 
cryoprotectants for bulk production. From Table 4.1, not all of them can be used for 
commercial vaccine production because of the clinical safety and regulatory requirements. In 
order to keep the cells viable, it is crucial to choose a cryoprotectant or combination of more 
than one which offers matrix, as well as protection. Since each CPA has its own limitations 
and advantageous, combination of CPAs was recommended from previous literatures for 
fastidious organism as the cells require additional protection because of its sensitivity [193]. 
Sulphoxides (DMSO, Me2SO) are widely used cryoprotectants because of the ability to 
penetrate the cells more rapidly than other CPA’s. However, toxic effect of these CPA is also 
observed during past studies in few of bacterial and other species on exposure of 60 min. The 
microbial toxicity of alcohols increases with chain length, while protective ability decreases. 
Glycerol has been used widely used for microbiology as a good preservative agent for most of 
routine bacterial stock preparation (20%, 50% of glycerol). For fastidious organism, it has 
been used with a combination of yeast extract or skim milk powder. For freeze drying, it is 
often used in combination as it only protects the extracellular environment of the cells and it 
is an excellent bulking agent. Previous literatures noted few of the organism that showed 
toxic effect when glycerol used as a cryoprotectant, which includes Aegyptianella pullorum, 
Chlamydia spp., Staphylococcus, Micrococcus,Lactococcus, Streptococcus, Pseudomonas, Coryne
bacteriumdiphtheriae,and E.coli, Chlorella,T.pyriformis, Trypanosoma spp., T. vaginalis  and  T. 
foetus [193]. Mannitol, sorbitol, dulcitol also been used for cyroprotection, but only in 
combination with other bulking agents like saccharides in order to mask the toxic effect 
rendered by them. 
Carbohydrates such as sucrose, glucose, trehalose and lactose are attractive excipients as 
they are innocuous and facilitate vitrification during freezing. When mannitol and sucrose are 
used in combination, it is observed that mannitol crystallizes during freezing and drying 
where sucrose remains amorphous. Sucrose (amorphous) enhances ice sublimation 
facilitating better product and tert-butanol modifies the ice crystal to needle shape (large 
surface area) and thus facilitates sublimation. During phase separation, (ice sublimation) 
salts such as ammonia formate acetate or bicarbonate carried away from the dried product. A 
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protective effect of acetamide is as effective as glycerol and often used in combination with 
0.2 to 5% skim milk [193].  
Serum albumins (inactivated serum) are often used for cyroprotection because of their ability 
to cryoprotectant to a certain level and it protects cells from possible toxic damage by other 
excipients such as glycerol, Me2SO, or other CPA’s during the freeze–thaw treatment. Even 
though various complex compounds like yeast extract, skim milk, egg yolk serves as good 
bulking agents as well as protecting agents during freeze drying, not all of them can be used 
for the commercial production of vaccine. Based on published experimental reports serum 
showed more cyroprotection after freezing than other CPAs listed Table 4.1, and it is 
reviewed in 2003 [193]. 
4.3 Objectives 
The main objectives of the chapter 4 includes- 
1. To investigate the effect of storage on H. parasuis harvest at different conditions (-80 
°C, -20 °C and 4 °C). 
2. To study the effect of a list of formulates at different storage conditions (-80 °C, -20 
°C). 
3. To optimise a freeze drying program, by studying its effect on viability of cells, 
resuspension and appearance for long time storage purpose. 
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4.4 Materials Methods and Results 
4.4.1 Effect of overnight storage at different temperatures on H. 
parasuis culture 
After the batch fermentation, it is needed to investigate whether H. parasuis culture is stable 
to keep overnight at different temperature -80 °C, -20 °C and 4 °C for storage prior to freeze 
drying. Effect of storage at different temperature -80 °C, -20 °C and 4 °C was studied using the 
sample (6 hours) obtained from 5 L glass fermenter run (Chapter 3, Section 3.9.8). Aliquots of 
samples in triplicate were labeled and stored at the designated temperatures. After 18 hours 
of storage, the samples were analysed for cell viability to compare with initial cell count 
before storage. 
4.4.1.1 Result on effect of storage on H. parasuis cell viability  
Samples were collected from the respective aliquots and analysed by serial dilution and 
plating onto CA plates in triplicates. The plates were incubated for 36 hours and counted 
manually to record the results. The results were plotted graphically between the total viable 
cells obtained and storage temperature to analyse the data.   
 
Figure 4.2: Effect of storage of H. parasuis culture at different temperatures on cell viability. 
Figure 4.2 demonstrated that there was a significant loss of viability when the culture was 
stored at 4 °C, -20 °C and -80 °C. It is not ideal to store the culture overnight at the tested 
conditions. It was found that the experiment has to be repeated to determine the viability of 
cells with the addition of protective formulants. Another study was designed with a set of the 
protective agent that could keep the cells viable and use as a cryoprotectant during freeze 
drying. 
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4.4.2 Short term investigation on the effect of different of formulates 
at different storage conditions 
Prior to freeze drying experiments it was necessary to perform a study on the effect of 
different types of formulates on vaccine strain viability at normal storage conditions such as -
80 °C and -20 °C. To perform this study different formulates listed in Table 4.2 were used 
with sample harvested from the run using 30 L fermenters (Section 3.9.9). 
Table 4.2: List of different formulates and its percentage used to study the effect of storage 
and formulates on H. parasuis viability. 
At the time of harvest, 10 mL of culture was aseptically taken out to determine viable cell 
count. The sample was serially diluted and plated to enumerate total viable cells before 
combining with formulates. Harvest was aliquoted inside laminar aseptically and combined 
with different cryoprotectives (Table 4.2). The mixture was then incubated at room 
temperature for 10 min. Samples were taken out to perform serial dilution for enumeration 
to determine the live count before storage. Aliquots of each formulation were prepared and 
stored at -80 °C, -20 °C for overnight (24 hours) and 5 days storage. 
4.4.2.1 Result and discussion on effect of different formulates on H. parasuis 
viability  
After overnight storage, samples from -80 °C and -20 °C was serially diluted and plated onto 
CA plates. Plates were incubated for 36 hours and counted manually. The counts were 
recorded and plotted graphically for temperature conditions. Initial cell concentration 
without formulation and before storage was determined as 1.87E+10 cfu/mL. 
Formulation Label Composition 
F1 10% total serum concentration 
F2 15% total serum concentration 
F3 20% total serum concentration 
F4 2.5% final sucrose concentration 
F5 5% final sucrose concentration 
F6 10% final sucrose concentration 
F7 6% final peptone concentration (1% from RCM + 5% added) 
F8 3.5% final peptone concentration (1% from RCM + 2.5% 
added), 5% final sucrose concentration 
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Figure 4.3: Effect of formulates on the survival rate of vaccine strain after overnight storage 
at -20 °C and -80 °C. 
 
Figure 4.4: Effect of formulates on the survival rate of vaccine strain after five days storage at 
-80 °C. 
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Overnight storage of culture at -80 °C with formulations F5 and F6 offered protection to the 
cells better than other formulations both at -80 °C and at -20 °C (Figure 4.3). Among that, 
formulation F5 overnight at -80 °C was the best, as it maintained the culture without any loss. 
Overnight storage of F5 at -20 °C resulted in approximately Log10 1 reduction from the initial 
cell concentration (Log10 10.27 cfu/mL to Log10 9.76 cfu/mL).  
 After five days of storage, samples from -80 °C and -20 °C were analysed by serial dilution 
and plate counting for enumeration of total viable cells. The counts from -20 °C after 5 days of 
storage showed very few cells were viable and hence the data was not comparable with -80 
°C cell count. The data (Figure 4.4) from five days storage at -80 °C was compared with 
overnight storage at -80 °C. The results were plotted graphically between total viable cells 
obtained and formulations used for the study. There was a significant loss of viability from 
the initial count of vaccine strain (Log10 10.27 cfu/m) after 5 days of storage at -80 °C and -20 
°C.  Even at formulation F5, Log10 2 reductions were observed at -80 °C after five days of 
storage. According to Figure 4.4 F5 provides best protection at -80 °C overnight. None of the 
combination supported vaccine strain viability for five days storage. Since H. parasuis is a 
very sensitive organism, it need a lot more formulation optimization study to select the right 
cryoprotectant for storage of culture at -80 °C for more than a day. 
4.4.3 Set up of freeze drying equipment and optimization study 
After completing the batch fermentation using 5 L glass fermenter (Section 3.9.8) and 30 L 
fermentations (Section 3.9.9) the culture was harvested and used for freeze drying. Different 
formulations were used as cryopreservative to freeze dry the culture. A few formulations 
from Table 4.1 were selected for this study as initial optimization study of cryopreservatives, 
which included different percentage of sucrose, pig serum, trehalose, mannitol, soy peptone 
(Table 4.4). Soy peptone was sterilized by autoclaving at 121 °C for 20 min. Pig serum was 
sterilized as mentioned in Section 3.9.1 and stored at 4 °C prior to formulation. All other 
formulants were filter sterilized using 0.2 µm syringe filters (Sartorius stedium) and stored at 
4 °C prior to formulation. Glass vials (10 mL) were placed onto a steel vial holding tray (for 
even heat distribution) with lid closed. The tray was then sterilized inside a dry heat oven at 
180 °C overnight and allowed it to cool inside a laminar hood by opening try lid before 
making aliquots of culture, and it was used for filling the culture for the freeze drying 
experiment. 
Harvest from the batch culture was collected in a sterile Schott bottle and placed onto ice 
block to maintain a low temperature. Formulations were done accordingly and the cell blend 
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(5 mL or 2.5 mL) was dispensed into 10 mL or 5 mL glass vials aseptically with sterile pipette 
or dispenser. Gamma irradiated and autoclaved fluted stoppers were pushed halfway into the 
neck of vials. After placing the tray on pre-cooled freeze dryer shelf, the probes were inserted 
in vials to ensure adequate recording of actual temperature profiles over time. Vials were 
freeze-dried in a Christ Epsilon 2-10 D pilot-scale shelf freeze drier (10 Kg ice condenser 
capacity). The standard cycle Epsilon 2- 10 D: up to 7 shelves 300 x 400 mm (W x D), distance 
34 mm, shelf area 0.84 m2 10 kg (2- 10 D), Ice condenser temperature –85 °C, with closed 
temperature control system via synthetic heat-transfer media, stainless steel chamber. 
Table 4.3: Different conditions used in freeze drying program cycle (Bioproperties Pty.Ltd. - 
Program 9-HPS 1.0). 
Freeze drying program 
     
Phase Section Temp °C Duration Vacuum (mbar) 
Start Vial 1 4 Load - 
Freezing 2 -40 7 h - 
Preparation 3 -40 30 min - 
Main dry 4 -40 5 min 0.2 
Main dry 5 -30 7 h 0.2 
Main dry 6 -20 18 h 0.2 
Main dry 7 -10 16 h 0.2 
Main dry 8 0 8 h 0.2 
Final dry 9 25 2 h 0.07 
Final dry 10 25 6 h 0.07 
Final dry 11 15 2 h 0.07 
Total time   66h 35min   
Section 1, 2, 3 in Table 4.3 facilitates freezing of the product- the material inside the glass vial 
to completely frozen, transition from liquid state to solid state. As rapid cooling tends to form 
small particles and it makes difficult for freeze drying, slow cooling for 7 hours is performed 
while freezing to make large particles and hence it creates less restrictive matrix while drying 
process. As the freezing stages proceeds, liquid formulation starts to ice nucleate and thus the 
water in the form of solid ice was detached from the crystalline solutes, forming more 
concentrated areas of solute. Moreover, the formation of crystal growth greatly depends on 
the physical state and morphology of final frozen cake and the stability of the product. 
Annealing step could be added to the cycle in case where crystallization is not happening 
completely and this helps to improve inter-vial heterogeneity and drying rates. Most of the 
solutes have lower freezing temperature than water, and hence the whole material appears to 
be frozen even though it is not. The temperature below at which the solutes completely get 
frozen without leaving unfrozen pockets can define as its eutectic temperature. Here the 
maximum lowest temperature was set at -40 °C, hypothesizing all solutes present in the 
material might have eutectic temperature below or within the designed temperature and that 
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was the lowest possible by the machine. There are materials (amorphous) that become 
viscous liquids and have a glass transition formation instead of eutectics, this materials form 
glass like structures and freezes at critical point forming vitreous solids (very hard to freeze 
dry). 
Section 4, 5, 6, 7, 8 in Table 4.3 facilitates primary drying - the formation of a dry, intact 
product by careful control of temperature and pressure, process in which the ice is 
completely taken out of the frozen solute by vapour pressure is called sublimation. Under 
pressure (0.2 mbar) applied by a vacuum pump, the ice crystals are slowly removed from the 
crystalline solute. Temperature of the product must be warmer than the cold trap that allows 
the gaseous water vapour to escape from the product. Energy is supplied in the form of heat 
to warm the product to remove the water in the form of gas, and it is critical to keep the 
product temperature under critical collapse temperature to prevent the collapsing of the 
structure. 
Section 9, 10, 11 in Table 4.3 facilitates secondary drying – After the ice from the product has 
sublimed, the remaining moisture can bound to the product, and this step helps to remove 
the total moisture present by an isothermal desorption. By increasing the temperature of the 
cold trap and by decreasing to the lowest, will facilitate desorption of moisture content from 
the product. 
4.4.3.1 Results on different freeze dried product 
The samples from each run were prepared with formulation mentioned Table 4.4 and freeze 
dried as mentioned in Section 4.4.3. Pre and post FD samples were analysed by plate counting 
for viable cell enumeration as well as the nature of the product (resuspension in “Mareks”  
diluent) and appearance after the run was analysed and recorded for data analysis 
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Table 4.4: Different formulations used for freeze drying H. parasuis culture. 
Label no. Formulations for freeze drying 
FD1 Neat (HPS culture from harvest) 
FD2 HPS culture + 5% serum 
FD3 HPS Culture + 10% serum 
FD4 5% Sucrose + HPS culture 
FD5 2.5% Sucrose +HPS culture 
FD6 10% Sucrose + HPS Culture 
FD7 15% Sucrose + HPS Culture 
FD8 10% sucrose + additional 10% serum + HPS culture 
FD9 5% Soy peptone + HPS culture 
FD10 2.5% Soy peptone+5% sucrose + HPS culture 
FD11 2.5% Soy peptone+10% serum + HPS culture 
FD12 7% Mannitol + HPS culture 
FD13 7% Mannitol + 10% l Serum + HPS Culture 
FD14 7% Mannitol + 10% Serum + HPS Culture 
FD15 10% Sucrose + 7% Mannitol + HPS Culture 
FD16 10% Trehalose + HPS Culture 
FD17 15% Trehalose + HPS Culture 
FD18 10% Trehalose + 7% Mannitol + HPS Culture 
 144 
 
Table 4.5: Observation recorded from the FD product of H. parasuis. 
Label no & Figure 
Formulations for freeze drying 
5m-fill 
Loss of viable cells Appearance and resuspension 
FD1&4.5a 
Neat (HPS culture from harvest) 
Program 9-HPS 1.0 
4 log 
Collapsed porous structure; sticky or caramelised and 
resuspended into clear solution 
FD2&4.5b 
HPS culture +  5% serum 
Program 9-HPS 1.0 
4 log 
Collapsed porous structure; powdered and resuspended into 
clear solution 
FD3&4.5c 
HPS Culture + 10% serum 
Program 9-HPS 1.0 
2 log 
Cake structure (less porous); powdered and resuspended 
into clear solution 
FD4 
2.5% Sucrose + HPS culture 
(program 9-HPS 1.2) 
2 log 
Porous, bottom of the cake collapsed; powdered and 
resuspended into clear solution 
FD5 
5% Sucrose +HPS culture 
(program 9-HPS 1.2) 
2 log 
Porous, bottom of the cake collapsed; powdered and 
resuspended into clear solution 
FD6 & 4.8a 
10% Sucrose + HPS Culture 
(program 9-HPS 1.2) 
1 log 
Cake structure (less porous); powdered and resuspended 
into clear solution 
FD7 & 4.8b 
15% Sucrose + HPS Culture 
(program 9-HPS 1.2) 
1 log 
Cake structure (less porous); powdered and resuspended 
into clear solution 
FD8 & 4.8c 
10% sucrose + additional 10% serum 
+ HPS culture (program 9-HPS 1.2) 
1 log 
Cake structure (less porous); powdered and resuspended 
into clear solution 
FD9 
5% Soy peptone + HPS culture 
(program 9-HPS 1.2) 
4 log 
Collapsed porous structure; caramelised and resuspended 
into clear solution 
FD10 2.5% Soy peptone+5% sucrose + HPS 4 log Collapsed porous structure; sticky and resuspended into 
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culture (program 9-HPS 1.2) clear solution 
FD11 
2.5% Soy peptone+10% serum + HPS 
culture (program 9-HPS 1.2) 
4 log 
Collapsed porous structure; sticky and resuspended into 
clear solution 
FD12 
7% Mannitol + HPS culture 
(program 9-HPS 1.2) 
3 log 
Solid cake structure (less porous); powdered and 
resuspended into clear solution 
FD13 
7% Mannitol +  5% Serum + HPS 
Culture (program 9-HPS 1.2) 
2 log 
Solid cake structure (less porous); powdered and 
resuspended into clear solution 
FD14 
7% Mannitol + 10% Serum + HPS 
Culture(program 9-HPS 1.2) 
2 log 
Solid cake structure (less porous); powdered and 
resuspended into clear solution 
FD15&4.8e 
10% Sucrose + 7% Mannitol + HPS 
Culture (program 9-HPS 1.2) 
3 log 
Collapsed at the bottom of the cake structure (porous); 
powdered and resuspended into clear solution 
FD16&4.8f 
10% Trehalose + HPS Culture 
(program 9-HPS 1.2) 
2 log 
Collapsed at the bottom of the cake structure (porous); 
powdered and resuspended into clear solution 
FD17&4.8g 
15% Trehalose + HPS Culture 
(program 9-HPS 1.2) 
2 log 
Collapsed at the bottom of the cake structure (porous); 
powdered and resuspended into clear solution 
FD18&4.8h 
10% Trehalose + 7% Mannitol + HPS 
Culture( program 9-HPS 1.2) 
2 log 
Collapsed at the bottom of the cake structure (porous); 
powdered and resuspended into clear solution 
FD19&4.8d 
Buffer exchange with 12% sucrose as 
formulant 
1 log 
cake structure (less porous); powdered and resuspended 
into clear solution 
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4.4.3.2 Pictures of FD product using different formulation in 5mL fill 
 (Program 9-HPS 1.0 –Table 4.3) 
 
 
 
  
Figure 4.5a: Freeze dried product – B4C6 vaccine strain 
culture without formulation (5 mL fill). 
The loss of viable cell was observed from 2.09E+10cfu/mL 
to1.11E+06cfu/mL. 
 
 
 
  
 
 
 
Figure 4.5b: Freeze dried product – B4C6 vaccine strain 
culture with 5% pig serum as formulant (5 mL fill). 
The loss of viable cell was observed from 1.00E+10cfu/mL to   
1.27E+06cfu/mL. 
 
 
 
 
Figure 4.5c: Freeze dried product – B4C6 vaccine strain culture 
with 10% pig serum as formulant (5 mL fill). 
The loss of viable cell was observed from 1.20E+10cfu/mL to 
1.43E+08cfu/mL. 
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4.4.3.3 Pictures of freeze dried product using different formulation in 5 mL fill  
(Modified program 9-HPS 1.1-Appendix IV,B) 
HPS-freeze drying program 9 HPS 1.0 modified by adding main dry step at -36 °C and altering 
time period- –Appendix IV, B 
 
 
 
 
 
 
Figure 4.6a: Freeze dried product – B4C6 vaccine strain 
culture without formulation (5 mL fill). 
The loss of viable cell was observed from 8.53E+10 cfu/mL to 
2.87E+07 cfu/mL. 
 
 
 
Figure 4.6b: Freeze dried product – B4C6 vaccine strain culture 
with 5% pig serum as formulant (5 mL fill). 
The loss of viable cell was observed from 8.00E+10 cfu/mL to 
1.63E+07 cfu/mL. 
 
 
 
Figure 4.6c: Freeze dried product – B4C6 vaccine strain culture with 
10% pig serum as formulant (5 mL fill). 
The loss of viable cell was observed from 8.53E+10 cfu/mL to 
3.44E+08 cfu/mL. 
 
 
 
 148 
 
4.4.3.4 Pictures of freeze dried product using different formulation in 2.5 mL fill 
(Modified program 9-HPS 1.1) 
HPS-freeze drying program 9 HPS 1.0 modified by adding main dry step at -36 °C and altering 
time –Appendix IV, B 
 
  
 
Figure 4.7a: Freeze dried product – B4C6 vaccine strain culture 
without formulation (2.5 mL fill). 
The loss of viable cell was observed from 8.53E+10 cfu/mL to 
1.21E+08 cfu/mL. 
 
Figure 4.7b: Freeze dried product – B4C6 vaccine strain culture 
with 5% pig serum as formulant (2.5 mL fill). 
The loss of viable cell was observed from 8.00E+10 cfu/mL to 
9.23E+07 cfu/mL. 
 
Figure 4.7c: Freeze dried product – B4C6 vaccine strain culture 
with 10% pig serum as formulant (2.5 mL fill). 
The loss of viable cell was observed from 8.53E+10 cfu/mL to 
7.20E+07cfu/mL. 
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4.4.3.5 Pictures of FD product using different formulation in 5 mL fill  
 
(Modified program 9-HPS 1.2)- Appendix IV, C; Program HPS 1.2 is modified by combining 
two steps in main dry and keeping at -30 °C by avoiding ramping down in program HPS 1.0 
 
 
 
 
Figure 4.8a: Freeze dried product – B4C6 vaccine strain culture 
with 10% sucrose as formulant (5 mL fill). 
The loss of viable cell was observed from 3.00E+09 cfu/mL to 
2.70E+08 cfu/mL. 
 
 
 
 
 
Figure 4.8d: Freeze dried product – B4C6 vaccine strain culture 
after buffer exchange with 12% sucrose as formulant (5 mL fill). 
The loss of viable cell was observed from 9.80E+09 cfu/mL to 
6.27E+08 cfu/mL. 
Figure 4.8b: Freeze dried product – B4C6 vaccine strain culture 
with 15% sucrose as formulant (5 mL fill). 
The loss of viable cell was observed from 1.40E+09 cfu/mL to 
2.27E+07 cfu/mL. 
 
 
 
 
Figure 4.8c: Freeze dried product – B4C6 vaccine strain culture 
with 10% sucrose and 10% pig serum as formulant (5 mL fill). 
The loss of viable cell was observed from 3.60E+09 cfu/mL to 
3.03E+08 cfu/mL. 
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Figure 4.8e: Freeze dried product – B4C6 vaccine strain culture 
with 10% Sucrose + 7% Mannitol as formulant (5 mL fill). 
The loss of viable cell was observed from 2.10E+09 cfu/mL to 
4.67E+06 cfu/mL. 
Figure 4.8f: Freeze dried product – B4C6 vaccine strain culture 
with 10% Trehalose as formulant (5 mL fill). 
The loss of viable cell was observed from 8.00E+08 cfu/mL to 
3.33E+06 cfu/mL. 
 
 
 
 
Figure 4.8g: Freeze dried product – B4C6 vaccine strain culture 
with 15% Trehalose as formulant (5 mL fill). 
The loss of viable cell was observed from 1.00E+09 cfu/mL to 
2.10E+07 cfu/mL. 
 
 
Figure 4.8h: Freeze dried product – B4C6 vaccine strain culture 
with 10% Trehalose + 7% Mannitol as formulant (5 mL fill). 
The loss of viable cell was observed from 2.00E+09 cfu/mL to 
9.87E+07 cfu/mL. 
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4.5 Discussion  
Very little is known about freeze drying H. parasuis culture. Hence, this study was based on 
numerous trial and error experiments. As high titre has been obtained by optimizing and 
performing different strategies, accessing the quality of titre is also important, especially 
because vaccine candidate is a live attenuated strain. Stability of the culture after freeze 
drying was analysed as part of post fermentation procedures. For the storage requirement, 
the stability or viability of the culture was investigated by different storage temperatures (-
80 °C, -20 °C and 4 °C). Since the organism is highly sensitive, and there were not many 
stabilizing protective ingredients in the medium, the viability of the organism reduced 
significantly by overnight storage (18 hours) even at low temperatures (Figure 4.2). Among 
different temperatures, -80 °C offered better conditions for storage when compared with -20 
°C and 4 °C. It was found from the study that the culture on its own is not ideal for storage, as 
it rapidly declines in viability even at -80 °C conditions overnight. A list of formulants (Table 
4.2) based on the literature review were studied under -80 °C, -20 °C for overnight and five 
days. From the results (Figure 4.3 and Figure 4.4) it was clearly demonstrated that -80 °C is 
the best storage temperature for vaccine culture. The viability of the vaccine was well 
supported by formulation F5 (5% final sucrose concentration) at -80 °C overnight storage, 
but after five days the viability of organism decreased with a reduction of two logs from the 
initial concentration of cells. However, the storage at -20 °C with the same combination of F5 
showed reduction in viability even by overnight storage. Compared to -80 °C, there was very 
less growth after five days of storage at -20 °C. Overnight storage at -80 °C could be used for 
R&D scale experiments, but not recommended for large-scale manufacturing. Sucrose has 
been used as an excellent cryoprotective agent for freeze drying and the data published in 
several literatures supports that it is not harmful as a vaccine ingredient. Further testing of 
sucrose could be used for better optimization of protective or stabilizing agents. 
The period over which a vaccine stays stable is called shelf life. It can be achieved by freeze 
drying. Various freeze dry programs with and without formulants were tested. A successful 
optimization of freeze dried program and cryoprotectant formulation should result in a well-
structured cake inside a glass vial without losing cell viability. When the vaccine culture was 
freeze dried without any formulation (Figure 4.5a), the medium used did not support 
viability or cake structure. The structure collapsed without having a good bulking agent. 
Addition of pig serum by 5% (Figure 4.5b) resulted in similar result with no formulation. 
Interestingly, addition of 10% pig serum (Figure 4.5c) resulted in better product compared to 
above two formulations. Alteration in programs such as by changing the annealing 
temperature, vacuum pressure or altering the working volumes had no effect in improving 
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the structure or viability. From the results obtained, the freeze dried products with no 
formulation (FD1) are shown in Figure 4.5a, 4.6a, 4.7a and neat. The results shown in the 
figures support the statement “Without any crystallizing agent or formulation, the structure 
created during freeze drying will be crushed when it passes through the sublimation phase” 
[194]. Addition of 10% serum (Figure 4.5c) to the harvest produced a better product as the 
serum acts as a bulking agent, but the formulation did not support the viability of the 
organism, as there were Log10 2 reductions in viability that is not acceptable. Even when 
different volume or fill (2.5 mL & 5 mL) used in 10mL glass vial the freeze drying was not 
successful (Figure 4.6, 4.7). 
To improve the product quality and appearance the crystallizing agent and temperature 
during primary drying to form cake structure before application of ice nucleation 
temperature should be optimized. For that reason program 9 (Table 4.3) has been modified 
by addition of longer duration on main dry and by using different formulants. Among those 
formulations, the only promising formulation was sucrose (10%, 15%) or sucrose (10%) 
with the addition of 10% pig serum (Figure 4.8a & 4.8c). Both formulations gave similar 
results, and the cake appeared much better than others. When mannitol (7%) was combined 
with different percentage of pig serum (0%, 5% and 10%), loss of cells was high (Log10 2 to 
Log10 3 cfu/mL reduction) and a solid cake structure was observed. Similar reductions in cells 
were found when mannitol (7%) was combined with sucrose (10%) and trehalose (10% and 
15%) used. The structure of the cake was also not acceptable as it collapsed at the bottom of 
the cake.  Interestingly, when the study was performed with different percentage of sucrose 
(10% and 15%) and sucrose (10%) with additional pig serum (10%), there was only Log10 1 
cfu/mL reduction from initial count and the structured appearance was less porous cake 
structure. Even though, all the sucrose combinations showed similar viability rates the 
appearance of the structure was close to prefer for sucrose (10%) with additional pig serum 
(10%). Buffer exchange of the harvest and formulation with 12% sucrose also resulted in a 
good product, but one log reduction in number of cells similar to the above result (Figure 
4.8d) was observed. Buffer exchange is not always recommended in industrial scale as the 
large volume creates risk of contamination and adds more labor. Freezing step is very crucial 
for the rest of primary and secondary drying to happen efficiently.  
Many of the formulations tested failed in supporting cell viability as well as maintaining a 
proper cake structure, but resuspension was successful for each formulation tried. It was 
clear that H. parasuis is an extremely unstable organism and requires considerable care to 
preserve. However, among those investigated formulations that provided the best 
performance was 10% sucrose combined with 10% pig serum. The loss upon freeze drying 
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using this formulation was a one log reduction in viability. This decrease in cell viability 
observed while post freeze dry was relatively high and will require further optimization 
study. Such work will likely involve changes to the cryopreservatives as well as the freeze dry 
program itself. Residual moisture analysis of the final product would also essential for large-
scale production to guarantee the maximum product stability is met. Product stability under 
various storage conditions should also be tested on an ongoing period to study the shelf 
period of freeze dried product. 
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CHAPTER 5:  
Development of molecular level analysis of 
vaccine strain using PCR and qPCR 
technology 
  
 155 
 
5.0 Introduction 
Molecular analysis of H. parasuis vaccine strain (B4C6) can be made through the careful 
design of specific PCR primers. A PCR based assay cannot only be used for primary diagnosis, 
but it can also be used in a number of ways that can be useful toward registration of a vaccine 
product. For example, PCR can be used to confirm the genetic stability of the vaccine strain 
over the various passage levels required to confirm the stability of the final product. PCR can 
be used in quality control of the final vaccine product to confirm identity and purity (i.e., 
freedom from other microorganisms). It can be useful in assisting vaccine production by 
monitoring growth rates during fermentation (e.g., qPCR assays). PCR assays can also be 
useful specifically to differentiate the vaccine strain from other strains or closely related 
species (e.g. DIVA–differentiation between infected and vaccinated animals) once the product 
is registered and used in the field. Overall, various PCR based assays can be designed to meet 
different needs. This chapter includes research to identify a gene or region of genomic DNA 
suitable to target for conventional PCR analysis that would provide the optimum sensitivity 
and the specificity to differentiate H. parasuis from common contaminates as well as from 
other closely related bacterial species. This chapter also covers research on potency 
determination and sensitivity analysis using quantitative PCR (qPCR). 
5.1 PCR analysis of H. parasuis 
PCR technology is one of the groundbreaking inventions that offers reliability, sensitivity, 
rapidness and has dramatically advanced progress in molecular biology. PCR was developed 
by Kary Mullis in 1983. It is now regarded as an indispensable technique that is widely 
applied for human, animal and plant research and diagnosis.  
PCR has been used for epidemiology as well as diagnostic studies of several H. parasuis 
outbreaks. For the epidemiology (local & global) and genotyping studies (Chapter 1, Table 
1.6) different PCR methodologies such as nested PCR, ERIC PCR, RFLP-PCR have been used by 
several research groups. These different PCR techniques are discussed in Chapter 1. In 
particular several types of PCR studies applied to epidemiology of H. parasuis have been 
detailed in section 1.9. 
16s ribosomal RNA gene (rDNA) amplicon PCR analysis remains as a standard approach for 
the investigation of microbial diversity (taxonomic and phylogenetic studies) and diagnostics 
of infectious diseases [195]. The complete genome of serovar 5 [196] and serovar 4 [197] 
have been deposited in NCBI. Therefore, the complete sequence of 16s rRNA gene is also 
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available online for H. parasuis. The usefulness of PCR depends strongly on the careful 
selection of genes and on the design of primers such that the amplification of the DNA offers 
the specificity to the target species, strain or isolate, depending on the purpose of the assay. 
Detection of H. parasuis from clinical samples can be difficult due to overgrowth of 
contaminating organisms. Oliveira had designed a specific PCR targeting a 821 bp region of 
16s rRNA gene [108]. Sensitivity of the PCR was confirmed to be 102 cfu/mL (100 colony 
forming units per mL). However, the assay failed in its specificity, especially when the sample 
was collected from nasal or tonsils due to the presence of A. indolicus. H. parasuis has been 
identified to be a close relative to A. indolicus sharing 97.4 to 97.7% similarity in the genome 
[106]. The above developed PCR reaction was used for clinical samples (except nasal cavity 
and tonsils) and confirmed that the sensitivity of PCR as 100 cfu/mL. To avoid cross reaction, 
a multiplex PCR was developed for more specific diagnostics of H. parasuis from clinical 
samples. In this multiplex PCR, three different primers targeting a single amplicon size of 
~1090 bp were designed (HP1F3: tat cgR gag atg aaa gap (182–199), HP2F2: gta atg tct aag 
gac tag (178–195), and HP-Revx: cct cgc ggc ttc gtc (1267–1253)). While the multiplex PCR 
proved to have 100% species specificity, it was not as sensitive as the PCR assay developed in 
2001. The two different PCR as described based on the 16s rRNA region have limitations 
concerning specificity and sensitivity when clinical samples were used. However, the PCR 
assays can be used successfully on pure cultures.  
When a short sequence of 16s rRNA was used for quantitative real time PCR, it was found 
that it could not distinguish between Pasteurella mairii and H. parasuis. A group of 
researchers subsequently identified the infB gene as an alternative target for real time 
quantitative PCR [119]. The infB gene is responsible for coding two translation initiation 
factors, namely IF2 alpha and IF2 beta. It was found that this gene could be used as an 
alternative for 16s rRNA in phylogenetic and epidemiological studies [118]. When infB gene 
was used in quantitative PCR for extracted DNA obtained from clinical samples, it showed 
sensitivity of detection comparable to conventional PCR as well as the culture based process. 
It also showed specificity when a group of closely related species (Table 5.1) was present 
within the test sample. Because of the limited intra-species variation of infB gene for H. 
parasuis [119] is the gene was also  used to establish a LAMP (loop-mediated isothermal 
amplification) assay in China. The LAMP assay showed improved specificity, sensitivity and 
ease of diagnosis. The LAMP assay is a simplified version of a conventional PCR assay 
whereby the target gene is amplified in 50 min of the incubation reaction at 63 °C in a 
laboratory water bath. The detection is possible visually by adding Syber green dye I. 
Therefore, a PCR machine is not required. A recent study showed that it could detect a low 
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number of H. parasuis cells (10 cfu/mL) in samples (lung, nasal swab, synovia and heart) and 
even differentiate from non- H. parasuis strains (A. pleuropneumoniae (serovar 5) and A. 
pleuropneumoniae (serovar 9), two strains of Bordetella bronchiseptica, Streptococcus suis, 
Pasteurella multocida, Salmonella Typhimurium and Escherichia coli) [198]. Unfortunately, A. 
indolicus, Pasteurella mairii were not included for analysis in the LAMP assay studies. These 
studies should be considered for developing a more specific and sensitive PCR with infB as 
the target region for this study, in which sample would be used directly from the culture or 
clinical specimens (without the requirement for DNA extraction). 
 H. parasuis aroA gene encodes 5-enolpyruvylshikimate-3-phosphate synthase, a crucial 
enzyme of aromatic amino acids and folate biosynthetic pathway (Figure 1.6).  The gene has 
been used in typing (RFLP-PCR) studies to investigate the diversity between H. parasuis and 
Actinobacillus species and found that this gene could be used potentially for taxonomic as 
well as diagnostic purpose [114]. As the studies in the project include both parent strain and 
vaccine strain, it was necessary to develop a technique that could effectively differentiate 
between the two strains. The vaccine candidate in this project is aroA attenuated (101 bp 
deletion) and hence specific PCR can be developed targeting the region where the deletion is 
located. A highly sensitive and specific PCR assay would be a valuable tool for many uses in 
the development of registered live bacterium based vaccine product. This chapter describes 
the development of PCR identity test specific to the vaccine strain, H. parasuis species 
conventional PCR for clinical diagnosis and finally a qPCR assay for use in monitoring the 
growth of H. parasuis vaccine strain during industrial fermentation. 
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Table 5.1: Closely related species of H. parasuis strains used to confirm the specificity of the 
quantitative PCR [119]. 
Species Strain Description 
Actinobacillus capsulalus  BR515* Field isolate 
Actinobacillus equuli CCUG 2401* Type strain 
  BR92 Field isolate 
Actinobacillus indolicus  CCUG39029* Type Strain 
  HS2394 Field Isolate 
Actinobacillus ligniersii  BR453* Field Isolate 
Actinobacillus minor        CCUG38923*  Type strain 
  HS2189 Field Isolate 
Actinobacillus 
pleuropneumoniae 
Shope 4074* Type and serovar 1 reference 
strain 
  K17          Serovar 5 reference strain 
  WF83  Serovar 7 reference strain 
  1096 Serovar 12 reference strain 
  HS143 Serovar 15 reference strain 
  HS 2924 Field Isolate 
Actinobacillus porcinus CCUG38924* Type strain 
  HS2108 Field Isolate 
Actinobacillus rossi    CCUG12395 Type strain 
  BR488* Field Isolate 
Actinobacillus suis CCUG11624* Type strain 
Bibersteinia trehalosi     BR458 Field isolate 
Bordelella bronchiseptica    BR467* Field isolate 
Bisgaard Taxon 8/A. equili/A. 
arthridis 
BR 509 Field isolate 
Escherichia coli    BR494* Field isolate 
Haemophilus parainfluenzae  NCTC7857* Type Strain 
Mannheimia haemolytica  CCUG408* Type Strain 
  BR441 Field isolate 
Mannheimia varigena CCUG38462* Type Strain 
Pasteurella aerogenes CCUG9995* Type Strain 
Pasteurella canis   NCTC11621* Type Strain 
Pasteurella langaaenis  NCTC11411* Type Strain 
Pasteurella mairii CCUG27189* Type Strain 
  BR133 Field isolate 
Pasteurella multocida NCTC10322 Type strain 
Pasteurella stomatis     NCTC11623* Type strain 
Pasteurella species B     SSIP683* Reference strain 
Streptococcus suis                                           CCUG7984* Type Strain 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
* Indicates that both DNA extraction methods were used with this strain/isolate 
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5.2 QPCR analysis  
Quantitative polymerase chain reaction (qPCR) is a highly sensitive technique that allows 
real-time quantification of DNA that is not possible when using an end point based 
(conventional) PCR. It allows accurate and sensitive quantification of starting amounts of 
DNA without post-PCR manipulation. Despite first being described in in 1993, it took time 
before it was widely implemented within the scientific field due to the expense of 
instruments and reagents. However, qPCR is far more accessible nowadays and it provides a 
more attractive and versatile diagnostic tool [200,201]. 
5.2.1 Introduction and principle of qPCR technology 
The purpose of the PCR technology is to specifically amplify a target from a minute amount of 
starting material. Conventional (endpoint based) PCR is qualitative. The final product is 
separated using gel electrophoresis and stained for detection of the product. That is, it allows 
for the detection of the presence or absence of a particular sequence in the sample. In qPCR 
(quantitative PCR) the product does not require detection on a gel since the technology 
utilizes fluorescent dyes or probes combined with the DNA amplification to permit the 
immediate detection of the products in the sample via a laser built into the qPCR unit. 
Associated software allows the fluorescent emissions to be recorded and presented on a 
computer screen. qPCR enables simultaneous amplification, quantification and detection of 
the gene of interest. Threshold cycle (Ct value) is defined as cycle number at which 
fluorescence signal crosses threshold fluorescence and where it detects the amplification of 
amplicon. Absolute or relative quantitation is possible by comparative analysis using Ct 
values or standard curve method. The quantity detected at a definite point of the run is 
directly related to the initial amount of targets in the sample [200].  
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Figure 5.1: Illustration of basic principle behind a qPCR with intercalating fluorescent dye 
(Syber Green I-QIAGEN protocol). 
Figure 5.1 shows the denaturing of DNA strand and attachments of primer’s while annealing 
the step followed by extension of DNA by Taq polymerase. It allows extension from the 3’ end 
of primers (short single-stranded synthetic oligonucleotides) during repeated cycles of heat 
denaturation, primer annealing and primer extension. As the amplicon is extended, the 
intercalating dye (Syber Green I) binds to the newly formed double-stranded DNA and the 
fluorescence increases with an increase in amplicon length. When DNA synthesis is 
completed, the function of both the amplicon length and number of copies of the amplicon is 
determined. As a final point, during denaturation, the dyes dissociate from the amplicon. 
qPCR has been used extensively for absolute (standard curve) and relative quantification in 
many scientific studies. Absolute quantification utilizes a standard curve of “known” to 
determine the unknown concentration of the starting DNA in the test sample. The standard 
curve can be established using known quantities of amplified PCR product, genomic DNA or 
commercially synthesized long oligonucleotide. Alternatively, it can be prepared from a 
recombinant plasmid that contains a single copy of the target gene that is used in the qPCR 
reaction. Of these various options, linear plasmid DNA is used more often because of its 
stability upon storage it is also less time consuming compared to other methods (Figure 5.2). 
The concentration of any unknown sample can then be determined by simple interpolation of 
its qPCR signal (Ct) against a standard curve. Relative method of quantification is an 
analytical approach where a control gene (e.g. housekeeping gene) is used to study the 
relativity of the expression to unknown DNA or cDNA expression in a sample [199]. The input 
amount for unknown samples is calculated from the standard curve of a specific gene in 
absolute method. Calibration or optimization of standard curve is highly important to obtain 
a reproducible and specific data for the quantification of unknown values [200]. 
 161 
 
 
Figure 5.2: Frequently used known standard for establishing standard curve in absolute 
quantification; Nucleic Acid Research Group, (NARG) survey 2007. 
The purpose of the qPCR assay described in this chapter is toward the detection and the 
quantification of the vaccine strain during fermentation. Absolute quantification based on a 
standard curve was used in this qPCR assay. Prepared linear plasmid was used to generate a 
standard curve based on a serial dilution of the starting amount that was quantified using a 
spectrophotometer. These known dilutions along with unknown samples were amplified to 
determine the amount of DNA present in the unknown sample. A standard curve was 
obtained by plotting the values of fluorescent signals received versus the PCR cycle number 
as shown in Figure 5.3 A and Figure 5.3 B. At the beginning of the cycle, the fluorescent signal 
will be beneath the detection level of instrument, a region termed as the baseline region. The 
fluorescent signal measure during baseline regions is used to set the threshold value (Figure 
5.3 B). Signals generated above this value are considered as real signals for the quantification 
purpose and are used to define cycle threshold (Ct*) for a sample [200]. Ct values are set over 
the baseline and below the plateau region. Known curves are then constructed by plotting the 
log of initial standard copy numbers on the horizontal axis and the corresponding Ct values 
on the vertical axis [201]. 
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Figure 5.3 A: Different phases of the amplification plot; qPCR amplification plot phases 
include baseline, exponential, linear, and plateau regions of the amplification curve [202]. 
Figure 5.3 B:  Theoretical amplification plot demonstrating the terminology normally used in 
real-time qPCR experiments [199].  
*Calculation of ΔCt is demonstrated as a difference between two cycles or samples and it is 
used in the final quantification of target. ΔRn is the difference between the fluorescent signal 
value and threshold value of a particular cycle. 
Fluorescent signals are generated by using dyes or probes within the qPCR mix. Different 
intercalating dyes such as Syber Green I, EvaGreen, YO-PRO-1 LC Green, BEBO, SYTO were 
introduced as an alternative to Taqman probes, molecular beacons, sunrise primers and light-
up probe. Among the intercalating dyes,  Syber Green I is extensively used for the qPCR 
applications [203]. It is a double stranded DNA intercalating dye (Figure 5.4). The amount of 
dye integrated with DNA is proportional to the amount of generated target, emitting 
fluorescence at 520 nm. 
A 
Figure 
5.3a 
Figure 
5.3a 
B 
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Figure 5.4: Action of intercalating dye during annealing step of qPCR. 
Consistency of qPCR is associated with its actual specificity, sensitivity, reproducibility, and 
robustness. There are studies carried out with qPCR to detect the presence of H. parasuis 
even from crude clinical samples. Investigation on infB gene found that this gene worked 
better than 16s rRNA gene as the reference gene for qPCR analysis for clinical samples. There 
are a number of studies published on RT-PCR (reverse transcriptase) targeting investigations 
on expression level but few on qPCR. Researches so far developed in regard to H. parasuis 
detection by qPCR are already discussed in Chapter 1. qPCR for H. parasuis showed promising 
results that will eventually resolve the limitations associated with culturing of H. parasuis in 
laboratories [119]. In this project, the qPCR has been developed for the approximate 
quantification of vaccine candidate in culture during fermentation as time saving approach to 
avoid conducting plate based colony counting for titre determination. 
  
 164 
 
5.3 Objectives 
The main objectives of Chapter 5 are:- 
1. To investigate the efficiency of conventional PCR to detect H. parasuis from pure 
culture and to differentiate from closely related species. 
2. To investigate the efficiency of infB gene in differentiating H. parasuis from closely 
related species. 
3. To develop a molecular level identification using PCR to differentiate vaccine strain 
from its parent strain. 
4. To develop a quantitative PCR for quantification vaccine candidate when grown in a 
fermentor as well as from field sample. 
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5.4 Materials Methods  and Results 
5.4.1 H. parasuis detection by PCR using 16s rRNA 
The procedure for the extraction of DNA from parent type and vaccine strains has been 
described in Chapter 2. The aliquots of extracted DNA were stored at -20 °C for PCR studies. 
16s rRNA primers [108] were used initially to detect the presence of H. parasuis in culture 
and colonies from the plate. The primers targeting a product size of 821 bp and the PCR 
conditions are provided below. 
Forward primer: - 5’GTGATGAGGAAGGGTGGTGT 3’ 
Reverse Primer: - 3’GGCTTCGTCACCCTCTGT 5’ 
Table 5.2: PCR reaction cycle using 16s rRNA gene as target. 
 
 
 
 
 
Table 5.3: Ingredients (PROMEGA) for PCR mix to run a PCR reaction with 16s rRNA gene. 
 
 
  
 
 
 
 
 
5X Green GoTaq® Flexi Buffer (catalogue no: M8295) was formulated along with yellow and 
blue dye for visible identification of band migration in the agarose gel. The blue dye migrates 
at the same rate as a 3–5 kb DNA fragment. The yellow dye migrates at a rate faster than 
primers (<50 bp). As the buffer does not contain magnesium, magnesium chloride solution, 
Step Temperature Time Stage Cycle 
Denaturing 94°C 5.0 min Stage 1 1 
Annealing 94°C 30 sec        Stage 2 : Stage1 35 
 54°C     40 sec      Stage 2 : Stage2  
 72°C 2.0 min     Stage 2 : Stage3  
Extension 72°C 10.0 min     Stage 3 1 
Store 4°C       Infinite Holding  
PCR MIX ingredients 1 X reaction  (ul) 
1. Molecular grade water 31.5 
2. 25 mm MgCl2 5 
3. 5X buffer-dye 10 
5. dNTP’s 1 
5. Taq polymerase 0.5 
6. Primers (10 picomole/µl) 
 1.16s-FW 1 
2. 16s-RW 1 
7. Template  1 
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25 mM was used in PCR mix. Primers (oligonucleotides) were synthesized from Gene Works 
Pty Ltd, and it was resuspended in nuclease free water to make aliquots of 10 picomole/µl (as 
per the concentration received from Gene Works Pty Ltd). DNA from colonies as well as from 
the broth culture was used as templates in the PCR reaction. After PCR reaction (Tables 5.2 
and Table 5.3), the sample was analysed by running the PCR sample on 1.5% agarose gel 
electrophoresis and viewed by ethidium bromide staining using gel DOC (Biorad). 
5.4.1.1Result on detection of H. parasuis by 16s rRNA gene amplification 
 
Figure 5.5: Agarose gel showing amplified 16s rRNA partial gene (821 bp) from parent 
strain; Lane 1: λ DNA pst1_DNA marker, Lane 3: Hps-29 (parent strain) from broth, Lane 4: 
Hps-29 (parent strain) from colony 
Figure 5.5 shows the amplification of 16s rRNA partial gene of H. parasuis parent strain both 
from colony and broth. It was confirmed that the designed primer amplified 821 bp size 
products. 
5.4.2 Investigating specificity of 16s rRNA with few closely related 
bacterial species 
Overnight culture of both parent strain, vaccine strain and other cultures* were prepared. 
16s rRNA primers [108] were used to study the specificity of primers with other bacterial 
species presents along with H. parasuis culture. The primers targeting a product size of 821 
bp were used with above-mentioned PCR cycle (Tables 5.2 and 5.3). 
  1        2          3        4   
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Result on specificity of 16s rRNA-PCR 
 
Figure 5.6: Agarose gel showing amplified 16s rRNA partial gene (821 bp) from parent strain 
and vaccine strain; Lane 1: 100 bp DNA marker, Lane 2&3: PCR mix without a template,  Lane 
4: Hps-29 (parent strain) from overnight culture, Lane 5: Hps-29 from colony, Lane 6: B4C6 
(vaccine strain) from overnight culture, Lane 7: B4C6 from colony, Lane 8 & 9: mixed 
bacterial population*, Lane 10 & 11: vaccine strain with mixed population*  
*Mixed bacterial population includes Actinobacillus pleuropneumoniae, Staphylococcus aureus, 
Streptococcus suis, Pasteurella multocida, Escherichia coli, Mycoplasma hyopneumoniae 
Figure 5.6 demonstrates amplification of 16s rRNA gene from both parent and vaccine strain. 
When a bacterial mixture* that did not comprise of Haemophilus sp. was used as template no 
amplification (lane 8, 9) was observed. When a bacterial mixture was mixed with H. parasuis 
parent and vaccine strain amplification was observed (lane 10, 11). Hence confirmed that the 
primers showed specificity and, therefore, could be used in laboratories where pure and 
mixed culture is handled. 
5.4.3 Result on H. parasuis sequence alignment (16s rRNA) analysis 
using BLAST 
Since the 16s rRNA of both parent strain and vaccine strain are identical, 16s rRNA partial 
gene was amplified from the extracted DNA of parent and vaccine strain as described above. 
The amplified product was then purified using PROMEGA kit and sequenced at the AGRF in 
Brisbane, Australia. The sequence obtained is presented Appendix VI, A. The 16s rRNA gene 
sequence was subjected to BLAST analysis comparing against the available sequence H. 
parasuis whole genome (NR_102829.1, AB004038) in the database. The sequence generated 
for H. parasuis parent type and vaccine strains showed 99% identity towards the complete 
sequence in the database. When a sequence alignment was performed against whole bacterial 
genome that excluded H. parasuis species the closest match found was with 99% identity of 
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16s rRNA sequences to  A. indolicus (AF268962) Salmonella sp.(FJ463824), A. minor 
(FJ435958) and A. porcinus (GU226323). If these bacterial species were included in the 
bacterial mixture which was used for above PCR analysis (Section 5.4.2), there is a possibility 
of appearance of bands and hence the specificity of 16s rRNA could be interrogated.  
5.4.4 H. parasuis detection by PCR using infB gene 
Since the developed PCR targeting 16s rRNA gave positive results for A. indolicus [108] and 
Pasteurella mairii [119], it was required to develop a PCR which could differentiate the 
closely related species. InfB gene could be used to differentiate H. parasuis from a larger 
bacterial population (Table 5.1) than 16s rRNA. It has also been validated for quantitative 
PCR [119]. However, for farm acquired samples, it would be ideal to have a conventional PCR 
assay which could effectively differentiate from closely related species. A set of primers 
targeting 254 bp of infB gene was designed for this purpose, and it is given below. 
Forward primer: - 5’ TGTTCTTGTAGTAGCAGCTGACG 3’ 
Reverse primer: - 3’ GAAGAATGGCTTCAAGTAAGTCG 5’ 
The PCR cycle used for this gene was exactly similar to 16s rRNA PCR (Table 5.2) except the 
annealing temperature was 52 °C. After PCR reaction, the product was loaded on to a 1.5 % 
agarose gel for electrophoresis. The bands were stained with ethidium bromide and viewed 
using gel DOC (Biorad). 
 
Figure 5.7: Agarose gel showing amplified infB gene (partial product-254 bp) of parent and 
vaccine strain of H. parasuis;  Lane 1: 100 bp DNA marker, Lane 2 & 3: PCR mix without a 
template, Lane 4 & 5: Hps29 parent strain from overnight culture, Lane 6 & 7: B4C6 vaccine 
strain from overnight culture, Lane 8 & 9: Mixed bacterial population*, Lane 10 & 11: Mixed 
bacterial population with Hps29 strain, Lane 12 & 13:  Mixed bacterial population with 
vaccine strain, Lane 14: Hps29 DNA as template. 
     1       2       3        4        5       6        7      8      9      10     11     12     13    14 
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*Mixed bacterial population includes A. pleuropneumoniae, Staphylococcus aureus, 
Streptococcus suis, Pasteurella multocida, Escherichia coli, Mycoplasma hyopneumoniae 
Figure 5.7 demonstrates amplified product of infB gene from parent strain and vaccine strain. 
The primers designed could successfully amplify even from a mixed bacterial population and 
hence this region could investigate further to use as differentiating PCR from closely related 
species. Because of the practical constraints in attainment of the samples (A. indolicus, 
Salmonella sp., A. minor and A. porcinus) which shown 99% identity to H. parasuis species in 
BLAST analysis of 16s rRNA analysis. It would be included in future studies to confirm the 
specificity of developed infB gene PCR analysis for H. parasuis samples. 
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5.4.5 Result on H. parasuis sequence alignment (infB gene) analysis 
using BLAST 
Table 5.4: Sequence alignment (BLAST) result on infB gene of H. parasuis with closely related 
organisms. 
Due to practical limitations for obtaining the strains in the laboratory, it was decided to 
perform BLAST analysis of designed region with closely related species (Table 5.1) 
demonstrated by Blackall [119]. The amplified product (Figure 5.6) was then purified using 
PROMEGA kit and sequenced at AGRF Brisbane. The sequence obtained from AGRF was 
presented in Appendix VI, B. The BLAST analysis were tabulated and are shown below (Table 
5.4). The result demonstrated that the percentag of  identity of infB - gene was not that 
significant as close as the BLAST analysis result for 16s rRNA gene. In which the BLAST 
Description Max score E -value Identity Accession no: 
A. arthritidis 315bits(170) 2e-82 89% AJ438120 
Actinobacillus capsulatus 309 bits (342) 1e-86 87% DQ666580 
Actinobacillus equuli 292 bits(358) 7e-76 87% AJ438445 
Actinobacillus indolicus 300 bits (332) 2e-84 87% EF059971 
Actinobacillus ligniersii 228 bits (123) 2e-56 85% AJ438102 
Actinobacillus minor 351 bits(190) 1e-100 92% EF055562 
Actinobacillus pleuropneumoniae 228 bits (123) 2e-56 85% AJ438444 
Actinobacillus porcinus 276 bits (149) 7e-71 86% EF059970 
Actinobacillus rossi 277 bits (306) 9e-77 84% DQ211779 
Actinobacillus suis 300 bits (332) 2e-82 86% DQ666576 
Bibersteinia trehalosi 282 bits(312) 5e-77 85% CP003745 
Bordetella bronchiseptica 28.3bits (3) 3.7 100% BX640447 
Escherichia coli 116 bits (128) 6e-25 82% CP002797 
Haemophilus parainfluenzae 265 bits (143) 2e-67 86% AJ289657 
Mannheimia haemolytica 279 bits(308) 5e-75 84% CP006619 
Mannheimia varigena 255 bits(282) 2e-70 83% DQ410888 
Pasteurella aerogenes 264 bits(292) 4e-73 85% DQ211792 
Pasteurella canis 208 bits(230) 1e-56 78% EF055567 
Pasteurella mairii 242 bits(268) 5e-67 82% DQ211785 
Pasteurella multocida 226bits(250) 1e-59 80% AY683522 
Pasteurella stomatis 21.1 0.87 93% JQ319773 
Salmonella Typhi. 120 bits(132) 3e-26 82% CP002099 
Streptococcus suis 96.9bits(106) 6e-20 76% CP003993 
 171 
 
analysis demonstrated 99% identity of 16s rRNA sequences towards A. indolicus, Salmonella 
sp., A. minor and A. porcinus.  
5.4.6 PCR for the differentiation of parent strain and vaccine strain  
The vaccine strain contains 101 bp deletions in aroA gene. This region provides a good target 
for differentiation based on PCR. The targeted region of aroA region in H. parasuis is shown in 
Appendix V1. BLAST analysis was also performed with targeted region to identify the close 
sequence similarity with other species. The primer pair was designed to have an annealing 
temperature of 54 °C using Primer 3 software and is shown below. 
Forward primer: - 5’GCGTCCGATTAAACATTTGGTTGA 3’ 
Reverse primer: - 3’ CCCAAGTGATTTTCGCGCCC 5’ 
One microliter sample was inoculated into 47 μl of PCR master mix (PROMEGA) 5X buffer dye 
(10 µl), 25 mM MgCl2 (5 µl), deoxyribonuceotides triphosphates (1 µl), Taq polymerase 
(0.5 µl), milli-Q water (31.5 µl) and 1 µl of each forward and reverse primers. Samples were 
subjected to initial denaturation step at 94 °C for 3 min followed by 35 cycles of denaturation 
at 94 °C for 5 min, annealing at 54 °C for 40 s, and extension at 72 °C for 10 min in a thermal 
cycler. Samples of PCR amplification products (10 μl) were subjected to electrophoresis in a 
1.5% agarose gel in TAE buffer according to standard protocols. DNA was pictured by UV 
fluorescence after staining with ethidium bromide (using gel DOC, Biorad). 
5.4.6.1 Result on aroA-PCR for parent strain and vaccine strain 
 
Figure 5.8: Agarose gel showing amplified aroA gene product of parent strain and vaccine 
strain with bands of 101 base pair difference; Lane 1: 100bp DNA marker, Lane 2 & 3: parent 
strain from overnight culture (500 bp), and Lane 4 & 5: vaccine strain from overnight culture 
(399 bp). 
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Sequencing result, which demonstrates the deletion of 101 bp sequences from aroA gene of 
the vaccine strain, was shown in Chapter 2, Section 2.6.2. The primer designed above targets 
the region of aroA that flanks the 101 bp deletion region of the vaccine strain. Differentiation 
between two strains was made possible by band size difference as found in Figure 5.8. PCR 
product was purified and sequenced for further analysis (Appendix VI, C). 
Megablast that was used for the generated sequence to retrieve very similar sequence, as it 
powerfully finds long alignments between highly similar sequences from the database. Blastn 
was used to find somewhat related sequence (vaguely related sequence). BLAST analysis 
(MEGABLAST) of the targeted sequence showed a significant match with 74% identity (E-
value 1e-42) to Mannheimia succiniciproducens (AE016827), but accepted range of similarity 
is above 95%. BLAST analysis (BLASTn) of the targeted sequence resulted in an 81% identity 
towards aroA gene of Pasteurella trehalosi strain (AY847810), 80% identity towards aroA 
gene of Bibersteinia trehalose (CP003745), 79% identity towards aroA gene of A. 
pleuropneumoniae (CP000569). There were no significant hits towards these organisms 
when MEGABLAST (highly similar sequence) used. 
5.5 Rapid quantitative method for the enumeration of vaccine strain 
from culture 
During liquid based fermentation of the vaccine strain, assessment of the growth profile can 
be determined by monitoring of bacterial counts on plates at various time intervals during 
the fermentation period. The result would achieve a growth profile, however, due to the time 
it takes for colonies to present on plates (24 to 48 hours) it would not be a practical way to 
monitor bacterial growth during a production run (i.e., in real time). However, due to the 
speed with which PCR can be conducted, qPCR can be used as in process design of routine 
monitoring the fermentation of the vaccine product. 
5.5.1 Construction of known standard reference plasmid 
 In order to construct a plasmid DNA with aroA gene of the vaccine strain for known standard 
reference for absolute quantification of vaccine candidate from culture, pGEM®T vector 
system was used. The aroA gene of vaccine strain was amplified with below primers,   
Forward primer: 5’ TCAAATCGTGCGTTGTTGTTGGC 3’ 
Reverse primer: 3’ GCCCCTAATTTGTTACCCTTA 5’ 
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Amplification of aroA gene (Tm-53 °C) was performed and detailed in Chapter 2 using the 
same cycle mentioned in Table 2.4. The amplified product was purified by PCR cleanup 
system (Wizard ® SV gel, Promega). The purified aroA gene was eluted in nuclease free water 
and made into aliquots of 50 µl of and stored at -20 °C for further works. From that aliquot 
one µl of aroA gene was used to measure the concentration by Nanodrop (spectral range: 
190-840 nm), and it was found that the aliquots contain 10 µg/ µl at 260 nm. 
5.5.2 Ligation and transformation 
pGEM®-T Easy vectors (3000 bp) are linearized vectors with a single 3´-terminal thymidine at 
both ends and hence these  T-overhangs at the insertion site (T4-SP6) greatly improve the 
efficiency of ligation. The amplified product was ligated using the pGME®T Easy vector 
system II (Table 5.5), pGEM®T Easy vector and insert aroA gene tubes were briefly 
centrifuged for 2 min at room temperature so that to collect the content at the bottom of the 
tube. 
Materials required for ligation (Vector: Insert DNA) = (1:10) 
1. Purified aroA gene from Vaccine strain (B4C6) – 10 µl (10 µg/ µl)   
2. PROMEGA Kit. 
2X Rapid Ligation buffer, T4 DNA Ligase—5 µl 
pGEM®T easy vector--- 1 µl 
T4 DNA ligase – 1 µl 
Molecular grade water – 2 µl 
3. Competent cells (JM109)  
4. LB plates with ampicillin/IPTG/X-gal 
5. SOC medium 
Table 5:5: pGEM®T Easy vector System II was used for the construction of known standard 
reference for qPCR. 
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Ligated reaction was mixed uniformly by pipetting and incubated overnight at 4 °C. After 
overnight incubation, the ligation was confirmed by agarose gel electrophoresis and the 
ligated product transformation was performed using high efficient, competent cells (JM109- 
PROMEGA). Ligated product was centrifuged briefly to collect the contents at the bottom and 
aliquots of 4 μl were made into sterile 1.5 mL microcentrifuge tube on ice. The frozen high 
efficiency competent cells were thawed by placing on ice water batch for 5 min and mixing by 
flicking the tube. 100 μl of cells were transferred from this tube to the 4 μl ligated product 
inside a 1.5 sterile microcentrifuge tube and mixed by gentle flicking of the tubes. Tubes were 
then placed on ice for 20 min. The cells were then exposed for heat shock by placing tubes 
inside a water bath at exactly 42 °C for 45–50 s and returning the tubes immediately to ice for 
2 min. At room temperature 900 μl of SOC medium (Super optimal broth with catabolite 
repression) was then transferred using pipette to the tubes containing cells with ligated 
product and incubated for 1.5 hours at 37 °C with shaking (~150 rpm). The incubated cells 
were then centrifuged at 1,000 × g for 10 min. The pellet was resuspended in 200 μl of SOC 
medium. 100 μl of each transformation culture were then plated onto LB/ampicillin/IPTG/ X-
Gal plates in duplicates and incubated overnight at 37 °C.  
5.5.3 Isolation of recombinant plasmid DNA and construction of 
linear plasmid 
Four different colonies were picked from the LB/ampicillin/IPTG/ X-Gal plates for plasmid 
isolation. E.coli constructs were grown separately in LB with ampicillin overnight at 37 °C 
warm room with 200 rpm shaking in 10 mL. The overnight culture was spin down at 5500g 
for 15 min at room temperature and followed the protocol for miniprep preparation (Wizard 
® plus SV miniprep plasmid DNA purification system, PROMEGA). Eluted plasmid DNA was 
pooled together and stored at -20 °C. Plasmid (50 µl) was then linearized at restriction site 
ApaI (between SP6 and T7 RNA polymerase promoter site) by ApaI enzyme (10 µl) as per the 
vector map of pGEM®-T Easy vector (Appendix VII, A, B). Linearized plasmid was then 
cleaned using Wizard ® plus SV miniprep plasmid DNA purification system (PROMEGA). 
Eluted plasmid DNA was pooled together, and aliquots were made into sterile 1.5 mL 
microcentrifuge tubes and stored at -20 °C. Both circular and linear plasmid was loaded onto 
0.7% agarose gel and ran for 140 min at 40 V. The bands were stained with ethidium bromide 
and gels were visualized on a UV transilluminator and photographed using the gel 
documentation system (BioRad, USA) and confirmed the expected band size. The gel picture 
with bands can be viewed in Figure 5.9. 
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5.5.3.1 Result illustrating the presence of isolated plasmid 
 
Figure 5.9: Agarose gel showing the presence of isolated circular and linearized plasmid with 
inserted aroA gene; Lane 1: 1 kb DNA ladder, Lane 2&3: circular plasmid (1 in 10 dilutions), 
Lane 4: λ DNA pst1_DNA marker, Lane 5&6: Plasmid after linearization (4220 bp). 
The presence of circular and linear plasmid in the agarose gel is illustrated in Figure 5.9. The 
isolation of plasmid that contains the insert was hence successful. As the pGEM-t vector was 
3000 bp and the insert DNA was 1275 bp, total product was 4275 bp. The linearized vector 
was observed at expected size and circular plasmid did not run according to its size due to its 
conformation. As the circular (supercoiled) form of DNA migrates faster than linearized 
plasmids, the circular plasmid band appeared at 2000 bp size. 
5.5.4 Confirmation of Insert DNA (mutated aroA gene of vaccine 
strain) 
Eluted plasmid was analysed to confirm insertion of the target DNA by amplifying the target 
gene using two set of primers. Primers for amplifying T7-SP6 region of pGEM-t vector is given 
below, 
Forward primer 5' - TAA TAC GAC TCA CTA TAG GG - 3' 
Reverse primer 5' - CGA TTT AGG TGA CAC TAT AG - 3' 
Primers for amplifying inserted aroA gene region of recombinant plasmid (pGEM-t vector) 
Forward primer:  5’ TCAAATCGTGCGTTGTTGTTGGC 3’  
Reverse primer:  3’ GCCCCTAATTTGTTACCCTTA 5’ 
Amplified products were run on agarose gel for 90 min at 100 V. The gels were stained with 
ethidium bromide and visualized on a UV transilluminator and photographed using the gel 
documentation system (BioRad, USA). The expected band size was confirmed. PCR product 
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was then cleaned using PCR product cleanup kit (Wizard SV gel, PROMEGA) and the samples 
were sent to AGRF, Brisbane for sequencing.  
Figure 5.10 show the presence of inserted aroA gene along with T7 and SP6 regions of 
pGEMT vector. The two different sizes of bands with 100 bp differences illustrated the 
presence of T7 and SP6 region attached to the inserted DNA. After confirming the insertion, 
the PCR products were sent out to AGRF Brisbane for sequencing. Sequence was analysed and 
edited using Chromas (sequence analyser software) (Appendix VII, C). 
5.5.4.1 Result showing confirmation of inserted aroA gene 
 
Figure 5.10: Agarose gel showing amplified inserted aroA gene (1275 bp). 
Table 5.6: Lane markings and details of sample loaded in the lane and primers used (Figure 
5.10). 
Lane marking Content Primers 
used 
Expected size 
(bp) 
Lane1 & 12 1Kb DNA ladder nil Ladder 
Lane 2  Negative control-PCR mix with no template aroA Nil 
Lane 3 Positive control-B4C6(DNA stock) aroA 1275 
Lane 4 & 5 Linearized Plasmid purified from Clone 3  T7,sp6 1375 
Lane 6 & 7 Linearized Plasmid purified from Clone 3  aroA 1275 
Lane 8&9 Linearized Plasmid purified from Clone 4 T7,sp6 1375 
Lane 10&11 Linearized Plasmid purified from Clone 4 aroA 1275 
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5.5.5 Copy Number calculation for linearized plasmid  
For the construction of standard known reference, one µl of plasmid DNA was taken out and 
used to measure the concentration using Nanodrop (absorbance at 260 nm and 280 nm). The 
concentration measured was used to calculate the copy number for the construction of 
known standard curve. Concentration of cleaned linearized plasmid was found out using 
Nanodrop was 27.8*10-7g/µl. 
Copy number was calculated using the concentration determined by nanodrop. 
 Number of copies (molecules/µl) = Amount of DNA (g/µl) X Weight in daltons (g/mol) 
                                                                                                                              Avogadro’s number 
Where,  
Weight in daltons (g/mol) = (base pair size of plasmid + insert) (330 Da X 2 
nucleotide/bp) 
 
          = (3015+1204) (330*2) 
 A serial dilution was made with the above plasmid copy number to plot a standard curve for 
the unknown samples. To make sure a thorough and even analysis of quantification range, 
sufficient dilutions (5 - point 10 fold serial standard curve) were prepared to cover the 
expected range of quantification within the sample. As the preparation and storage of 
standard curve material have enormous influence in the interpretation qPCR results, 
dilutions were made using TE buffer (Appendix V) to offer more stability during storage of 
plasmids and stored at -20 °C. Linear plasmid stock was stored at -20 °C. Serial dilution of the 
plasmid is prepared on day of assay [204]. The calculated copy numbers were used in this 
study to determine the unknown quantity of H. parasuis vaccine candidate in various samples 
harvested. From each dilution, a minimum five µl of culture was pipetted out to avoid the 
possible pipetting error and to reduce the percentage of variance between the samples in the 
assay. 
In this study, the following criteria were considered in order to choose appropriate standard 
curve for unknown quantification which includes PCR efficiency [1.00(±0.1)], regression 
curve (R2= 0.99) and percentage of variance (≤10%) between given copy numbers and 
calculated copy numbers per microlitre. 
Amount of DNA 
(g/µl) 
Weight in daltons 
(g/mol) 
Avogadro’s number Concentration of plasmid 
(g/μl)/copy number 
27.8*10-7g/µl 2.784540*106 
g/mol 
6.02214199 × 10
23
 6.01 *10
11 copy numbers/ µl 
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5.5.6 Primer designed for qPCR 
qPCR was performed using SYBR green PCR Master Mix (Kappa SYBER FAST, gene works) on 
a Rotorgene 6000/3000 quantitative PCR system (Qiagen). Short primers were designed 
using aroA gene of vaccine strain which is given below, 
Forward primer  5’ CACTTTGTTTGAAAGGTGAGCAAG 3’   
Reverse primer 3’ATTATTATGCGACACGTGCGGAC 5’  
The designed primers were used to amplify 255 bp target region of aroA gene in vaccine 
strain and standard plasmids (five points 10 fold dilution). The product was amplified using 
plasmid DNA as template with PCR cycle reaction described in Table 5.2. Following the PCR 
reaction the amplified product was loaded onto a 1.5 % agarose gel for electrophoresis and 
run for 75 min at 80 V. The bands were stained with ethidium bromide and gels were 
visualized on a UV transilluminator and photographed using the gel documentation system 
(BioRad, USA) 
 
Figure 5.11: Agarose gel showing short amplified product (255 bp size) for qPCR primers on 
vaccine strain and standard plasmid dilutions; Lane 1: 100 bp DNA ladder (Promega), Lane 2: 
vaccine strain (B4C6-DNA stock), Lane 3&4: a plasmid dilution containing 107 copies, Lane 
5&6: a plasmid dilution containing 106 copies, Lane 7&8: plasmid dilution containing 105 
copies, Lane 9&10: plasmid dilution containing 103 copies, Lane 11&12: plasmid dilution 
containing 102 copies.  
Plasmid was cloned with target gene (mutated aroA gene) from the vaccine strain and used as 
the standard in quantitative real-time PCR due to high stability over time. Concentrated 
stocks were made into aliquots in sterile Eppendorf tubes and stored at -20 °C and serial 
dilutions were made as10 fold dilutions just prior to each experiment. Triplicates were used 
to reduce intra assay variations. Specificity of amplified products (255 bp size) using qPCR 
primers were demonstrated on agarose gel (Figure 5.11). 
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5.5.7 qPCR reaction mixture 
For the quantification of unknown template, qPCR reaction set up was made using Kapa 
Syber fast master mix. The reaction components were thawed on ice completely and the 
mixture (minus template) was prepared aseptically according to Table 5.7 A into a 1.5 mL 
sterile microcentrifuge tube inside a laminar. After mixing the reaction components 
thoroughly, it has been dispensed accurately into another sterile microcentrifuge tubes. The 
templates were then pipetted into the appropriate tubes. After uniform mixing, the total 
mixture was dispensed into qPCR tubes (25 µl). All qPCR reactions were conducted in 
triplicate. The reaction setup was conducted using a metal ice block to avoid enzyme 
degradation and to allow a hot start to take place once the qPCR reaction cycle was initiated. 
Then the reaction was performed using Rotorgene - 3000 (QIAGEN) using the optimized 
program cycle (Table 5.7 B). Melt curve analysis was performed by including a melt cycle 
with temperatures 65 °C to 95 °C ramping by 0.2 °C/s.  
Table 5.7 A: qPCR reaction mixture for the amplification of template using Kapa Syber fast 
qPCR master mix. 
 
 
 
 
 
 
Table 5.7 B:  qPCR program cycling conditions for fast two step qPCR on Rotor-gene cycler. 
  
 
 
 
 
 
  
Reaction components per 25 µl reactions (µl) 
2x KAPA SYBR® FAST qPCR Master Mix  12.5 
Primer 1-Forward 0.5 (200 nm per tube) 
Primer 2-Reverse 0.5 (200 nm per tube) 
Plasmid template /unknown  1 
Mol. Grade water 10.5 
Cycling step Temperature & time  
Initial denaturation 3 min at 95 °C  
Denaturation 10 s at 95 °C 40 cycles 
Annealing 30 s at 55 °C  
Extension 1 s at 72 °C 
Data acquisition point 
Melt Ramp from 65 °C  to 95 ° C  
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5.5.8 Efficiency of primer set and standard reference gene 
The standard curve was used to define the reaction efficiency for any qPCR and hence it was 
an indication of problems related with qPCR reference itself. The determined increase of 
amplicon per cycle in a PCR was exponential, and it represents a reaction that was 100% 
efficient. Syber green system was used to analyse the amplification efficiency of both primer 
set and standard reference gene (plasmid construct with aroA gene insert). A broad dynamic 
range that includes a set of five points 10 fold dilution was used to study. qPCR reaction 
(Tables 5.7 A and Table 5.7 B) were made with five points at 10 fold dilutions (103, 104, 105, 
106, 107 copies) of the plasmid construct with known concentration (6.01E+11 copies/µl). A 
melt curve cycle was also included to check the primer and annealing temperature 
optimization efficiency and specificity. The data was analysed using Rotor-Gene 2.0.3.2 
software (QIAGEN). 
Figure 5.12: Amplification curve constructed using dilution of standard reference gene 103 
to 107 copies per µl using Rotor gene 3000. 
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Figure 5.13: Melt curve for standard curve showing specific peak confirming primer 
specificity for standard reference gene analysis. 
 
Figure 5.14: Agarose gel showing qPCR product (255 bp) at expected size (short aroA 
sequence); specific amplification of designed primer was confirmed; Lane 1: negative control 
(without primer); Lane 2: Empty; Lane 3: Non template control (with no DNA); Lane 4: 100 
bp DNA ladder (PROMEGA); Lane 5&6: plasmid dilution containing 107 copies, Lane 7&8: 
plasmid dilution containing 106 copies, Lane 9&10: plasmid dilution containing 105 copies, 
Lane 11&12: plasmid dilution containing 104 copies, Lane 13&14: plasmid dilution 
containing 103 copies. 
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It was found that the standard reference gene 103 to 107 copies per µl were amplified 
successfully resulting in an amplification efficiency of 1.01 (Figure 5.12). Melt curve analysis 
(Figure 5.13) of amplified DNA was automatically proceeded for the samples, and it gave a 
single peak for the product by slow heating from 60 °C to 95 °C at 0.2 °C/s, with continuous 
fluorescence collection. Specificity of the primer in that reaction was confirmed by running 
the qPCR product on an agarose gel (Figure 5.14). There was only a single band seen on gel, 
each from the tube. As the melt curve represented a single sharp peak, the efficiency of the 
designed primer for the target gene was sccessfully demonstrated. 
Figure 5.15: Standard curve construction using dilution of standard reference gene 103 to 
107 copies per µl; Ct values were obtained for each dilution and plotted against the number of 
plasmid copies per reaction. Corresponding Ct values obtained from the assay to plot this 
standard curve are also indicated in the figure. 
 Known standard reference 
The data presented above signify a representative result from five independent experiments 
with samples analysed in triplicate. A high level of reproducibility and PCR efficiency was 
observed when the plasmid standard reference dilution was freshly prepared. This 
quantification determines the actual copy numbers of target genes by relating the Ct value to 
a standard curve [205]. Ct values in each dilution were measured in triplicate and were 
plotted against the logarithm of their calculated template copy numbers. Each standard curve 
was generated by a correlation coefficient (R2) of the plotted points. PCR efficiency plays an 
important role in absolute quantification and so the slope of each standard curve. PCR 
amplification efficiency (Figure 5.15) [ 2 0 6 ]  was calculated according to the equation 
E = 1 0 ( − 1 / s l o p e )  − 1 .  
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5.5.9 Comparison between linear and circular plasmid standard 
efficiency 
For qPCR analysis, linear plasmid standards are commonly used as an efficient methodology 
for a stable and reproducible standard reference for the construction of standard curve [201]. 
Since samples for qPCR analysis can be derived directly from culture where the DNA will be 
supercoiled, it was decided to analyse the difference in amplification and detection of both 
linear and circular plasmid in qPCR reaction. Both linear and circular plasmid contained aroA 
insert and the primers used for this experiment targeted 255 bp of the inserted aroA gene. To 
perform this experiment, both circular plasmid 218.1 ng/ul (5.74E+10 copies/µl) and linear 
plasmid 163.4 ng/ul (3.52E+10 copies/ µl) concentrations were quantified by Nano drop and 
copy numbers were calculated as mentioned above (Section 5.5.5). The standards were then 
diluted 10 fold (5 point) in TE buffer and the stocks were stored at -20 °C. Stocks were used 
to perform a qPCR run as per Table 5.7 A and Table 5.7 B. 
 
Figure 5.16: Standard curve determination to compare the amplification and detection 
circular plasmid and linear plasmid. 
      Blue denotes – linear plasmid 
Red denotes – circular plasmid 
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Table 5.8: Comparing calculated qPCR count and plate count of vaccine strain at different 
time intervals during fermentation. 
From Figure 5.16 and Table 5.8 it was clear that the linear plasmid amplified efficiently as the 
calculated qPCR count, and calculated copy number (Nanodrop) variation was less that 10%. 
Although the circular plasmid amplified, there was a significant difference of Log10 1 between 
the calculated qPCR counts and calculated concentration from Nanodrop. The percentage of 
variance (>10%) between the circular plasmid triplicates was also higher, where for the 
linear plasmid it was within the desired limit (<10%).  
  
Sample ID: Ct 
value 
Calculated from qPCR 
(cfu/µl)-Log cfu/ µl  
Approximate concentration of each 
dilution (cfu/µl) -                Log cfu/ µl 
Linear plasmid-103 25.9 2.88E+03 3.46 3.52E+03  3.55 
Linear plasmid-104 21.1 5.1E+04 4.71 3.52E+04 4.55 
Linear plasmid-105 18.5 3.8E+05 5.58 3.52E+05 5.55 
Linear plasmid-106 15.8 2.9E+06 6.46 3.52E+06 6.55 
Linear plasmid-107 12.6 3.45E+07 7.54 3.52E+07 7.55 
Circular plasmid-103 26.5 6.03E+02 2.78 5.74E+03 3.76 
Circular plasmid-104 25.2 5.44E+03 3.74 5.74E+04 4.76 
Circular plasmid-105 20.9 2.6E+04 4.41 5.74E+05 5.76 
Circular plasmid-106 17.2 3.9E+05 5.59 5.74E+06 6.76 
Circular plasmid-107 13.6 5.16E+06 6.71 5.74E+07 7.76 
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5.5.10 qPCR analysis of samples direct from culture 
A qPCR methodology for the quantification of short gene sequence (255 bp of aroA-mutated 
sequence) in the vaccine strain was developed using above demonstrated standard curve (Ct 
values). Specific primers designed were confirmed for plasmid construct with the gene of 
interest and for vaccine strain (B4C6) in conventional PCR (Figure 5.11). The origin of the 
samples is from a fermentation run (5 L glass fermenter). Fermentation samples at different 
intervals (0, 4, 6, 8, 10, 12, 14, 20 hours) were included in the study.  
 
Figure 5.17: Standard curve constructed with samples at different time points during the 
fermentation of H. parasuis vaccine strain inside a glass fermenter. 
      Blue denotes – linear plasmid 
 Red denotes – circular plasmid 
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Table 5.9: Comparing calculated qPCR count and plate count of vaccine strain at different 
time intervals during fermentation.  
Figure 5.17 demonstrates the PCR efficiency as 1.00 (E), Regression curve as 0.99 (R2) and 
the samples points are tightly covered within known reference. In this experiment, though 
the qPCR standard curve showed good efficiency the result was not as expected. The increase 
in growth (from 0 hour to 4 hour) was not sufficiently demonstrated from the qPCR count. 
There was a significant difference between the actual plate count and calculated qPCR count. 
In Table 5.9, it was evident that there was no increase in count from four hour incubation to 
20 hours. PCR amplification was clearly hindered and hence enumeration was not accurate. It 
was important to understand because the observed inhibition of the PCR reaction. Precision 
of the acquired data is primarily depends on several other factors such as sample 
preparation, quality of the standard and choice of gene [204]. 
5.5.11 qPCR analysis of diluted samples and samples direct from 
culture 
The previous qPCR experiment results (Section 5.5.10) were significantly different to the 
plate counts. The likely culprit was that the concentration of the bacteria was too high and so 
a simple solution was to dilute the test samples by tenfold dilution prior to undergoing the 
qPCR reaction. The unknown sample could be diluted with TE buffer or fresh medium 
without pig serum for qPCR analysis. However, when the qPCR analysis was being compared 
with plate count, fresh medium is preferred because of the sensitivity of H. parasuis cells to 
salts (TE buffer). The samples were harvested and diluted in fresh medium without serum as 
10 folds (7 points). A 100 µl volume of each dilution was plated onto CA plates and incubated 
Sample 
ID: 
Ct 
value 
Calculated 
from qPCR 
(cfu/µl) - 
Log cfu/ µl Actual Plate 
count (cfu/µl) 
- 
Log cfu/ µl 
0 hour 23.5 7.21E+03 3.86 2.10E+04 4.32 
4 hour 21.33 1.69E+04 4.23 1.80E+07 7.26 
6 hour 21.13 1.85E+04 4.27 1.40E+07 7.15 
8 hour 21.92 2.66E+04 4.42 1.80E+08 8.26 
10 hour 21.83 3.07E+04 4.49 6.70E+07 7.83 
12 hour 21.72 3.20E+04 4.51 3.10E+06 6.49 
14 hour 21.17 2.15E+04 4.336 2.50E+06 6.39 
20 hour 21.53 3.07E+04 4.49 1.20E+05 5.08 
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for 24 hours inside candle jar at 37 °C to obtain plate count results. A fresh sample (neat) and 
diluted (1:2 diluting and 103 fold dilution) was used in the qPCR reaction for analysis. The 
qPCR reaction was performed inside Rotor gene according to the reaction program cycle and 
set up mentioned above (Table 5.7 A and Table 5.7 B). 
Table 5.10: Comparing calculated qPCR count and plate count of vaccine strain to study the 
effect of dilution of sample. 
 
Figure 5.18: Standard curve constructed with different dilution of a sample from 
fermentation of H. parasuis vaccine strain inside a glass fermenter. 
  Blue denotes –known standard reference 
  Red denotes - unknown sample 
Sample ID: Ct value qPCR count -Log Calculated 
from qPCR 
(cfu/µl) 
Actual Plate 
count 
(cfu/µl) 
6 hour neat 17.9 5.43E+05 5.73 5.43E+05 3.5E+08 
6 hour (1 in 2 
dilution) 
18.7 2.98E+05 5.47 6.1E+05 3.5E+08 
6 hour diluted 
103 times 
21.9 2.18E+04 4.34 2.18E+07 3.5E+08 
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Figure 5.18 and Table 5.10 show the effect of sample processing prior to qPCR. Previously, 
samples from the direct culture were analysed by qPCR at different time intervals and a 
similar count was seen throughout the intervals even though there was an increase in growth 
rate as determined by plate count. This experiment permitted comparison of diluted samples 
in fresh media (without serum) with neat by comparing calculated qPCR count and actual 
plate count. Figure 5.18 demonstrates the efficiency of the run. The unknown sample points 
fell within the designed known standard reference that shows the efficiency of 1.03. While 
the diluted samples did show increased qPCR counts, even the highest diluted samples still 
showed a Log10 1 lower count as calculated qPCR compared to the actual plate count. 
5.5.12 qPCR analysis of samples from log phase and stationary 
phase of culture  
The samples for this experiment were used from fermentation run obtained from the 
disposable bioreactor bag experiment. It was observed during scale study that the vaccine 
strain could reach a high titre of 108 cfu/ µl in large-scale fermentations in stainless steel 
fermenters and bioreactor bags. High titre was normally achieved in the first 6 hours of 
incubation before viability declines as discussed in Chapter 3. For this experiment 6 hour 
(100 fold diluted) and 24 hour (100 fold diluted) samples were used in the qPCR assay. The 
samples from each period were harvested and diluted in fresh medium without serum in 10 
folds (7 points). A 100 µl volume of each dilution was plated onto CA plates and incubated for 
24 hours inside candle jar at 37 °C to determine plate count results. One of dilutions (102 
dilution factors) was used in the qPCR reaction for analysis. The qPCR reaction was 
performed inside Rotor gene according to the reaction program cycle and set up as described 
above (Table 5.7 A and Table 5.7 B). 
Table 5.11: qPCR analysis result of two different point samples from fermentation run. 
 
Sample ID: Ct 
value 
qPCR count Calculated from 
qPCR (cfu/µl) 
Actual Plate 
count (cfu/µl) 
6 hour diluted 100 
times 
19.06 2.68E+05 5.43 2.68E+07 1.5E+08 
24 hour diluted 100 
times 
19.32 2.23E+05 5.35 2.23E+07 2.5E+05 
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Figure 5.19: Standard curve constructed with known plasmid standards to determine the 
unknown concentration of cells present in two different time point samples from bioreactor 
bag fermentation. 
Blue denotes –known standard reference 
Red denotes - unknown sample 
Figure 5.19 and Table 5.11 represent the outcome of a result that was repeated five times 
each time showing similar results. Figure 5.19 shows the standard curve that was used to 
enumerate the number of cells present in 6 hours (log phase) and 24 hours 
(stationary/decline phase) sample harvested from fermentation run. The Ct values for both 
samples were relatively close, falling within linear portions of the standard curve. 
Consequently, the calculated qPCR results as tabulated in Table 5.11 were similar for both the 
6 hours and the 24 hour samples. The qPCR count obtained for the 6 hour sample was Log10 
0.7 lower than the counts obtained on plates. The qPCR count obtained for the 24 hour 
sample was 100 times higher than the counts obtained on plates. It was important to note 
that the plate counts will determine only viable cell counts. However, qPCR will determine 
both live and dead cell counts. Therefore, it was understandable that the 24 hours sample 
would give a much higher count as the dead cells would accumulate in the culture along with 
the viable counts (which would be steadily decreasing with time). Therefore, the correlation 
of living cell counts between qPCR-derived counts and agar plate counts would only be 
possible during the early to log phase of growth while the cells are still mostly viable. 
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5.5.13 Investigating the sensitivity of qPCR targeting aroA gene of 
vaccine strain 
Sensitivity of the designed qPCR was analysed by preparation of fresh culture. Vaccine strain 
stock (B4C6 - 100 µl) was spread onto chocolate agar plates and incubated overnight. One of 
the plates containing a lawn culture was washed and resuspended with fresh sterile medium 
(2 mL) and inoculated into regulatory compliant medium (50 mL). The inoculated medium 
was incubated overnight stationary at 37 °C for 24 hours. The overnight culture (20 mL) was 
inoculated into 80 mL of fresh medium and incubated overnight stationary at 37 °C for 24 
hours. The incubated culture was serially diluted (10 fold) and made into aliquots in sterile 
Eppendorf tubes inside laminar aseptically. A 100 µl volume of each of the dilutions (10-1 to 
10-8) were plated onto chocolate agar plates and incubated inside candle jar at 37 °C for 36 
hours. The same dilutions and neat were used for qPCR assay. qPCR assay was performed 
using above mentioned qPCR reaction and program cycle (Table 5.7 A and Table 5.7 B).  
 
Figure 5.20: Standard curve constructed for the determination of lowest possible detection 
of qPCR of vaccine strain (aroA gene of 255 bp). 
   Blue denotes –known standard reference 
   Red denotes - unknown sample  
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Table 5.12: Comparing calculated qPCR count and plate count of vaccine strain with Ct 
values to study the detection level of designed qPCR; Samples used for this experiment is 
incubated for 24 hours in Schott bottle at 37 °C; plate count is tabulated by back calculation. 
This experiment was repeated five times to study the reproducibility of the assay and 
attained similar results; hence the result (Figure 5.20 and Table 5.11) represents one among 
them. Since there was variation in intra-assays, by Ct value ±1, the combined Ct values were 
not shown. In Figure 5.20, the unknown sample concentration was covered with 
extrapolation of the regression line (from the Ct value 24 to 30) in order to provide an 
estimate of the minimum cell detection limit of the designed qPCR reaction for vaccine strain. 
The efficiency of the run (E = 1.01) and qPCR count was calculated (Table 5.11) using the 
known standard reference concentration. Table 5.11 details the calculated qPCR counts per µl 
against actual plate counts (cfu/µl) for establishing a relationship between two counting 
methods. The minimum detection Ct value of the developed qPCR was found as 30.46 and the 
assay could detect 102 cfu/µl. It is studied that when target concentration of the template was 
low, it is possible to except a higher variability in Ct values amplification because of stochastic 
amplification. Hence, dilution from sample 6 resulted in an incorrect quantification.  
Sample ID: Ct 
value 
qPCR  count  cfu/µl- Log 
cfu/ µl 
Plate count cfu/ µl on plate - 
Log cfu/ µl 
Sample 1: diluted 
101 
17.52 3.78E+05 5.58 5.40E+06 6.73 
Sample 2: diluted 
102 
20.88 3.55E+04 4.55 5.40E+05 5.73 
Sample 3: diluted 
103  
25.14 1.83E+03 3.26 5.40E+04 4.73 
Sample 4: diluted 
104  
27.97 2.55E+02 2.41 5.40E+03 3.73 
Sample 5: diluted 
105 
30.46 5.41E+01 1.73 5.40E+02 2.73 
Sample 6: diluted 
106 
25.45 2.49E+03 3.40 5.40E+01 1.73 
Sample 7: diluted 
107  
20.71 3.04E+04 4.48 0.00E+00 - 
Sample 8: diluted 
108  
32.80 8.62E+00 0.94 0.00E+00 - 
Sample 9 : Neat 16.8 7.5E+05 5.88 5.40E+07 7.73 
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5.6 Discussion 
Diagnosis of H. parasuis is complicated when the pig is infected with heterogeneous H. 
parasuis strains. The complexity increases when the infection is presented with the existence 
of non-virulent strains. In recent times, the molecular diagnostic tools (PCR) have been 
popular along with biochemical or bacteriological culture techniques. In this project, partial 
16s rRNA and infB gene was targeted for PCR analysis of H. parasuis from a pure sample as 
well as field sample. 16s rRNA-PCR is a standard approach for many other organisms to study 
phylogeny and taxonomic differentiation. Since 16s rRNA region is highly conserved between 
different bacterial populations, it is ideal to use this gene region for differentiation of H. 
parasuis from other bacterial species.  
Most of the experiments performed in this study involved H. parasuis broth as well as 
colonies. After performing each experiments, the purity of the culture was confirmed using 
16s rRNA PCR developed by Oliviera in 2001 for H. parasuis and running on agarose gel 
electrophoresis (Figure 5.5).  The specificity of 16s rRNA PCR was examined using a mixture 
of bacterial strains (mostly present in pig micro flora) and demonstrated that the primers 
targeting 821 bp of 16s rRNA could successfully amplify H. parasuis strains (Figure 5.6). 
However, the BLAST analysis of amplified gene showed a higher percentage (99%) of 
similarity towards closely related species (Section 5.4.3). Furthermore, it is published that A. 
indolicus and Pasteurella mairii gave false positive result when this PCR was used. The 16s 
rRNA based PCR was found to be specific to H. parasuis parent and vaccine strain to 
differentiate from common laboratory contaminants. While the closely related species (Table 
5.1) were not involved in this study, it is likely that the samples contaminated with these 
organisms might found to be positive using the 16s rRNA PCR and hence this PCR cannot be 
used for field samples [110].  
As an alternative to 16s rRNA - PCR, infB gene was selected for developing a conventional 
PCR analysis. The results showed the capability of a new conventional PCR targeting infB 
gene (254 bp) (Figure 5.7) for laboratory as well as field samples. There was no amplification 
found with bacterial mixture containing related but non-Haemophilus species. This is a new 
approach in which infB gene is targeted for conventional PCR analysis. Field samples are yet 
to be tested. The amplified product was sequenced and aligned with closely related species 
using BLAST (Table 5.4). From the alignment result, it was found most of the closely related 
species showed some percentage of identity but not significantly for amplification during 
PCR.  
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A PCR assay that specifically differentiates between H. parasuis parent strain and vaccine 
strain was developed in this project. The PCR primers were designed around aroA gene since 
the vaccine strain carries a deletion within this gene. Therefore, the deletion site was targeted 
for amplification, so that size differentiation between the vaccine strain and H. parasuis 
strains was possible. Sequence analysis (Section 2.6.2) showed that the size of the full aroA 
gene of parent strain and vaccine strain having 101 bp differences. A set of primers was 
designed flanking the deletion site that produced a 500 bp product from H. parasuis parent 
strain and a 399 bp PCR product from the vaccine strain. Differentiation based on size of the 
amplicon was visible on agarose gel (Figure 5.8). This identity PCR test can be used as a DIVA 
(Differentiating Infected from Vaccinated Animals) test. That is, since wild type strains of H. 
parasuis do not contain deletions (particularly large deletions) within their aroA region; this 
test can differentiate between infected and vaccinated animals. It is important as farmers and 
veterinarians would like to know whether their pigs are infected with wild type H. parasuis or 
that they are carrying the vaccine strain itself. During manufacturing, this test could be used 
as an effective test for purity determination and thereby it facilitates to release a batch. 
Rapid and sensitive method of enumeration and detection is crucial for the timely 
manufacturing of the vaccine, especially to enable the operators to control a large-scale 
fermentation batch. Culture based enumeration method is still widely used and regarded as 
sensitive and specific detection for live microorganisms. The qPCR assay has the advantage of 
avoiding the incubation period of agar plates. It becomes effective by careful and specific 
design of primers for the target gene. In this project, the quantitative PCR was developed 
especially for the detection and amplification of H. parasuis vaccine strain (B4C6) and hence 
the mutated aroA region was aimed for designing a specific primer. As per the published 
whole genome sequence of H. parasuis (Accession no: CP001321), there is only one copy of 
aroA gene present in whole genome and hence the calculations were straightforward.  
For the development of qPCR, it was necessary to build a standard reference set for analysis. 
During the construction of standards, both linear and circular plasmid constructs were 
created. Linear plasmid was successfully amplified, and there was no significant difference 
between the actual concentration (Nanodrop) and calculated qPCR concentration in contrast 
there was significant difference for circular plasmid (Figure 5.16 and Table 5.8). Linear 
plasmid standard curve determined in this study (Figure 5.15) was successful enough to use 
for qPCR analysis. In order to avoid the known inhibition factors such as serum the surest 
way was to prevent the inhibitor from being processed within the sample. Hence, the 
dilutions of unknown samples were made with TE buffer or fresh regulatory compliant 
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medium without serum. Serum is known PCR inhibitor because of its colour and undefined 
content present. 
In the actual experiment, from the plate count (Table 5.9) it was clear that there was an 
increase in growth from 0 hour to 6 hour. When calculated qPCR count was compared with 
actual plate count, there was one log reduction in calculated qPCR count in “0” hour sample 
and significantly greater difference for other samples (even at different time point). It was 
demonstrated in few experiments that the known linear plasmid could amplify successfully 
even if the concentration were 1011 cfu/µl (Ct value -8.0), and the results were reproducible. 
Therefore, the reduced amplification capability might not be only because of high 
concentration of DNA present in the samples.  
Therefore, it might be two main reasons why the qPCR-calculated count could not 
differentiate the count as growth rate increased from time point. Firstly, it might be because 
of the media ingredients as well as by products present in the sample. At “0” hour, it was 
expected to have less growth and by products than other samples. Secondly, it might be 
because of the complex circular structure of DNA that obstructing the efficiency of 
amplification and detection in the reaction by blocking access to the gene of interest. Beside 
these two reasons, the direct culture also consists of dead cells with DNA, with this expected 
qPCR counts should show above plate count results. In short, amplification might be 
suppressed because of the crude sample (direct) used for the qPCR assay and hence 
calculated qPCR count is not accurate. So there was another set of study designed to compare 
the diluted and undiluted sample using the designed qPCR program. 
The dilution of the sample by 1000 fold resulted in two log increases in calculated qPCR count 
compared to neat or half-diluted sample and hence the result confirmed there is an effect of 
using crude or dilute samples on qPCR results analyses. The thousand-fold dilution of the 
sample facilitated the dilution of hindering ingredients and, therefore, a close match with 
actual plate count was achieved. Even though the 1000 fold dilution facilitated to obtain a 
closer count to actual plate count, the calculated qPCR count was one log lesser. The one log 
reduction of calculated qPCR count from actual plate count might be because of supercoiled 
structure as observed in the study that compares linear and circular plasmid amplification. 
Right methodologies for detecting, and reducing inhibition in qPCR could improve 
quantification of cells for better enumeration as demonstrated in this study by diluting the 
samples. The methodology used to obtain the result in this study was in agreement with the 
study conducted with enterococcus [207], as five-fold dilution and the use of reagent 
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improved the qPCR quantification efficiency. Developed qPCR was not successful to 
determine the actual concentration of live cells present in the sample. 
The samples from growth curve experiments (Chapter 3) were analysed from log phase and 
as well as decline phase. The results obtained demonstrated the designed qPCR was not 
capable of differentiating dead cells from living cells (Section 5.5.12). As qPCR counts 
obtained from 6 hours, sample and 24 hours sample shown similar counts even though its 
actual plate counts were significantly different. Therefore, it was decided to analyse only log 
phase or early stationary phase samples (i.e., 0 to 8 hour in fermentors).  This is because 
when the cell growth declines the percentage of dead cells along with the by-products in the 
media increases. The sensitivity of designed qPCR was studied using 24 hours culture from 
Schott bottle (Section 5.5.13). The designed qPCR could detect 102 cfu/µl in diluted crude 
samples. The sensitivity of qPCR was less compared to the sensitivity of conventional PCR or 
other quantitative PCR as this study used cells not extracted DNA as other publications. 
Previously in chapter 3 it was studied to maintain an initial load of Log10 7.5 to Log10 8.5 cells 
per mL to attain a high titre during fermentation. Therefore, the demonstrated sensitivity of 
designed quantitative PCR could estimate the number of cells presents in different time 
intervals to study the progress of fermentation. 
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CHAPTER 6: 
MLST analysis of Australian field strains of   
Haemophilus parasuis 
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6.0 Introduction 
Chapter 6 describes the molecular sequence typing method called MLST (multi-locus 
sequence typing). MLST utilizes internal fragments of six to ten housekeeping gene sequences 
of many pathogens for characterization of isolates especially for tracking strain evolution [21, 
208]. Recently an MLST database was developed for H. parasuis to characterize different 
strains of H. parasuis [21, 115]. The characterization of H. parasuis strains facilitates 
epidemiological surveillance and development of vaccines and thereby it is vitally important 
for swine health management. It enables comparison of vaccine strain (the aroA deletion 
mutant) with other Australian isolates as well as global isolates that are deposited in the 
MLST- H. parasuis database.  Seven housekeeping genes were amplified and sequenced 
following the method of Olvera for the analysis of sequences using the developed MLST H. 
parasuis database [115]. The procedure includes molecular techniques such as DNA 
extraction, PCR amplification of selected genes, PCR clean up, nucleotide sequencing, 
sequence alignment, sequence trimming, and MLST data analysis. The studies outlined in this 
chapter comprise of sequence analysis of a H. parasuis vaccine strain as well as twenty 
different H. parasuis strains isolated from Australian pigs. 
6.1 Necessity for H. parasuis MLST database 
The capacity to identify or differentiate the strains that causes disease is crucial for 
epidemiological surveillance. Serotyping has been used historically for classifying strains of 
many pathogens including the fifteen reference strains of H. parasuis. Although traditional 
methods such as serotyping, serogrouping and serosubtyping have been successful over the 
years and have provided significant information that led to remarkable discoveries, they have 
several limitations that include inadequate discrimination, limited availability of reagents, 
poor reproducibility within and between laboratories and an inability to quantitate the 
genetic relationships between isolates [21]. Serotyping is generally conducted by only a few 
laboratories that specialize in the area. These limitations prevent others from performing 
these traditional methods and limit the effectiveness compared to genotyping especially for 
epidemiological analysis of the population structure of H. parasuis. In Australia, serotyping of 
field isolates yielded between 15% and 41% strains and that could not be typed (non-
typeable). This figure was found to be higher when compared to the USA (15%) and Germany 
(26%) [111]. The occurrence of non-typeable strains suggests that there are more than 15 
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serovars and hence the traditional serotyping does not provide enough discrimination for 
epidemiological studies.  
Based on size fractionation of multiple DNA fragments there are a number of molecular 
typing methods used to generate a genomic finger print of H. parasuis strains for short-term 
epidemiological studies which includes PFGE, ERIC - PCR, RFLP - PCR, Rep - PCR (Chapter 1) 
and more recently multiple-locus variable number of tandem repeats analysis (MLVA) [116, 
209]. MLEE is used as a typing tool in which electrophoretic mobilities of housekeeping 
enzymes on starch gels is studied. The different charge variants of each enzyme assigned with 
allele and alleles at each loci define an electrophoretic type (ET). Even though all techniques 
mentioned above demonstrate high discriminatory power and can be used for a large number 
of isolates at low costs, the major problem is the difficulty in standardization of these 
methods or results between laboratories [210]. Single-locus sequence typing targeting partial 
sequence of hsp60 was introduced for the epidemiological studies of H. parasuis. Even though 
virulent cluster was identified it was not enough for classification of H. parasuis strains and 
the study specified a chance of lateral gene transfer within H. parasuis species or between H. 
parasuis and Actinobacillus spp. [115]. As the results obtained from genotyping and 
serotyping are not comparable as genotyping is completely based on sequence information 
and serotyping on expressed antigens of bacteria. In summary, the techniques used for 
genotyping H. parasuis have not yet reached the satisfactory level due to variability of results 
between laboratories. In order to overcome the limitations, the MLST system that uses the 
conserved housekeeping genes is now the choice for high-resolution characteristics for many 
pathogens. MLST identifies alleles of housekeeping genes rather than comparing the 
electrophoretic mobilities of the enzymes the gene encode [211]. Since single locus sequence 
typing failed for H. parasuis, MLST was introduced to overcome the effects of recombinational 
exchanges or lateral gene transfers that could happen between the strains or species to 
maintain an adequate resolution for classification [115]. The recent release of the whole 
genome sequence H. parasuis strains enhanced the development of an optimized MLST 
scheme [21]. The sequence data generated across the laboratories are more consistent and 
hence it permitted expansion of global database per species to be placed on a World Wide 
Web site. Such an exchange of sequence data allows global and long-term epidemiology and 
ecological patterns to be established for specific microbial populations such as H. parasuis. 
Several recent studies have used gene sequence information to characterize the virulence 
nature of H. parasuis using MLST analysis. The database also includes information pertaining 
to the site of isolation and place of origin of the strains. It is also suggested that MLST data 
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could be used for pre and post surveillance and be part of the overall development of 
vaccines [212]. 
 Box 1 Glossary [213, 214]. 
6.2 MLST database 
MLST database is a deposit of standardized variants of housekeeping genes (sequence 
variation of multiple genes) from global strains of a particular bacterial species. 
Housekeeping genes are much more reliable for global epidemiology as it diversify slowly by 
the random accumulation of neutral or nearly neutral variations [211]. The known variants of 
housekeeping genes or intraspecific variants can be cross-examined to generate genetic 
fingerprints of an isolate. The analysis is based on direct sequencing of portions of seven to 
ten housekeeping genes and for each gene fragment, every unique sequence is allocated as a 
different allele. Difference in single nucleotide in the generated sequence was determined and 
for each locus, alleles were assigned by a unique number and thus allelic profile is generated 
for each strain. Recombinational exchanges can happen within housekeeping genes and 
hence multiple variations can be observed in sequences. The increase in number of variants 
in a gene fragment does not necessarily imply that particular allele is distantly related as 
recombinational exchanges can occur happen frequently in certain bacterial species. So the 
number of nucleotide differences in alleles is not regarded in this analysis but the analysis is 
based on single nucleotide variation [211]. The software behind the MLST database detects 
allelic variations by comparing the variation to already present sequences and therefore the 
sequence type (ST) is defined by the allelic profile (Figure 6.1). As the occurrence of 
nucleotide variation is not very frequent in housekeeping genes, allelic profiles are stable 
over time to distinguish the strains and thus high discrimination is possible by MLST analysis 
Allele profile: The alleles at each of the seven housekeeping genes used for MLST that
unamiguously define a strain. For example, the allelic profile of SH0165, serovar 5
prevalent in China is 10-1-7-1-19-1-17.
Clone: Strains that are shown to be indistiguishable, or very closely related, by MLST or
other molecular typing methods and that can be assumed to be descended from a recent
common ancestor.
Sequence Type (ST): Defined by the allelic profile, for example ST31 defines the virulent
H. parasuis strain SH0165 originated from China with allelic profile 10-1-7-1-19-1-17.
Clonal complex: Clonal complex is a group in which every strain shares at least five
identical alleles out of seven with at least one other genotype in the group or has four
alleles out of seven that are identical to alleles in a consensus or ancestral clone .
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[215]. A MLST database for each pathogen is established by depositing sequence information 
of different isolates from different location from different laboratories across the world and 
thus creating a boost in accumulation of allelic profiles.  
For MLST analysis, designing of primers, which targets ~450 bp portions of seven 
housekeeping genes and amplification using conventional PCR is crucial and it involves 
optimization of amplification parameters. Advancements in sequencing technology allows for 
the internal ~450 bp fragments of housekeeping genes used in the MLST to be sequenced 
with accuracy.  
Figure 6.1: Multilocus Sequence typing; The sequence of processes to determine the allelic 
profile and assign a sequence type (ST) for the sequenced portion of housekeeping genes of a 
bacterial isolate is shown [211]. 
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6.3 H. parasuis - MLST database 
MLST database of H. parasuis was developed by Keith Jolley, which now consists of 148 MLST 
profiles (last update 18 Feb 2014) with 198 sequences from different countries (Figure 6.2). 
A high genetic diversity of H. parasuis is observed when it compared to MLST database of the 
closely related organism Pasteurella multocida. For P. multocida only 60 MLST profile were 
generated out of 169isolates, while for H. parasuis 131 MLST profiles were generated out of 
166 isolates. Even though whole-genome sequencing is advancing tremendously, the central 
MLST databases for H. parasuis and other organisms delivers a unique index of genetic 
variations using housekeeping genes. Serotyping was the traditional typing method for 
classification of H. parasuis isolates and it resulted in an increased amount of non-typeable 
isolates. It was necessary to develop an optimal typing method for H. parasuis to track the 
strain evolution by providing each isolate with a unique tag and thus develop an effective 
epidemiological surveillance tool. The MLST database has provided a high degree of 
reproducibility and unique resolving power for nearly hundred species and hence it is 
regarded as more effective than several sequence based methods [216]. The advantage of 
MLST scheme for H. parasuis  includes rapidness of result analysis when handling with pure 
cultures [213]. The strain associations obtained from MLST analysis were more consistent 
and portable than techniques like MLEE and it thus permits to establish a global database per 
species to be placed on a world-wide website [215]. Each isolate information generated from 
anywhere in the world could be deposited through the website and information could 
compare with other global isolates which includes site of isolation, disease status. Software’s 
like eBURST, phylogenetic trees based on distance-matrix methods such as neighbor-joining 
or UPGMA, which calculate genetic distance from multiple sequence alignment could be used 
for cluster analysis to study association of isolates in the cluster and their relation. MLST 
analysis on Neisseria meningitides used six loci and it successfully recognized the major 
meningococcal lineages connected with invasive disease. 
 H. parasuis MLST system using partial sequences of the housekeeping genes atpD, infB, mdh, 
rpoB, 6pgd, g3pd and frdB was developed initially with 131 isolates (120 field strain and 11 
reference strain) (Figure 6.3) [21].  To generate data for MLST analysis, the sample must be 
grown to obtain material for DNA extraction, PCR amplification, PCR clean up and 
sequencing. The generated sequence data is then compared against the whole collection of 
isolates present in database with identical or similar sequence types. A high genetic 
heterogeneity was confirmed by the initial MLST analysis, specifically for 6pgd which showed 
the highest diversity [115]. Using the BURST (Based Upon Related Sequence Type) algorithm, 
among 109 sequence types, thirteen clonal complexes were found and when further analysed 
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with UPGMA (unweighted-pair group method with arithmetic mean) it was found that one 
cluster linked with nasal isolates (putative, non-virulent) and another cluster indicated 
substantial linked with clinical lesions (putative virulent) [115].Therefore MLST analysis may 
facilitate in the differentiation of H. parasuis isolates depending on the site of isolation (lung, 
nasal cavity, joints) and its association with virulence. This association may strengthen as the 
database accumulation increases over years. But if the variability in gene sequence 
(housekeeping genes) is not a slow accumulation the power of discrimination using MLST 
analysis reduces. Recently for the first time, a number of Australian strains were also 
deposited to MLST database of H. parasuis and hence the number of samples within the 
database increased from 131 to 146 isolates (Table 6.1). 
By performing MLST analysis, the end result is a sequence type (ST, e.g. ST124) that is 
comprised of the allelic profile for the seven loci (i.e., 7 34 30 17 12 3 31 for ST124) and it is 
associated with useful information, like antibiotic resistance, site of isolation and disease 
caused. Identifying the exact sequence types of the strains from the outbreaks facilitates the 
study of relationship as well as providing information to study the long-term trend of disease 
pattern caused by H. parasuis. Thus, the analysis constantly improves the understanding of H. 
parasuis species, genera and populations to supply enough information for global 
epidemiological studies as well as for swine health management. Eventually H. parasuis 
population structure information using MLST database could be useful towards revealing the 
underlying relationship between serovar and virulence.  
 
Figure 6.2: Estimation of sequences deposited in H. parasuis MLST database from different 
countries (http://pubmlst.org/hparasuis).  
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Figure 6.3: Circular orientation of H. parasuis (SH0165) genome from which MLST 
housekeeping genes are selected [21, 196]. 
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Table 6.1: Recently submitted Australian strains (n=16) in MLST - H. parasuis database by Dr Conny Turni. 
Id Isolate Site Region Comments atpD infB mdh rpoB 6pgd g3pd frdB ST 
10  HS2863 nasal cavity South Australia Non-typeable 7 13 18  16 37 3 4 117 
132  HS2866 nasal cavity South Australia serovar 5 2 30 6 1 38 3 9 118 
133  HS2979 lung Victoria serovar 12 22 11 29  1 39 3 34 131 
134  HS2958 nasal cavity New South Wales serovar 9 7 5 19  17 40 3 6 119 
135  HS2954 nasal cavity New South Wales serovar 15 7 28 22  18 15 3 2 120 
136  HS2878 nasal cavity South Australia serovar 1 7 1 29  6 4 3 22 121 
137  HS2875 nasal cavity South Australia serovar 4 2 30 6 1 38 3 9 118 
138  HS2857 nasal cavity South Australia serovar 1/2 7 31 4 2 4 3 6 122 
139  HS2851 nasal cavity New South Wales serovar 4 23 32 5 1 38 3 9 123 
140  HS2834 nasal cavity New South Wales serovar 7 7 34 30  17 12 3 31 124 
141  HS2792 lung Victoria serovar 13 24 35 31  1 3 3 32 130 
142  HS2569 nasal cavity Queensland serovar 15 7 28 22  18 38 15 2 125 
143  HS2774 nasal cavity New South Wales serovar 12 7 33 4 1 38 3 9 126 
144  HS2817 nasal cavity Queensland serovar 4 2 28 4 6 41 3 33 127 
145  HS2828 nasal cavity New South Wales serovar 10 7 5 6 17 15 3 6 128 
146  HS2884 nasal cavity Queensland serovar 6 24 11 1 1 3 1 32 129 
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Figure 6.4 Different stages involved in MLST analysis using housekeeping gene [212]. 
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6.4 Objectives 
The main objectives of the Chapter 6 include:- 
1. To sequence housekeeping genes of twenty Australian H. parasuis strains. 
2. To assign allelic profile to each strains using MLST-H. parasuis database. 
3. Compare the allelic profile of twenty Australian strains with a vaccine candidate. 
4. To construct a phylogeny tree (UPGMA) for cluster analysis for the twenty Australian 
H. parasuis strains. 
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6.5 Materials and Methods 
Twenty Australian H. parasuis isolates were received from Dr Conny Turni, DPI&F 
Queensland (Table 6.2).  
Table 6.2: List of H. parasuis strains with serovar information used in this study. 
Strain ID Serotype 
HS3398 13 
HS3127 15 
HS2002 3 
HS2871 unknown 
HS2157 12 
HS3432 4 
HS3554 9 
HS3169 10 
HS3110 unknown 
HS2561 1 
HS2541 15 
HS3521 2 
H22093 11 
HS3332 NT 
HS3048 NT 
HS3218 NT 
HS3152 5 
HS3456 14 
HS3289 5 
HS1957  7 
Hps29 2 
6.5.1 Recovery and storage of strains 
Strains were transported using sterile swabs. Chocolate agar plates were prepared (Section 
2.6.4) and spread with 0.1% NAD solution for recovery of strains from the swabs from the 
transport medium. Swabs were spread aseptically onto chocolate agar plates inside a laminar 
and incubated at 37 °C for 24 hours inside a candle jar. After the lawn culture was visible on 
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each plate, the lawn was harvested using a sterile loop and resuspended in 1 mL of storage 
media (Table 2.5) and aliquoted into sterile Eppendorf tubes (pre-labeled). The Eppendorf 
tubes were then stored at -20 °C. 
Table 6.3: Primer sequences used in this study for gene amplification and sequencing- MLST 
primers [115]. 
Gene Base pair Primer (forward and reverse) 
atpD 
  
582 bp 
  
atpDF    CAAGATGCAGTACCAAAAGTTTA 
atpDR    ACGACCTTCATCACGGAAT 
infB 
  
501 bp 
  
infBF    CCTGACTAYATTCGTAAAGC 
infBR    ACGACCTTTATCGAGGTAAG 
mdh 
  
537 bp 
  
mdh-up   TCATTGTATGATATTGCCCC 
mdh-dn   ACTTCTGTACCTGCATTTTG 
rpoB 
  
470 bp 
  
rpoBF    TCACAACTTTCICAATTTATG 
rpoBR    ACAGAAACCACTTGTTGCG 
6pgd 
  
599 bp 
  
6pgdF    TTATTACCGCACTTAGAAG 
6pgdR    CGTTGATCTTTGAATGAAGA 
g3pd 
  
564 bp 
  
3gpdF    GGTCAAGACATCGTTTCTAAC 
3gpdR    TCTAATACTTTGTTTGAGTAACC 
frdB 
  
553 bp 
  
frdBF    CATATCGTTGGTCTTGCCGT 
frdBR    TTGGCACTTTCGATCTTACCTT 
6.5.2 PCR amplification with MLST primers 
Housekeeping genes were amplified using MLST primers (Table 6.3) by conventional PCR. 
The PCR master mix from PROMEGA (Australia) was used and amplification parameters as 
listed in Table 6.3 were used. Reaction ratios were stated under Table 2.4 B. Amplified genes 
were optimized for annealing temperature and the optimized annealing temperatures were 
listed in appendix VII. Amplification was confirmed by running the PCR product onto 2% 
agarose gel. The amplified product was then cleaned by PCR clean up system (Wizard ® SV 
gel, Promega). The purified housekeeping genes from twenty strains and vaccine candidate 
were eluted in nuclease free water and made into aliquots of 50 µl and stored at -20 °C. From 
the aliquots, one µl of each gene was used to measure the concentration by nanodrop and 
concentrations were recorded for sequencing purposes. 
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Table 6.4: PCR amplification conditions for the housekeeping genes using MLST primers. 
 
 
 
 
 
 
 
 
*Different annealing temperature were used for some of the genes in each strain (Appendix 
VIII) 
6.5.2.1 Result on Amplification and purification of housekeeping genes 
 
Figure 6.5: Agarose gel showing purified housekeeping genes of H. parasuis strain-HS3398 
using MLST primers; Lane 1: 100bp DNA ladder, Lane 2: atpD (582 bp), Lane 3: infB (501 bp), 
Lane 4: mdh (537 bp), Lane 4: rpoB (470 bp), Lane 4: 6pgd (599 bp), Lane 4: g3pd (564 bp), 
Lane 4: frdB (553 bp). 
Amplified housekeeping genes of twenty strains and vaccine candidate were cleaned and 
aliquots were made with one specific primer in each aliquot according to AGRF (Australian 
Genome Research Facility Ltd.) specifications. Figure 6.5 demonstrates amplification and 
confirmation of housekeeping genes from HS3398 strain. Similarly, seven housekeeping 
genes from each strain listed in Table 6.2 was amplified and purified. After confirmation by 
agarose gel electrophoresis, the aliquots were sent out to AGRF, Brisbane for sequencing. The 
obtained sequence was analysed and edited using Chromas (sequence analyser software). 
Step Temperature Time Stage Cycle 
Denaturing 94 °C 5.0 min Stage 1 1 
Annealing 94 °C 30 s       Stage 2:Stage 1 35 
 * 40 s    Stage 2:Stage 2  
 72 °C 2.0 min     Stage 2:Stage 3  
Extension 72 °C 10.0 min     Stage 3 1 
Store 4 °C       Infinite Holding  
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6.6 Results 
6.6.1 Result on assignment of allelic profiles using MLST database 
Using MLST- H. parasuis database (http://pubmLst.org/hparasuis) allelic profile of each 
single strain was done by depositing the sequence data of each gene into database. The 
primers used in original design of the MLST method [115] (Table  6.3) were used for this 
study. The annealing temperatures of some of the genes of some of the isolates were required 
to be optimized using conventional PCR (Appendix X). This work has been done prior to the 
recent modification to primers [21]. The sequence data obtained from each locus has been 
aligned using BLAST, MEGA 6.0.5 and the genotype of all H. parasuis isolates except for one 
isolate (HS3218) has been confirmed. Raw sequence received was trimmed and edited with 
currently presented MLST database sequences and used for further analyses in this study. In 
Figure 6.6, atpD housekeeping gene of HS3398 was submitted and an exact allele match was 
found in the database for the atpD allele 7. Similarly, the allelic profile for all the strains was 
retrieved using the MLST- H. parasuis database. 
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Figure 6.6: MLST- H. parasuis database has been used to assign allelic profile; for example atpD gene sequence of HS3398 submitted and 
an exact match was found at atpD allele 7.  
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Table 6.5: MLST profile generated from MLST- H. parasuis website using seven housekeeping gene sequences. 
 
 
 
 
 
 
 
 
 
 
 
*Unknown; NT-Non-typeable
Strain 
ID 
Serotype MLST profile Closest matching strain 
(no. of loci match) 
  atpD infB mdh rpoB 6pgd g3pd frdB ST Region/Country 
HS3398 13 7 33 29 1 39 3 9 ST126(5) NSW/Australia 
HS3127 15 4 5 19 1 26 3 2 ST50(5) Spain 
HS2002 3 7 34 4 17 12 3 2 ST124(4) NSW/Australia 
HS2871 * 4 5 17 6 26 3 5 ST131(4) VIC/Australia 
HS2157 12 7 11 22 1 39 1 34 ST131(4) VIC/Australia 
HS3432 4 7 9 19 6 26 3 2 ST121(3) SA/Australia 
HS3554 9 7 5 12 17 26 3 6 ST128(5) NSW/Australia 
HS3169 10 7 4 12 1 29 3 9 ST126(4) NSW/Australia 
HS3110 * 23 32 5 1 38 3 9 ST123(7) NSW/Australia 
HS2561 1 7 2 24 1 14 1 2 ST76(7) Spain 
HS2541 15 7 5 19 17 40 3 6 ST119(7) NSW/Australia 
HS3521 2 7 5 6 6 29 3 6 ST128(5) NSW/Australia 
H22093 11 2 9 4 9 21 3 2 ST94(4) Spain 
HS3332 NT 3 33 22 1 3 1 20 ST46(5) Argentina 
HS3048 NT 4 5 6 4 6 15 5 ST26(4) Japan 
HS3218 NT - - - - - - - - - 
HS3152 5 22 4 31 1 29 3 9 ST91(4) Belgium 
HS3456 14 5 11 29 1 39 3 20 ST131(5) VIC/Australia 
HS3289 5 3 11 29 1 39 1 9 ST131(4) VIC/Australia 
HS1957 7 7 2 4 6 39 3 2 ST1(4 ) Oklahoma 
Hps29 2 7 12 19 16 21 3 23 ST119(3) NSW/Australia 
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Sequencing data was generated for each of the seven housekeeping genes for each of the 
twenty different strains of H. parasuis strains and from the data, the MLST profile was 
subsequently generated. Among the twenty strains, three strains had a perfect match with 
strains already presented in the database and so it was assigned the same ST (sequence type) 
(highlighted in Table 6.5). All other strains had similarity of 3 to 6 loci match and the closest 
matching sequence type is also listed in the Table 6.5. There were many examples of isolates 
with identical serotypes but different allelic proﬁles among the collection of H. parasuis in the 
database. In order to illustrate the heterogeneity of H. parasuis isolates, serotype 5 from the 
database and from this work is tabulated below with allelic profile (Table 6.6). The presence 
of multiple isolates of same serotypes from different countries of the world provided the 
opportunity to examine whether there was any potential association between allelic profile 
and already identified serotypes. From Table 6.6, two isolates (HS2866 and HS3289) from 
Australia was chosen to perform an allele-to-allele nucleotide difference study. It also 
demonstrates how the each profile was constructed unique for each sequence type. 
Table 6.6: Serotypically identical but genotypically different H. parasuis isolates; MLST 
profile of serotype 5 from MLST database and from this work. 
 
 
 
Isolate/country atpD infB mdh rpoB 6pgd g3pd frdB Site of 
isolation/disease 
Nagasaki -Japan 1 8 7 1 1 1 3 Lung/septicemia 
29755–United States 9 1 1 1 1 1 13 Lung/polyserositis 
SH0165-China 10 1 7 1 19 1 17 Lung/polyserositis 
7204123-Denmark 19 26 7 1 29 1 2 Joint/polyserositis 
7403746-Denamrk 9 22 7 1 29 1 11 Diseased pig 
Hs2866-Australia 2 30 6 1 38 3 9 Nasal cavity 
HS3289-Australia 3 11 29 1 39 1 9 From this work 
HS3152-Australia 22 4 31 1 29 3 9  From this work 
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Table 6.7: List of isolates selected from the global database and this work which have similar rpoB and g3pD alleles. 
Strain Isolation site Disease Country/Region Serovar atpD infB mdh rpoB 6pgd g3pd frdB ST 
2170B joint polyserositis US/lowa * 1 1 1 1 1 1 1 5 
NADC2 lung * US/lowa * 3 3 3 1 3 1 3 22 
Nagasaki lung 
septicemia & 
meningitis 
Japan 5 1 8 7 1 1 1 3 24 
H367 * * Germany 10 5 9 5 1 10 1 10 18 
H425 lung * unknown 12 3 1 9 1 3 1 2 19 
84-15995 lung pneumonia United States 15 6 10 3 1 3 3 2 15 
24054 lung polyserositis US/lowa * 1 12 1 1 1 1 12 6 
831542 * * US/lowa * 8 1 11 1 1 1 2 14 
464-99 joint polyserositis US * 1 1 12 1 1 1 7 12 
685-99 pericardium polyserositis United States * 7 1 13 1 4 3 3 13 
1050-99 lung polyserositis US * 1 1 12 1 1 1 7 12 
831541 * * US/lowa * 8 1 11 1 1 1 2 14 
29755 lung polyserositis US/lowa 5 9 1 1 1 1 1 13 8 
84-17975 lung * US 13 1 1 1 1 1 1 1 5 
228/04 lung polyserositis Spain/Catalunya * 7 24 16 1 14 1 2 80 
SH0165 lung polyserositis China 5 10 1 7 1 19 1 17 31 
CA38-4 nasal cavity - Spain/Segovia * 5 11 3 1 24 1 2 42 
34/03 pericardium polyserositis Argentina * 12 1 22 1 3 1 20 46 
7204122 joint polyserositis Denmark 13 4 2 4 1 9 3 22 56 
AZ1-5 nasal cavity * Spain - 1 12 3 1 3 3 23 62 
9904809 * * Denmark 12 8 26 7 1 32 3 3 106 
ER-6P pericardium polyserositis Spain/Catalunya * 7 24 7 1 29 1 29 109 
P462/03 lung Polyserositis Argentina/Cordoba * 14 17 13 1 3 1 24 64 
4503 * * Germany * 15 11 4 1 29 1 25 65 
CC6-7 nasal cavity * Spain/Catalunya * 7 18 7 1 29 1 29 105 
373/03A pericardium polyserositis Spain * 18 24 3 1 29 1 26 83 
7204123 joint polyserositis Denmark 5 19 26 7 1 29 1 2 104 
9904574 - - Denmark 5 4 26 4 1 9 3 22 112 
2725 joint polyserositis Germany * 9 11 25 1 29 1 9 74 
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7403746 * * Denmark 5 9 22 7 1 29 1 11 75 
GN-257 * * Spain * 7 2 24 1 14 1 2 76 
SL7-2 nasal cavity healthy Spain/Catalunya * 5 23 27 1 3 3 2 78 
04-100691 joint polyserositis Belgium * 2 1 7 1 29 1 9 90 
May-08 pericardium polyserositis Belgium * 9 11 7 1 29 3 9 91 
05-85149 lung pneumonia Belgium * 1 11 8 1 3 1 3 95 
04-26867 lung polyserositis Belgium * 1 1 3 1 3 3 4 97 
IT169031-1 lung pneumonia Italy * 2 1 3 1 29 1 9 99 
84-22113 joint * United States 14 3 29 1 1 1 1 20 113 
HS2866 nasal cavity * Australia/SA 5 2 30 6 1 38 3 9 118 
HS2979 lung * Australia/VIC 12 22 11 29 1 39 3 34 131 
HS2875 nasal cavity * Australia/SA 4 2 30 6 1 38 3 9 118 
HS2851 nasal cavity * Australia/NSW 4 23 32 5 1 38 3 9 123 
HS2792 lung * Australia/VIC 13 24 35 31 1 3 3 32 130 
HS2774 nasal cavity * Australia/NSW 12 7 33 4 1 38 3 9 126 
HS2884 nasal cavity * Australia/QLD 6 24 11 1 1 3 1 32 129 
HS3398 * * Australia 13 7 33 29 1 39 3 9 132 
HS3127 * * Australia 15 4 5 19 1 26 3 2 133 
HS2157 * * Australia 12 7 11 22 1 39 1 34 136 
HS3169 * * Australia 10 7 4 12 1 29 3 9 139 
HS3110 * * Australia * 23 32 5 1 38 3 9 123 
HS2561 * * Australia 1 7 2 24 1 14 1 2 76 
HS3332 * * Australia NT 3 33 22 1 3 1 20 142 
HS3152 * * Australia 5 22 4 31 1 29 3 9 144 
HS3456 * * Australia 14 5 11 29 1 39 3 20 145 
HS3289 * * Australia 5 3 11 29 1 39 1 9 146 
* Unknown; NT- non-typeable 
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Table 6.7 represents a list of isolates which shared similar allele of g3pd (1, 3) and rpoB (1). 
The list of isolates comprised of both isolates from the database and isolates from this work 
(highlighted). According to serotyping, serovars 1, 5, 10, 12, 13 and 14 have been shown to be 
highly virulent as defined by their ability to cause death or morbidity within four days [13]. 
Serovars 2, 4 and 15 have been found to be moderately virulent and serovar 8 mildly virulent, 
while serovar 3, 6, 7, 9 and 11 have been shown to be avirulent [13]. Interestingly most of the 
isolates with information listed in the above Table 6.7 caused disease in pig specifically 
polyserositis or pneumonia except one isolate SL7-2 from Spain. Even the most virulent 
reference strain of H. parasuis, Nagasaki (serovar 5) which was recovered from a case of 
meningitis and H. parasuis SH0165, a high virulent serovar 5 strain was also recovered from 
the lung of a diseased piglet in North China. These virulent strains also share the same allele 
for g3pd and rpoB gene. Allele 1 and 3 of g3pD shares 99.7% of similarity as shown in Figure 
6.7 e. Unfortunately, very few isolates included the serovar or the type of disease, so it was 
difficult to make correlations. More information might help better correlation between the 
association of these genes and disease. 
6.6.2 Nucleotide variation between alleles of each gene fragment 
MEGA 6.0.6 software is used to edit assemble and align the sequences. In order to compare 
the allele to an allele difference, the MLST- H. parasuis database was used (sequences and 
profile definition  compare alleles). Comparison between alleles of the isolates HS2866 and 
HS3289 (serotype 5) is demonstrated by Figure 6.7 a to Figure 6.7 e. Percentage of each 
nucleotide differentiation in each housekeeping gene of isolates deposited in the database can 
be retrieved from the MLST database for polymorphism study and the interface further helps 
to acquire the profile and allele information regarding the isolate. Figure 6.8 shows the 
percentage of nucleotide differentiation in atpD gene of 146 isolates, similarly other gene 
information is also available from the database for analysis. The sequences obtained for rpoB 
and frdB however showed 100% homology between HS2866 and HS3289. 
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 Figure 6.7 a: Percentage of identity was calculated and nucleotide difference between the 
alleles of atpD from two different MLST profile is studied (MLST profile of HS2866 and 
HS3289-Table 6.6). 
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Figure 6.7 b: Percentage of identity was calculated and nucleotide difference between the 
alleles of infB from two different MLST profile is studied (MLST profile of HS2866 and 
HS3289-Table 6.6). 
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Figure 6.7 c: Percentage of identity was calculated and nucleotide difference between 
the alleles of mdH from two different MLST profile is studied (MLST profile of HS2866 
and HS3289-Table 6.6).  
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Figure 6.7 d: Percentage of identity was calculated and nucleotide difference between the 
alleles of 6pgd from two different MLST profile is studied (MLST profile of HS2866 and 
HS3289-Table 6.6).  
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Figure 6.7 e: Percentage of identity was calculated and nucleotide difference between the 
alleles of g3pd from two different MLST profile is studied (MLST profile of HS2866 and 
HS3289-Table 6.6). 
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Figure 6.8: Nucleotide variation presented in different alleles of atpD gene (24 alleles) MLST- 
H. parasuis; Colour codes represent the percentage nucleotide variation according to current 
MLST database isolate deposit (35 polymorphic sites identified). 
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6.6.3 Construction of phylogeny for cluster analysis 
By submitting the MLST profile of H. parasuis isolates from this work to the curator (Karen 
Register) of the pubMLST H. parasuis database ST of each isolates was obtained (Table  6.8). 
Concatenated sequences from all seven housekeeping gene fragments of 16 isolates of H. 
parasuis  and twenty strains from this work was used to construct an UPGMA and NJ tree. 
Sequences from twenty strains were trimmed to the exact size of the isolates from the MLST 
database and aligned. Sequences were arranged in the order of 6pgd (465 bp), atpD (519 bp), 
frdB (453 bp), g3pd (440 bp), infB (399 bp), mdh (444 bp) to form concatenated sequences 
which comprises 3051 base pairs in total (Appendix IX). Concatenated sequences of twenty 
isolates from this work along with 16 Australian isolates from database were aligned using 
MEGA 6 [217]. UPGMA trees (Unweighted Pair Group Method with Arithmetic mean) used 
statistical sampling for reliability of typing or Multi sequence alignment (MSA) in this work. It 
was generated by setting bootstrap value 1000 using the same software. It facilitates to 
evaluate the reliability of the constructed tree, by calculating how often certain clusters in a 
tree appear when nucleotides are resampled. Isolates from the current work is highlighted by 
yellow colour and the clade in which vaccine candidate belong in green texture in Figure 6.9.  
Table 6.8: Sequence type (ST) of isolates were obtained from pubMLST H. parasuis database 
using generated MLST profiles. 
Isolate Serotype ST atpD infB mdh rpoB 6pgd g3pd frdB 
HS3398 serovar 13 132 7 33 29 1 39 3 9 
HS3127 serovar 15 133 4 5 19 1 26 3 2 
HS2002 serovar 3 134 7 34 4 17 12 3 2 
HS2871 unknown 135 4 5 17 6 26 3 5 
HS2157 serovar 12 136 7 11 22 1 39 1 34 
HS3432 serovar 4 137 7 9 19 6 26 3 2 
HS3554 serovar 9 138 7 5 12 17 26 3 6 
HS3169 serovar 10 139 7 4 12 1 29 3 9 
HS3110 unknown 123 23 32 5 1 38 3 9 
HS2561 serovar 1 76 7 2 24 1 14 1 2 
HS2541 serovar 15 119 7 5 19 17 40 3 6 
HS3521 serovar 2 140 7 5 6 6 29 3 6 
H22093 serovar 11 141 2 9 4 9 21 3 2 
HS3332 non-serotypeable 142 3 33 22 1 3 1 20 
HS3048 non-serotypeable 143 4 5 6 4 6 15 5 
HS3152 serovar 5 144 22 4 31 1 29 3 9 
HS3456 serovar 14 145 5 11 29 1 39 3 20 
HS3289 serovar 5 146 3 11 29 1 39 1 9 
HS1957 serovar 7 147 7 2 4 6 39 3 2 
Hps29 serovar 2 148 7 12 19 16 21 3 23 
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Figure 6:9: UPGMA Dendrogram constructed using MEGA 6.0.6 with pairwise mean 
differences and bootstrap value of 1000; comprised of 36 Australian isolates including 
vaccine candidate (Hps29). Isolates from this work are highlighted by a yellow background; 
Numerical value marked at each clade represents the frequency (red) with which the given 
branch recorded during bootstrapping. Frequency of population below value below 50% is 
not displayed in the tree; Green colored phyla represent the clade where vaccine candidate 
belongs among other number of clades. 
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6.6.4 eBURST analysis 
eBURST is principally an epidemiological tool designed for exploring clonal divergence over 
short evolutionary spans. In this study eBUSRT analysis was used to identify the close 
relationship between the isolates or sequence types using MLST data (housekeeping genes). 
eBURST analysis was performed using Phyloviz software (available: 
http://goeburst.phyloviz.net/). The core of this algorithm is based on parsimony-based 
search for founders of clonal complexes (CC’s), where clonal complex refers to cluster of 
genotypically related ST’s that have diversified very recently from a mutual founder. When 
allelic profile differs from that of the founder at only one of the seven MLST loci it is called 
Single-locus variant (SLV’s) and at two of the seven loci double-locus variants (DLV’s), at 
three of the loci triple-locus variants (TLV’s). Using the predicted founder within each clonal 
complex, this approach distinguishes the most parsimonious patterns of descent isolates. For 
diagrammatic illustration, eBURST analysis uses circles to represent each ST’s and the size of 
the circle is scalable depends on the number of isolates of the ST present in the database. 
6.6.4.1 Result on eBURST analysis on Australian and global isolates of H. 
parasuis using MLST 
eBURST analysis allowed clustering analysis using minimum spanning tree. The analysis ST’s 
of H. parasuis global data based on seven housekeeping genes and its available information. In 
Figure 6.10, spread of ST’s illustrates the heterogeneity of H. parasuis organism. The vaccine 
candidate was assigned with sequence type 148 by pubMLST and the closest match to this ST 
was ST117 and ST119 in which the isolates are of Australian origin. In Figure 6.11, global 
distribution of isolates based on country of origin was depicted. Cluster of isolates from the 
same country were spotted and hence evolutionary relationship based on geographic pattern 
is established except for a few. One of the isolates from this study (HS2561) shares the same 
sequence type (ST76) with two of the isolates from Spain. Clonal complexes (11 no’s) were 
identified among 166 isolates (Figure 6.12) as per single locus variants. 
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Figure 6.10: Minimum spanning tree (MST) obtained from 166 global isolates of H. parasuis 
(148 sequence types) using MLST information; Each circle represents a different sequence 
type, vaccine candidate ST is highlighted in red created using goeBURST full MST algorithm in 
which darker links represent less allelic differences in the profile than lighter links; size of 
nodes propitiate to number of isolate that ST representing. 
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Figure 6.11: Minimum spanning tree (MST) of 166 global isoaltes of H. parasuis using MLST 
information; colourdistributon of nodes (ST’s) based on different country of origin in which 
few nodes share different countries. 
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Figure 6.12: Clonal complexes (11 no’s) constructed using goeBURST algorithm using single-
locus variants (SLV’s).Only twenty six isolates out of 166 isolates deposited in the database 
demonstrated identity of six locus out seven. 
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6.7 Discussion 
MLST assists with the analysis of genetic diversity of H. parasuis and allows epidemiological 
evaluations during outbreaks. Due to heterogeneity of H. parasuis strains, many techniques 
developed for diagnosis face challenges. This chapter focused on genotypic analysis of the 
vaccine candidate along with twenty Australian H. parasuis isolates using seven housekeeping 
genes by utilizing the recently developed MLST database to determine the relatedness of 
Australian isolates with globally isolated strains. The twenty Australian H. parasuis isolates 
and one vaccine candidate (Hps29-serotype 2) received from Dr Conny Turni, Department of 
Primary Industries and Fisheries (Qld) from this study was used for the analysis (total 
number (n) isolates used was 21). The analysis collated genetic information with the isolates 
origin and site of isolation and serotypes but this information may not exist for every isolate. 
At the time of analysis, concatenated sequence from 146 isolates existed in the database from 
which the twenty Australian isolates analysed in this study were compared against. MLST 
analyses of Australian collection of H. parasuis evidently confirmed a high genetic diversity in 
the population which is in agreement with other papers published from different countries 
[11, 132, 218].  
Upon analysis against the database, one of the Australian isolates (HS3218) appeared to be 
contaminated. That is sequencing result showed amplification from two closely related 
species. Amplification of all other isolates (twenty strains including vaccine strain) were 
cleaned for sequencing as shown in Figure 6.5 and hence the sequencing result was analysed 
using MEGA 6 for alignment. During the analysis, seven alleles present in each isolate were 
allocated with a unique set of numbers from the database creating a profile for each isolate. 
Hence, the isolates were highly unlikely to have identical allelic profile even by chance. The 
isolates with the same allelic profile in the database were assigned as members of the same 
clone of the same sequence type (Table 6.5). A MLST profile was generated for each isolate 
and the closest match for each isolate was retrieved from the database (Table 6.5). Among the 
twenty isolates, MLST profile of three isolates (HS3110-ST 123, HS2561-ST 76, and HS2541- 
ST 119) were assigned with already presented sequence type (ST) as all seven loci acquired 
exact match within the database. Isolate HS3110 and HS2541 showed ST identical matches to 
isolates from Australia itself, as well as matching to an isolate from Spain (HS2561). 
The sequence types 117 to 131 are Australian isolates (Table 6.1). They were recently 
deposited by Dr Conny Turni. Most of the isolates from this work only showed three or more 
locus identity towards those Australian isolates present in the database, as the strains were 
isolated from different farms. Among the Australian isolates (including the isolates generated 
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in this work), housekeeping gene g3pd showed less nucleotide variation (limited to three 
alleles 3, 1, 15). Allele 3 and 1 of g3pd showed 99.7 % of nucleotide identity and it is mostly 
seen in global isolates (Table 6.7). This suggests that of the core housekeeping genes, g3pd is 
slow to accumulate polymorphisms in these Australian isolates. A similar observation can be 
seen for this gene also for global isolates. Gene rpoB is also conserved in Australian isolates 
compared to other housekeeping genes (Table 6.5 and Table 6.1). Specifically allele 1 of rpoB 
is most frequently observed allele among the global isolates (Table 6.7). 
Serotype 5 of H. parasuis isolates were listed from the database and tabulated along with 
serotype 5 isolates tested in this work for the purpose of investigating the relationship 
between serotypes and MLST profiles which indicated that there was no correlation between 
serotype and (MLST based) genotype (Table 6.6). Similar findings were observed with MLST 
analysis of P. multocida [219]. Furthermore, there was no correlation for the site of isolation 
of H. parasuis isolate and its MLST profile. The MLST profile comparison of two (serotype 5) 
Australian isolates has been conducted as shown in Figure 6.6. Despite the alleles sharing a 
high level of sequence identity, the isolates were assigned as different alleles. These examples 
demonstrate the high discriminatory power of MLST analysis, which is based on single base 
changes. The database also provides an option to view all the nucleotide differences in a 
single gene and accesses additional information of the isolate (such as the site of isolation, 
country and disease cause) simply by clicking onto the nucleotide (Figure 6.8). From the 
MLST published data, it was evident that atpD allele 4 and 2 are most commonly present in 
isolates from Spain and allele 7 was most abundant among Australian isolates. However, atpD 
allele 10 was found only in SH0165, a virulent isolate from China which caused polyserositis, 
similarly atpD allele 12 and 14 only present in isolates from Argentina, atpD allele 13 was 
only found in isolates from Denmark. Likewise, many other unique combinations or unique 
alleles can be investigated further using this database for better correlation or future works.  
New alleles were assigned to Australian isolates highlighting that pattern of mutation could 
differ based on geographical distinction. As per the current MLST database of H. parasuis, new 
alleles were introduced to seven housekeeping genes, gene atpD (22 - 24), infB (30-35), mdH 
(29 - 31), rpoB (17), 6pgd (37 - 40), g3pd (15), frdB (31 - 34) (pubMLST H. parasuis database). 
Therefore, a new set of alleles and combinations were established for MLST profile of these 
Australian isolates and hence all of them received new “Sequence Type”. There is no specific 
correlation between created sequence type and serotypes according to the current update of 
pubMLST data. These features of MLST are user-friendly and analysis is reproducible 
compared to more dated techniques for population structure studies. Monitoring of isolates 
in this way allows for rapid investigation of H. parasuis outbreaks globally as well as tracks 
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strain evolution. This can ultimately assist in better control over disease outbreaks. The 
power of the MLST analysis will be greater as more isolates are deposited into the database 
from isolates around the world. Alternatively, it can be possible to track the disease 
progression within Australia if new isolates and their pathological characteristics are 
deposited into the database.  
However, there is no robust link between genotypes and virulence, according to serotyping, 
serovars 1, 5, 10, 12, 13 and 14 have been shown to be highly virulent as defined by their 
ability to cause death or morbidity within four days. Serovars 2, 4 and 15 have been found to 
be moderately virulent and serovar 8 mildly virulent, while serovar 3, 6, 7, 9 and 11 have 
been shown avirulent [13]. Interestingly most of the isolates with information listed in the 
Table 6.7 caused disease in pig specifically polyserositis or pneumonia and the serotypes 
belonged to one of the highly virulent strains except for serovar 4 (n=2). Information 
regarding isolates is crucial for a successful correlation study or for conclusion regarding the 
effectiveness of MLST analysis. Even the most virulent reference strain of H. parasuis, 
Nagasaki (serovar 5) recovered from a case of meningitis and H. parasuis SH0165, a high 
virulent serovar 5 strain recovered from the lung of a diseased piglet in North China were 
included in Table 6.7. These virulent strains shares same allele for g3pd and rpoB gene. 
Association of these genes and its correlation with severity of disease could be studied 
further as the accumulation of database increases. Allele 1 and 3 of g3pD shared 99.7% of 
similarity as shown in Figure 6.7 e. 
Cluster analysis of MLST data would be useful to determine whether an unknown or non-
typeable isolates of H. parasuis would be virulent or not and hence, it could assist with 
choosing a vaccine candidate. For this study, seven housekeeping genes of H. parasuis were 
used to construct an UPGMA (Unweighted Pair Group Method with Arithmetic mean) tree. It 
was constructed using aligned concatenated sequence of 166 isolates including twenty 
strains from this work (in addition to 146 isolates already present in the database). Figure 6.9 
shows the UPGMA dendrogram (bootstrap value - 1000) of H. parasuis Australian isolates in 
which a cluster of related genotypes were identified. The dendrogram identified six 
monophyletic clusters (A, B, C, D, E, and F) of related genotypes. The vaccine candidate 
belongs to cluster C, which is largest populated cluster from the tree. The vaccine candidate 
(Hps29 - serovar 2) was genotypically closely related to other isolate (HS2093 - serovar 11) 
from this work as well as Australian isolates. However, the MLST clusters did not correlate 
with serovars. Cluster analysis using eBUSRT was also performed on 166 isolates of H. 
parasuis (Australian and global isolates) using the generated sequence types (Figure 6.11).  
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The cluster analysis using minimum spanning tree enabled to analyse the global distribution 
of H. parasuis isolates, in which three main clusters were identified Software (goeBURST) 
facilitated to associate the isolates according to the country of origin and hence geographical 
correlation was made possible. Similar to the UPGMA analysis, this analysis also lacked 
correlation with serovar. Out of 166 isolates, only 11 clonal complexes (Single Locus 
Variants) could be found (Figure 6.12). As six out of seven loci identity was determined only 
in twenty six isolates out of 166 total isolates, this study also supports the observation of high 
level genetic diversity in the of H. parasuis species (globally spread). Due to the lack of 
information regarding isolates, accurate correlation could not be accomplished. 
Over time, MLST- H. parasuis database will be accumulated of closely related strains and the 
data will give insight into the evolution process of strains. Thus, it will bring us closer to 
understand the missing links of heterogeneity and the population structure pattern of H. 
parasuis, which successively might facilitate to produce effective vaccines. Results and 
observations from this work are also in agreement with the statement of Oliviera in 2007, 
epidemiology of H. parasuis isolates become more understandable when the information 
from isolation site, serotyping, genotyping, and antimicrobial susceptibility profiles were 
gathered together for investigation [58].  
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CHAPTER 7: 
OVERVIEW
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7.1 Introduction 
This project set out to investigate the live vaccine development in the context of developing a 
live attenuated H. parasuis vaccine that is suitable for commercialisation. In the course of this 
work, media components and physical parameters were optimized to develop a regulatory 
compliant media that was capable of supporting high titres of viable cells. The final media 
was then tested in different fermentation platforms including glass fermenters as well as 
sterile disposable ‘wave’ bags. Support diagnostics useful for quality control was also 
developed in this project resulting in the development of useful molecular methods such as 
PCR and qPCR. A PCR was developed as an identity test that specifically looked at the aroA 
deletion site as the differentiating marker. While all strains of H. parasuis contain an intact 
aroA gene, the candidate vaccine strain contains 101 bp deletions, which was subsequently 
targeted for PCR amplification. A qPCR was developed to permit assessment of growth of the 
vaccine strain during fermentation runs so that the culture growth could be monitored and 
subsequently harvested at its optimal growth. However, various limitations to qPCR 
unfortunately limited its usefulness. This project also explored other genetic analysis such as 
MLST used to study the relatedness of the vaccine candidate strain to other H. parasuis 
isolated found both within Australia and globally. 
The chapter aims to conclude how the previous chapters addressed each of the research 
questions given below. 
1) What are the nutritional requirements for attenuated vaccine candidate that would 
allow for commercial large-scale production? 
2) What are the physical parameters required for optimal growth in different 
fermentation platforms to achieve high production titres? 
3) What are the formulation and program parameters required to permit long-term 
stability with low loss rate post freeze drying? 
4) What molecular methods can be used to differentiate the vaccine candidate from 
other field strains of H. parasuis and other closely related species? 
5) How can MLST be used to characterise Australian isolates of H. parasuis and are they 
different to globally isolated strains of H. parasuis? 
7.1.1 Storage of pre-master and secondary seeds 
H.  parasuis is considered as fastidious organism [58] that requires special attention 
for its growth as well as storage. For this study, the original stock of the vaccine strain 
received was maintained using (pre-master seeds) for research and development 
studies. It was displayed that the storage using CryoBeads™ tubes for H. parasuis is 
operative as recovery of cells was successful for three years from the initial time of 
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storage. Eventually Master seed would be developed out of pre-master seeds under 
GMP conditions for production as well as long-term storage. No published 
information exists on raw materials necessary for maintaining the stability of H. 
parasuis cells on storage. Therefore, the stability of H. parasuis cells in a liquid storage 
media for the preparation of secondary seed was analysed over time. Already 
published storage media was initially studied and proved that the raw materials were 
not supporting the stability of H. parasuis cells (wild and vaccine strain) when stored 
at -20 °C. Hence, the storage media was modified by the addition of pig serum and 
demonstrated good cell stability with little loss in viability. Subsequently, secondary 
seed was used for all the experiments performed.  For each experiment, the results 
were analysed by determining the potency. As H. parasuis was regarded as a sensitive 
organism, it was necessary to evaluate the efficiency of serial diluents. Among the 
number of serial diluents tested, “Mareks” diluent came out with the best result and 
hence it was used in this research as serial diluent for H. parasuis culture.  
7.1.2 Physical and chemical requirement of H. parasuis for in vitro 
growth 
In the developmental work conducted in the course of this project, the physical parameters 
were established firstly using complex liquid media. Physical parameters required for initial 
experiments with Schott bottle were firstly optimized using a complex liquid media. The 
culture starting pH (7.5), oxygen requirement (stationary), percentage of inoculum (10%), 
free air space (80%) was factors that were optimized using Schott bottles as the fermentation 
vessel (small-scale) to establish a growth pattern for both wild type and vaccine strain. 
Although the vaccine strain was aroA attenuated, a similar growth pattern was observed for 
the wild and vaccine strains, which confirm the rich nutrient source of the complex liquid 
media. However, growth of the vaccine strain (36 hours) on solid media (chocolate agar) 
required an additional 12 hours of incubation for colonies to appear on the plate compared to 
the wild strain (24 hours). When grown inside Schott bottle, a high titre for vaccine strain 
was seen when incubated for 24 hours in complex liquid media with optimized physical 
parameters. The growth obtained was similar to the growth of the wild strain. The 
requirement of aromatic amino acids for the vaccine strain was fully supplemented from 
nutrient rich complex liquid media itself. Therefore, similar growth pattern was presented by 
wild and attenuated strains.  
Once the physical parameters were identified, the nutritional requirement of H. parasuis 
vaccine candidate was established. As the medium raw materials must comply with 
regulatory requirements, this section was considered as crucial for the development of this 
candidate vaccine as a commercial product. Most studies with H. parasuis involve the use of 
solid media such as Casman Agar Base [220] or chocolate agar (supplemented NADH) [59]. 
Tripticase Soy Broth [221] and tryptone based medium was used as liquid medium for H. 
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parasuis but not for optimal growth sudies [98]. Liquid medium used for the initial studies is 
a complex mixture that includes biostate peptone, BSA, yeast extract and swine serum 
(supplemented with NADH). There are no reports of fully defined or even a regulatory 
compliant media that can support a high titre growth for H. parasuis or attenuated strains. It 
was, therefore, necessary to determine the nutritional requirements for H. parasuis for 
manufacturing the vaccine candidate to large-scale. Importantly, the media needed to be 
defined and to comply with the regulatory requirement.  
Utilizing the optimized physical parameters, the nutritional requirement of H. parasuis was 
studied. Experiments were mainly focused on replacing animal protein sources with plant 
based protein sources that could result in high titre. By systematically replacing raw 
materials within the complex liquid media, it was found likely to identify the regulatory 
compliant alternatives. To replace biostate peptone (pancreatic digest), different alternatives 
of nitrogen sources such as tryptone, soy peptone, yeast extract, ammonium chloride, 
ammonium sulphate were used. The study successfully replaced 1% of biostate peptone with 
combination of 1% soypeptone and 0.5% yeast extract. The optimum percentage of glucose 
required to keep the buffering capacity of the media was determined by testing different 
percentages of glucose. The glucose optimization study used different concentrations of 
glucose (0.05%, 0.1%, 0.5%, 1%, 2% and 3%) to study effect on growth of vaccine strain. 
Interestingly, it was observed that the low concentration of glucose is suitable for high titre 
than the higher concentration of glucose in the media; it was studied for 24 hours inside 
Schott bottle. Glucose percentage was increased from 0.05% to 0.1% as the growth rates 
were similar.  In order to ensure the safety profile of vaccine candidate during formulation, 
the presence of BSA (bovine serum albumin) in the media should be replaced (Chapter 3). 
Serum is composed of several amino acids, vitamins and growth factors, and the composition 
is still considered as undefined. Original complex liquid media is composed of two different 
sources of serum (BSA and pig serum). Therefore, it was essential to investigate the necessity 
of including both sources. Study explored the effect of different percentage of pig serum (1%, 
5%, 15% 10%, and 20% of total medium) as a replacement to BSA in comparison to original 
media. As the serum is very rich, it was found that there was no significant effect on 
increasing pig serum beyond 10% to the total medium. This study also discovered by using 
10% pig serum (without BSA), similar growth was obtained in comparison with control 
(original complex liquid media). Therefore, BSA was replaced by increasing the percentage of 
pig serum in the medium. Pig serum was still used, as it is free from exogenous agents by 
gamma irradiation, heat inactivation and filter sterilization prior to use. Pig serum is also 
widely used and it complies with regulatory requirements for vaccine manufacturing. For 
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example, Vaxsafe®MS for Mycoplasma synoviae and Vaxsafe®MG for Mycoplasma gallisepticum 
comprised of pig serum. Importantly, the harvest yield of the modified media was similar 
with the original complex liquid medium. That is, the replacement of these raw materials in 
the media did not negatively impact growth of the organism. By conducting further 
experiments, it was also found that increasing percentage of Thiamine.HCl or removing it all 
together had no effect on growth of H. parasuis. Hence, it is removed from raw material list. 
The addition of extra percentage of pig serum may have compensated for Thiamine.HCl. 
Over the series of replacement trials of raw materials, resulted in the development of a 
regulatory compliant media (RCM) for the in vitro growth of H. parasuis vaccine strain. RCM 
was tested for the growth of wild type strain and the vaccine strain. The results were 
compared with the growth profile obtained from these strains when grown in complex liquid 
medium. An interesting observation was made that despite the titre obtained after 24 hours 
of incubation was similar between the RCM and the complex liquid media, the pattern of the 
growth curve differed as depicted in Figure 7.1. Presence of stationary phase to the growth 
curve was observed when RCM used in contrast to growth pattern in complex liquid media. 
This observation is an advantage for the operators during manufacturing as it allows omitting 
a critical time point for harvest; rather RCM gives a period for harvest.  
 
Figure 7.1: Demonstration of difference in growth pattern when complex liquid media and 
regulatory compliant media were used. 
7.1.3 The dynamics of H. parasuis growth in different fermentation 
vessels 
The growth of H. parasuis live attenuated vaccine in the regulatory compliant media and 
under the optimized growth conditions were studied at large-scale volumes. Different pattern 
of the growth curve was observed when vaccine strain grown inside fermentor, therefore, a 
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new set of physical parameters were studied specifically for large-scale feremtnation in this 
project. Fermentation using different vessels was tested for growth reproducibility from one 
run to the next. The potency (i.e., viable counts) was used as a measure of reproducibility and 
efficiency of fermentation run.  The initial optimal physical parameters used were: 
1. Cultures were grown under stagnant (i.e., no mixing or aeration) conditions. 
2. Starting pH of the media was set to pH 7.5. 
3. A 10% inoculum was used. 
4. 80% free air space was used. 
These conditions were found to work well when cultures were grown in Schott bottles up to a 
working volume of 3 L. However, these growth conditions were found not suitable to 
fermentors. It was found that the dynamics of growth in a fermentor was different to that in 
Schott bottles for H. parasuis. Hence, it was required to optimize the physical parameters for 
fermentation of H. parasuis in fermentors. In order to produce a successful product for the 
market, large-scale vessels (bioreactors or fermentors) are necessary as they hold the 
required volume as well as maintain uniform growth conditions. The developed RCM was 
used in different fermentation vessels: 
1. 5 L glass fermentor. 
2. 30 L stainless steel fermentor. 
3. Disposable sterile bioreactor bags. 
The changes were made to the physical parameters when cultivation was transferred from 
small-scale to large-scale fermentation. Modification of physical parameters included; 
reducing the percentage of free air space from 80% to 40%, incorporating low speed 
agitation (60 rpm), and the percentage of inoculum was increased from 10% to 20%. Initial 
media pH remained unchanged at pH 7.5. The range of number of cells for inoculation was set 
for the final modified conditions of growth in RCM. That is, the initial starting titre of Log10 7.5 
to Log10 8.5 cells per mL was kept constant for all experiments. Short period of incubation (six 
to eight hours) was demonstrated in fermentors to yield high titres (Log10 11 cfu/mL) using 
above modified parameters. Low speed (60 rpm) agitation allowed cells to be kept in 
suspension rather than settling to the bottom of the vessel. A minimum of 40% free air space 
assisted to meet the oxygen requirement of cells, which freshly inoculated from a closed 
system (deprived of oxygen). These modified parameters were experimented a number of 
time and found that the results are reproducible to produce high titres in fermentors or large-
scale vessels of ≥ 5 L capacity.  
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When these modified conditions were used, a Log10 1 cfu/mL increase in titre was obtained 
compared to growth yield obtained in Schott bottles.  The total growth yield of the three 
different vessels (5 L glass fermentor, 30 L stainless steel fermentor and the disposable 
bioreactor bag) were compared with respect to final yield. It was found that the efficiency of 
disposable bag was higher than the other two (hard bodied) vessels.  Interestingly, the 
disposable bag fermentation offered a total yield of Log10 15 cells in only 3 L of culture. 
Therefore, the sterile disposable bags are not only highly efficient vessels for the commercial 
production of H. parasuis vaccine candidate but it also provides the added benefits. As this 
technology reduces cleaning, validations requirements, risk of contamination, the labor and 
thus the cost associated with quality control when compares with re-useable fermentation 
vessels. There is no published data on cultivation of H. parasuis using bioreactor bags, and 
hence this platform is a novel approach.  
7.1.4 Quantification of endotoxin in H. parasuis culture by LAL assay 
H. parasuis endotoxin studies are performed most commonly in animal studies by directly 
studying the response of animals following administration of a set number of cells (and 
associated endotoxin). No literature is available on LAL assay performed on H. parasuis 
culture. For accessing the quality of the harvest in this study, endotoxin concentration of H. 
parasuis culture was determined using LAL (chromogenic) assay as a preliminary study. The 
H. parasuis vaccine strain is a gram negative bacteria that contains a capsule that is expressed 
when grown in both liquid and solid media. Therefore, high concentration of endotoxin can 
be expected in the final product. For this vaccine candidate, dose is determined by animal 
models. Therefore, dose is not yet determined. Examination of materials for the 
quantification of endotoxin was performed on samples obtained following growth in 
fermentor. The endotoxin level in samples from fermentor was found to be 2.6 x 103 EU/mL 
compared to 3.6 x 103 EU/mL when samples of H. parasuis were tested following growth in 
Schott bottles. It must be noted that the assay performed is only an approximate estimate due 
to interferences of the LAL reagents with media raw materials that can interfere with the 
result.  According to European pharmacopoeia (LAL assay by gel clot method), endotoxin 
concentration  is less than 1 x 106 IU/dose and is acceptable unless a higher amount is shown 
to be safe by clinical trials. One USP - EU is equal to one international unit of endotoxin; one 
EU equals approximately 0.1 to 0.2 ng endotoxin/mL of solution (FDA). Using these criteria, 
the level of endotoxin obtained for H. parasuis is considerably lower than what is provided by 
the European pharmacopoeia.  
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7.1.5 Optimization of freeze drying program and cryopreservation 
There is very little information published pertaining to freeze drying techniques for H. 
parasuis culture. Hence, it was necessary to develop a basic freeze drying program as well as 
cryoprotectants that could protect the organism from the effects of drying and retain their 
stability and viability. Early work conducted in this project clearly showed that H. parasuis 
culture was not stable at 4 °C or even at -20 °C.  However, viability was maintained when cells 
were stored at -80 °C. Freeze drying of the material was studied with different percentage of 
cryopreservatives and combinations. Different percentage of sucrose, pig serum, trehalose, 
mannitol, soy peptone (Table 4.4) and buffer-exchanged culture were included in the 
optimization study. The study was looking out for best results, which included minimum loss 
of a number of viable cells, solubility of the product in “Mareks” diluent, appearance of the 
cake structure. Different conditions used in freeze drying program cycle (Bioproperties Pty. 
Ltd. - Program 9-HPS 1.0) was formerly used and made modifications accordingly. Two 
different modifications were made to the program as part of program optimization. Among 
that, program HPS 1.2 studied extensively. The program was modified by combining two 
steps in main dry and keeping at -30 °C by avoiding ramping down in program HPS 1.0 
(Appendix IV, A). It was successfully compared to other two modifications made. In addition, 
the study confirmed there was no effect of fill volume to freeze dried product efficacy in the 
trials carried out in the experiment and hence 5 mL fill in 10 mL glass vials was kept constant 
for the studies. 
When the harvest (H. parasuis culture) was attempted to freeze dry without any 
cryoprotective agents the loss was remarkable (Log10 4 cfu/mL reduction), and the final 
freeze dried product was caramelized. However, the additional of pig serum (10%) resulted 
in a visible improvement and better cell viability (Log10 2 cfu/mL reduction) as well as the 
appearance was not caramelized. Among all the sucrose combinations tested sucrose (10%) 
with additional pig serum (10%) showed best viability rates as well as the appearance of the 
structure was close to prefect. The loss upon freeze drying using this formulation was Log10 1 
cfu/mL reduction in viability. As the loss of viability remains relatively high, further 
optimization is required to identify a better cryopreservative agent as well as the freeze dry 
program itself.  
7.1.6 Molecular analysis of vaccine strain using PCR 
This work developed a PCR methodology for the identification and differentiation of the 
vaccine strain from the parent strain as well as other H. parasuis strain from the field. 
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Therefore, a primer set was constructed that targeted the mutated region of aroA. The 
designed primers were able to distinguish the vaccine strain from its parental wild strain. 
Therefore, this PCR assay can be used as a quality control test to confirm identity and purity 
of the final vaccine product. The developed molecular analysis for vaccine strain 
identification allows confirming the genetic stability of the vaccine strain over the various 
passage levels required to yield the final product.   
In order to differentiate H. parasuis from other bacterial species, partial 16s rRNA as well as 
the infB gene was targeted.  The PCR analysis of H. parasuis targeted both pure sample as well 
as field samples. The high level of homology present in 16s rRNA region between closely 
related species emphasized possibility of finding false positive results, particularly if field 
samples are diagnosed, where these species may also be present in the sample. Despite the 
recognized limitation of the assay, it was used in this work performed on this project for the 
identification and confirmation of H. parasuis on pure cultures as well as differentiation from 
other common bacterial contamination (i.e., those species that did not show a high level of 
identity).  
Work conducted on this project developed a PCR that could distinguish H. parasuis from 
closely related species. Primers targeting 254 base pairs of infB gene were designed. Analysis 
results found there were not many identities towards closely related species like 16s rRNA 
PCR demonstrated during BLAST analysis. Hence, infB PCR could be potential PCR 
methodology to differentiate H. parasuis from other closely related species. No amplification 
was observed with a bacterial mixture consisting of Mixed bacterial population includes A. 
pleuropneumoniae, Staphylococcus aureus, Streptococcus suis, Pasteurella multocida, 
Escherichia coli, Mycoplasma hyopneumoniae. Above bacterial species were commonly 
identified as a secondary infection along with active H. parasuis infection. Therefore, the 
(partial) infB gene was capable of specifically amplifying H. parasuis from within the bacterial 
mixture used in the study.  
7.1.7 Quantitative PCR for vaccine strain 
Quantitative PCR (qPCR) was developed targeting aroA gene (attenuated region) of vaccine 
strain. It was developed specifically for the vaccine strain for enumerating number of cells 
present in log phase, as it would be particularly useful during commercial fermentation runs. 
The development of the qPCR assay involved the construction of reference plasmid clone that 
contained the target region. It was found that linear plasmid amplification efficiency was 
better in comparison with circular plasmid standard efficiency.  
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A qPCR can potentially provide information on the growth rate of the vaccine strain during 
fermentation without depending upon the cultural techniques, which take at least 24 hours to 
achieve a result. The results of the qPCR were validated by comparing directly to plate counts. 
Amplification efficiency of undiluted culture was failed compared to diluted samples. Dilution 
of samples reduced the concentration of the media raw materials that were causing 
interference with the PCR reaction. Even though, after the dilution made there was a Log10 1 
cfu/mL difference between the qPCR calculated count and actual plate count. Correlation 
with plate count was hindered and it might be due to the interference of serum present in the 
sample. From the experiments performed, the correlation between qPCR-based titre count 
and plate titre count was impossible. Therefore, the developed qPCR has significant 
limitations. 
7.1.8 MLST analysis of H. parasuis isolates from Australia 
Multilocus sequence typing involving seven housekeeping genes were conducted on twenty 
Australian isolates including vaccine strain. The sequence data generated in this study was 
deposited into the publically available MLST H. parasuis database. The outcome of this study 
is expected to contribute to the characterization and epidemiological surveillance of 
Australian isolates. Most of the isolates deposited were assigned with a new sequence type as 
each isolate showed a previously unrecorded set of alleles. Such new alleles assigned to the 
Australian isolates highlighted the pattern of mutation across different geographic areas. 
Three isolates showed known sequence types as the allele set had an exact match to other 
alleles found in the database. The Australian isolates HS3110 and isolate HS2541 was 
assigned with sequence type of other Australian isolates, but isolate HS2561 was assigned 
with sequence type of an isolate identified in Spain.  
Among the seven alleles, it was found that g3pd and rpoB showed the least level of nucleotide 
variation in Australian isolates. An observation was found for the same two alleles in global 
isolates. Interestingly, most of the isolates with g3pd (1/3) and rpoB (1) combination in the 
allele sets belonged to one of the highly virulent strains, except for two isolates of  serovar 4) 
and one isolate of serovar 6. 
Cluster analysis was performed to determine whether the virulent strains (groups) belong to 
any particular cluster and to determine the possible association. A UPGMA tree was 
constructed. The tree demonstrated six monophyletic clusters (A, B, C, D, E, and F) of related 
genotypes. However, there was no association with serovars of the isolates. The vaccine 
strain was belonged to cluster C, and it is closely related to another isolate (HS2093) that was 
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analysed in this work. It was clear in this study that an association could not be drawn 
between genotypic data and serotype data. Serotyping methodology is completely dependent 
upon antigens expressed by isolates inside the hosts and genotyping is the difference in gene 
sequence over time (housekeeping gene sequence for this study). The above fact explains 
why the association between the two parameters were could not be made. 
eBUSRT analysis was also performed on 166 isolates of H. parasuis (Australian and global 
isolates) using the generated sequence types. The cluster analysis using minimum spanning 
tree enabled analysis of the global distribution of H. parasuis isolates. Three main clusters 
were identified. Software (goeBURST) facilitated the association of the isolates according to 
the country of origin and hence a geographical correlation could be made. Out of 166 isolates, 
only 11 clonal complexes (CC) were identified using the eBUSRT analysis (using Single Locus 
Variants. Twenty seven isolates were included in the identified 11 Clonal complexes; i.e., only 
27 isolates exhibited six out of seven loci match out of 166 isolates present in the database. 
The observation found in the study supports a high level of genetic diversity published in H. 
parasuis species and which are globally spread. 
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7.2 Accomplishments 
Regulatory compliant media was successfully developed, and it resulted in high viable titre 
within a short period inside fermentors. The physical parameters for both small-scale and 
large-scale fermentations were optimized. The media components were optimized by 
eliminating use of animal product would seriously complicate registration of the vaccine. The 
animal-based protein was replaced with plant proteins. Investigation on physical and 
chemical requirement of H. parasuis organism allowed yielding high titres of Log10 11 cfu/mL 
in Schott bottles and Log10 11 cfu/mL in large fermentors. Largest volume of 15 L was 
cultivated in a short period (4 hours) inside a 30 L stainless steel fermentor, which facilitated 
to yield Log10 11 cfu/mL. The parameters optimized in this study were reproducible and 
hence could be used for manufacturing requirements. Despite considerable effort of 
preservation of H. parasuis by freeze drying and the use of cryoprotectants, successful freeze-
dried product of H. parasuis was not fully achieved. Further investigation is required to build 
upon the work carried out in this study so that the freeze drying losses are minimized and the 
lyophilized cells are stable over long periods. 
Molecular analysis to differentiate and identify vaccine strain was developed. The developed 
PCR, which targets mutated region of aroA, facilitates quality control department to confirm 
the product purity. This assay can be used for quality testing of the released product. Thus, 
this project has made significant strides towards the commercialisation of a live bacterial H. 
parasuis vaccine product. Clearly, animal safety and efficacy trial will need to be conducted to 
confirm whether this vaccine candidate is suitably safe and efficacious. 
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APPENDICES 
Appendix I 
1.0 Media Preparation Protocol [59] 
1. Weigh the ingredients listed on table 1 accurately on a weighing balance 
         Table1: Ingredients for Broth Preparation 
 
 
 
 
 
 
 
 
2. Add the volume of distilled water into a clean beaker and mix it properly until  all 
the components dissolves 
3. Adjust the pH to 7.5 using NaOH solution 
4. Dispense the solution into 500 ml Schott bottle for Autoclaving 
5. Autoclave the solution at 120°C for 20 min. 
6. Allow the bottle to cool for at least 30 minutes 
 
1.1 Supplement Preparation 
1. In a biohazard cabinet, aseptically combine the supplements for the required 
volume of broth using the table 2 ingredients in a sterile container 
2. Add combined supplements to broth and mix it 
 
           Table 2: Supplements for Medium 
 
 
 
 
 
 
 
Media ingredients Total volume - 100 ml 
Biostate peptone 1g 
NaCl 1g 
Starch 0.1g 
Glucose 0.05g 
Yeast Extract 0.05g 
Distilled Water 91 ml 
Supplements 10ml 100 ml 
0.1% NADH 0.25 2.5ml 
0.1% Thiamine HCl 0.05 .5ml 
Heat inactivated Pig serum 0.1 1ml 
O-A complex 0.5 5ml 
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a) 1% NADH -- 0.1g of NADH in 10ml of sterile Milli Q & filter sterilise 1ml  
b) 0.05% Thiamine HCl-0.5mg of thiamine in 1ml of sterile Milli Q & filter sterilise 1ml 
c) Pig Serum-- 1 ml of Filter sterilised pig serum 
d) O-A complex ---       
1. Add 0.3 ml of oleic acid into 25ml of 0.05 NaOH (Sodium Oleate) 
2. Dissolve 23.75 g of bovine albumin faction V in 475 ml normal saline 
3. Mix 1 & 2 
4. Adjust pH to 6.8 
5. Filter sterilise and aliquot to 50 ml tubes  
6. Incubate the tubes in 37°C water bath overnight 
7. Incubate in 56°C water bath for 30 min. 
8. Store at 4°C 
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Appendix II :Different modification made to the original media 
A. Version 1.1 –Modification to the original protocol (Appendix I) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Version 1.2 –Modification to the original protocol (Appendix I) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Media ingredients 100 ml 
Neutralised Soy peptone 1g 
NaCl 1g 
Starch 0.1g 
Glucose 0.05g 
Yeast Extract 0.5g 
Distilled Water 91 ml 
0.1% NADH 2.5ml 
0.1% Thiamine HCl .5ml 
 Pig serum 1ml 
O-A complex 5ml 
Media ingredients 100 ml 
Neutralised Soy peptone 1g 
NaCl 1g 
Starch 0.1g 
Glucose 0.05g 
Yeast Extract 0.5g 
Distilled Water 87 ml 
0.1% NADH 2.5ml 
0.1% Thiamine HCl .5ml 
 Pig serum 10ml 
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C. Version 1.3 –Modification to the original protocol (Appendix I) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D. Version 1.4 –Modification to the original protocol (Appendix I) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Media ingredients 100 ml 
Neutralised Soy peptone 1 g 
NaCl 1 g 
Starch 0.1 g 
Glucose 0.05 g 
Yeast Extract 0.5 g 
Distilled Water 87.5ml 
0.1% NADH 2.5 ml 
 Pig serum 10 ml 
Media ingredients 100 ml 
Neutralised Soy peptone 1 g 
NaCl 1 g 
Starch 0.1 g 
Glucose 0.1 g 
Yeast Extract 0.5 g 
Distilled Water 87.5 ml 
0.1% NADH 2.5 ml 
 Pig serum 10 ml 
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Appendix III  
A. USDA National Nutrient Database for Standard Reference, Release 23 (2010) 
 
 Value per Value per 
  100 grams 100 grams 
Nutrients Biostate peptone Soy peptone neutralised 
Proximates     
Water 37g 7.25g 
Energy 158kcal 330kcal 
Energy 663kJ 1379kJ 
Protein 27.8g 47.01g 
Total lipid (fat) 0 1.22g 
Ash 23.4g 6.15g 
Carbohydrate, by 
difference 
11.8g 38.37g 
Fiber, total dietary 3g 17.5g 
Sugars, total 0 18.88g 
Minerals     
Calcium, Ca 86mg 241mg 
Iron, Fe 3.7mg 9.24mg 
Magnesium, Mg 180mg 290mg 
Phosphorus, P 104mg 674mg 
Potassium, K 2600mg 2384mg 
Sodium, Na 3600mg 20mg 
Zinc, Zn 2.1mg 2.46mg 
Copper, Cu 0.3mg 4.065mg 
Manganese, Mn 0 3.018mg 
Selenium, Se 18mcg 1.7mcg 
Amino Acids     
Alanine 2.87g 2.215g 
Arginine 3.31g 3.647g 
Asparagine 0 0 
Aspartic acid 6.52g 5.911g 
Cysteine 0 0 
Cystine 0.4g 0.757g 
Glutamic acid 18.7g 9.106g 
Glutamine 0 0 
Glycine 1.79g 2.174g 
Histidine 2.29g 1.268g 
Isoleucine 4.48g 2.281g 
Leucine 7.63g 3.828g 
Lysine 6.51g 3.129g 
Methionine 2.35g 0.634g 
Ornithine 0 0 
Phenylalanine 4.09g 2.453g 
Proline 8.65g 2.75g 
Serine 5.08g 2.725g 
Threonine 3.91g 2.042g 
Tryptophan 1.05g 0.683g 
Tyrosine 1.86g 1.778g 
Valine 5.51g 2.346g 
Vitamins     
Vitamin C, total 
ascorbic acid 
0 0 
Thiamin 9.7mg 0.698mg 
Riboflavin 14.3mg 0.253mg 
Niacin 97mg 2.612mg 
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Vitamin B-6 1.3mg 0.574mg 
Folate, total 1010mg 305mcg 
Folic acid 0 0 
Folate, food 1010mcg 305mcg 
Folate, DFE 1010 mcg_DFE 305 mcg_DFE 
Choline, total 65.1mg 11.3mcg 
Vitamin B-12 0.5mcg 0 
Vitamin B-12, added 0 0 
Vitamin A, RAE 0 2 mcg_RAE 
Retinol 0 0 
Carotene, beta 0 24mcg 
Carotene, alpha 0 0 
Cryptoxanthin, beta 0 0 
Vitamin A, IU 0 40IU 
Lycopene 0 0 
Lutein + zeaxanthin 0 0 
Vitamin E (alpha-
tocopherol) 
0 0.12mg 
Vitamin E, added 0 0 
Vitamin D (D2 + 
D3) 
0 0 
Vitamin D 0 0 
Vitamin K 
(phylloquinone) 
0 4.1mcg 
Pantothenic acid 0 1.995mg 
Lipids     
Fatty acids, total 
saturated 
0 0.136g 
4:00 0 0 
6:00 0 0 
8:00 0 0 
10:00 0 0 
12:00 0 0 
14:00 0 0.003g 
16:00 0 0.1g 
18:00 0 0.034g 
Fatty acids, total 
monounsaturated 
0 0.208g 
16:1 undifferentiated 0 0.003g 
18:1 undifferentiated 0 0.206g 
20:01 0 0 
22:1 undifferentiated 0 0 
Fatty acids, total 
polyunsaturated 
0 0.533g 
18:2 undifferentiated 0 0.47g 
18:3 undifferentiated 0 0.063g 
18:04 0 0 
20:4 undifferentiated 0 0 
20:5 n-3 (EPA) 0 0 
22:5 n-3 (DPA) 0 0 
22:6 n-3 (DHA) 0 0 
Cholesterol 0 0 
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Appendix IV: Different versions of freeze drying program 
A. Version HPS 1.0 
Freeze drying program 
     
Phase Section Temp °C Duration Vacuum 
(mbar) 
Start Vial 1 4 Load - 
Freezing 2 -40 7 h - 
Preparation 3 -40 30 min - 
Main dry 4 -40 5 min 0.2 
Main dry 5 -30 7 h 0.2 
Main dry 6 -20 18 h 0.2 
Main dry 7 -10 16 h 0.2 
Main dry 8 0 8 h 0.2 
Final dry 9 25 2 h 0.07 
Final dry 10 25 6 h 0.07 
Final dry 11 15 2 h 0.07 
Total time   66h 35min   
 
B. Version HPS 1.1 
 
Note: HPS-freeze drying program modified by longer freezing period and by adding main dry 
step at -36 °C and altering duration of main dry steps 
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C. Version HPS 1.2 
 
Note: Program HPS 1.2 is modified by combining two steps in main dry and keeping at -30 °C by 
avoiding ramping down in program HPS 1.0. 
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Appendix V: List of reagents used 
Agarose 
1.0-1.5% (w/v) multipurpose agarose (Bioline) 
Alkaline lysis solution I 
50 mM glucose (BDH), 10 mM EDTA (Merck), 25 mM trisbase (Roche), pH to 8.0 with 
HCl; stored at 4 °C 
Alkaline lysis solution II 
0.2 M NaOH (BDH), 1% (w/v) SDS (Merck); prepared by fresh on day 
Alkaline lysis solution III 
5 M potassium acetate (Sigma), 2 M glacial acetic acid (BDH); stored at 4 °C 
Cetyltrimethylammonium bromide (CTAB)/NaCl 
10 % (w/v) CTAB (Sigma), 0.7 M NaCl (Chem Supply); heated to 65 °C 
Chloroform/isoamylalcohol (C: I) 
24 volumes chloroform: 1 volume isoamylalcohol (Research Organics), pH 8.0; stored at 
4 °C 
Deoxynucleotide triphosphates (dNTPs) 
25 mM of each datp, dttp, dgtp, and dctp (PROMEGA); stored at -20 °C 
EDTA 
0.5 M EDTA, pH 8.0 
Ethanol 
70 % (v/v) ethanol prepared from absolute ethanol (96%) commercial grade (Merck) 
Ethidium Bromide 
0.5 μg /ml ethidium Bromide (Fluka) = 1 mg per 2 L MQ water bath 
10x Gel loading dye 
10% (w/v) Ficoll 400, 50% (v/v) glycerol (Ajax), 0.5% (w/v) Orange G (BDH), 1% SDS, 
10 mM EDTA, 50 mM Tris-base, pH to 8.0 with HCl; stored at 4 °C 
Glycerol 
10-80% (v/v) glycerol, autoclaved 
KOAC: 60 ml 5 M KOAC, 11.5 mL acetic acid, 28.5 mL water 
Lambda ( ) PstI DNA ladder 
100 μg DNA (500 μg/mL, Promega), 100 U PstI (10 U/μl, Promega), 90 μl 10x restriction 
enzyme Buffer H (Promega), MQ water to 900 μl; incubated overnight at 
37 °C, then added 100 μl 10x gel loading dye; stored at -20 °C 
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Milli-Q water 
Sterile MQ water (Millipore) or deionised water was used to prepare reagents 
Molecular grade water 
Distilled water, DNAse-free and RNAse-free (Invitrogen) for PCR reactions and genomic 
DNA 
NaCl  5 M NaCl 
(P: C: I) 25 volumes phenol: 24 volumes chloroform: 1 volume isoamylalcohol 
(Research Organics), pH 7.8; stored at 4 °C  
Propan-2-ol (Isopropanol) 100% (v/v) Isopropanol (BDH) 
Phenol: Phenol 
Sodium acetate (NaOAc) 
3 M NaOAc (BDH), pH 4.6 with HCl, autoclaved 
Sodium dodecyl sulphate (SDS) 
10% (w/v) SDS 
TAE buffer 
40 mM Tris-base, 20 mM glacial acetic acid, 2 mM EDTA 
TE buffer, pH 8.0 
10 mM Tris-base, 1 mM EDTA, pH to 8.0 with HCl 
PBS 
5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal) 
40 mg/mL X-gal (Progen) in dimethylformamide (BDH); stored at -20 °C protected from 
light 
Electrophoresis Power Supply 
EPS600 Pharmacia Biotech 
POWER PAC 300 BioRad 
PP Basic Bio-Rad 
Electrophoresis unit 
DNA midi gel Bio-Rad 
DNA mini gel Bio-Rad 
Ethidium Bromide (EtBr) Sigma-Aldrich Pty, Ltd, USA 
Gel Doc Image System Bio-Rad 
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Appendix VI:  
A. 16s rRNA partial gene of H. parasuis (Hps29) sequence result from AGRF 
 
5’GTGTTTTAATAGAACATTACATTGACGTTAGTCACAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCG
CGGTAATACGGAGGGTGCGAGCGTTAATCGGAATGACTGGGCGTAAAGGGCACGCAGGCGGTGACTTAA
GTGAGATGTGAAAGCCCCGAGCTTAACTTGGGAATTGCATTTCATACTGGGTTGCTAGAGTATTTTAGG
GAGGGGTAGAATTCCACGTGTAGCGGTGAAATGCGTAGAGATGTGGAGGAATACCGAAGGCGAAGGCAG
CCCCTTGGGAAAATACTGACGCTCATGTGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAG
TCCACGCTGTAAACGCTGTCGATTTGGGGATTGGGCTTAGAGCTTGGTGCCCGTAGCTAACGTGATAAA
TCGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGT
GGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTACTCTTGACATCCTAAGAAGAACTCA
GAGATGAGTTTGTGCCTTCGGGAACTTAGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGAA
ATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGATTCGGTCGGGAACTCA
AAGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTTACGAGTA
GGGCTACACACGTGCTACAATGGTGCATACAGAGGGTGACG 3’ 
 
B. infB partial gene of H. parasuis (Hps29) sequence result from AGRF 
 
5’TGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAAGCAATCCAACACGCGAAAGCA
GCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGAAGCAAACCTAGAGCGTGTAGAG
CAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTGATGTTCAATTTGTTCCTGTCTCA
GCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTTC 3’ 
 
C. Sequence targeted from aroA gene of H. parasuis for developing aroA–PCR 
for the differentiation of vaccine strain and wild strain 
 
5’GCGTCCGATTAAACATTTGGTTGATGCGTTATTGCAAGCGGGGGCTTCCGTGCAATATCTTGAAAATGAA
GGCTATCCGCCGATTGCTATTCGTAATTTGGGTATTCAAGGCGGCAAAATTCAGATTGATGGTTCGATT
TCTTCGCAATTTTTGACCGCACTTTTGATGTCCGCACCCCTTGCCTCTGGCGATATGGAAATTGAGATT
GTCGGTGAGTTGGTCTCCAAGCCTTATATTGATATTACCCTTGCGATGATGAAGGATTTTAGCGTGACA
GTGTCGCATAATAATTATCAAACTTTCTTTGTTAAAGGTAATCAGCATTATGTTTCTCCGCAAAAATAT
TTGGTTGAGGGCGATGCGTCCTCTGCCTCTTATTTCTTAGCCGCAGGGGCAATTAAGGGGAAAGTGAAA
GTGACGGGGATTGGTAAAAATTCCATTCAAGGCGACCGCTTGTTTGCGGATGTGCTTGAGAAAATGGGC
GCGAAAATCACTTGGG 3’ [500 Base Pairs] HPS29  WILD STRAIN SEQUENCE 
TARGETED 
Note: Yellow highlighted region (101 base pair) shows deletion in vaccine strain and the product 
from vaccine strain has 399 base pairs – Sequence received from AGRF 
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Appendix VII 
A. pGEM®-T Vector Map and Sequence Reference points 
 
 
B. Sequence and multiple cloning site of pGEM-t Easy vector 
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C. Sequence received from AGRF (T7 and SP6 primers used to amplify) 
 
T7 region from pGEM-T-aroA insert from vaccine strain-SP6 Region from pGEM-T vector 
CTCCCGGCCGCCATGGCGGCCGCGGGATTCGATTTCAAATCGTGCGTTGTTGTTGGCAGCCTTGGCACAGGG
GACAACGCAAGTAACGAATTTATTGGATAGCGATGATATTCGCCATATGCTCAATGCCTTGAAAGCTTT
GGGGGTGAATTATCAGCTTTCTGATAATAAAACCGTTTGTACCGTTGAGGGCGTGGGCGGTGCGTTTCA
GTGGCAAAATGGTTTGTCGCTGTTTTTAGGTAATGCCGGCACCGCAATGCGTCCTTTAACAGCGGCACT
TTGTTTGAAAGGTGAGCAAGAGGCTGAGGTGATTTTAACGGGCGAGCCGCGTATGAAAGAGCGTCCGAT
TAAACATTTGGTTGATGCGTTATTGCAAGCGGGGGCTTCCGTGCAATATCTTGAAAATGAAGGCTTCCG
CCGATTGCTATTCGTAATTTGGGTTTCAAGGCGGCAAAATTCAGATTGATGGTTCGATTTCTTCGCAAT
TTTTGACCGCACTTTTGATGTCCGCACGTGTCGCATAATAATTATCAAACTTTCTTTGTTAAAGGTAA
TCAGCATTATGTTTCTCCGCAAAAATATTTGGTTGAGGGCGATGCGTCCTCTGCCTCTTATTTCTTAGC
CGCAGGGGCAATTAAGGGGAAAGTGAAAGTGACGGGGATTGGTAAAAATTCCATTCAAGGCGACCGCTT
GTTTGCGGATGTGCTTGAGAAAATGGGCGCGAAAATCACTTGGGGCGAAGATTTTATCCAAGCAGAGCA
GGGGGAGCTTAAAGGCATTGATATGGATATGAACCATATTCCTGATGCGGCAATGACGATTGCAACTAC
CGCTCTTTTTGCTGAGGGTGAAACCGTTATTCGTAATATTTATAACTGGCGTGTGAAGGAAACAGATCG
CTTGACAGCAATGGCAACAGAGTTGCGTAAAGTTGGGGCGGAAGTGGAAGAAGGGGAAGATTTTATTCG
TATTCAACCGCTTGCGTTAGATAAGTTCCAACACGCTGAGATCGAAACCTATAACGATCACCGTATGGC
GATGTGTTTCTCTTTGGTGGCATTGTCAAATACGCCACTGACGATTTTAGATCCGAAATGTACCGCAAA
AACTTTCCCGACGTATTTTGATGAATTTGGGAAGATGTCTTGTAATTTTAGTAGGGAAGAAAAATAATC
TTATTGGGATTGAGGCTATTTTAAACAAGCATTAAGAGGATTCAAAAGACGGGTACTGTCTACCTGTTA
AGGTTTTAATTACTATTTTTTGTCTATTATGCCAAAGTCTTTATTAAGGGTAACAAATTAGGGGCTTAG
TGATCACGCCGGCGGACGTCCA 
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Appendix VIII  
A. Optimized annealing temperature for amplification of housekeeping genes 
 
Isolate Gene 
Annealing 
temperature 
Hs3398 
 
atpD 52 
infB 53 
mdh 50 
rpoB 53 
6pgd 53 
g3pd 53 
frdB 49 
HS3127 
 
atpD 53 
infB 53 
mdh 48 
rpoB 53 
6pgd 53 
g3pd 53 
frdB 48 
HS2002 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
 
HS2872 
 
atpD 52 
infB 52 
mdh 46 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
 
HS2157 
 
atpD 53 
infB 53 
mdh 48 
rpoB 53 
6pgd 53 
g3pd 53 
frdB 48 
HS3432 
 
atpD 53 
infB 53 
mdh 48 
rpoB 53 
6pgd 53 
g3pd 53 
frdB 49 
HS3554 
 
atpD 50 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 50 
HS3169 
 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS3110 
atpD 52 
infB 52 
mdh 50 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 50 
 
HS2561 
 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS2541 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
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HS3521 
 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
H22093 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS3332 
 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS3048 
 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS3218 
 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS3152 atpD 52 
 infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS3456 
 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS3289 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 52 
g3pd 52 
frdB 48 
HS1957 
atpD 52 
infB 52 
mdh 48 
rpoB 52 
6pgd 53 
g3pd 52 
frdB 48 
Hps 29 
atpD 53 
infB 53 
mdh 50 
rpoB 53 
6pgd 53 
g3pd 53 
frdB 49 
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Appendix IX 
A. Concatenated Sequence of twenty strains used for phylogeny  
    
>A1 | Hps29 | Australian isolate | Serotype2 | vaccine candidate  
 
GAGGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCAAACTACCCAGA
CACAAACCGCCGTGTGAAAGCCTTAGCGGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTGTCGGGCG
GTGAAGAAGGCGCACGTCACGGCCCTTCGATTATGCCGGGTGGTAATGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCGATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAATGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAATTCTTAAAAGATGGTTTAGGTTTAAGCTACAATGAAATGCAAGCGATCTTTGCT
GAATGGAAAAAAACGGAACTTGATAGCTATTTAATCGATATCACGACCGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTGCCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAGAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAT
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTCTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGTCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTCAAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGAGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACTGATACTTATGTAACC 
 
>A2 | HS3398 | Australian isolate | Serotype13 
 
GATGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGAGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCAATCTTTTCT
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GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAACTGGCGTGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAATTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTTGATAACCGTGACAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTGCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCTGGCA
TGGATCGTTCTGATCTGTTCAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
  
>A3 | HS3127 | Australian isolates |Serotype 15 
 
GAAGCGTTATTACCGCACTTAGAAGAAGGCGACATCGTCATTGATGGCGGCAACTCAAACTACCCTGA
TACCAACCGCCGCGTGAAAGCGTTGGCAGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTATCGGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCGGGCGGTAACGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCAATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCTGGCCACTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCC
GAATGGAAAAACACTGAATTAGATAGCTATTTAATTGATATTACAACGGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTGTTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
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CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGTCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
 
>A4 | HS2002 | Australian isolate | 
 
GAGGCATTATTACCGCATTTAGAAAAAGGCGACATCATCATTGATGGCGGTAACTCAAACTACCCAGA
CACAAACCGCCGTGTGAAAGCGTTAGCGGAAAAAGGTATTCGCTTTATCGGTTCGGGCGTGTCGGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCGGGCGGTAATAGCGAGGCGTGGCAATATGTG
AAACCAATTTTCCAAGCGATTTCAGCGAAAACCGACAAAGGTGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GCGAAGCCTACCAGTTCTTAAAAGATGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCC
GAATGGAAAAAAACGGAACTTGATAGCTATTTAATCGACATCACGACCGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCGGGTGCGCCGATCGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAACAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
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ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCCGCAGA
AGTCTTGAAAAAAGCAGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGT
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGATTTACTGATACTTATGTAACC 
 
>A5 | HS2871 | Australian isolate | 
 
GAAGCGTTATTACCGCACTTAGAAGAAGGCGACATCGTCATTGATGGCGGCAACTCAAACTACCCTGA
TACCAACCGCCGCGTGAAAGCGTTGGCAGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTATCGGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCGGGCGGTAACGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCAATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCTGGCCACTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCC
GAATGGAAAAACACTGAATTAGATAGCTATTTAATTGATATTACAACGGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTGTTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACGTTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTAGCTGGCTATGCGGGTGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCTGGCATTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGCGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGCCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACTGATACTTATGTAACC 
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>A6 | HS2157 | Australian isolate| serotype 12 
 
GATGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGAGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCAATCTTTTCT
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAACTGGCGTGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGCACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCATGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATCGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTCTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCCGGTA
TGGATCGTTCTGATCTGTTCAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
 
>A7 | HS3432 | Australian isolate |serotype 4 
 
GAAGCGTTATTACCGCACTTAGAAGAAGGCGACATCGTCATTGATGGCGGCAACTCAAACTACCCTGA
TACCAACCGCCGCGTGAAAGCGTTGGCAGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTATCGGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCGGGCGGTAACGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCAATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCTGGCCACTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCC
GAATGGAAAAACACTGAATTAGATAGCTATTTAATTGATATTACAACGGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
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CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGTCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGCCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACTGATACTTATGTAACC 
 
>A8 | HS3554 | Australian isolate | serotype 9 
 
GAAGCGTTATTACCGCACTTAGAAGAAGGCGACATCGTCATTGATGGCGGCAACTCAAACTACCCTGA
TACCAACCGCCGCGTGAAAGCGTTGGCAGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTATCGGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCGGGCGGTAACGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCAATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCTGGCCACTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCC
GAATGGAAAAACACTGAATTAGATAGCTATTTAATTGATATTACAACGGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAGCGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
 292 
 
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACGGCTGTAAAAGTAGTTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCTGGTA
TGGATCGTTCTGATCTGTTCAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAAAACTTCCGCTTTACTGATACTTATGTAACC 
 
>A9 | HS3169 | Australian Isolate| serotype 10 
 
GATGCATTATTACCGCACTTAGAAGAAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGTGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGTTATGATGAAATGCAGGCGATCTTTGCA
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAACTGGCGTGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTTGATAACCGTGACAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACGGCTGTAAAAGTAGTTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCTGGTA
TGGATCGTTCTGATCTGTTCAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
 293 
 
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
 
>A10 | HS3110 | Australian Isolate| non-typeable 
 
GATGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGAGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCAATCTTTTCT
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGTCCTATCGGTGAAGAAGAGCGTTGGACGATTCACCGTGCAGCACC
AAGCTATGAAGAGCAAGCAAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGACTTGATCG
CTCCGTTTGCTAAAGGGGGTAAAGTTGGCTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAATGACTTCTACCACGAGATGGAAGACTCTAACGTATTAGATAAAGTATCATTGG
TTTATGGTCAGATGAACGAGCCACCAGGTAACCCAAAACTGGCGTGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTTGATAACCGTGACAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCAGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTAGCTGGCTATGCGGGTGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCTGGCATTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
 
>A11 | HS2561 | Australian isolate| serotype 1 
 
GAAGCGTTATTACCGCACTTAGAAGAAGGCGACATCATCATTGATGGCGGCAACTCAAACTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAGTGGAAAAAGGTATTCGCTTTATCGGTTCGGGCGTATCGGGCG
 294 
 
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCGGGCGGTAACGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCAATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCTGGCCACTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCC
GAATGGAAAAACACTGAATTAGATAGCTATTTAATCGATATCACGACCGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCATGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTAGCTGGCTATGCGGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCAGGCGTTTACGATAAACATAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAAAACTTCCGCTTTACTGATACTTATGTAACC 
 
>A12 | HS2541 | Australian isolate | serotype 15 
 
GAAGCGTTATTACCGCACTTAGAAGAAGGCGACATCGTCATTGATGGCGGCAACTCAAACTACCCTGA
TACCAACCGCCGCGTGAAAGCGTTGGCAGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTATCGGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCGGGCGGTAACGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCAATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCTGGCCACTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCC
GAATGGAAAAACACTGAATTAGATAGCTATTTAATTGATATTACAACGGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
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AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAGCGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGTCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAAAACTTCCGCTTTACTGATACTTATGTAACC 
 
>A13 | HS3521 | Australian isolate| serotype 2 
 
GATGCATTATTACCGCACTTAGAAGAAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGTGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGTTATGATGAAATGCAGGCGATCTTTGCA
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAGCGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
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CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTAGCTGGCTATGCGGGTGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCAGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGCCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACTGATACTTATGTAACC 
 
>A14 | HS2093 | Australian isolate |Serotype 11 
 
GAGGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCAAACTACCCAGA
CACAAACCGCCGTGTGAAAGCCTTAGCGGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTGTCGGGCG
GTGAAGAAGGCGCACGTCACGGTCCTTCGATTATGCCGGGTGGTAATGAAGAAGCGTGGCAATATGTA
AAACCGATTTTCCAAGCGATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGATTGGGTGGGTAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAATGGTATCGAATACGGCGATATGCAGCTAATCT
GTGAAGCCTACCAATTCTTAAAAGATGGTTTAGGTTTAAGCTACAATGAAATGCAAGCGATCTTTGCT
GAATGGAAAAAAACGGAACTTGATAGCTATTTAATCGATATCACGACCGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGACTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCCGCAGA
AGTCTTGAAAAAAGCAGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGT
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
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GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACAAACAACTACGGCTTCTTAGAAACACCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACTGATACTTATGTAACC 
 
>A15 | HS3332 |Australian Isolate| Non-typeable 
 
GATGCATTATTACCGCACTTAGAAGAAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCAATCTTTTCT
GAATGGAAAAAAACTGAACTTGACAGTTACTTAATCGACATCACGACCGATATTCTACAACAACAATT
AGGCGGTGGTGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACGCTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGTCCTATCGGTGAAGAAGAGCGTTGGACGATTCACCGTGCAGCACC
AAGCTATGAAGAGCAAGCAAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGACTTGATCG
CTCCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCTGGTTACTCAGTATTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAATGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGATAAAGTATCATTGG
TTTATGGTCAGATGAACGAGCCACCAGGTAACCCAAAACTGGCATGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTTGATAACCGTGACAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCATGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTGCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCCGGTA
TGGATCGTTCTGATCTGTTCAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
 
>A16 | HS3048 | Australian isolate | Non-typeable 
 
GAAGCGTTATTACCGCACTTAGAAGAAGGCGACATCATCATTGATGGCGGCAACTCAAACTACCCTGA
TACCAACCGCCGCGTGAAAGCGTTGGCAGAAAAAGGCATTCGCTTTATCGGTTCGGGCGTATCGGGCG
GTGAAGAAGGCGCACGTCACGGGCCTTCTATTATGCCGGGTGGGAATGAAGAAGCGTGGCAATATGTG
AAACCGATTTTCCAAGCAATTTCAGCGAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGTAA
AGAAGGTGCTGGTCATTTCGTGAAAATGGTACATAACGGTATCGAGTACGGCGATATGCAGTTAATCT
GTGAAGCCTACCAATTCTTAAAAGATGGTTTAGGTTTAAGCTATGATGAAATGCAAGCGATCTTTGCT
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GAATGGAAAAAAACGGAACTTGATAGCTATTTAATCGACATTACGACCGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTGTTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACGTTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTAGCTGGCTATGCGGGTGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCAGCAGA
AGTCTTGAAAAAAGCAGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGC
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGATTTACTGATACTTATGTAACC 
 
>A17 | HS3152 | Australian Isolate | Serotype 5 
 
GATGCATTATTACCGCACTTAGAAGAAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGCGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGTGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGTTATGATGAAATGCAGGCGATCTTTGCA
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGTCCTATCGGTGAAGAAGAGCGTTGGACGATTCATCGTGCAGCACC
AAGCTATGAAGAGCAAGCAAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGACTTGATCG
CTCCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAATGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGATAAAGTATCATTGG
TTTATGGTCAGATGAACGAGCCACCAGGTAACCCAAAACTGGCGTGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
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CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTTGATAACCGTGACAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACGGCTGTAAAAGTAGTTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCCGGTA
TGGATCGTTCTGATCTGTTTAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
 
>A18 | HS3456 |Australian Isolate | Serotype 14 
 
GATGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGAGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCAATCTTTTCT
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAACAAAGCAATTGAAGTGCCAGTGGGTACAAAAACGCTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGTCCTATCGGTGAAGAAGAGCGTTGGACGATTCATCGTGCAGCACC
AAGCTATGAAGAGCAAGCAAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGACTTGATCG
CTCCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAATGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGATAAAGTATCATTGG
TTTATGGTCAGATGAACGAGCCACCAGGTAACCCAAAACTGGCATGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTTGATAACCGTGACAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCAGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATCGTGGTTGCGGTAAACAAAATTGATAAACCAGA
ACCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
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ATGTTCAATTTGTTCCTGTCTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCTGGCA
TGGATCGTTCTGATCTGTTCAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
 
>A19 | HS3289 | Australian isolate| Serotype 5 
 
GATGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGAGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCAATCTTTTCT
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGTGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACGCTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGTCCTATCGGTGAAGAAGAGCGTTGGACGATTCACCGTGCAGCACC
AAGCTATGAAGAGCAAGCAAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGACTTGATCG
CTCCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCTGGTTACTCAGTATTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAATGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGATAAAGTATCATTGG
TTTATGGTCAGATGAACGAGCCACCAGGTAACCCAAAACTGGCGTGTAAAACGTTCTTACGTGATTAC
AGCGGTTACATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGATTTAGTGGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGTATCAAACCATACATTATTGACAACAAAGCACCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGCACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACATTCTCAATGTGTATCAACTGTGGTTTATGTTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTAGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTTGATAACCGTGACAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGTAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCATGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATCGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCCAGAGCGTGTAGAGCAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTCTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCGGTAACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGTGCAAATTTAGTTTTAATTTCTGCAGGTGTGGCACGTAAACCTGGCA
TGGATCGTTCTGATCTGTTCAATATCAATGCAGGTATTGTGCGTAACTTAATTGAAAAAGTCGCAACG
GTTTGTCCGACGGCTTGTGTGGGAATTATTACTAACCCAGTAAATACCACAGTAGCTATTGCTGCAGA
AGTTTTGAAAAAAGCTGGCGTTTACGATAAACGTAAATTATTCGGTGTGACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTGGCTGAATTAAAAGGCAAAGATGTCAATGATGTAAAAGTACCTGTTATTGGT
GGTCACTCAGGCGTAACCATCCTACCACTACTTTCTCAAGCATTTGAAGAAGATAAAATTGACTTTAC
TCACAAACGTCGTATTTCAGCGTTAGGTTCGGGCGGTTTAACTCGTGAACGTGCAGGCTTTGAAGTGC
GTGACGTACACACCACTCACTATGGTCGCTTATGTCCGATTGAAACCCCAGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTATATGCACGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTCGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACCGATACTTATGTGACC 
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GATGCATTATTACCGCACTTAGAAGCAGGCGACATCATCATTGATGGCGGTAACTCGAATTACCCTGA
TACCAACCGCCGTGTGAAAGCGTTAACGGAAAAAGGTATTCGCTTTATCGGCTCGGGTGTGTCAGGCG
GTGAAGAAGGAGCACGTCACGGACCTTCGATTATGCCAGGTGGTAATGAAGAAGCATGGCAATATGTG
AAACCGATTTTCCAAGCGATTTCAGCAAAAACCGACAAAGGCGAGCCTTGCTGTGACTGGGTGGGCAA
AGAAGGTGCCGGTCATTTCGTGAAAATGGTACACAACGGTATCGAATACGGCGATATGCAGTTAATCT
GTGAAGCTTACCAGTTCTTAAAAGACGGTTTAGGTTTAAGCTATGATGAAATGCAAGCAATCTTTTCT
GAATGGAAAAAAACTGAACTTGACAGCTATCTAATTGATATTACAACAGATATTTTACAACAACAATT
AGGCGGTGGCGTAGTACGCTGTATCGCTCTTGGTACATCTGATGGTTTAAAACGTGGCTTAAAAGTTG
AAAATACGAATAAAGCGATTGAAGTACCAGTGGGTACAAAAACACTTGGTCGTATTATGAACGTATTA
GGTGAGCCTATTGATGAAGCAGGCCCTATCGGTGAAGAAGAGCGCTGGACGATTCATCGTGCAGCACC
AAGTTATGAAGATCAAGCTAACAGCACAGAACTTTTAGAAACAGGGATCAAAGTTATCGATTTGATCG
CACCGTTTGCTAAAGGGGGTAAAGTTGGTTTATTCGGTGGTGCTGGCGTAGGTAAAACGGTAAATATG
ATGGAGTTAATCCGTAACATCGCAATCGAACACTCAGGTTACTCTGTGTTCGCAGGTGTTGGTGAGCG
TACTCGTGAAGGTAACGACTTCTACCACGAGATGAAAGACTCTAACGTATTAGACAAAGTATCACTGG
TTTATGGTCAGATGAATGAGCCACCAGGTAACCCAAAGCTTGCATGTAAAACATTCTTACGCGATTAC
AGGGGTTATATGCGAATTGAACCGCTTGCAAACTTCCCGATTGAACGTGACTTAGTTGTTGATTTAAG
CCACTTCATCGAAAGTTTAGAAAGCATCAAGCCATACATTATTGACAACAAAGCGCCTGAACTTGATG
GCAAACCACACCCATCAGCAGAGCTTGCGAAAAGCCGTACCAAACAAACCCCAGCACAACTTGAGAAA
TACCGTACCTTCTCAATGTGTATTAACTGCGGTTTATGCTATGCCGCTTGCCCACAATTTGGCTTAAA
CCCTGAATTTGTTGGCCCAGCAGCATTAACCTTAGCTCACCGTTACAACCTAGATAACCGTGATAATG
GTAAAGCGGAACGTATGAAAATTATCAACGGCAAAAACGGTGTATGGAGCTGTACATTCGTCGGCTAC
TGCTCTGAAGTTATCCACGAAACATTTGGTATCAAAGAAGGTTTAATGACAACTGTTCACGCAACAAC
AGCAACACAAAAAACTGTTGATGGTCCATCAGCAAAAGACTGGCGCGGTGGTCGTGGTGCGGCACAAA
ACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCAGCATTAAACGGTAAA
TTAACAGGTATGGCGTTCCGTGTTCCAACAGCAAACGTATCTGTTGTTGATTTAACTGTAAACTTAGA
AAAACCAGCAAGCTACGAAGAGATCAAAAAAGCGATCAAAGATGCAGCAGAAGGTAAAACATTCAACG
GCGAATTAAAAGGCGTTTTAGGTTATACTGAAGATGCAGTAGTATCAACAGACTTCAACGGTGCAGTT
GAAACTTCTGTATTTGATGCAGATGCAGGTATCGCATTAACAGGTGCATATCACGTTGAAACCGACGA
CGGTAAGATGATTACCTTCTTAGATACACCAGGACACGCGGCATTTACCTCAATGCGTGCGCGTGGTG
CGAAAGCAACGGATATCGTTGTTCTTGTAGTAGCAGCTGACGATGGCGTAATGCCACAAACCATTGAA
GCAATCCAACACGCGAAAGCAGCTGGTGCGCCGATTGTGGTTGCGGTAAACAAAATTGATAAACCAGA
AGCAAACCTAGAGCGTGTAGAACAAGAGTTATTACAACACGAAGTGATTTCTGAGAAATTCGGTGGTG
ATGTTCAATTTGTTCCTGTTTCAGCGAAAAAAGGAATGGGGATTGACGACTTACTTGAAGCCATTCTT
CTTCAATCGGAAGTATTAGAATTAAGTGCAGTGACAGCCGTAAAAGTGGCTGGCTATGCAGGCGAAGA
TCCAACACCAGCTTTAGAAGGAGCAAATTTAGTTTTAATTTCTGCGGGTGTGGCTCGTAAACCAGGTA
TGGATCGTTCTGATCTATTCAATATTAATGCAGGTATTGTTCGTAACTTAATTGAAAAAGTCGCAACA
GTTTGCCCAACTGCTTGCGTAGGGATTATTACTAACCCAGTAAATACCACTGTTGCTATCGCCGCAGA
AGTCTTGAAAAAAGCAGGCGTTTACGATAAACGTAAATTATTCGGCGTTACATCACTCGATGTATTAC
GTTCAGAAACCTTTGTAGCTGAATTAAAAGGTAAAGATGTCAATGATGTTAAAGTGCCTGTTATTGGT
GGTCACTCAGGTGTAACCATTCTGCCTTTACTATCTCAAGCTTCTGAAGAAGATAAAATTGACTTCAC
CCACAAACGTCGTATTTCAGCGTTAGGTCCAGGCGGTTTAACTCGTGAACGTGCAGGCTTCGAAGTGC
GTGACGTACACACCACTCACTATGGCCGCTTATGTCCGATCGAAACCCCTGAGGGTCCAAACATCGGT
TTGATTAACTCGCTTTCTGTGTATGCGCGTACCAACAACTACGGCTTCTTAGAAACCCCATTCCGTAA
AGTTGTGAATGGTCAAGTGACTGAAGAGATCGAATACTTATCAGCGATTGAAGAAGGTGCTTACGTTA
TCGCACAGGCGAACTCAAACTTAGATGAGAACTTCCGCTTTACTGATACTTATGTAACC 
  
 302 
 
Appendix X: Statistical analysis 
Software used: Minitab 16 
Note: Kolmogorov–Smirnov (KS) test was used to test the goodness of fit of the statistical 
model (ANOVA). 
A. Effect on total viable count of H. parasuis using different diluents 
 
One-way ANOVA: Log10cfu/ml versus Treatment (statistical test) 
Source DF SS MS F P 
Treatment 6 27.53173   4.58862   5298.89   <0.001 
Error 14 0.01212   0.00087   
Total 20 27.54385    
S = 0.02943   R-Sq = 99.96%   R-Sq(adj) = 99.94% 
 
 
Level N Mean StDev 
0.1% Peptone 3 5.8509 0.0219 
0.1% Saline 3 4.9789 0.0205 
Mareks diluent 3 7.8856 0.0351 
Milli-Q 3 6.7529 0.0232 
PBS 3 5.4994 0.0387 
Supplemented Complex med 3 7.8586 0.0305 
Un-supplemented Complex 3 7.8444 0.0311 
                
Individual 95% CIs For Mean Based on 
Pooled StDev 
Level                     --------+---------+---------+---------+- 
0.1% Peptone                         *) 
0.1% Saline               *) 
Mareks diluent                                                (* 
Milli-Q                                         *) 
PBS                             (* 
Supplemented Complex med                                      *) 
Un-supplemented Complex                                       *) 
                          --------+---------+---------+---------+- 
                                5.60      6.40      7.20      8.00 
 
Pooled StDev = 0.0294 
 
Grouping Information Using Tukey Method 
Treatment                      N   Mean  Grouping 
Mareks diluent                 3  7.8856  A 
Supplemented Complex media     3  7.8586  A 
Un-supplemented Complex media  3  7.8444  A 
Milli-Q                        3  6.7529    B 
0.1% Peptone                   3  5.8509      C 
PBS                            3  5.4994        D 
0.1% Saline                    3  4.9789          E 
 Means that do not share a letter are significantly different. 
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Probability Plot of RESI1  
Kolmogorov-Smirnov (KS) test p>0.150 so ANOVA is valid 
 
Test for Equal Variances: log10cfu/ml versus Treatment  
95% Bonferroni confidence intervals for standard deviations 
                    Treatment  N      Lower      StDev     Upper 
                 0.1% Peptone  3  0.0092087  0.0218593  0.365450 
                  0.1% Saline  3  0.0086384  0.0205056  0.342817 
               Mareks diluent  3  0.0148046  0.0351428  0.587525 
                      Milli-Q  3  0.0097910  0.0232415  0.388557 
                          PBS  3  0.0162828  0.0386517  0.646189 
   Supplemented Complex media  3  0.0128350  0.0304675  0.509362 
Un-supplemented Complex media  3  0.0130933  0.0310806  0.519613 
 
Bartlett's Test (Normal Distribution) 
Test statistic = 1.19, p-value = 0.977 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.07, p-value = 0.998 
 
Test for Equal Variances: log10cfu/ml versus Treatment  
Passes both tests for equal variances, so ANOVA valid 
 
B. Effect of initial medium pH on growth of H. parasuis B4C6  
 
Test for Equal Variances: log10cfu/ml versus Treatment  
95% Bonferroni confidence intervals for standard deviations 
Treatment  N      Lower     StDev    Upper 
      6.0  3  0.0499676  0.116978  1.81032 
      6.5  3  0.0143018  0.033482  0.51815 
      7.0  3  0.0189118  0.044274  0.68518 
      7.5  3  0.0193190  0.045227  0.69993 
      8.0  3  0.0496182  0.116160  1.79767 
      8.5  3  0.0586359  0.137271  2.12438 
 
Bartlett's Test (Normal Distribution) 
Test statistic = 5.36, p-value = 0.374 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.66, p-value = 0.662 
 
Test for Equal Variances: log10cfu/ml versus Treatment  
 
One-way ANOVA: log10cfu/ml versus Treatment (statistical test)  
Source DF      SS MS F P   
Treatment 5 187.9200 37.5840 4408.93 <0.001   
Error 12 0.1023 0.0085     
Total 17 188.0223      
 
       
S = 0.09233   R-Sq = 99.95%   R-Sq(adj) = 99.92% 
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Individual 95% CIs For Mean Based on 
Pooled StDev 
Level  N    Mean   StDev  -----+---------+---------+---------+---- 
6.0    3  1.1757  0.1170  (* 
6.5    3  1.1848  0.0335  (*) 
7.0    3  5.5342  0.0443                        (* 
7.5    3  8.8136  0.0452                                        (*) 
8.0    3  8.6325  0.1162                                        *) 
8.5    3  2.5089  0.1373         (* 
                          -----+---------+---------+---------+---- 
                             2.0       4.0       6.0       8.0 
Pooled StDev = 0.0923 
 
Grouping Information Using Tukey Method 
Treatment  N    Mean  Grouping 
7.5        3  8.8136  A 
8.0        3  8.6325  A 
7.0        3  5.5342    B 
8.5        3  2.5089      C 
6.5        3  1.1848        D 
6.0        3  1.1757        D 
Means that do not share a letter are significantly different. 
 
Probability Plot of RESI1  
KS test p>0.150 
 
C. Effect of agitation of B4C6 cell growth in complex liquid media  
 
Test for Equal Variances: log10cfu/ml versus Treatment  
 95% Bonferroni confidence intervals for standard deviations 
            Treatment  N     Lower     StDev    Upper 
   Inside candle jar  3  0.046277  0.104254  1.31665 
             Shaking  3  0.285481  0.643135  8.12236 
Stationary (control)  3  0.025228  0.056833  0.71776 
            Stirring  3  0.071618  0.161342  2.03763 
 
 
Bartlett's Test (Normal Distribution) 
Test statistic = 10.07, p-value = 0.018 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.65, p-value = 0.602 
Test for Equal Variances: log10cfu/ml versus Treatment  
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One-way ANOVA: log10cfu/ml versus Treatment (statistical test)  
 Source      DF       SS      MS       F       P 
Treatment    3    179.442   59.814   527.28  <0.001 
Error        8    0.908     0.113 
Total       11    180.350 
 S = 0.3368   R-Sq = 99.50%   R-Sq(adj) = 99.31% 
 Level                 N    Mean   StDev 
Inside candle jar     3  2.6330  0.1043 
Shaking               3  0.3713  0.6431 
Stationary (control)  3  8.9798  0.0568 
Stirring              3  9.1561  0.1613 
                       Individual 95% CIs For Mean Based on Pooled StDev 
Level                   +---------+---------+---------+--------- 
Inside candle jar                (-*) 
Shaking                 (*-) 
Stationary (control)                                      (-*-) 
Stirring                                                   (-*) 
                        +---------+---------+---------+--------- 
                      0.0       2.5       5.0       7.5 
 Pooled StDev = 0.3368 
 
 
 
Grouping Information Using Tukey Method 
 Treatment             N   Mean  Grouping 
Stirring              3  9.156  A 
Stationary (control)  3  8.980  A 
Inside candle jar     3  2.633    B 
Shaking               3  0.371      C 
 Means that do not share a letter are significantly different. 
 
Probability Plot of RESI1  
   KS p>0.150 
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D. Effect of free air space on B4C6 cell growth 
 
Probability Plot of log10cfu/ml  
KS p=0.072 
Test for Equal Variances: log10cfu/ml versus Air space (%)  
 95% Bonferroni confidence intervals for standard deviations 
   Air Space (%)  N      Lower      StDev     Upper 
   50           3    0.0232573   0.052394   0.66171 
   70           3    0.0551757   0.124301   1.56983 
   80           3    0.0727904   0.163983   2.07100 
   90           3    0.0415724   0.093655   1.18280 
Bartlett's Test (Normal Distribution) 
Test statistic = 1.97, p-value = 0.579 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.33, p-value = 0.807 
Test for Equal Variances: log10cfu/ml versus Air space (%)  
One-way ANOVA: log10cfu/ml versus Air space (%)(statistical test)  
 Source         DF       SS      MS       F      P 
Air space (%)   3  17.4176  5.8059  431.20  <0.001 
Error           8   0.1077  0.0135 
Total          11  17.5253 
 S = 0.1160   R-Sq = 99.39%   R-Sq(adj) = 99.15% 
 
                           Individual 95% CIs For Mean Based on 
                          Pooled StDev 
Level  N    Mean   StDev  -----+---------+---------+---------+---- 
50     3  6.6381  0.0524  (*-) 
70     3  7.2436  0.1243        (*-) 
80     3  9.5683  0.1640                               (-*) 
90     3  8.9830  0.0937                         (-*) 
                          -----+---------+---------+---------+---- 
                             7.0       8.0       9.0      10.0 
 Pooled StDev = 0.1160 
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Grouping Information Using Tukey Method 
 Air Space (%)   N    Mean  Grouping 
80              3    9.5683   A 
90              3    8.9830     B 
70              3    7.2436       C 
50              3    6.6381         D 
 Means that do not share a letter are significantly different. 
  
Probability Plot of RESI1  
KS p>0.150 
E. Effect of B4C6 growth on different inoculum percentage  
 
Probability Plot of log10cfu/ml  
KS p>0.150 
Histogram of log10cfu/ml  
Test for Equal Variances: log10cfu/ml versus %inoculum, Time (h)  
 95% Bonferroni confidence intervals for standard deviations 
            Time 
%inoculum   (h)  N      Lower     StDev    Upper 
        1     0  3  0.0447805  0.111267  2.43646 
        1    12  3  0.0577839  0.143576  3.14396 
        1    24  3  0.0553383  0.137500  3.01090 
        5     0  3  0.0447805  0.111267  2.43646 
        5    12  3  0.0823901  0.204716  4.48276 
        5    24  3  0.0212301  0.052751  1.15511 
       10     0  3  0.0447805  0.111267  2.43646 
       10    12  3  0.0402085  0.099906  2.18770 
       10    24  3  0.0346972  0.086213  1.88784 
       20     0  3  0.0447805  0.111267  2.43646 
       20    12  3  0.0857630  0.213096  4.66627 
       20    24  3  0.0199690  0.049617  1.08649 
Bartlett's Test (Normal Distribution) 
Test statistic = 6.59, p-value = 0.831 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.40, p-value = 0.941 
Test for Equal Variances: log10cfu/ml versus %inoculum, Time (h)  
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Two-way ANOVA: log10cfu/ml versus %inoculum, Time (h) (statistical test) 
 Source       DF       SS       MS        F      P 
%inoculum     3   51.248  17.0827  1030.02  <0.001 
Time (h)      2   25.285  12.6427   762.30  <0.001 
Interaction   6   29.153   4.8588   292.97  <0.001 
Error        24    0.398   0.0166 
Total        35  106.085 
 S = 0.1288   R-Sq = 99.62%   R-Sq(adj) = 99.45% 
   
One-way ANOVA: log10cfu/ml versus Treatment (24 hours) (statistical test) 
 Source     DF        SS      MS       F      P 
Treatment  11  105.6865  9.6079  579.32  <0.001 
Error      24    0.3980  0.0166 
Total      35  106.0845 
 S = 0.1288   R-Sq = 99.62%   R-Sq(adj) = 99.45% 
 
                           Individual 95% CIs For Mean Based on 
                          Pooled StDev 
Level  N    Mean   StDev  -----+---------+---------+---------+---- 
 1     3  5.4161  0.1113             (*) 
 2     3  3.2057  0.1436  (*) 
 3     3  4.5649  0.1375         (*) 
 4     3  6.1150  0.1113                 (* 
 5     3  4.1573  0.2047       (*) 
 6     3  6.7383  0.0528                    (* 
 7     3  7.1150  0.1113                      (* 
 8     3  5.7381  0.0999               (* 
 9     3  9.6786  0.0862                                   *) 
10     3  8.4161  0.1113                            (*) 
11     3  6.6267  0.2131                   (*) 
12     3  5.6109  0.0496              (*) 
                          -----+---------+---------+---------+---- 
                             4.0       6.0       8.0      10.0 
 Pooled StDev = 0.1288 
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Grouping Information Using Tukey Method 
 Treatment  N    Mean  Grouping 
 9         3  9.6786  A 
10         3  8.4161    B 
 7         3  7.1150      C 
 6         3  6.7383      C D 
11         3  6.6267        D 
 4         3  6.1150          E 
 8         3  5.7381          E F 
12         3  5.6109            F 
 1         3  5.4161            F 
 3         3  4.5649              G 
 5         3  4.1573                H 
 2         3  3.2057                  I 
 
Means that do not share a letter are significantly different. 
Probability Plot of RESI2  
KS test p=0.077 
 
Including rows where 'Time (h)'=24 
24 rows excluded 
 
One-way ANOVA: log10cfu/ml_1 versus %inoculum_(statistical test)  
 Source       DF        SS        MS        F      P 
%inoculum_1   3  43.82241  14.60747  1850.02   <0.001 
Error         8   0.06317   0.00790 
Total        11  43.88557 
 S = 0.08886   R-Sq = 99.86%   R-Sq(adj) = 99.80% 
 
                           Individual 95% CIs For Mean Based on Pooled StDev 
Level  N    Mean   StDev    +---------+---------+---------+--------- 
 1     3  4.5649  0.1375    *) 
 5     3  6.7383  0.0528                  (*) 
10     3  9.6786  0.0862                                      (* 
20     3  5.6109  0.0496           *) 
                            +---------+---------+---------+--------- 
                          4.5       6.0       7.5       9.0 
 Pooled StDev = 0.0889 
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Grouping Information Using Tukey Method (24 hours) 
 %inoculum    N    Mean  Grouping 
10           3  9.6786  A 
 5           3  6.7383    B 
20           3  5.6109      C 
 1           3  4.5649        D 
 Means that do not share a letter are significantly different. 
Probability Plot of RESI3  
KS test p>0.150 
 
 
F. Effect of nitrogen source on B4C6 cell growth  
  
One-way ANOVA: Log cfu/ml versus Treatment (statistical test) 
Source     DF        SS       MS        F      P 
Treatment   8  144.0813  18.0102  1173.36  <0.001 
Error      18    0.2763   0.0153 
Total      26  144.3575 
S = 0.1239   R-Sq = 99.81%   R-Sq(adj) = 99.72% 
 
Level                     N    Mean   StDev 
1% Biostate peptone       3  9.3466  0.1057 
1% Nzcase                 3  8.5174  0.1701 
1% Soypeptone             3  9.3612  0.1305 
1% Soypeptone + 0.5% yea  3  9.8274  0.0612 
1% Soypeptone+0.5% trypt  3  9.1699  0.1419 
1% Tryptone               3  6.6736  0.2021 
1% Yeast extract          3  6.6395  0.0985 
10% Ammonium sulfate      3  3.7629  0.0274 
                          Individual 95% CIs For Mean Based on 
                          Pooled StDev Pooled StDev = 0.1239 
 
Level                     ----+---------+---------+---------+----- 
1% Biostate peptone                                     (* 
1% Nzcase                                           (* 
1% Soypeptone                                           (*) 
1% Soypeptone + 0.5% yea                                  (*) 
1% Soypeptone+0.5% trypt                                (*) 
1% Tryptone                                *) 
1% Yeast extract                          (*) 
10% Ammonium sulfate        (*) 
10% Ammonium chloride       (*) 
                          ----+---------+---------+---------+----- 
                            4.0       6.0       8.0      10.0 
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Grouping Information Using Tukey Method 
 Treatment                          N    Mean  Grouping 
1% Soypeptone + 0.5%YE             3  9.8274  A 
1% Soypeptone                      3  9.3612    B 
1% Biostate peptone                3  9.3466    B 
1% Soypeptone+0.5% tryptone        3  9.1699    B 
1% Nzcase                          3  8.5174      C 
1% Tryptone                        3  6.6736        D 
1% Yeast extract (YE)              3  6.6395        D 
10% Ammonium sulfate               3  3.7629          E 
10% Ammonium chloride              3  3.4270          E 
 Means that do not share a letter are significantly different. 
Probability Plot of RESI1  
KS test >0.150 
 
Test for Equal Variances: RESI1 versus Treatment  
 95% Bonferroni confidence intervals for standard deviations 
                         Treatment  N      Lower     StDev    Upper 
              1% Biostate peptone  3  0.0435667  0.105698  2.00409 
                        1% Nzcase  3  0.0701186  0.170117  3.22550 
                    1% Soypeptone  3  0.0537718  0.130457  2.47353 
1% Soypeptone + 0.5% yeat extract  3  0.0252223  0.061193  1.16024 
      1% Soypeptone+0.5% tryptone  3  0.0584949  0.141916  2.69080 
                      1% Tryptone  3  0.0832862  0.202063  3.83121 
                 1% Yeast extract  3  0.0405912  0.098480  1.86722 
             10% Ammonium sulfate  3  0.0112765  0.027358  0.51873 
             10% Ammonium chloride 3  0.0315285  0.076492  1.45033 
 
 Bartlett's Test (Normal Distribution) 
Test statistic = 7.06, p-value = 0.530 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.69, p-value = 0.697 
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G. Effect of replacement of BSA with different percentage of pig serum 
 
 
Test for Equal Variances: Log cfu/ml versus Treatment  
 95% Bonferroni confidence intervals for standard deviations 
 Treatment        N      Lower      StDev     Upper 
  control        3     0.0114677  0.0268467  0.415473 
        1        3     0.0132121  0.0309305  0.478673 
        5        3     0.0173499  0.0406175  0.628587 
       10        3     0.0106706  0.0249807  0.386596 
       15        3     0.0059435  0.0139141  0.215332 
       20        3     0.0043135  0.0100983  0.156279 
 
 Bartlett's Test (Normal Distribution) 
Test statistic = 3.67, p-value = 0.597 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.43, p-value = 0.820 
 Test for Equal Variances: Log cfu/ml versus Treatment  
One-way ANOVA: Log cfu/ml versus Treatment (statistical test) 
 Source     DF        SS       MS        F      P 
Treatment   5  18.10491  3.62098  5115.79  <0.001 
Error      12   0.00849  0.00071 
Total      17  18.11340 
 S = 0.02660   R-Sq = 99.95%   R-Sq(adj) = 99.93% 
                           Individual 95% CIs For Mean Based on 
                          Pooled StDev 
Level       N    Mean   StDev   -+---------+---------+---------+-------- 
control     3  9.9079  0.0268                                       *) 
 1          3  7.7577  0.0309   *) 
 5          3  7.7864  0.0406   (* 
10          3  9.9203  0.0250                                       *) 
15          3  9.8938  0.0139                                      (* 
20          3  9.8750  0.0101                                      (* 
                               -+---------+---------+---------+-------- 
                                7.80      8.40      9.00      9.60 
 Pooled StDev = 0.0266 
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 Grouping Information Using Tukey Method 
 Treatment       N    Mean  Grouping 
10              3  9.9203  A 
control         3  9.9079  A 
15              3  9.8938  A 
20              3  9.8750  A 
 5              3  7.7864    B 
 1              3  7.7577    B 
 Means that do not share a letter are significantly different. 
Probability Plot of RESI1  
KS test > 0.150  
 Test for Equal Variances: RESI1 versus Treatment  
 95% Bonferroni confidence intervals for standard deviations 
 Treatment  N      Lower      StDev     Upper 
control    3  0.0114677  0.0268467  0.415473 
        1  3  0.0132121  0.0309305  0.478673 
        5  3  0.0173499  0.0406175  0.628587 
       10  3  0.0106706  0.0249807  0.386596 
       15  3  0.0059435  0.0139141  0.215332 
       20  3  0.0043135  0.0100983  0.156279 
 
 Bartlett's Test (Normal Distribution) 
Test statistic = 3.67, p-value = 0.597 
Levene's Test (Any Continuous Distribution) 
Test statistic = 0.43, p-value = 0.820 
    
 
**************************************************************************************** 
